






































European Guideline Craniofacial Microsomia
Ruben W. Renkema, MD and the ERN CRANIO Working Group on Craniofacial Microsomia
Index
Summary 2387
Chapter 1. Introduction 2393
1.1 Incentive for making the guideline 2393
1.2 Purpose of the guideline 2393
1.3 Scope of the guideline 2393
1.4 Relationship to other congenital facial malformations 2394
1.5 Intended users of the guideline 2394
1.6 About craniofacial microsomia 2394
1.7 European Reference Networks 2394
Chapter 2. Methodology 2394
2.1 Validity of the guideline 2394
2.2 General information 2394
2.3 Aim and target audience guideline 2394
2.3.1 Aim of the Guideline 2394
2.3.2 Target audience 2395
2.3.3 Patient population 2395
2.4 Steering group 2395
2.5 Conflicts of interest 2395
2.6 Patient perspectives 2396
2.7 Implementation 2397
2.8 Methods 2397
2.8.1 Bottleneck analysis 2397
2.8.2 Questions and outcomes 2397
2.8.3 Literature search and selection of literature 2397
2.8.4 Quality assessment of individual studies 2398
2.8.5 Summary of literature 2398
2.8.6 Quality of evidence 2398
2.8.7 Formulating conclusions 2398
2.8.8 Considerations 2398
2.8.9 Formulating recommendations 2400
2.8.10 Conditions (organisation of care) 2400
2.8.11 Knowledge gap 2400
2.8.12 Evaluation and authorisation phase 2400
Chapter 3. Diagnostic criteria for craniofacial microsomia 2400
3.1 Based on which criteria is a child or adult with craniofacial microsomia diagnosed? 2401
Chapter 4. Screening, monitoring and indication for treatment 2403
4.1 Breathing difficulties in craniofacial microsomia 2403
From the Department of Plastic and Reconstructive Surgery and Hand Surgery and Department of Maxillofacial Surgery, Dutch Craniofacial Center,
Erasmus Medical Center, Rotterdam, The Netherlands.
Received March 29, 2020.
Accepted for publication April 21, 2020.
Address correspondence and reprint requests to Ruben W. Renkema, Dutch Craniofacial Center, Erasmus Medical Center, Rotterdam, The Netherlands;
E-mail: r.renkema@erasmusmc.nl
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of
this article on the journal’s Web site (www.jcraniofacialsurgery.com).
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND),
where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without
permission from the journal.




The Journal of Craniofacial Surgery  Volume 31, Number 8S, November/December 2020 2385
4.1.1 What is the type, prevalence and severity of breathing difficulties in craniofacial microsomia? 2404
4.1.2 What is the policy for screening and monitoring of breathing difficulties (OSA) in patients with craniofacial microsomia? 2405
4.1.3 What are the indications and policy for treatment of breathing difficulties (OSA) in patients with craniofacial microsomia? 2406
4.2 Feeding difficulties in craniofacial microsomia 2409
4.2.1 What is the type, prevalence and severity of feeding difficulties in craniofacial microsomia? 2409
4.2.2 What is the policy for screening and monitoring of feeding difficulties in patients with craniofacial microsomia? 2411
4.2.3 What are the indications and policy for treatment of feeding difficulties in patients with craniofacial microsomia? 2412
4.3 Speech and Language difficulties in craniofacial microsomia 2413
4.3.1 What is the type, prevalence and severity of speech difficulties in craniofacial microsomia? 2414
4.3.2 What is the policy for screening and monitoring of speech and language difficulties in patients with craniofacial microsomia? 2416
4.3.3 What are the indications and policy for treatment of speech difficulties in patients with craniofacial microsomia? 2418
4.4 Hearing difficulties in craniofacial microsomia 2420
4.4.1 What is the type, prevalence and severity of hearing difficulties in craniofacial microsomia? 2420
4.4.2 What is the policy for screening and monitoring of hearing difficulties in patients with craniofacial microsomia? 2424
4.4.3 What are the indications and policy for treatment of hearing difficulties in patients with craniofacial microsomia? 2425
4.5 Eye anomalies in craniofacial microsomia 2426
4.5.1 What is the type, prevalence and severity of eye anomalies in craniofacial microsomia? 2427
4.5.2 What is the policy for screening and monitoring of eye anomalies in patients with craniofacial microsomia? 2428
4.5.3 What are the indications and policy for treatment of eye anomalies in patients with craniofacial microsomia? 2429
4.6 Dental deformities in craniofacial microsomia 2432
4.6.1 What is the type, prevalence and severity of dental deformities in craniofacial microsomia? 2432
4.6.2 What is the policy for screening and monitoring of dental deformities in patients with craniofacial microsomia? 2433
4.6.3 What are the indications and policy for treatment of dental deformities in patients with craniofacial microsomia? 2434
4.7 Vertebral anomalies in craniofacial microsomia 2436
4.7.1 What is the type, prevalence and severity of vertebral anomalies in craniofacial microsomia? 2437
4.7.2 What is the policy for screening and monitoring of vertebral anomalies in patients with craniofacial microsomia? 2438
4.7.3 What are the indications and policy for treatment of vertebral anomalies in patients with craniofacial microsomia? 2439
4.8 Psychosocial difficulties in craniofacial microsomia 2442
4.8.1 What are the type, prevalence and severity of psychosocial difficulties in craniofacial microsomia? 2443
4.8.2 What is the policy for the screening and monitoring of psychosocial difficulties in patients with craniofacial microsomia? 2445
4.8.3 What are the indications and policies for the treatment of psychosocial difficulties in patients with craniofacial microsomia? 2446
Chapter 5. Surgical treatment 2449
5.1 Mandible & Maxilla 2449
5.1.1 What is the indication for surgical treatment of mandibular and maxillary deformity in patients with craniofacial microsomia? 2450
5.1.2 What is the most optimal treatment modality and its timing for mandibular/maxillary deformity in patients with craniofacial
microsomia regarding severity, breathing problems, occlusal problems and aesthetics?
2452
5.2 Facial nerve 2460
5.2.1 What is the indication for surgical treatment of facial nerve anomaly in patients with craniofacial microsomia? 2461
5.2.2 What is the most optimal treatment modality for facial nerve anomaly in patients with craniofacial microsomia
related to functional deficits and aesthetics?
2463
5.3 Soft tissues 2468
5.3.1 What is the indication for surgical treatment of soft tissue deficiency in patients with craniofacial microsomia? 2469
5.3.2 What is the most optimal treatment modality for soft tissue deficiency in patients with craniofacial microsomia
related to severity and its timing?
2470
5.4 Microtia 2473
5.4.1 What is the indication for surgical treatment of ear deformity in patients with craniofacial microsomia? 2474
5.4.2 What is the most optimal treatment modality for ear deformity in patients with craniofacial microsomia related to its timing? 2475
Chapter 6. Organisation of care 2480
Minimal care standards and monitoring outcomes 2480
6.1 What are the minimal care standards to treat patients with craniofacial microsomia and how should outcomes of care be monitored? 2481
Appendix 1. Additional questions
Appendix 2. Literature searches
Appendix 3. Bottlenecks from patient’s perspective
Appendix 4. Definitions
Appendix 5. Reporting speech outcomes
Appendix 6. Evidence table
Renkema et al The Journal of Craniofacial Surgery  Volume 31, Number 8S, November/December 2020
2386 # 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of Mutaz B. Habal, MD
SUMMARY
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Chapter 6 Organisation of care
The following recommendations were agreed on:
Chapter 3. Diagnostic criteria for craniofacial microsomia
3.1 On which criteria is a child or adult with craniofacial
microsomia diagnosed?
Terminology
 It is advised to exclusively use the term craniofacial
microsomia. Discard the use of other terms such as
Goldenhar syndrome, hemifacial microsomia or aur-
iculo-oculo-vertebral spectrum.
Diagnostic criteria
 It is advised to use the diagnostic criteria for craniofacial
microsomia developed by the ICHOM Craniofacial Microsomia
group.
CFM is defined by: 2 major criteria, or
1 major þ 1 minor criteria, or
3þ minor criteria
Major criteria Mandibular hypoplasia
Microtia
Orbital / facial bone hypoplasia
Asymmetric facial movement






Chapter 4.1 Breathing difficulties in craniofacial microsomia
4.1.1 What is the type, prevalence and severity of breathing
difficulties in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.1.2 What is the policy for screening and monitoring of
breathing difficulties (OSA) in patients with craniofacial micro-
somia?
 All patients with craniofacial microsomia should be
screened with a questionnaire biannually, at least up to
the age of six, in the outpatient department for a clinical
history of obstructive sleep apnoea.
 If there is a suspicion of obstructive sleep apnoea based
on a questionnaire, a polysomnography (sleep study)
has to be performed.
 All patients who have Pruzansky-Kaban IIb or III
mandibles and/or are bilaterally affected have to
undergo a polysomnography (sleep study) to screen
for obstructive sleep apnoea in the first year of life.
4.1.3 What are the indications and policy for treatment of
breathing difficulties (OSA) in patients with craniofacial micro-
somia?
 Treatment of children with craniofacial microsomia and
obstructive sleep apnoea has to be discussed in a
multidisciplinary team.
 Treatment of children with craniofacial microsomia and
obstructive sleep apnoea depends on the age of the child,
the severity of symptoms and the level of obstruction.
 In older children with mild to severe obstructive sleep
apnoea, adenotonsillectomy (ATE) may be the treat-
ment of first choice.
 In young infants and children with craniofacial
microsomia and obstructive sleep apnoea non-surgical
respiratory support has to be considered to treat
obstructive sleep apnoea.
 In children with craniofacial microsomia and severe
obstructive sleep apnoea a tracheostomy has to be
considered at all ages.
 Mandibular distraction osteogenesis (MDO) should be
considered to treat patients with severe obstructive sleep
apnoea who have a tracheostomy or to reduce the
necessity for a tracheostomy or respiratory support.
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Chapter 4.2 Feeding difficulties in craniofacial microsomia
4.2.1 What is the type, prevalence and severity of feeding
difficulties in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.2.2 What is the policy for screening and monitoring of feeding
difficulties in patients with craniofacial microsomia?
 Children with craniofacial microsomia should be
screened with a questionnaire biannually, at least up
to the age of six, and monitored regularly for feeding
difficulties by a paediatrician or multidisciplinary team.
 The WHO or national Growth Charts can be used to
monitor growth and screen for feeding difficulties.
 A speech and language therapist should be involved in
patients who require tube feeding.
4.2.3 What are the indications and policy for treatment of
feeding difficulties in patients with craniofacial microsomia?
 Children with craniofacial microsomia with feeding
difficulties should be treated by a multidisciplinary
team.
 Feeding strategies are guided by the severity of feeding
difficulties.
Chapter 4.3 Speech difficulties in craniofacial microsomia
4.3.1 What is the type, prevalence and severity of speech and
language difficulties in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.3.2 What is the policy for screening and monitoring of speech
and language difficulties in patients with craniofacial microsomia?
 Screen preverbal communication and babbling skills at
the age of nine months to decide if intervention
is warranted.
 Evaluate receptive and expressive language skills at the
age of two years and biannually until the age of eight
years in all patients with craniofacial microsomia.
Those identified with difficulties should be referred to
their community speech and language therapist service
for ongoing intervention.
 Oral-facial evaluation of structure and function is
recommended at each screening consultation to
examine any impact of asymmetry on speech produc-
tion. This should include examination of facial
symmetry, lips, dental occlusion and intra-oral exami-
nation of tongue movement, dentition, hard palate and
soft palate movement on sustained ‘ah’ vowel.
 Screen patients with tracheostomy for speaking valve
suitability or an augmentative and alternative commu-
nication system.
 Social communication skills should be monitored in
tangent with all of the afore-mentioned communication
skills.
 Children with craniofacial microsomia and associated
cleft palate should be screened annually from 2–5 years
by the Cleft-Craniofacial speech and language therapist
and should follow the local Cleft Palate Protocol.
Velopharyngeal dysfunction should be assessed from
the age of two years or when verbal output has emerged.
 Children with craniofacial microsomia without a cleft
palate should also be screened at the age of two years to
examine for potential risk of velopharyngeal dysfunc-
tion related to their asymmetrical structure. If velo-
pharyngeal dysfunction is identified, these children
should follow the same pathway as children with a
cleft palate.
4.3.3 What are the indications and policy for treatment of speech
and language difficulties in patients with craniofacial microsomia?
 Recommend early language stimulation for delayed
babble onset from nine months.
 Facilitate receptive and expressive language develop-
ment using a range of behavioural techniques such as
modelling, imitation, repetition and extension.
 Patients with cleft speech characteristics should have
articulation therapy when identified. Direct therapy
using an articulation approach is recommended from
age three onwards
 Monitor patients with tracheostomy and speaking valve
use on a regular base.
 Introduce low or high tech augmentative and alternative
communication systems to children who are non-verbal
or whose speech is unintelligible. These include
gestures, signing, symbols, word boards, communica-
tion boards and books, as well as Voice Output
Communication Aids (VOCAs). A low-tech system
such as signing can be introduced from one.
 Intervention for social communication difficulties is
recommended; e.g. development of non-verbal com-
munication skills (e.g. eye contact, turn-taking);
conversational skills, recognitions of emotions and
emotional regulation.
Chapter 4.4 Hearing difficulties in craniofacial microsomia
4.4.1 What is the type, prevalence and severity of hearing
difficulties in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.4.2 What is the policy for screening and monitoring of hearing
difficulties in patients with craniofacial microsomia?
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 Perform neonatal hearing test in all new-borns with
craniofacial microsomia. If indicated, complete audio-
logical evaluation in an experienced audiology centre
should be performed before the age of three months to
ensure timely treatment.
 Re-evaluate hearing tests in patients with craniofacial
microsomia by the age of 24–30 months.
 Regularly perform otoscopy and audiometry in patients
with craniofacial microsomia including microtia and/or
cleft palate by the ENT doctor/otolaryngologist.
 Audiologic intervention should be initiated before the
age of six months in patients with congenital hearing
loss.
4.4.3 What are the indications and policy for treatment of
hearing difficulties in patients with craniofacial microsomia?
 Treat moderate to severe hearing loss, either with non-
surgical or surgical options.
 Coordinate surgical approach and timing in a multidis-
ciplinary team regarding hearing augmentation and
other surgical procedures including ear reconstruction
and mandibular surgeries.
Chapter 4.5 Eye anomalies in craniofacial microsomia
4.5.1 What is the type, prevalence and severity of eye anomalies
in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.5.2 What is the policy for screening and monitoring of eye
anomalies in patients with craniofacial microsomia?
 All patients with craniofacial microsomia should be
screened at least once during the visual development
(before the age of five) by an orthoptist and
ophthalmologist. Depending on the results, follow-up
visits need to be scheduled on a regular basis.
4.5.3 What are the indications and policy for treatment of eye
anomalies in patients with craniofacial microsomia?
 Children with ocular disturbances need to be evaluated
by a specialised orthoptist and ophthalmologist during
the visual development (before the age of five).
 Optimal spectacle correction should be provided in case
of a refractive error.
 Amblyopia should be treated before the age of six.
 When surgery is considered this has to be discussed in a
multidisciplinary team, carefully evaluating the harms
and the benefits, especially in the case of young children
in whom vision is still developing.
 Ultrasound imaging of the ocular dermoid needs to be
conducted if extension posteriorly and into the orbit
is suspected.
Chapter 4.6 Dental deformities in craniofacial microsomia
4.6.1 What is the type, prevalence and severity of dental
deformities in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.6.2 What is the policy for screening and monitoring of dental
deformities in patients with craniofacial microsomia?
 Patients with craniofacial microsomia should have
routine dental care.
 Patients with craniofacial microsomia should be seen
from age five by an orthodontist within a multidisci-
plinary team to diagnose dental deformities.
 Perform screening for dental deformities by intra-oral
inspection and standard dental records.
 Take orthodontic records in a structured schedule, at 6,
9, 12, 15 and 18 years of age.
4.6.3 What are the indications and policy for treatment of dental
deformities in patients with craniofacial microsomia?
 Dentofacial orthopaedic treatment can be considered
appropriate in very mild craniofacial microsomia
cases. In severe craniofacial microsomia patients,
current evidence does not promote activator
treatment.
 Orthodontic treatment should be discussed and coordi-
nated in a multidisciplinary team depending on the
decision to conduct orthognathic surgery or not.
Chapter 4.7 Vertebral anomalies in craniofacial
microsomia
4.7.1 What is the type, prevalence and severity of vertebral
anomalies in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.7.2 What is the policy for screening and monitoring of
vertebral anomalies in patients with craniofacial microsomia?
 Screening questions and clinical examinations related
to neck/back symptoms should be undertaken at
initial consultation and as part of pre-operative
workup.
 All patients with craniofacial microsomia who have
neurologic symptoms (e.g., paraesthesia, numbness, or
weakness) or neck pain suggestive of neuronal injury
should be evaluated as soon as possible by a
(paediatric) neurologist.
 Patients should be referred appropriately and attention
to the cervical spine should be payed when patients are
undergoing general anaesthesia.
4.7.3 What are the indications and policy for treatment of
vertebral anomalies in patients with craniofacial microsomia?
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 Surgical fusion and/or bracing in patients with vertebral
anomalies may be necessary to obtain spinal stability
and to prevent secondary injury of the spinal structures.
 A multidisciplinary approach in treatment and timing is
warranted to optimise outcomes for these patients.
Chapter 4.8 Psychosocial difficulties in craniofacial microsomia
4.8.1 What is the type, prevalence and severity of psychosocial
difficulties in craniofacial microsomia?
Since this question does not relate to interventions or diagnos-
tics, only conclusions without any considerations, rationale or
recommendations are provided.
4.8.2 What is the policy for screening and monitoring of
psychosocial difficulties in patients with craniofacial microsomia?
 All craniofacial microsomia patients should have access to
a clinical psychology servicewith appropriate professional
expertise and knowledge of craniofacial microsomia.
 Time points for reviews and screening should observe
key life transitions such as birth, starting school,
transition to secondary school, etc.
 To measure psychosocial wellbeing and family stress,
validated self-reported psychological outcome measures
should be obtained from to all craniofacial microsomia
patients as a matter of routine to screen for the presence of
behavioural, emotional, social and/or learning difficul-
ties. This includes the CleftQ, CFEQ, YP-CORE, HADS
and Distress Thermometer for Parents and should be
performed at age 2, 5, 8 and 22. Elevated scores should
alert clinicians to the potential need for further
assessment or support. Standardised measures should
assess levels of emotional distress as well as evaluate
difficulties related to visible differences.
4.8.3 What are the indications and policy for treatment of
psychosocial difficulties in patients with craniofacial microsomia?
Parental adjustment and support
 Parents of newly diagnosed children with craniofacial
microsomia should have access to a specialist clinical
psychology service with expertise and knowledge of
the condition.
 Information on support groups and organisations should
be provided, both at initial contact and at regular review.
Behavioural and/or learning difficulties
 When appropriate, clinicians should liaise with local
services and schools to discuss the child’s support needs.
 Cognitive assessment may be offered if warranted
Coping with visible difference
 Patients with craniofacial microsomia should have
access to specialist psychological support, particularly
those who are presenting with low self-esteem,
depression/low mood, anxiety, appearance- or treat-
ment-related concerns, including adjustment difficul-
ties or trauma as a result of surgical/medical
interventions.
 Clinicians with appropriate professional expertise in
craniofacial microsomia should consider liaising with
local schools to offer advice on how to support children
who have visible differences.
 Information about support groups and organisations
should be provided.
 Psychological input is required pre- and post- facial
surgery to monitor expectation and acceptance.
 The psychologist is part of the coordinated care in the
multidisciplinary team. See recommendations in
Chapter 6.
Chapter 5.1 Mandible & Maxilla
5.1.1 What is the indication for surgical treatment of mandibular
and maxillary deformity in patients with craniofacial microsomia?
 Consider surgical management (tracheostomy, adeno-
tonsillectomy, mandibular and/or maxillary surgery) in
patients with craniofacial microsomia for the treatment
of breathing problems if non-surgical therapy fails or to
end non-surgical therapy.
 Inform patients and parents about of the uncertainty of
respiratory outcomes following mandibular and/or
maxillary surgery for OSA in patients with CFM.
 If surgical treatment of the mandibular/maxillary
deformity in patients with craniofacial microsomia is
indicated to prevent or treat psychosocial problems, it is
important to inform the patient about the potential
benefits and harms and to ensure that the patients/
parents have a realistic view of what can be expected.
 It is advised to integrate the (surgical) treatment of the
mandibular/maxillary deformity in patients with cra-
niofacial microsomia in the planning of other surgeries,
especially for those that affect facial symmetry, palsy,
soft tissue augmentation and treatment of atresia
or microtia.
5.1.2 What is the most optimal treatment modality and its timing
for mandibular/maxillary deformity in craniofacial microsomia
regarding severity, breathing problems, occlusal problems and
aesthetics?
Obstructive sleep apnoea
 Start with non-surgical treatment for the management
(e.g. oxygen, CPAP) of mild-moderate OSA in infants
with craniofacial microsomia. See Chapter 4.1 –
Breathing difficulties for recommendations.
 Perform a tracheostomy or mandibular distraction
osteogenesis in infants with mandibular hypoplasia
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and severe OSA who do not respond to non-
surgical treatment.
 If the aim of surgical treatment is to end non-surgical
treatment (e.g. CPAP), perform elective mandibular
distraction osteogenesis.
 Mandibular reconstruction with costochondral bone
grafts should be performed after the age of six.
Occlusal problems
 For patients with craniofacial microsomia and severe
occlusal problems, perform mandibular distraction
osteogenesis in mixed dentition phase.
 A combined orthodontic and orthognathic surgery plan
is mandatory to achieve and optimise stable long-
term outcomes.
 Perform secondary orthognathic surgery to correct
occlusion at skeletal maturity.
Aesthetic problems
 Postpone surgical correction of the mandibular/maxil-
lary deformity for aesthetic reasons in patients with
craniofacial microsomia until skeletal maturity.
 The implications of early surgery (i.e. repeat surgery)
for psychosocial reasons should be discussed within the
multidisciplinary team and with patient and caregivers.
 Psychological input is required pre- and post-opera-
tively to monitor expectation and acceptance.
3D planning
 Use 3D planning to optimise surgical outcome of
mandibular and maxillary surgery in patients with
CFM.
Chapter 5.2 Facial nerve
5.2.1 What is the indication for surgical treatment of facial nerve
anomaly in patients with craniofacial microsomia?
Indications for treatment
 Provide all patients with craniofacial microsomia with
psychosocial support.
 Refer all craniofacial microsomia patients with
lagophthalmos to an ophthalmologist.
 Surgical treatment of the upper or lower eyelids should
be considered in patients with craniofacial microsomia
and loss of function of the upper facial nerve branches.
 Coordinate the timing of facial reanimation surgery in
patients with craniofacial microsomia in the planning of
other major surgeries.
 Facial movement should by assessed with the CleftQ
Appearance at age 8, 12, and 22.
5.2.2 What is the most optimal treatment modality for facial
nerve anomaly in patients with craniofacial microsomia related to
functional deficits and aesthetics?
Eye
 Correct lagophthalmos due to facial palsy in patients
with craniofacial microsomia with placement of a gold
weight or platinum chain, muscle transfers and/or
tendon slings, or cross-facial nerve grafting.
 Tarsorrhaphy as a treatment for lagophthalmos in
patient with craniofacial microsomia is discouraged.
Oral
 Start with the injection of botulinum toxin in the non-
affected depressor labii inferioris muscle if therapy is
indicated in patients with craniofacial microsomia and
asymmetrical lip depression due to facial palsy.
 Consider myomectomy of the non-affected depressor
labii inferioris muscle if the outcome of treatment with
botulinum toxin injections are satisfactory.
 Consider the use of dynamic techniques such as
digastric muscle transfers if the outcome of treatment
with botulinum toxin injections are not satisfactory.
 Perform imaging of the digastric muscle prior to
surgical muscle transfer due to the high prevalence of
agenesis of the anterior belly of the digastric muscle.
Aesthetics
 Psychological input is required pre- and post-opera-
tively to monitor expectation and acceptance.
 Strive for spontaneous facial animations by using a
cross-facial nerve graft with a free flap.
 Consider functional muscle transfer from the age of
four onwards.
 Reserve the use of the masseteric nerve to innervate the
free muscle transfer for patients in whom cross-facial
nerve grafting is not favourable, in bilateral cases, or as
a babysit procedure.
 Consider the use of regional muscle transfers to achieve
facial animation in patients with craniofacial micro-
somia and facial palsy if cross-facial nerve grafting with
free muscle transfers is not preferred.
 A facial physical therapist is part of the multidisciplin-
ary team.
 Collect clinician- and patient-reported outcome mea-
sures pre- and posttreatment.
Chapter 5.3 Soft tissues
5.3.1 What is the indication for surgical treatment of soft tissue
deficiency in patients with craniofacial microsomia?
 The indication for surgical treatment of soft tissue
deficiency in patients with craniofacial microsomia is
mainly aesthetic. Inform the patient about the potential
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benefits and harms to ensure that the patient has a
realistic view of what can be expected.
 Patients’ difficulties with facial form/asymmetry should
be assessed with the CleftQ Appearance at age 8, 12,
and 22.
5.3.2 What is the most optimal treatment modality for soft tissue
deficiency in patients with craniofacial microsomia related to
severity and its timing?
 Psychological input is required pre- and post-opera-
tively to monitor expectations and acceptance.
 Reconstruct soft tissue deficiencies in patients with
craniofacial microsomia with fat grafting from childhood.
 Free tissue transfer is only considered in patients with a
very severe soft tissue deficiency.
 Alloplastic implants to correct soft tissue deficiency in
patients with craniofacial microsomia are ideally
performed at skeletal maturity.
 The use of pedicled flaps for correction of soft tissue
deficiency in patients with craniofacial microsomia is
strongly discouraged.
 Coordinate the timing of surgical treatment of soft
tissue deficiency in patients with craniofacial micro-
somia with the planning of other surgeries, especially
for surgeries that affect facial symmetry such as
mandibular surgeries or placement of facial implants.
Chapter 5.4 Microtia
5.4.1 What is the indication for surgical treatment of ear
deformity in patients with craniofacial microsomia?
 The indication for auricular reconstruction in patients
with craniofacial microsomia is aesthetic and psycho-
social. Inform the patient about the potential benefits
and harms to ensure that the patient has a realistic view
of what can be expected.
 Provide all patients with craniofacial microsomia with
psychosocial support.
 Use the PROM Ear-Q pre- and postoperatively to assess
benefit of treatment.
5.4.2 What is the most optimal treatment modality for ear
deformity in patients with craniofacial microsomia related to its
timing?
 Patients should be treated within a multidisciplinary
team setting.
 Discuss the advantages and disadvantages of the various
treatment modalities with the patient and base the
choice for treatment on patients’ preferences.
 Psychological input is required pre- and postoperatively
to monitor expectation and acceptance.
 Ear reconstruction with rib grafts is the first choice
of treatment.
 Perform ear reconstruction with rib from the age of
eight onwards.
 Treatment before the age of eight is not recommended,
but if chosen, use external silicone prosthesis attached
with adhesives.
 If chosen, place polyethylene implants (Medpore) from
the age of six onwards.
 Osseointegrated implants are an option for
salvage procedures.
 Outcome measures should be obtained pre- and
postoperatively with all techniques and interventions.
Chapter 6 What are the minimal care standards to treat
patients with craniofacial microsomia and how should outcomes
of care be monitored?
Information
 The multidisciplinary team should provide information
regarding the condition and treatment options based on
the present craniofacial microsomia guideline in their
own language.
Referral
 Patients should be referred to the multidisciplinary
craniofacial microsomia team in a timely manner.
Collaboration
 Care for patients with craniofacial microsomia should
be delivered by the multidisciplinary team.
 The clinical pathway based on this guideline should
be followed.
Communication
 Communication between and within teams (also in
different hospitals) should be initiated to facilitate the
best possible treatment. A contact person in each centre
- a care coordinator - clarify and facilitate communica-
tion between different institutions and within her/his
own institution.
Conditions
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A craniofacial centre has access to the following care
facilities:
 (3D)photography, roentgen, CT, MRI, 3D-planning
facility
 Paediatric ICU




 Continuity of care should be ensured for patients with
craniofacial microsomia who reach adulthood.
Centralisation
 Patients with craniofacial microsomia are only treated
for craniofacial microsomia-related difficulties in a
centres that meets the criteria (including volume of
care) defined by the ERN-CRANIO.
Monitoring
 Patient measure should be performed as stated in
each chapter.
 Adhere to the ERN-CRANIO registry.
CHAPTER 1. INTRODUCTION
1.1 Incentive for making the guideline
Craniofacial microsomia (CFM) is estimated to occur in 1:3000
to 1:5000 live births and is the second most common congenital
disorder of the face after cleft lip and palate (1). Diagnosis,
treatment and outcome assessment is challenging due to a wide
phenotypic spectrum (1). The diagnosis is based on clinical
assessment, and no clear diagnosis criteria exist. As a result,
treatment options vary within and among different European coun-
tries and are often based on expert opinion. So far, no international
guideline has been developed. Since practice and expert opinions
vary, it is relevant to discuss the available literature, current practice
and current experiences with different healthcare professionals in
Europe. An international guideline will result in a more aligned and
uniform organisation of care for patients with CFM European
countries.
1.2 Purpose of the guideline
There is a need to establish an international guideline regarding
patients with CFM in collaboration with a number of European
countries due to the wide phenotypic spectrum and variety of
diagnostic criteria and treatment options for CFM. The guideline
should fit the current practice in the countries involved and will give
healthcare professionals tools to align and standardise healthcare in
their own country and in other European countries.
The guideline can support healthcare professionals in discuss-
ing the use of certain techniques or instruments with other health-
care professionals or their national council. In addition, this
guideline will provide CFM patients (and their parents) and
healthcare professionals with an overview of the optimal care
concerning the various and multidisciplinary aspects of craniofa-
cial microsomia.
1.3 Scope of the guideline
The guideline focusses on all patients with CFM. This includes
patients with Goldenhar syndrome, hemifacial microsomia, oculo-
auriculo-vertebral spectrum/dysplasia and facio-auriculo-vertebral
sequence. The guideline will focus on the various and multidisci-
plinary aspects of CFM.
Recommendations on the following questions are provided in
this guideline:
Chapter 3 – Diagnostic criteria for craniofacial microsomia
3.1 Based on which criteria is a child or adult with craniofacial
microsomia diagnosed?
Chapter 4 – Screening, monitoring and indication for treatment
4.1 Breathing difficulties in craniofacial microsomia
4.2 Feeding difficulties in craniofacial microsomia
4.3 Speech difficulties in craniofacial microsomia
4.4 Hearing difficulties in craniofacial microsomia
4.5 Eye anomalies in craniofacial microsomia
4.6 Dental deformities in craniofacial microsomia
4.7 Vertebral anomalies in craniofacial microsomia
4.8 Psychosocial difficulties in craniofacial microsomia
Each chapter includes the following questions:
4.-.1 What is the type, prevalence and severity of .. difficulties
in craniofacial microsomia?
4.-.2 What is the policy for screening and monitoring of ..
difficulties in patients with craniofacial microsomia?
4.-.3 What are the indications and policy for treatment of ..
difficulties in patients with craniofacial microsomia?
Chapter 5 – Surgical treatment of craniofacial microsomia
5.1 Mandible & Maxilla
5.1.1 What is the indication for surgical treatment of
mandibular and maxillary deformity in patients with craniofacial
microsomia?
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5.1.2 What is the most optimal treatment modality and its
timing for mandibular/maxillary deformity in craniofacial
microsomia regarding severity, breathing difficulties, occlusal
problems and aesthetics?
5.2 Facial nerve
5.2.1 What is the indication for surgical treatment of facial
nerve anomaly in patients with craniofacial microsomia?
5.2.2 What is the most optimal treatment modality for facial
nerve anomaly in patients with craniofacial microsomia related to
functional deficits and aesthetics?
5.3 Soft tissues
5.3.1 What is the indication for surgical treatment of soft tissue
deficiency in patients with craniofacial microsomia?
5.3.2 What is the most optimal treatment modality for soft
tissue deficiency in patients with craniofacial microsomia related
to severity and its timing?
5.4 Microtia
5.4.1 What is the indication for surgical treatment of ear
deformity in patients with craniofacial microsomia?
5.4.2 What is the most optimal treatment modality for ear
deformity in patients with craniofacial microsomia related to its
timing?
Chapter 6 – Organisation of care
6.1 Minimal care standards and monitoring outcomes
6.1.1 What are the minimal care standards to treat patients with
craniofacial microsomia and how should outcomes of care be
monitored?
1.4 Relationship to other congenital facial
malformations
The facial characteristics of patients with CFM show an overlap
with other craniofacial anomalies, such as facial clefts or Treacher
Collins (mandibulofacial dysostosis). These patients experience
similar difficulties due to the underdevelopment of craniofacial
structures, such as the mandible, midface, eyes and/or ears (2). This
may include difficulties with breathing, feeding, speech, hearing,
and/or developmental delay. Potential screening and treatment and
the multidisciplinary approach needed for these patients has overlap
with the policy for patients with CFM. This guideline might be
helpful to organise and optimise care for patients with similar
craniofacial characteristics.
1.5 Intended users of the guideline
This guideline is primarily written for all healthcare profes-
sionals involved in the care for patients with CFM, including:
paediatricians, oral and maxillofacial surgeons, plastic surgeons,
orthodontists, otorhinolaryngologists, neurosurgeons, orthopaedic
surgeons, ophthalmologists, anaesthesiologists, geneticists, psy-
chologists, and speech therapists. Secondly, this guideline is made
to provide patients and parents or other persons who are involved in
the medical care of adults or children with CFM with more
information about the care process.
1.6 About craniofacial microsomia
Craniofacial microsomia (CFM) is one of the most common
congenital conditions treated in craniofacial centres worldwide. It is
a heterogeneous congenital disorder which is characterised by a
unilateral or bilateral underdevelopment of the structures arising
from the first and second pharyngeal arch. The mandible, zygoma,
ears, facial soft tissue, orbits, and facial nerve may be underdevel-
oped in patients with CFM and extracranial anomalies such as
vertebral, renal or cardiac anomalies may be present. The cause of
this condition is unknown, though CFM has been associated with
prenatal exposures and genetic abnormalities (1). No clear diag-
nostic criteria exist. Although microtia is common in patients with
CFM, it is still debated in literature whether isolated microtia is a
separate entity or part of the CFM ‘spectrum’ (3, 4).
1.7 European Reference Networks
European Reference Networks (ERNs) are virtual networks of
healthcare providers from across Europe. The networks aim to pool
expertise on complex and rare diseases and concentrate knowledge
and resources. There are 24 ERNs, each focusing on a particular
disease area. ERN-CRANIO focuses on rare and/or complex cra-
niofacial anomalies and ear, nose and throat (ENT) disorders. More
information and updates can be found on the website of the ERN-
CRANIO: https://ern-cranio.eu/
ERN-CRANIO seeks to facilitate cooperation between multi-
disciplinary experts across Europe to support the provision of high-
quality care. It is a multidisciplinary network of highly specialised
healthcare professionals. The name ‘subgroup’ will be used when
referring to all healthcare professionals incorporated in the ERN-
CRANIO.
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CHAPTER 2. METHODOLOGY
2.1 Validity of the guideline
The board of the ERN-CRANIO will determine whether the
guideline is still up to date in 2025. If necessary, a new workgroup
will be installed to review the guideline or some of its chapters. The
validity of the guideline will expire sooner if new developments are
of large influence on the current guideline.
The ERN-CRANIO is primarily responsible for the validity of
the guideline. The cooperating associations share the responsibility
and inform the ERN-CRANIO when new developments are of
influence on the guideline.
2.2 General information
The development of this guideline was supported by Qualicura,
an independent consultancy firm that develops medical guidelines.
2.3 Aim and target audience guideline
2.3.1 Aim of the Guideline
The aim of this guideline is to provide healthcare professionals
and patients (and parents of patients) with craniofacial microsomia
(CFM) with an overview of the optimal care concerning the various
and multidisciplinary aspects of CFM and offer with recommenda-
tions to improve health outcomes and organisation of care.
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2.3.2 Target audience
 Healthcare professionals dealing with craniofacial micro-
somia
 Patients with craniofacial microsomia and parents of patients
2.3.3 Patient population
Patients with CFM or syndromes that are considered to be a
variant of CFM. These are: hemifacial microsomia, Goldenhar
syndrome, oculo-auriculo-vertebral spectrum/dysplasia or facio-
auriculo-vertebral sequence. According to the Orphanet, Snomed
and ICD10 coding systems, this considers:
Orphanet: ORPHA:374; ORPHA:141132; ORPHA:141136;
ORPHA:2549
Snomed: 367462009; 109393007; 15557005; 205418005;
254026007; 254025006; 254027003
ICD10: Q75.8; Q87.0; Q75.9
2.4 Steering group
A multidisciplinary steering group was appointed to develop the
guideline in November 2018. The members of the steering group are
primarily members of the subgroup ERN-CRANIO. The guideline
steering group consisted of eight professionals specialised in maxillo-
facial surgery and plastic surgery. Professionals represented the fol-
lowing countries: the Netherlands, the United Kingdom, France, Spain,
and Finland. The guideline steering group was chaired by a maxillofa-
cial surgeon. The literature search and the grading of the literature was
performed by a research fellow, R.W. Renkema. The literature review
and its conclusions were also written by R.W. Renkema. The review of
literature and discussion with the steering group led to the final
recommendations and considerations. These were written by R.W.
Renkema. Qualicura was responsible for the coordination and meth-
odological quality of the guideline development process. The steering
group members were mandated by their professional organisation.
Steering group
- Prof. E.B. Wolvius, MD, DMD, PhD, maxillofacial surgeon,
Erasmus Medical Center, Rotterdam, the Netherlands
- Prof. I.M.J. Mathijssen, MD, PhD, plastic surgeon, Erasmus
Medical Center, Rotterdam, the Netherlands
- Dr. A.I. Romance, MD, DMD, maxillofacial surgeon, Hospital
12 de Octobre, Madrid, Spain
- Dr. M.S.M. Muradin, MD, DMD, PhD, Maxillofacial surgeon,
Utrecht Medical Center, Utrecht, the Netherlands
- Dr. R.H. Khonsari, MD, PhD, maxillofacial surgeon, Hôpital
Necker des Enfants Malades, Paris, France
- Dr. N.W. Bulstrode, MBBS, BSc(Hons), MD, FRCS(Plast),
Plastic surgeon, Great Ormond Street Hospital, London,
United Kingdom
- Dr. T. Pihlamaa, MD, PhD, plastic surgeon, Helsinki University
Hospital, Helsinki, Finland
- Drs. R.W. Renkema, MD, research fellow, Erasmus Medical
Center, Rotterdam, the Netherlands
Supported by
- Dr. L.F.J. Welling - van Overveld, MSc, PhD, guideline
methodologist, Qualicura, Breda, the Netherlands
- Drs. V.R. Krones, MSc, guideline methodologist, Qualicura,
Breda, the Netherlands
- Drs. E.L. Weissbach, nurse specialist, Erasmus Medical Center,
Rotterdam, the Netherlands
Experts on each topic of the guideline were consulted to review
the chapters and write recommendations:
- Dr. K. Joosten, MD, PhD, pediatrician, Erasmus Medical Center,
Rotterdam, the Netherlands
- N. Prendeville, MRes, MSc, MRCSLT, Speech and Language
therapist, Great Ormond Street Hospital NHS Foundation Trust,
London, United Kingdom
- N. Behari, N. Behari, MECI, MRCSLT, speech and language
therapist, Great Ormond Street Hospital NHS Foundation Trust,
London, United Kingdom
- Dr. M.P. Van der Schroeff, MD, PhD, otolaryngologist, Erasmus
Medical Center, Rotterdam, the Netherlands
- Dr. S.E. Loudon, MD, PhD, ophthalmologist, Erasmus Medical
Center, Rotterdam, the Netherlands
- Dr. E. Ongkosuwito, DDS, PhD, orthodontist, Radboud
University Medical Centre, Nijmegen, the Netherlands
- Dr. B.S. Harhangi, MD, PhD, neurosurgeon, Erasmus Medical
Center, Rotterdam, the Netherlands
- Drs. C. Moffat, clinical psychologist, NHS Lothian, Scotland,
United Kingdom
- Drs. N. Rooney, clinical psychologist, Great Ormond Street
Hospital, London, United Kingdom
2.5 Conflicts of interest
All members of the steering group declared their conflicts of
interest. An overview is given in Table 1.
Table 1. Overview of conflicts of interest.
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Dr. A.I. Romance Maxillofacial surgeon None None None None None None
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Dr. R.H. Khonsari Maxillofacial surgeon None None None None None None
Dr. N.W. Bulstrode Plastic surgeon Will follow Will follow Will follow Will follow Will follow Will follow
Dr. T. Pihlamaa Plastic surgeon Private practice, Plastic
surgeon, Pihlajalinna
Tilkka Hospital & Plastic
Surgery Center, Helsinki,
Finland
None None None None None
Drs. R.W. Renkema Research fellow None None None None None None




None None None None None None
Drs. V.R. Krones Guideline methodologist None None None None None None
Prof. dr. K. Joosten Paediatric-intensivist None None None None None None
N. Prendeville Specialist speech and
language therapist
None None None None None None
N. Behari Specialist speech and
language therapist
None None None None None None
Dr. M.P. Van der
Schroeff
Otolaryngologist None None None None None None
Dr. S.E. Loudon Paediatric
ophthalmologist
None None None None None None
Dr. E. Ongkosuwito Orthodontist Deputy director of the
Postgraduate training in




Medical Center, Nijmegen, the
Netherlands
Private practice in Orthodontics,
Orthopraktijk Capelle,
Capelle aan den ljssel, The
Netherlands
None None None None None
Dr. B.S. Harhangi Neurosurgeon None None None None None None
Dr. C. Moffat Clinical psychologist Will follow Will follow Will follow Will follow Will follow Will follow
Dr. N. Rooney Clinical psychologist None None None None None None
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2.6 Patient perspectives
Since the guideline will be developed for patients and parents
of patients, the patient perspective will be of major importance in
this guideline. The perspective of patients was included by
analysing relevant bottlenecks from the online survey (see
Chapter 2.8.1).
2.7 Implementation
The implementation of the guideline and the practical feasibility
of the recommendations were taken into account during the differ-
ent phases of guideline development. In doing so, explicit consid-
eration was given to factors that could promote or hinder the
implementation of the guideline in practice.
2.8 Methods
2.8.1 Bottleneck analysis
A draft list of bottlenecks from a professional perspective was
written by the chair and vice chair. Members of the steering group
were asked to give feedback on the draft bottleneck analysis. The
first set of bottlenecks were discussed during the first international
conference in February 2019. No additional chapters were added
regarding the bottlenecks of the professionals.
All doctors included in the ERN-CRANIO, subgroup ‘craniofa-
cial microsomia’, were asked to approach their CFM patients. This
led to the identification of a group of 32 interviewees: 14 from Italy,
13 from Germany, 4 from the Netherlands, and 1 from Sweden,
including 9 patients and 23 parents of patients. An online survey
was set up with open and closed questions. All patients and parents
of patients were asked what difficulties they (had) experienced in
the healthcare process and in their lives. The questionnaire was built
up according to the proposed guideline chapters and the healthcare
process, namely diagnosis and referral, organisation of care, com-
munication and information, breathing difficulties, feeding diffi-
culties or speech difficulties, surgical treatments, care for microtia,
orthodontic treatment, vertebral anomalies, psychosocial aspects of
care, and follow-up. Additionally, all patients were asked to name
the top three difficulties they experienced in the care process.
Results were analysed by the research fellow (R.W. Renkema)
and nurse specialist (E.L. Weissbach). Most frequently mentioned
difficulties included difficulties in receiving adequate information
on the diagnosis and the treatment, difficulties in getting referred to
an experienced medical centre, and absence of psychological care.
Based on the patient perspectives, a chapter on psychosocial
difficulties was added. Other relevant bottlenecks were included
in the chapter on organisation of care.
Bottlenecks of both patients and specialists were forwarded to
relevant people in participating countries in March 2019, giving
them the opportunity to give feedback on the bottlenecks. After-
wards, a draft framework of the guideline was set up and questions
and outcomes were formulated.
2.8.2 Questions and outcomes
The bottleneck analysis formed the basis for the questions for the
guideline. The questions were formed according to the PICOT
Framework and presented in each guideline chapter. To maintain a
clear and readable chapter, questions in the guideline were formu-
lated in a broad and clinically relevant way. The terms for and more
specified questions to facilitate the literature search were specified
in the summary of literature and Appendix 1, http://links.lww.com/
SCS/B697.
The guideline is divided into a non-surgical and surgical part.
Questions for the non-surgical chapters (Chapter 4 (4.1 to 4.8)) are
formulated in a similar way. Likewise, questions for the surgical
chapters (Chapter 5 (5.1 to 5.4)) are also formulated in a
similar way.
For questions in the surgical chapters specific patient outcomes
such as aesthetic results, quality of life, or complications were
formulated. The patient outcomes were described in the summary of
literature. Patient outcomes were taken into account when formu-
lating the recommendations. In addition, patients’ outcomes were
included in the summary of literature when they were reported
in literature.
2.8.3 Literature search and selection of literature
One systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient
quality:
- The question in the
systematic review matches the
question of the guideline.
- The search of the systematic
review was conducted in at
least two relevant databases,
such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was
reported.
- No relevant items were
missing in the search strategy.
Type of patients - Patients with craniofacial
microsomia
Subject - Psychosocial functioning/
difficulties, neurodevelopment
Exclusion criteria - Original studies with< 10
included patients






A total of 1,747 articles were screened on title and abstract. Most
articles (1,488) were excluded and 259 articles were reviewed on
full text. A total of 101 articles were included in the guideline.
The selected studies were categorised according to the frame-
work of the guideline.
No narrative reviews were taken into account except for Chapter
4.5, 5.2, and 5.3. Since there was hardly any evidence, the available
narrative review was of importance.
For a couple of chapters, hardly no evidence was found. In these
cases an additional literature search was performed, regarding a
specific treatment in a different patient population for example. The
full extra search strategy is reported in the supplementary material.
Table 5 gives an overview of the chapters for which an additional
literature search was performed. In a couple of chapters, additional
literature is only included in the considerations and/or the rationale.
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2.8.4 Quality assessment of individual studies
Individual studies were systematically assessed, based on pre-
established methodological quality criteria, in order to estimate the
risk of biased study results. The evidence table of all individual
studies is displayed in Appendix 6, http://links.lww.com/SCS/
B697.
2.8.5 Summary of literature
The most important findings from the literature were described
in the summary of literature. Literature with a high risk of bias was
found for a number of chapters and hardly any evidence was found
for a couple of chapters. Percentages were rounded in the conclu-
sions. The steering group decided to include expert opinions for the
chapters with hardly any evidence. Therefore, specific experts on
each topic of the guideline were consulted to review the chapter. In
addition, experts were asked to write considerations and recom-
mendations to initiate the discussion during the meeting in
September 2019. In the end, all written text was discussed during
the meeting in September 2019.
2.8.6 Quality of evidence
The quality of evidence for included studies was assessed using
the EBRO method. The methodological quality of individual
studies was categorised in five levels (Table 2), the level of
evidence was categorised in four levels (Table 3) and grading
of the study was categorised in four levels (Table 4). The level
of conclusion was not assessed for studies referring to prevalence.























who have all had
























research but not with
all characteristics




C Not comparative research
D Opinion of experts
This classification only applies in situations were controlled trials are not possible
for ethical reasons. If they are possible, then the classification applies to interventions.
Table 3. Level of conclusion
Conclusion based on
1 Research of level A1 or at least two independent
studies of level A2
2 One study of level A2 or at least two independent
studies of level B
3 One study of level B or C
4 Opinion of experts
Table 4. Grading of qualitative research
Level Study
þþ Credible meta-synthesis (meta-ethnography, qualitative meta-analysis,
meta-study) of qualitative studies
þ Credible studies
þ/- Studies in which the credibility is questionable
- Studies of low credibility
2.8.7 Formulating conclusions
For each chapter a conclusion was given when literature was
available. Conclusions are drawn on the basis of all studies
combined. If no literature was available, no conclusions
were drawn.
2.8.8 Considerations
To determine the strength and direction of a recommendation,
the following aspects were examined in addition to the quality of
evidence:
 Balance of benefits and harms
 Outcome importance
 Costs and resources
 Inequity of the recommendation
 Feasibility of the recommendation
 Acceptability of the recommendation
Conclusions were mostly written by the fellow (R. W.
Renkema) based on the available literature. When no evidence
was available, experts were consulted to write draft considerations.
The draft considerations were discussed in the meeting in
September 2019.
The steering group decided to include expert opinions for
the chapters with hardly any evidence. Therefore, specific
experts on each topic of the guideline were consulted to review
the chapters and to write recommendations and considerations
to initiate the discussion in September 2019. In the end, all
written text was reviewed and discussed by the steering
group. Table 5 gives an overview of the chapters with recom-
mendations written by an expert. For the remaining chapters,
the draft recommendations were written by the fellow (R.W.
Renkema).
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3.1 Based on which criteria is a child or adult with craniofacial microsomia diagnosed?
Yes
4.1 Breathing difficulties
4.1.1 What is the type, prevalence and severity of breathing difficulties in craniofacial microsomia?
4.1.2 What is the policy for screening and monitoring of breathing difficulties (OSA) in patients with
craniofacial microsomia?
4.1.3 What are the indications and policy for treatment of breathing difficulties (OSA) in patients
with craniofacial microsomia?
Yes, except for type of
breathing difficulties
No
Yes, except for indications of
breathing difficulties. That





4.2.1 What is the type, prevalence and severity of feeding difficulties in craniofacial microsomia?
4.2.2 What is the policy for screening and monitoring of feeding difficulties (OSA) in patients with
craniofacial microsomia?







4.3.1 What is the type, prevalence and severity of speech difficulties in craniofacial microsomia?
4.3.2 What is the policy for screening and monitoring of speech difficulties in patients with
craniofacial microsomia?





N. Prendeville, MRes, MSc,
MRCSLT
N. Behari, MECI, MRCSLT
4.4 Hearing difficulties
4.4.1 What is the type, prevalence and severity of hearing difficulties in craniofacial microsomia?
4.4.2 What is the policy for screening and monitoring of hearing difficulties in patients with
craniofacial microsomia?





Dr. M.P. van der Schroeff
4.5 Eye anomalies
4.5.1 What is the type, prevalence and severity of eye anomalies in craniofacial microsomia?
4.5.2 What is the policy for screening and monitoring of eye anomalies in patients with craniofacial
microsomia?










4.6.1 What is the type, prevalence and severity of dental deformities in craniofacial microsomia?
4.6.2 What is the policy for screening and monitoring of dental deformities in patients with
craniofacial microsomia?







4.7.1 What is the type, prevalence and severity of vertebral deformities in craniofacial microsomia?
4.7.2 What is the policy for screening and monitoring of vertebral deformities in patients with
craniofacial microsomia?







4.8.1 What is the type, prevalence and severity of psychosocial difficulties in craniofacial
microsomia?
4.8.2 What is the policy for screening and monitoring of psychosocial difficulties in patients with
craniofacial microsomia?







5.1 Mandible and Maxilla
5.1.1 What is the indication for surgical treatment of mandibular and maxillary deformity in patients
with craniofacial microsomia?
5.1.2 What is the most optimal treatment modality and its timing for mandibular/maxillary deformity in









5.2.1 What is the indication for surgical treatment of facial nerve anomaly in patients with
craniofacial microsomia?
5.2.2 What is the most optimal treatment modality for facial nerve anomaly in patients with








with an extra literature
search
5.3 Soft tissue
5.3.1 What is the indication for surgical treatment of soft tissue deficiency in patients with
craniofacial microsomia?
5.3.2 What is the most optimal treatment modality for soft tissue deficiency in patients with




5.4.1 What is the indication for surgical treatment of ear deformity in patients with CFM?
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2.8.9 Formulating recommendations
The recommendations provide an answer to the basic question and
are based on the best available scientific evidence and the most
important considerations. The strength of the scientific evidence and
the weight that the working group assigns to the considerations
together determine the strength of the recommendation. In accor-
dance with the EBRO method, a low probative value of conclusions in
the systematic literature analysis does not exclude a strong recom-
mendation in advance, and weak recommendations are also possible
with a high probative value. The strength of the recommendation is
always determined by weighing all relevant arguments.
Recommendations were mostly written by the fellow (R.W.
Renkema) based on the available literature. When no evidence was
available, experts were consulted to write draft recommendations.
The draft recommendations were discussed in the meeting in
September 2019.
2.8.10 Conditions (organisation of care)
The bottleneck analysis and the development of the guideline
explicitly take into account the aspects related to organisation of
care. This contains all aspects that are preconditions for providing
care, such as coordination, communication, (financial) resources,
manpower and infrastructure. More general, overarching, and
additional aspects of the organisation of care are discussed in
Chapter 6.
2.8.11 Knowledge gap
During the development of this guideline a systematic literature
search was performed to answer the questions. For each question the
steering group investigated whether (additional) scientific research
is necessary. An overview of recommendations for further research
can be found in Chapter 7.
2.8.12 Evaluation and authorisation phase
The draft guideline was submitted to all craniofacial centres
involved in the care for patients with CFM and affiliated with the
ERN-CRANIO. The comments were collected and discussed with
the steering group. As a result of the comments, the draft guideline
was adapted and finally adopted by the steering group.
CHAPTER 3. DIAGNOSTIC CRITERIA FOR
CRANIOFACIAL MICROSOMIA
Introduction
In patients with craniofacial microsomia (CFM), the facial struc-
tures arising from the first and second pharyngeal arches may be
underdeveloped. The characteristic features are malformation, hypo-
plasia or aplasia of the outer and inner ear, orbit, zygoma, maxilla,
mandible, facial musculature, facial nerve, and/or soft tissue, but
extracraniofacial anomalies may be present as well (1, 2). The variety
in type and severity of underdevelopment of these structures make
CFM a heterogeneous disorder. The diagnosis of CFM is based on
clinical assessment, though no clear diagnostic criteria exist.
Various classification models have been proposed to categorise
patients with CFM based on its severity (3–8). The most commonly
used system is the O.M.E.N.S. classification, which describes the
degree of hypoplasia of the Orbit (O), Mandible (M), Ears (E),
Facial Nerve (N), and Soft Tissue (S) (2, 3). Extracraniofacial
anomalies, facial clefting, canting of the occlusal plane, and
detailed assessment of eye and ear anomalies is included in this
classification as well (2, 9). A more detailed classification of the
mandibular deformity, based on radiography, was proposed by
Pruzansky and later subcategorised by Kaban (5, 10, 11). In this
classification model the level of underdevelopment of the mandible
is graded as I, IIA, IIB, and III.
A wide range of terminology is used to refer to patients with
CFM: hemifacial microsomia, Goldenhar syndrome, oculo-auri-
culo-vertebral spectrum or dysplasia, first and second branchial
arch syndrome, or facio-auriculo-vertebral syndrome or sequence.
The term CFM is preferred for two main reasons. Firstly, as slightly
more than 10% of the patients with CFM are bilaterally affected the
term hemifacial microsomia (HFM), which has been commonly used,
is not considered to cover the extensiveness of the syndrome (9, 12).
Secondly, the side that has the more significant hypoplasia causes
deformity on the contralateral side making this a condition that affects
both sides. Therefore CFM is a more precise term.
Microtia is an important and common aspect of patients with
CFM. Whether patients with isolated microtia fit the diagnosis CFM
is still being debated (1, 4, 13, 14). Some authors advocate the
inclusion of patients with isolated microtia as CFM, as the cause and
types of ear malformations are similar in both groups. In addition,
the incidence of ear malformations found in family members of
patients with CFM is much higher than in the general population
(15). However, no consensus has been reached.
Goldenhar syndrome was originally regarded as an association
of mandibular dysostosis, ear malformations and epibulbar der-
moids (16). Although there are no clear diagnostic criteria for
Goldenhar syndrome, currently the diagnosis is often seen as
CFM with the additional presence of epibulbar dermoids and
vertebral/cervical spine anomalies (the triad of Goldenhar). Some
consider the diagnosis Goldenhar syndrome to be an entity distinct
from CFM, while others include Goldenhar syndrome as a variant of
CFM (15, 17). However, no consensus exists.
Another term used to describe patients with CFM is the oculo-
auriculo-vertebral spectrum or dysplasia (OAVS) (18). OAVS is
often used to describe the expanded spectrum of CFM including
facial malformations such as macrostomia or epibulbar dermoids,
and extracraniofacial anomalies. Again, no consensus on diagnostic
criteria exists.
The use of different terminology and lack of diagnostic criteria is
confusing for patients and healthcare professionals. Therefore, the
following question was posed:
3.1 On which criteria is a child or adult with
craniofacial microsomia diagnosed?
Uniform terminology would be helpful to provide better infor-
mation to patients and increase awareness of the disorder. Addi-
tionally, it would be beneficial for the communication between
professionals and patients, between healthcare professionals, and in
research projects.
Literature search
A systematic search was performed to identify all available
literature on craniofacial microsomia and synonyms. The search
was conducted in Embase, Pubmed/Medline Ovid. The full search
strategy is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the question of
the guideline.
- The search of the systematic review was conducted in at least
two relevant databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with craniofacial microsomia
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Subject - Diagnosis, diagnostic criteria
Exclusion criteria - Original studies with< 10 included patients






All articles were screened on title and abstract. Literature on the
diagnosis of CFM or synonyms was included. A total of four articles
were included: a case-control study by Heike et al. (19), a retro-
spective cohort study by Caron et al. (20), and two retrospective
cohort studies by Tuin et al. (21, 22). Additional documents on
diagnostic criteria available in the International Consortium for
Health Outcomes Measurement (ICHOM) Craniofacial Microso-
mia were included as well (23).
3.1 Based on which criteria is a child or adult
with craniofacial microsomia diagnosed?
The literature search for this question was directed towards more
specific questions related to classification scores, the correlation of
abnormalities, clusters within CFM, and Goldenhar syndrome
(Appendix 1, http://links.lww.com/SCS/B697).
Review of literature
Classification score and clusters within craniofacial
microsomia
A case-control study, set up by Heike et al. (19), aimed to develop
a standardised approach to assess and describe facial characteristics
of a study cohort. A total of 142 patients with CFM and 316 healthy
controls were included. The assessment of the O.M.E.N.S. score was
performed in both groups. This led to the observation that orbital
displacement (O) was found in 40% of the patients with CFM, but in
20% of the controls as well. Abnormal orbital size was less frequently
found in controls (1%), but in 13% of the patients with CFM. The
authors advocate a threshold for an ‘affected’ orbit (O) that requires
both displacement and an abnormal size, consistent with an ‘O-3’
score. Mild mandibular hypoplasia (M) was present in 25% of the
cases and 12% of the controls. Therefore, the threshold for mandibu-
lar hypoplasia (M) was set on grade 2 or higher. Similarly, mild ear
malformations (E) were present in 15% of the cases and 5% of the
controls and the threshold for microtia (E) was set on grade 2 or
higher. The threshold for soft tissue deformity (S), which was present
in 34% of the patients and 5% of the controls, was set on grade 2 or
higher. These results show that mild facial deformities are also
present in the normal population, which should be taken into account
in diagnosing CFM. The authors define four groups of CFM (19).
First, the patients with microtia only. Secondly the patients with
microtia and mandibular hypoplasia. Thirdly, patients with more than
two CFM features (i.e. epibulbar dermoid, facial tags, macrostomia,
orbital deformity, facial nerve palsy), but not with the combination of
both microtia and mandibular hypoplasia. And lastly, an atypical
CFM group that has fewer than two CFM features and no microtia.
The components of the O.M.E.N.S score in patients with CFM
were studied by Tuin et al. (21). Their retrospective study included
105 patients. Most of the included patients had an ear deformity
(92%), mandibular abnormality (88%) and/or soft tissue deficiency
(77%). Facial nerve abnormalities and orbital deficiency or dis-
placement were less common, and present in 39% and 28% of the
patients, respectively. Logistic regression showed a significant
correlation between the orbit, mandible and soft tissue score;
between the soft tissue score and the ear deformity; and between
the ear deformity and facial nerve. This study shows that there may
be clusters of patients within CFM. The authors suggest that this
may be due to their shared origin, since the orbit, mandible and soft
tissue originate from the first pharyngeal arch, and the ear and facial
nerve from the second pharyngeal arch (21).
To study any clusters within CFM, a large retrospective study was
performed by Caron et al. (20). A total of 755 patients were included.
In this study, mandible (91% of the patients), soft tissue (82%) and ear
(83%) deformities were most common. Orbital malformation was
present in 45% of the patients. The facial nerve score could only be
assessed in 238 patients (32%), of which 34% had a paresis. The
authors investigated the presence of any clusters within the studied
cohort by using principle component analysis. A correlation between
the severity of the mandibular deformity, orbital deformity and soft
tissue deficiency was found. The analysis did not show any specific
clusters within CFM. Interestingly, an analysis on patients with data
on the ‘triad of Goldenhar’ (mandibular hypoplasia, epibulbar der-
moids and vertebral anomalies) showed no correlation among these
three variables. Therefore, the authors conclude that the term Gold-
enhar syndrome should be discarded. Also, the absence of clusters
suggest that CFM is a continuum of anomalies including different
types and severities (20).
Goldenhar syndrome
The use of the term Goldenhar syndrome in general practice was
assessed in more detail by Tuin et al. (22). A total of 138 patients with
CFM were retrospectively included. Thirty-four percent of the patients
had vertebral anomalies, 17% epibulbar dermoids and 7.2% a combi-
nation of these. Although only 7.2% of the patients fit the ‘criteria’ for
Goldenhar syndrome, 32% were diagnosed with the syndrome accord-
ing to clinical records. Eighty percent of the patients with epibulbar
dermoids and vertebral anomalies were diagnosed with Goldenhar
syndrome. The authors found that the term Goldenhar syndrome was
used significantly more often for patients with bilateral CFM, or a more
severely affected mandible or soft tissue deformity. Patients with
epibulbar dermoids and vertebral anomalies had no differences in
severity of the facial deformities compared to the patients without these
anomalies. The authors conclude that the term Goldenhar syndrome is
often misused for patients with a more severe form of CFM and show
that Goldenhar syndrome is part of the CFM spectrum instead of a
distinct condition (22).
International criteria
The International Consortium for Health Outcomes Measure-
ment (ICHOM) started an initiative to gather prospective informa-
tion on patients with CFM on set time points (23). The members of
the ICHOM Craniofacial Microsomia working group consisted of
healthcare professionals from around the world active in the care of
patients with CFM. This group reached consensus on diagnostic
criteria for CFM, to be used to include patients in their dataset. The
following diagnostic criteria are used:
Table 1. Diagnostic criteria CFM, by ICHOM Craniofacial
Microsomia (23)
CFM defined as: 2 major criteria, or
1 major þ 1 minor criteria, or
3þ minor criteria
Major criteria Mandibular hypoplasia
Microtia
Orbital / facial bone hypoplasia
Asymmetric facial movement
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Conclusions
Level 3 Correlation and clusters
In patients with craniofacial microsomia the mandibular
deformity, orbital deformity and soft tissue deficiency are
correlated. However, no specific clusters of patient groups
within craniofacial microsomia are present, indicating
craniofacial microsomia is a continuum of anomalies.
Ref (20, 21)
Level 3 Goldenhar syndrome
Goldenhar syndrome is not a separate diagnosis from craniofacial
microsomia but is part of the phenotypic spectrum of
craniofacial microsomia:
 Clinically, patients diagnosed with Goldenhar syndrome
have a more severe facial deformity compared to patients with
craniofacial microsomia.
 Objectively, by using the O.M.E.N.S. score, no
differences are present in the severity of facial anomalies in
patients with craniofacial microsomia compared to patients
with the triad of Goldenhar syndrome (craniofacial
microsomia þ epibulbar dermoids þ vertebral anomalies).
 No correlation exist between the triad of Goldenhar
syndrome (craniofacial microsomia þ epibulbar dermoids þ
vertebral anomalies).
 A substantial number of patients with the triad of
Goldenhar syndrome (craniofacial microsomia þ epibulbar




 Overall quality of evidence
Two studies reported on correlations of facial deformities in
patients with CFM, based on the O.M.E.N.S. classification. The
correlation between the facial deformities was reported in both
studies. The studies are descriptive retrospective cohort studies and
were therefore graded on level 3 (20, 21).
Concerning the conclusions on Goldenhar syndrome, two stud-
ies were included as well. Both studies showed the absence of a
correlation between the triad of Goldenhar syndrome and concluded
that Goldenhar syndrome is part of CFM, instead of a variant. The
studies are descriptive retrospective cohort studies and were there-
fore graded on level 3 (20, 22).
The diagnostic criteria proposed by the ICHOM Craniofacial
Microsomia group were based on consensus between healthcare
professionals (23). No research has been done to test the criteria.
Since CFM is a clinical diagnosis and no specific criteria exist for
CFM, verifying the criteria may be difficult. Since the criteria are
based on consensus and expert opinion, the evidence is graded on
level 5.
 Balance of benefits and harms
No harm is produced for the patients with CFM by applying the
diagnostic criteria. Unambiguous use of diagnostic criteria and
terminology promotes clarity for both patients and healthcare
professionals. Standardised use of the term CFM, by using clear
diagnostic criteria, helps patients receive the right diagnosis and
treatment, and improves access to information about the disease. In
research, clear use of terminology promotes the exchange of ideas
and findings.
 Outcome importance
The use of diagnostic criteria for CFM is considered to be of
importance to healthcare professionals to improve communication,
research, and provision of information to patients. Several recent
studies confirm that CFM is a continuum of anomalies and dis-
courage the use of the term Goldenhar syndrome. The consensus of
this steering group is to solely use the term CFM.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an expert
centre for CFM, or the level of provided care does not (yet) meet all the
requirements that are outlined in this guideline. By defining the
baseline of required care for CFM, this guideline will help these
member states to reach the appropriate level. The ERN on craniofacial
anomalies and ENT disorders (ERN-CRANIO) can guide a patient in
Europe to the available centres of expertise (www.ern-cranio.eu) and
can support care providers with diagnosis and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Since the evidence suggests no difference between CFM and
Goldenhar syndrome, OAVS, or hemifacial microsomia, the steer-
ing group advocate the use of a single term: CFM. To increase
awareness of this diagnosis and provide clarity for patients and
healthcare professionals, the diagnostic criteria agreed on by the
‘ICHOM Craniofacial Microsomia’ working group are recom-
mended for use in practice.
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Recommendations
Terminology
 It is advised to exclusively use the term craniofacial
microsomia. Discard the use of other terms such as
Goldenhar syndrome, hemifacial microsomia or aur-
iculo-oculo-vertebral spectrum.
Diagnostic criteria
 It is advised to use the diagnostic criteria for craniofacial microsomia developed
by the ICHOM Craniofacial Microsomia group.
CFM is defined by: 2 major criteria, or
1 major þ 1 minor criteria, or
3þ minor criteria
Major criteria Mandibular hypoplasia
Microtia
Orbital / facial bone hypoplasia
Asymmetric facial movement
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.1 Breathing difficulties in craniofacial
microsomia
Introduction
Obstructive sleep disordered breathing (SDB) can be considered
to be a syndrome of upper airway dysfunction during sleep (1). It is
characterised by snoring and/or increased respiratory effort due to
increased airway resistance and pharyngeal collapsibility (2, 3).
Various clinical entities with intermittent upper airway obstruction
are included in obstructive SDB, such as: primary snoring, upper
airway resistance syndrome, obstructive hypoventilation, and
obstructive sleep apnoea (OSA) (4, 5). Polysomnography (sleep
study) is the golden standard to diagnose presence and severity of
sleep disordered breathing (SDB). Of the obstructive SDB entities,
OSA in particular is known to be of clinical significance as it relates
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to failure to thrive, morning headache, excessive daytime sleepi-
ness, decline of school achievements, feeding difficulties, upper
airway infections, hypertension, and may lead to metabolic, cogni-
tive and cardiovascular consequences (6). OSA is defined by a
disruption of the normal oxygenation, ventilation and sleep pattern
due to recurrent upper airway obstructions. The severity of OSA is
described by the Apnoea-Hypopnea Index (AHI).
The prevalence of OSA in children in the healthy population is
2–4%, and is thought to be caused by adenotonsillar hypertrophy,
obesity, or decrease in neuromuscular tone (7-10). Patients with
craniofacial microsomia (CFM) are at increased risk for obstructive
SDB and OSA due to the underdevelopment of the mandible, which
leads to obstruction of the upper airway. In addition, pharyngeal
and/or laryngeal anomalies may play a role in causing OSA in
patients with CFM (11, 12). Since OSA in patients with CFM relates
to congenital malformations, symptoms occur shortly after birth or
during childhood.
The European Respiratory Society provided a stepwise
approach to diagnose, manage and treat obstructive SDB and
OSA in children (1, 13). Treatment of OSA in patients with major
craniofacial abnormalities, such as CFM, is reported as a priority.
Obstructive SDB, including OSA, is treated by a stepwise approach
and can require pharmacological treatment such as nasal cortico-
steroids, non-surgical treatment by continuous positive airway
pressure (CPAP) or non-invasive positive-pressure ventilation
(NPPV), or surgical treatment such as adenotonsillectomy or
craniofacial surgery. In addition to the regular treatment modali-
ties, patients with CFM may require surgical correction of the
mandible by using mandibular distraction, costochondral grafting
or osteotomy (11).
To describe the policy for breathing difficulties in
patients with CFM the following questions were included in
this chapter:
4.1.1 What is the type, prevalence and severity of breathing
difficulties in craniofacial microsomia?
4.1.2 What is the policy for screening and monitoring of
breathing difficulties (OSA) in patients with craniofacial
microsomia?
4.1.3 What are the indications and policy for treatment of
breathing difficulties (OSA) in patients with craniofacial
microsomia?
Describing the policy for breathing difficulties in patients
with CFM is of importance since these patients are at increased
risk for OSA. Untreated OSA may lead to metabolic, cognitive
and/or cardiovascular pathology and can have a negative impact
on the quality of life. Therefore, timely diagnosis and treatment
of OSA in patients with CFM is considered of importance
to patients.
Definitions
The definitions of apnoea’s, hypopnea and OSA severity are
displayed in Appendix 4, http://links.lww.com/SCS/B697. This is
based on the Manual for the Scoring of Sleep and Associated Events
of the American Academy of Sleep Medicine (14). The severity of
OSA is graded according to the New Zealand Guideline for
obstructive sleep apnoea syndrome in children (15).
Literature search
A systematic search of literature was performed to identify all
available literature on CFM and synonyms. The search was con-
ducted in Embase, Pubmed/Medline Ovid. The full search strategy
is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the question of
the guideline.
- The search of the systematic review was conducted in at least
two relevant databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Breathing, airway, sleep
Exclusion criteria - Original studies with< 10 included patients






Literature was screened on title and abstract. A total of eight
articles were included. One systematic review by Caron et al. was
included (11). Five studies were retrospective cohort studies:
Szpalski et al. (6), Cohen et al. (16), Sculerati et al. (17), Sher
et al. (18), and Caron et al. (19). The other two included studies were
a cross-sectional study by D’Antonio et al. (12) and a case-control
study by Cloonan et al. (20).
4.1.1 What is the type, prevalence and severity of breathing
difficulties in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type (primary snoring, upper airway
resistance syndrome, obstructive hypoventilation, and OSA), prev-
alence and severity (mild, moderate or severe) of breathing diffi-
culties in CFM (Appendix 1, http://links.lww.com/SCS/B697).
Unfortunately, none of the included studies reported information
on the type of breathing difficulties in CFM. Studies only reported
on one of the types of breathing difficulties, OSA. Since this
question does not relate to interventions or diagnostics, no consid-
erations, rationale or recommendations are provided.
Review of literature
A systematic review on obstructive sleep apnoea by Caron et al. was
published in 2015. The aim of the study was to report the prevalence
and treatment modalities of OSA in patients with CFM. Six studies
describing the prevalence of OSA in CFM were included in the
systematic review. However, one study included fewer than ten patients
and was not taken into account in this guideline (21). The prevalence of
OSA in CFM varied from 7% to 24% (12, 16-18, 20). The number of
patients included in these studies varied from 38 to 124 patients. Most
studies were retrospective cohort studies and the diagnosis of OSA was
based on chart review and polysomnography. Although some studies
defined the used diagnostic criteria for OSA (16, 18), other studies did
not (12, 17, 20). Sculerati et al. included 41 patients of which 9 patients
required a tracheostomy (17). Therefore, the prevalence of OSA in this
study, which can be considered to be severe, is found to be 22%.
However, no additional data is available on the presence of OSA in the
other included patients. One of the other included studies analysed 124
patients with CFM and 349 controls (20). Patients with CFM had a
higher frequency of SDB (23% vs 9%, OR: 3.0, CI: 1.5–5.1,
p¼ 0.001), which includes OSA, compared to controls. None of the
included studies reported information on the type of breathing diffi-
culties in CFM. The severity of OSA and risk factors for OSA in
patients with CFM were assessed by multiple studies. Cloonan et al.
reported that patients with moderate/severe CFM presented more often
with snoring and SDB than patients with mild CFM. In this study, the
diagnosis mild, moderate or severe CFM was based on specialists’
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assessment of craniofacial anomalies. The prevalence of OSA was
found to be significantly higher in patients with a more severe form of
CFM, i.e. severe mandibular hypoplasia and/or bilateral involvement
(16, 20). Bilateral hearing loss or a more severe orbital deformity was
found to be a risk factor for OSA too (16).
Besides patients with bilateral CFM, patients with unilateral
CFM may be at risk for OSA too. Szpalski et al. included 62 patients
with unilateral CFM and retrospectively studied the prevalence of
OSA and any significant associations (6). Polysomnography was
only assessed in patients with signs or symptoms of OSA. The
severity of OSA was scored as defined in this guideline. The
reported prevalence of OSA in unilateral CFM was 11.3% (7 out
of 62 patients). Severe OSA was found in three patients, moderate
OSA in two patients, and two patients had mild OSA. Interestingly,
all patients with OSA had a mandibular deformity Pruzansky IIB or
higher. Of the six patients with unilateral CFM and a Pruzansky III
deformity only one patient did not have OSA.
A large, multicentre, retrospective study on obstructive sleep
apnoea in CFM was undertaken by Caron et al. in 2017 (19). This
study aimed to report the prevalence of OSA in CFM, study the
relationship of OSA and CFM severity and analyse treatment modal-
ities for OSA in CFM. The severity of OSA in children was defined as
follows: mild OSA, obstructive apnoea-hypopnea index (oAHI) 1-5;
moderate OSA, oAHI 5-24; severe OSA, oAHI >24. In adults the
criteria were: mild OSA, AHI 5-15; moderate OSA, AHI 15-30;
severe OSA, AHI >30. Of the 755 patients included, a total of 133
were reported to have OSA. Thus, the prevalence of OSA in CFM was
17.6%. OSA was diagnosed at a median age of 2.4 years (range 0–
25.8 years). Only five patients were adult patients (>18 years) at the
time of diagnosis. The severity of OSA was mild in 25 patients,
moderate in 22 patients, severe in 48 patients, and in 38 patients the
severity of OSA was unknown. Patients with bilateral CFM had a
higher prevalence of OSA than unilateral patients. Patient with a
Pruzansky IIB/III mandibular deformity, both uni- and bilateral, had a
higher prevalence of OSA than patients with Pruzansky I or IIA.
Severe OSA was thus found more frequently in patients with a
Pruzansky IIB/III deformity. Of the patients with a Pruzansky III
and OSA, OSA was severe in 52% of the cases.
Moraleda-Cibrián studied patients with various craniofacial mal-
formations who underwent PSG (22). Of the 153 patients included, 18
patients were diagnosed with CFM. After PSG, one patient did not
have OSA, 11 patients were diagnosed with mild OSA, 5 patients had
moderate OSA and one patient had severe OSA. No further informa-
tion on patient characteristics or specification of breathing difficulties
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Figure 1. Prevalence of OSA in CFM relative to sample size.
Conclusions
- Prevalence
The prevalence of obstructive sleep apnoea in craniofacial microsomia
is 7–24%, presumably approximating 18%.
Ref (6, 12, 16–20)
Level 3 Prevalence
Patients with bilateral craniofacial microsomia have a higher




Patients with a Pruzansky grade IIB or III mandibular deformity,
both unilateral or bilateral, have a higher prevalence of
obstructive sleep apnoea compared to patients with a
Pruzansky grade I or IIA.
Ref (6, 16, 19)
Level 3 Prevalence
The prevalence of severe obstructive sleep apnoea is higher in




The severity of obstructive sleep apnoea was mild in 19–29% of
cases, moderate in 17–29%, severe in 36–43%, and in 29%
the severity of obstructive sleep apnoea was unknown.
Ref (6, 19)
4.1.2 What is the policy for screening and monitoring of
breathing difficulties (OSA) in patients with craniofacial
microsomia?
This question was focussed on OSA since none of the included
studies reported information on other types of breathing difficul-
ties in CFM. Additionally, OSA is a diagnosis that is confirmed
with objective measures and is important to diagnose and/or treat
due to its clinical significance and potential consequences. The
literature search for this question was directed towards more
specific questions related to the consequences and impact of
screening and monitoring, the available screening tests and pro-
cedures for monitoring, and responsibilities for screening and
monitoring (Appendix 1, http://links.lww.com/SCS/B697). Unfor-
tunately, no literature is available on the policy for screening and/
or monitoring of OSA in patients with CFM. Therefore no con-
clusions were written. Considerations for this question were only
based on expert opinion.
Considerations
 Overall quality of evidence
The overall quality of evidence is low because there is no
literature available and therefore the recommendations are based
on expert opinion with a low quality of evidence.
 Balance of benefits and harms
Due to the high prevalence of breathing disorders all patients
with CFM should be screened for OSA. Patients who have Pru-
zansky-Kaban IIb or III mandibles and/or are bilaterally affected
should undergo a polysomnography because of the high risk of
developing OSA. Because OSA is associated with adverse outcome,
the benefits of screening outweigh the harms.
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 Outcome importance
Untreated OSA may have severe consequences in growth, daily
functioning and (cognitive) development. Therefore, screening and
monitoring at regular times is necessary.
 Costs and resources
The impact on costs and resources of the given recommendations
will vary per member state, depending on the available care providers
and facilities. The recommendations concern the essential require-
ments for adequate treatment of patients with CFM and should thus be
implemented. Costs are lowest and resources are most efficiently
used when care for craniofacial disorders is centralised in a limited
number of expert centres per member state. A general rule that can be
applied is one expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Undiagnosed or untreated OSA has been associated with learn-
ing impairment and behavioural problems such as daytime hyper-
activity, aggression or attention deficit hyperactivity disorder
(ADHD). More serious complications include neurologic and
developmental delay, failure to thrive, cardiovascular disease,
including pulmonary hypertension and right ventricular hypertro-
phy, and sudden death. Patients with OSA are at increased risk for
feeding difficulties (23). Several authors, including the European
Respiratory Society, have emphasised early and accurate diagnosis
of OSA by routinely screening patients who are at higher risk for
OSA such as patients with CFM. Biannual screening should be
performed by using the Paediatric Sleep Questionnaire (PSQ),
which is agreed on in the ICHOM Standard Set for Craniofacial
Microsomia (24). Screening should be performed at least up to the
age of six in the outpatient department. This questionnaire is free for
all healthcare organisations and a license is not needed.
Recommendations
 All patients with craniofacial microsomia should be
screened with a questionnaire biannually, at least up to
the age of six, in the outpatient department for a clinical
history of obstructive sleep apnoea.
 If there is a suspicion of obstructive sleep apnoea based
on a questionnaire, a polysomnography (sleep study)
has to be performed.
 All patients who have Pruzansky-Kaban IIb or III
mandibles and/or are bilaterally affected have to
undergo a polysomnography (sleep study) to screen
for obstructive sleep apnoea in the first year of life.
Research gap
Studies on the consequences of mild, moderate or severe OSA in
patients with CFM are not available. Future studies on detailed
assessment of PSG’s and the consequences of OSA in CFM are
needed.
4.1.3 What are the indications and policy for treatment of
breathing difficulties (OSA) in patients with craniofacial
microsomia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of breathing difficulties (Appendix 1, http://links.lww.-
com/SCS/B697). Unfortunately, no literature on the indications to
treat OSA based on its severity in patients with CFM is present.
However, descriptive studies on treatment modalities used for OSA
in patients with CFM are available. These studies may provide more
insight on the indications and policy for treatment of OSA in
patients with CFM and are thus included in this chapter. Therefore,
conclusions were only written for the policy for treatment of
breathing difficulties. Considerations for these questions were
based on both literature and expert opinion.
Review of literature
A systematic review by Caron et al. included twelve studies
involving treatment modalities for OSA in CFM (11). Most of these
studies were case reports or case series including fewer than ten
patients. Two of the included studies were included in this guide-
line (17, 18). Sculerati et al. studied 41 patients, of which nine
needed tracheostomy (17). No additional information on follow-up
treatment of OSA was provided. In the study by Sher et al., 84
patients with CFM were included; six patients were diagnosed with
OSA (18). All patients with OSA underwent nasopharyngoscopic
examination of the upper airway. In three patients there was a
circular constriction of the pharynx. Two of these patients required
tracheotomy and one patient refused treatment. Obstruction of the
upper airway due to posterior movement of the tongue to the
posterior pharyngeal wall was observed in two patients. Both
patients had a mandibular advancement. The last patient also
had an obstruction of the upper airway due to movement of the
tongue, but in this case the tongue compressed the soft palate
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causing closure in the oropharynx. This patient also required
tracheostomy. Caron et al. concluded that good literature on
non-surgical and/or surgical treatment modalities for OSA in
CFM is not available (11). Due to the lack of information no ideal
treatment plan for OSA in patients with CFM could be proposed.
One of the aims of the retrospective study by Caron et al. was to
analyse the treatment modalities of OSA and their outcomes in
patients with CFM (19). Of the 133 patients with OSA included,
102 required treatment, 20 patients were not treated, and of 11
patients the treatment status was unknown. Different treatment
modalities were chosen for initial treatment: adenotonsillectomy
(ATE) (47%), tracheostomy (31%), continuous positive airway
pressure (CPAP) (13%), placement of a nasal pharyngeal airway
(4%), prone positioning (1%), mandibular distraction osteogenesis
(MDO) (1%), or other surgical procedures such as nasal septum
correction (3%). In 84 of the 102 patients (80%) requiring treatment, a
surgical procedure such as ATE, tracheostomy or MDO was treat-
ment of first choice. Of the 48 patients receiving ATE as initial
treatment for OSA, 41 patients (85%) did not receive additional
treatment. Thirty-two patients did not have a post-treatment PSG, in
eight patients the post-treatment PSG was normal and in one patient
the ATE had no effect on the severity of OSA. Of the patients treated
by ATE, seven patients did receive additional treatment: CPAP in
three patients, placement of a nasal pharyngeal airway in two patients,
one patient had a tracheotomy and one patient had other therapy not
specified. ATE was the initial therapy for most patients with mild and
moderate OSA but was applied in patients with severe OSA too.
Tracheostomy was the initial therapy in 32 patients and the first
choice of treatment for 67% of the patients with severe OSA. Eighteen
patients received additional treatment, nine patients with the trache-
ostomy still in situ and nine patients without tracheostomy. Of all
patients with a tracheostomy, 51.4% were decannulated or their post-
treatment PSG was normal. CPAP was the first choice of treatment in
thirteen patients (13%) and the secondary choice of treatment in
thirteen patients too. After additional therapy with CPAP, 46.2% of
the patients needed additional therapy. Although eleven patients
(unilateral) were treated by mandibular distraction osteogenesis, it
was the initial therapy in only one patient. The outcome of MDO
on OSA was good in four patients, having a normal post-treatment
PSG. In five patients no post-treatment PSG was performed. Two
patients still required CPAP and one patient had a persistent
tracheostomy.
Conclusions
Level 3 Treatment modalities
Treatment modalities for obstructive sleep apnoea in craniofacial
microsomia are: prone positioning, nasal pharyngeal airway
tube, continuous positive airway pressure (CPAP),
adenotonsillectomy (ATE), tracheostomy, mandibular
distraction osteogenesis, and mandibular osteotomy.
Ref (11, 18, 19)
Level 3 Policy
In patients with mild to severe obstructive sleep apnoea and
adenotonsillar hypertrophy, adenotonsillectomy (ATE) may be the
treatment of first choice. Most patients do not require additional
therapy for their obstructive sleep apnoea.
Continuous positive airway pressure (CPAP) appears to be a good
treatment for moderate to severe obstructive sleep apnoea in
craniofacial microsomia.
In patients with severe obstructive sleep apnoea, tracheostomy is often
considered the first choice of treatment.
Mandibular distraction osteogenesis (MDO) is often applied as
secondary treatment for obstructive sleep apnoea caused by
obstruction at the tongue base in craniofacial microsomia.
Additional therapy after MDO is indicated in some patients.
Ref (19)
Considerations
 Overall quality of evidence
The treatment modalities for OSA in CFM were described in two
retrospective studies (18, 19) and the systematic review by Caron
et al (11). The studies are descriptive retrospective cohort studies
and were therefore graded on level 3.
The choice of treatment for OSA in CFM was analysed in the
retrospective study by Caron et al (19). Treatment modalities and
outcomes were retrospectively studied and no controls were used.
The quality of evidence was graded on level 3.
 Balance of benefits and harms
Untreated OSA may lead to serious morbidity and worse out-
comes. Treatment of OSA will be beneficial for the child suffering
from OSA and outweigh the harms.
 Outcome importance
Untreated OSA will impair outcome, specially growth and
development. Therefore OSA has to be treated.
Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
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CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Untreated OSA has been associated with major impairments
to growth and (cognitive) development and may lead to serious
complications. Several authors, including the European Respira-
tory Society, have emphasised the need to treat OSA. There is no
uniform protocol or treatment algorithm available for treatment
of OSA in children with CFM. Non-surgical treatment for
breathing difficulties should always be considered in children
with OSA. Treatment modalities depend on the experience of a
centre, the age of the child, the possibility to perform an
endoscopy to detect the level of obstruction and the severity
of symptoms. Therefore, because of the complexity of the
treatment, a multidisciplinary team has to discuss clinical find-
ings and results of additional investigations to decide on the
appropriate treatment. As described in the literature, MDO
should be considered to prevent a tracheostomy or aim for
decannulation in patients with severe OSA.
Recommendations
 Treatment of children with craniofacial microsomia and
obstructive sleep apnoea has to be discussed in a
multidisciplinary team.
 Treatment of children with craniofacial microsomia and
obstructive sleep apnoea depends on the age of the
child, the severity of symptoms and the level
of obstruction.
 In older children with mild to severe obstructive sleep
apnoea, adenotonsillectomy (ATE) may be the treat-
ment of first choice.
 In young infants and children with craniofacial
microsomia and obstructive sleep apnoea non-surgical
respiratory support has to be considered to treat
obstructive sleep apnoea.
 In children with craniofacial microsomia and severe
obstructive sleep apnoea a tracheostomy has to be
considered at all ages.
 Mandibular distraction osteogenesis (MDO) should be
considered to treat patients with severe obstructive sleep
apnoea who have a tracheostomy or to reduce the
necessity for a tracheostomy or respiratory support.
Research gap
The literature on treatment modalities for OSA in CFM is
retrospective and no comparative studies have been done. The
preferred type of treatment for mild, moderate or severe OSA in
CFM has not been studied. Future studies on this subject, with long-
term follow-up and patient-specific outcomes, are needed.
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.2 Feeding difficulties in craniofacial
microsomia
Introduction
Besides aesthetic malformations, patients with craniofacial
microsomia (CFM) also have functional difficulties. Characteristic
features of patients with CFM, such as mandibular hypoplasia,
facial nerve and/or masticatory muscle weakness, or anomalies of
the oropharynx and larynx may all play a contributing factor in the
feeding difficulties. Feeding difficulties may relate to difficulties
in suckling, mastication, dysphagia, and/or failure to thrive. In 15-
22% of the cases a cleft lip/palate is diagnosed in patients with
CFM, which may further enhance the risk for feeding difficulties
(1, 2).
Potential factors that may cause feeding difficulties in patients
with CFM were discussed in a systematic review on this issue (3).
Mandibular hypoplasia may cause a restricted mouth opening and
limited sucking efficiency, causing feeding difficulties. Facial
nerve weakness and/or –musculature hypoplasia may lead to
limited cheek and lip movements, causing sucking and feeding
difficulties. Also, anomalies of the tongue, oropharynx, and/or
larynx may cause feeding difficulties in patients with CFM. Besides
the facial malformations, extracraniofacial anomalies such as car-
diac- or gastrointestinal anomalies may also play an important role
in the presence of feeding difficulties.
To describe the policy for feeding difficulties in patients with
craniofacial microsomia the following questions were included in
this chapter:
4.2.1 What is the type, prevalence and severity of feeding
difficulties in craniofacial microsomia?
4.2.2 What is the policy for screening and monitoring of
feeding difficulties in patients with craniofacial microsomia?
4.2.3 What are the indications and policy for treatment of
feeding difficulties in patients with craniofacial microsomia?
Diagnosis and treatment of feeding difficulties in an early phase
is essential to prevent further harm. Especially in children with
CFM, who may be at increased risk for these difficulties, vigilance
for feeding difficulties is essential.
Literature search
A systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the
question of the guideline.
- The search of the systematic review was conducted in
at least two relevant databases, such as the Cochrane
Library, Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with Craniofacial Microsomia
Subject - Feeding, suckling, chewing, dysphagia, failure
to thrive
Exclusion criteria - Original studies with< 10 included patients






Literature was screened on title and abstract. Six articles were
included in this chapter. A systematic review by Caron et al. (3) and
cross-sectional study by Cohen et al. (4) were included. The other
four articles were al retrospective cohort studies: Strömland et al.
(5), Caron et al. (6), Van de Lande et al. (7), and Brotto et al. (8).
4.2.1 What is the type, prevalence and severity of feeding
difficulties in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type (suckling, mastication, dys-
phagia, and/or failure to thrive), prevalence and severity (mild,
moderate or severe) of feeding difficulties in CFM (Appendix 1,
http://links.lww.com/SCS/B697). Since this question is not relate to




In 2015 a systematic review of literature was undertaken by
Caron et al. to provide an overview of literature on the prevalence
and treatment of feeding difficulties in patients with CFM (3). A
total of eight articles were included in this review. Six of the eight
articles were excluded in this chapter due to inclusion of less than
ten patients or publication before 1980. The other studies included
24 and 18 patients, respectively (4, 5). Of the 24 patients studied by
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Cohen et al. (4), ten patients (42%) had feeding difficulties. The
type of feeding difficulties were: swallowing dysfunction, feeding
difficulties not specified and/or failure to thrive. Of the patients with
feeding difficulties, three patients had bilateral CFM, seven patients
had unilateral CFM, and nine patients had extracraniofacial anom-
alies. In addition, nine of the ten patients with feeding difficulties
had orofacial hypotonia, which was associated with poor expressive
language skills. A similar outcome was found by Strömland et al.
(5). Of the eighteen patients included, twelve patients (63%) had
feeding difficulties. Tube feeding was indicated in all patients.
Three patients (25%) required gastrostomy. It is unclear whether the
nine patients who were tube fed were also able to feed orally.
Dysphagia was reported in nine patients of the twelve patients with
feeding difficulties. The type of feeding difficulties in the other
three patients is unknown, although six patients complained of
drooling. Of the nine patients with dysphagia, seven patients had
impaired speech. All patients with cleft palate (n¼ 5) had feeding
difficulties. The authors state that dysphagia may be the result of
oral motor impairment and orofacial dysmorphology, but cardiac,
gastrointestinal, or breathing difficulties may also cause feeding
difficulties (5).
Severity
A large retrospective multicentre study to analyse feeding
difficulties in CFM was performed by Caron et al. (6). The authors
graded the severity of feeding difficulties based on type of treatment
and scored as ‘mild’, ‘moderate’, or ‘severe’:
1. Mild feeding difficulties: patients able to feed pureed or solid
foods orally regardless of minor adjustments such as the use of a
bottle or nipple.
2. Moderate feeding difficulties: patients able to feed orally, but
also dependent on additional tube feeding.
3. Severe feeding difficulties: patients dependent on tube feedings,
i.e. nasopharyngeal, percutaneous, or parenteral.
A total of 755 patients with CFM were included. Feeding
difficulties were present in 26% of the patients (n¼ 199): 92
patients (46%) with mild, 25 patients (13%) with moderate, and
82 patients (41%) with severe feeding difficulties. Feeding
difficulties were diagnosed before the age of six months in
60% of the patients. Patients presented with difficulties in
suckling, swallowing, chewing, complaints of reflux and/or a
restricted mouth opening. Of the 120 patients with a cleft lip/
palate, 62 patients had feeding difficulties. Patients with obstruc-
tive sleep apnoea (OSA) were significantly more frequently
diagnosed with feeding difficulties compared to non-OSA
patients (Pearson’s x2 (df1) ¼ 47.084; p< 0.001). The authors
studied the risk factors for feeding difficulties and found that
patients with cleft lip/palate, bilateral CFM, extracraniofacial
anomalies such as heart or gastrointestinal anomalies, obstructive
sleep apnoea, and/or more severe mandibular hypoplasia had a
higher risk for feeding difficulties. Of the patients with bilateral
CFM, 49% had feeding difficulties, 50% of the patients with
extracraniofacial anomalies had feeding difficulties, and 60% of
the patients with obstructive sleep apnoea had feeding difficul-
ties. Patients with macrostomia, which is part of the CFM
‘spectrum’, did not have a higher risk for feeding difficulties
compared to patients without macrostomia. Patient-specific out-
comes of feeding difficulties, such as growth or developmental
delay, have not been assessed in this study. The authors conclude
that all patients with CFM should be screened for feeding
difficulties by a speech and language therapist before the age
of one. After the age of one, patients should be monitored by a
feeding specialist on a regular basis (6).
Swallowing difficulties
Feeding difficulties may be the result of swallowing difficulties.
To study swallowing difficulties and their incidence in patients with
CFM, videofluoroscopic swallowing studies were evaluated by Van
de Lande et al. (7). A total of 755 patients with CFM were included.
Feeding difficulties were present in 208 patients (27.5%) and 102
patients (13.5%) had swallowing difficulties. A total of 42 patients
with swallowing difficulties who underwent videofluoroscopic
swallowing studies were analysed. swallowing studies were sepa-
rated in an oral and pharyngeal phase. Patients younger than six
months (n¼ 11) showed difficulties in all phases, but especially
nasopharyngeal reflux (75%), bolus formation (62.5%), and aspi-
ration (62.5%) were seen frequently. Patients older than six months
(n¼ 31) mostly had difficulties in bolus formation (55%), delayed/
variable swallow trigger (47.4%), and post-swallow stasis (47.1%).
Aspiration occurred less frequently in patients older than six months
(23.8%). Patients with a more severe mandibular deformity, Pru-
zansky-Kaban III malformation, had difficulties in appropriate
bolus formation significantly more often. In the pharyngeal phase,
no difference was found between more and less severely affected
patients. No difference in outcome of the videofluoroscopic swal-
lowing studies was seen between unilateral and bilateral CFM
patients. The authors recommend screening for swallowing diffi-
culties by a speech and language therapist in all patients with CFM.
In addition, patients who have a Pruzansky-Kaban III mandibular
deformity or are at high risk for swallowing difficulties should be
screened using videofluoroscopic swallowing studies (7).
Hypoplasia and aplasia
Saliva is required for adequate swallowing function and digestion.
Loss of salivary flow may therefore contribute to feeding difficulties.
Brotto et al. studied the rate of parotid and submandibular gland
abnormalities in CFM (8). They found that 21 of their 25 included
patients had hypoplasia or aplasia of the parotid gland. Aplasia was
reported in eight patients: three patients had bilateral aplasia and five
patients unilateral aplasia of the parotid gland. Of the 21 patients with
parotid gland hypoplasia/aplasia, six patients had submandibular
salivary gland hypoplasia too. No patient had isolated hypoplasia
of the submandibular salivary gland. A significant association was
found between parotid gland hypoplasia/aplasia and ipsilateral tri-
geminal and/or facial nerve abnormalities. Although most patients
had hypoplasia/aplasia of the salivary glands, no patients had com-
plaints of decreased saliva production. Besides salivation deficits,
other factors such as jaw deformities and oral apraxia presumably
play a more significant role in feeding difficulties (8).
Conclusions
- Prevalence
The prevalence of feeding difficulties in craniofacial microsomia
varies from 26% to 63%, presumably approximating 26%.
Ref (3–7)
Level 3 Prevalence
Patients with craniofacial microsomia and obstructive sleep
apnoea are at increased risk for feeding difficulties
(studied in 755 patients).
Ref (6)
Level 3 Type
Type of feeding difficulties encountered in craniofacial
microsomia are: difficulties in suckling, swallowing, chewing,
complains of reflux, a restricted mouth opening, failure to thrive.
Ref (4–6)
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Level 3 Incidence
The incidence of feeding difficulties is higher in craniofacial
microsomia patients with:
- Bilateral craniofacial microsomia
- Cleft lip/palate
- Cardiac or gastrointestinal anomalies
- Obstructive sleep apnoea




Severity of feeding difficulties in patients with craniofacial
microsomia (studied in 755 patients):
- 46% of the patients had mild feeding difficulties
- 13% of the patients had moderate feeding difficulties
- 41% of the patients had severe feeding difficulties
based on the criteria defined by Caron et al (6).
Ref (6)
Level 3 Type
Swallowing difficulties were reported in 13.5% of
patients with craniofacial microsomia.
Videofluoroscopic swallowing studies showed no
differences in type of swallowing difficulties between
unilateral and bilateral craniofacial microsomia
patients.
Hypoplasia or aplasia of the parotid or submandibular
salivary gland is common in craniofacial microsomia.
Symptoms of decreased saliva production are not
seen.
An association between facial- and/or trigeminal nerve
abnormalities and parotid gland hypoplasia/aplasia
was found in patients with craniofacial microsomia.
Ref (7, 8)
4.2.2 What is the policy for screening and monitoring of
feeding difficulties in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the consequences and impact of screen-
ing and monitoring, the available screening tests and procedures for
monitoring, and responsibilities for screening and monitoring
(Appendix 1, http://links.lww.com/SCS/B697). Unfortunately, no
literature is available on the policy for screening and/or monitoring
of feeding difficulties in patients with CFM. Therefore, no conclu-
sions were written. Considerations for this question were only based
on expert opinion.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
The literature shows that feeding difficulties occur in 42–83%
of patients with CFM and are mostly the result of oral impairment or
orofacial deformities. Difficulties with swallowing, chewing and
choking are the most frequently described types of feeding diffi-
culties. Because most patients are diagnosed with feeding difficul-
ties before the age of one and a significant number of patients with
severe feeding difficulties needed tube feeding, it is plausible to
recommend to screen and monitor for feeding difficulties regularly.
 Outcome importance
In none of the studies the indication for treatment, treatment
outcome and follow-up were described; however, this should be of
the utmost importance in children because feeding difficulties can
lead to impaired growth and development.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Considering the high prevalence of feeding difficulties in CFM
and potential negative consequences of these difficulties, biannual
screening for feeding difficulties is indicated in children with CFM.
The role of the paediatrician, speech and language therapist and
dietician is hardly described in existing research but should be
standard care in children with feeding difficulties and growth
failure. Paediatricians will screen for symptoms affecting the
general condition of patients, growth and development. The
WHO or national Growth Charts can be used to monitor growth
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and screen for feeding difficulties. In case of feeding difficulties,
speech and language therapy should be the first step to improve
oral-motor behaviour and swallowing difficulties. When children
need tube feeding, a speech and language therapist has to be
involved in follow-up of oral-motor behaviour. Therefore, close
cooperation between the paediatrician and speech and language
therapist is required at all times for the treatment of feeding
difficulties in patients with CFM.
Recommendations
 Children with craniofacial microsomia should be
screened with a questionnaire biannually, at least up
to the age of six, and monitored regularly for feeding
difficulties by a paediatrician or multidisciplinary team.
 The WHO or national Growth Charts can be used to
monitor growth and screen for feeding difficulties.
 A speech and language therapist should be involved in
patients who require tube feeding.
Research gap
No literature is available regarding the policy of screening and
monitoring of feeding difficulties in patients with craniofacial
microsomia. Availability of studies could help to develop better
screening and monitoring.
4.2.3 What are the indications and policy for treatment of
feeding difficulties in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of feeding difficulties (Appendix 1, http://links.lww.com/
SCS/B697). Literature was found on the indications of treatment
options.
Review of literature
Treatment modalities for feeding difficulties in patients with CFM
were further delineated in the retrospective study by Caron et al. (6).
Table 1. shows the reported symptoms and treatment options in
patients with mild, moderate, and severe feeding difficulties. Results
were based on retrospective evaluation without comparison between
treatment modalities based on patients specific outcomes, such as
growth or developmental delay. Patients with mild feeding difficul-
ties presented with chewing difficulties more frequently than with
swallowing difficulties. Of the patients with moderate feeding diffi-
culties, most had a Pruzansky-Kaban III mandibular deformity.
Patients receiving tube feeding needed this for a median duration
of 11.7 months (range 1.1 month – 16.4 years). Patients with severe
feeding difficulties were more frequently diagnosed with a Pru-
zansky-Kaban III mandibular deformity too. Four patients needed
parenteral feeding, which was always followed by tube feedings.
Tube feeding in patients with severe feeding difficulties was indicated
for a median duration of 7.1 months (range 2 days – 12.9 years). The
authors discussed that in patients with bilateral CFM, and/or a severe
mandibular deformity (i.e. Pruzansky-Kaban III), the presence of
OSA, cleft lip/palate or extracraniofacial anomalies, surgical therapy
such as cleft lip repair or mandibular distraction osteogenesis, may be
indicated to treat feeding difficulties. In other patients, conservative
treatment by using bottle/nipple feeding, supplemented (breast)milk,
and/or antireflux medication, may be sufficient to treat feeding
difficulties (6).







Cleft lip/palate 16 patients 8 patients 38 patients

























based on the criteria applied by Caron et al (6). #OSA: obstructive sleep apnoea.
Conclusion
Level 3 Indications
Surgical treatment, such as cleft lip/palate repair or
mandibular distraction osteogenesis, may be indicated
for treatment of feeding difficulties in craniofacial
microsomia.
Conservative treatment, such as bottle/nipple feeding,
supplemented milk, or anti-reflux medication may be
sufficient in some patient for treatment of feeding
difficulties in craniofacial microsomia.
Ref (6)
Considerations
 Overall quality of evidence
Data on treatment modalities was based on a single retrospective
study without comparison between treatment modalities based on
patient specific outcomes (6). The indication for a certain type of
treatment was not described in this study. Conclusions on CFM-
specific factors of importance for a certain type of treatment could
not be drawn. The quality of evidence was graded on level 3.
 Balance of benefits and harms
Difficulties with swallowing, with chewing and choking are the
most frequently described types of feeding difficulties necessitating
different nutritional strategies depending on the severity of the
feeding difficulties. Because most patients are diagnosed with
feeding difficulties before the age of one and this is the period
of rapid growth and development, the benefits of appropriate and
early nutritional intervention outweigh the possible harms.
 Outcome importance
With regard to the optimal growth and development of young
children it is of the utmost importance to focus on nutritional
therapy, growth and follow-up.
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 Costs and resources
The impact on costs and resources of the given recommendations
will vary per member state, depending on the available care providers
and facilities. The recommendations concern the essential require-
ments for adequate treatment of patients with CFM and should thus be
implemented. Costs are lowest and resources are most efficiently
used when care for craniofacial disorders is centralised in a limited
number of expert centres per member state. A general rule that can be
applied is one expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an expert
centre for CFM, or the level of provided care does not (yet) meet all the
requirements that are outlined in this guideline. By defining the
baseline of required care for CFM, this guideline will help these
member states to reach the appropriate level. The ERN on craniofacial
anomalies and ENT disorders (ERN-CRANIO) can guide a patient in
Europe to the available centres of expertise (www.ern-cranio.eu) and
can support care providers with diagnosis and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The role of a multidisciplinary team to guide nutritional therapy
has been advocated by many societies to improve nutritional intake
and to optimise growth. In case of children with CFM a paediatri-
cian or a paediatric gastroenterologist, speech and language thera-
pist and dietician are involved in a multidisciplinary team. When
children need tube feeding, a speech and language therapist has to
be involved in follow-up of oral-motor behaviour. The indication
for a gastrostomy has to be discussed in close cooperation with a
paediatric gastro-enterologist. After discharge from the hospital
monitoring of appropriate growth is needed and it should be clear
who is responsible for growth and development in follow-up.
Recommendations
 Children with craniofacial microsomia with feeding
difficulties should be treated by a multidisciplinary
team.
 Feeding strategies are guided by the severity of feeding
difficulties.
Research gap
The literature on treatment modalities for feeding difficulties in
CFM is retrospective and no comparative studies have been done.
Future prospective studies on this subject, with long-term follow-up
and patient specific outcomes, are needed. The ICHOM Craniofa-
cial Microsomia standard set will help to create a good prospective
dataset from a large number of patients with CFM (9).
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.3 Speech and Language difficulties in
craniofacial microsomia
Introduction
Speech, language and communication are crucial to the devel-
opment of children and young people which impact on educational
achievement; emotional, social and mental wellbeing, and oppor-
tunities in life. Individuals with speech, language and communica-
tion needs (SLCN) present with a range of receptive and expressive
difficulties. These include: verbal, written or non-verbal expression;
understanding spoken or written word, body language and facial
expressions; listening and remembering; expressing feelings and
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emotions in an appropriate and adaptive way; or being able to relate
to others in socially acceptable ways (1).
Oral-facial features of CFM such as mandibular hypoplasia,
tongue anomalies, facial asymmetry, facial weakness, teeth anom-
alies, dental malocclusion, cleft palate and macrosomia may all
contribute to speech difficulties, in particular articulation difficul-
ties (2, 3). Presentation may range from mild difficulties affecting
the appearance of speech but not intelligibility to severe articulatory
errors making speech unintelligible. Cleft lip/palate is reported in
15-22% of the patients with CFM (3–5). This may result in
velopharyngeal dysfunction (VPD) and atypical articulatory pat-
terns knowns as cleft speech characteristics (CSCs), both of which
can compromise speech intelligibility. VPD is characterised by
hypernasal resonance and the nasal airflow features of nasal turbu-
lence and emission, which may warrant surgical intervention if
intelligibility is compromised. In the absence of a cleft palate, there
remains a risk of VPD due to asymmetry and hypoplasticity on the
microsomic side which can affect the velopharyngeal anatomy and
function (6). VPD has also been reported to occur with palatal
paresis or paralysis (7).
Good hearing is essential for speech and language develop-
ment. Patients with CFM are at an increased risk of hearing
problems due to external and/or internal ear abnormalities, audi-
tory canal atresia, and eustachian tube dysfunction (8). Conclu-
sions of literature and recommendations for care of hearing
difficulties in CFM is described in chapter 4.4. The condition of
CFM can predispose children to early language delay which may
be unrelated to hearing impairment. Language difficulties in older
children have been reported.
To gain a deeper understanding of the broad communication
profile in CFM and to inform recommendations on screening,
assessment and management, the following guiding questions are
posed:
4.3.1 What is the type, prevalence and severity of speech and
language difficulties in craniofacial microsomia?
4.3.2 What is the policy for screening and monitoring of
speech and language difficulties in patients with craniofacial
microsomia?
4.3.3 What are the indications and policy for treatment of
speech and language difficulties in patients with craniofacial
microsomia?
Early detection of delays in the development of speech and
language is imperative to facilitate good communication, social
interaction and improved quality of life (9, 10). As patients with
CFM may be of increased risk for and language difficulties, early
screening is indicated.
Literature search
A systematic search of the evidence base was performed to
identify all available literature on craniofacial microsomia and
appropriate synonyms. The search was conducted in Embase,
Pubmed/Medline Ovid. The full search strategy is reported in the
supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the question of
the guideline.
- The search of the systematic review was conducted in at least
two relevant databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Speech, velopharyngeal dysfunction
Exclusion criteria - Original studies with< 10 included patients






Literature was screened on title and abstract. Five articles were
included: a cross-sectional study by Funayama et al. (11), a retro-
spective cohort study by Strömland et al. (12), a cross-sectional
study by D’Antonio et al. (13), a cross-sectional study by Cohen
et al. (14), and a retrospective cohort study by Chen et al. (15).
4.3.1 What is the type, prevalence and severity of speech
difficulties in craniofacial microsomia?
The literature was specifically examined for evidence on the
type of speech and language difficulties, including resonance
disorders, articulation difficulties voice disorders, the prevalence
and severity (rating scales) in CFM (Appendix 1, http://links.lww.-
com/SCS/B697). Since this question does not relate to interventions
or diagnostics, no considerations, rationale or recommendations
are provided.
REVIEW OF LITERATURE
A range of communication difficulties and their associated preva-
lence in CFM was reported inconsistently across the included
studies, specifically language difficulties, velopharyngeal dysfunc-
tion, articulation difficulties secondary to tongue abnormalities,
facial nerve palsy, social communication difficulties and voice
disorder. Oral motor difficulties were referred to in one study,
while a further paper reported on tracheostomy management for
airway difficulties, with no reference to the impact on communica-
tion. Many of these communication features were not systemati-
cally reported using validated assessment tools, with inadequate
descriptive reporting as well as the use of subjective terms and
ratings. Furthermore, the description of the individual communica-
tion difficulties was inaccurately described in a number of papers;
e.g. non-verbal children described as having speech articulation
difficulties, when in fact, this is a language deficit. ‘Speech
difficulties’ is not defined in any study, making it unclear if the
reported speech difficulties are structural, developmental or disor-
dered. This is important in terms of the nature of the communication
difficulty reported and the intervention that is recommended.
Receptive and expressive language skills
Cohen et al. studied communication disorders in patients with
CFM (14). In this study, receptive- and expressive language skills
were found to be -2 standard deviations below the normal popula-
tion in one-third of the cohort (n¼ 24). Receptive and expressive
language was assessed using the Early Language Milestone Scales
for children aged one month to three. This is a norm-referenced
language screen that uses parental report, clinical observation and
direct testing. The Expressive One-Word Picture Vocabulary Test
or Peabody Picture Vocabulary Test was used with older children
aged three to five years to assess expressive and receptive
vocabulary respectively.
The same study also found that the children with oral-facial
hypotonia, diagnosed with neurological examination, had a signifi-
cantly lower expressive language score with an average of 69 versus
100 in the ‘‘normal tone’’ group. (14). Oral-facial hypotonia was
diagnosed following a neurological examination, which was not
further specified. In addition, receptive and expressive language
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scores scores were 2 s.d. below the mean of the normal population in
32% (n¼ 6) and 37% (n¼ 7) of the patients respectively. Patients
with unilateral CFM scored significantly higher on the receptive
and expressive language scores compared to bilateral patients
(respectively 100 versus 58, p¼ 0.003; 100 versus 64, p¼ 0.02)
(14).
Speech articulation difficulties
Most facial structures are underdeveloped in patients with CFM,
including tongue anomalies which can contribute to atypical speech
articulation (15). Chen and colleagues’ (15) retrospective case-note
review of 167 patients revealed that only eight patients (4.8%) had a
tongue anomaly, e.g. ankyloglossia, tongue hypoplasia or a bifid
tongue. Seven of these 8 cases had speech delay or deficits, though
the nature or severity of the articulation difficulties is not described.
Resolution of these speech patterns occurred in seven cases, five of
whom had speech therapy, while the eighth patient was non-verbal.
Alternative communication modes for this patient were not
reported. The study also included a prospective arm, in which 55
patients with CFM underwent evaluation for tongue anomalies.
Patients with a higher Mandible or Soft tissue score on the
O.M.E.N.S. scale were found to be at increased risk of tongue
anomalies: a correlation coefficient of 0.527, p¼ < 0.001 was
found for the Mandible score while a correlation coefficient
0.464, p¼ < 0.001 was confirmed for the Soft Tissue score. The
presence of tongue anomalies was much higher in this prospective
sample, yielding a 44% prevalence. The type of speech evaluation is
not described. However, speech difficulties were reported in 21
patients (38%) while four children were described as being deaf and
non-verbal. As nineteen patients were too young to be evaluated, the
incidence of speech difficulties in this cohort may indeed be higher.
It is unclear what proportion of children with a tongue deformity
had a speech deficit.
Strömland et al reported on oral-motor function and speech
characteristics using the Mun-H-Center Observation chart (12).
This observation chart is described as a record chart to collect
clinical observations made not only about speech and oral motor
function, but also orofacial morphology and odontology. This is not
a validated assessment tool nor is reference made to the use of a
formal speech assessment with a standardised speech sample,
making it difficult to interpret speech findings and to appreciate
the impact upon intelligibility. Of the 15 patients aged between 2–
17 years old, 53% were found to have articulation difficulties. A
general description of the severity of the speech difficulty is
provided, i.e. five children were non-verbal, one child had ‘severe’
speech difficulties while two children had speech articulation
difficulties considered to be ‘slight’. No information is provided
regarding the articulatory patterns or phonetic deviations is pro-
vided, underscoring the limited detail of the nature of the speech
sound disorder. The study alludes to a potential association between
these speech and language difficulties and the children’s cognitive
function. Six children were reported to present with drooling, with
no further information provided.
Velopharyngeal dysfunction
D’Antonio and colleagues (13) conducted a cross-sectional
study by means of a retrospective chart review and a prospective
examination of a portion of the same patients to examine the
pharyngeal and laryngeal structure and function of patients with
CFM. Cleft palate was a reported feature in 15% of the sample of 41
patients, while 10% had a submucous cleft palate. Hypernasality
was noted in 39% of the cohort with less than half of these having a
cleft palate (9 patients without a palatal cleft and 6 patients with a
cleft palate). Of cases without a cleft palate, 29% presented with
hypernasal resonance or nasal emission. Two patients with cleft
palate had oral resonance.
In the prospective arm of the study (13), perceptual evaluation
of velopharyngeal function for speech of 19 patients demonstrated
hypernasality in five patients (26%) and hyponasality in three
patients (16%). Of the five patients with hypernasality, two had a
cleft palate. Twenty-three patients in this study arm underwent
nasendoscopic evaluation of the velopharyngeal mechanism dur-
ing speech, though four of these were later excluded due to the
inability to interpret the speech findings as they were too young or
non-verbal at the time of investigation. Nasendoscopic view
revealed asymmetric velopharyngeal function in 35% of this
cohort. 13% presented with incomplete velopharyngeal closure
during speech, with anteroposterior narrowing of the velopharynx
reported in 9% of the sample. Aerodynamic evaluations were also
completed for 18 of the 23 cases, adding to the rigorous investiga-
tive protocol. These aerodynamic evaluations supported the per-
ceptual findings in all cases but one, which was felt to have been
influenced by the patient’s variable performance between tests.
The study concludes that there may be a relationship VPD and the
severity of the mandibular deformity in this condition, given that
the entire cohort with stage III mandibular deviation presented with
asymmetrical velopharyngeal function. By contrast, less than a
fifth of the group with stage I mandibular dysmorphology had an
asymmetrical velopharynx.
Articulation, resonance and intelligibility were reported using
a 7-point scale, however there is no reported validation of this,
nor description of the scale (13). Impaired articulation was
reported in 74% of the sample, with five cases in the severe
range, four considered to have moderate difficulty and five
having mild difficulty. However, no transcription of the phonetic
or phonological deviations are provided. Intelligibility was
reported to be impaired in 56% of cases, with 5/23 cases rated
as severely unintelligible.
Funayama et al. studied 52 patients with CFM and reported on
the correlation between VPD and the velopharyngeal phenotypes
(11). 48 patients with unilateral CFM and isolated microtia were
included, with an additional 4 patients with a repaired cleft palate in
CFM evaluated for comparison. 50% (n¼ 24) of the patients
without a cleft lip/palate had a unilateral hypodynamic palate,
though interestingly, only seven of these 24 patients (29%) had
VPD. Velopharyngeal dysfunction was found to correlate with
mandibular deficiency (Spearman’s rank correlation coefficient:
1.00, p¼ < 0.01) and Soft Tissue score (Spearman’s rank correla-
tion coefficient: 0.74, p¼ < 0.05) on the O.M.E.N.S. classification
(orbit, mandible, ear, nerve, soft tissue) (11). Correlations between
VPD and macrostomia (3 out of 7 patients had VPD, p¼ < 0.05)
and cognitive function (5 of the 5 patients had VPD, p¼<0.01)
were analysed. Of the 4 patients with cleft lip/palate, all presented
with VPD. Their post mandibular distraction nasendoscopic inves-
tigations revealed decreased unilateral velopharyngeal movement
on the microsomic side. Two of these patients, both of whom had
UCLP, underwent secondary speech surgery to manage their
hypernasality.
Voice
D’Antonio and colleagues (13) reported hoarseness in 24% of
the retrospective cohort. This study examined laryngeal function
under endoscopy in 22 patients in the prospective study arm. A
range of observations were reported, occurring in 86% of cases,
including infantile larynges, anteroposterior narrowing, asymmet-
rical arytenoidal movement, significant asymmetrical laryngeal
movement. Vocal cord and epiglottic abnormalities were also
reported (13). The authors did not report a relationship between
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these laryngeal pathologies and mandibular hypoplasia, though no
statistical testing is reported.
Impact of hearing difficulties on
communication development
Chapter 4.4 Hearing focuses on hearing loss in CFM. However,
two articles described that hearing loss may have an effect on speech
sound and language development in patients with CFM. Hearing loss
was observed in 22 of the 24 children with CFM in the Neurodeve-
lopmental Profile Study by Cohen et al. (14). They hypothesized that
this may have contributed to the low language scores. This however
was not analysed due to the small size of the cohort. In another study
by Strömland et al. (12), 15 of the 18 patients were documented as
having a hearing loss, bilateral hearing loss being most prevalent
(N¼ 11). Seven patients with bilateral hearing loss presented with
speech difficulties. Information on hearing intervention i.e. hearing
aid use or surgical intervention was not included. No statistical tests
were performed to assess the relationship between speech difficulties
and hearing defects. In this study, speech difficulties may not have
arisen exclusively due to hearing loss, but were likely to have been
influenced by the comorbid factors of cognitive impairment and oral
facial malformation.
The authors of both studies recommend screening for hearing
problems early in childhood and repeat hearing tests if the results
are inconclusive (12, 14).
Social communication difficulties
Strömland et al. reported severe social communication difficul-
ties and limited communication, rendering a diagnosis of autistic
spectrum disorder in 11% of children (12).
Conclusions
- Prevalence & Type
Communication difficulties that may present in
craniofacial microsomia include: velopharyngeal
dysfunction; dysphonia; impaired speech
articulation; receptive and expressive language
difficulties and social communication difficulties.
Prevalence rates of speech difficulties reported in
CFM vary from 38% - 74%.
Receptive and expressive language difficulties are
reported in 33% of the reported cohort of 24
patients.
Dysphonia was reported in 24% of a retrospective
cohort of 41 patients.
Social Communication difficulties including autistic




The reported prevalence of velopharyngeal
dysfunction in CFM without cleft palate is 15%. In
a sample of 48 patients, submucous cleft palate was
not reported.
Velopharyngeal dysfunction was observed in 35% of
a cohort due to asymmetric velopharyngeal
closure. No comparison with a healthy control
group was made.
Ref (11, 13)
4.3.2 What is the policy for screening and monitoring of
speech and language difficulties in patients with craniofacial
microsomia?
Review of literature
The literature was specifically examined for evidence on the
consequences and impact of screening and monitoring, the available
screening tests and procedures for monitoring, and responsibilities
for screening and monitoring (appendix 1, http://links.lww.com/
SCS/B697). Unfortunately, no literature is available on the policy
for screening and/or monitoring of speech and language difficulties
in patients with CFM. Considerations for this question were based
on the evidence and expert opinion. Therefore no conclusions were
written. Considerations for this question were only based on
expert opinion.
Considerations
 Overall quality of evidence
The evidence currently available on speech difficulties in CFM
is limited. Only five studies met the inclusion criteria, all of which
profiled different speech and language characteristics. Three stud-
ies had prospective designs (11, 12, 14), a further study had both a
retrospective chart review and a prospective arm (15), while the
remaining study was a retrospective cross-sectional chart review.
A range of methodological weaknesses were found across the
studies, ranging from a lack of detail about consecutiveness and
comparison groups, to ill-defined and incorrect use of terminology
relating to the communication aspects being profiled. Furthermore,
all but one study did not report the use of a validated assessment
tool. These weaknesses are reflective of the inherent potential for
bias within the studies. Thus, these studies represent Level
III evidence.
 Balance of benefits and harms
Children with CFM warrant early screening of their preverbal
and early language skills due to the risk of visual and hearing
impairment as well as oral-facial difference that can impact on
early social development and receptive and expressive language
skills. Children with the condition are at increased risk of receptive
and expressive language difficulties. Conti-Ramsden and collea-
gues (16) found that when these language difficulties persist into
adolescence and adulthood in the non-CFM population, lower
academic and vocational qualifications than their peers were
found. Therefore, early screening and intervention for language
difficulties is advised. Articulation difficulties, velopharyngeal
dysfunction and voice disorders and can all result in reduced
intelligibility which impacts on self-esteem and compromises an
individual’s QoL.
 Outcome importance
To date, patient reported outcomes for speech and language in
CFM have not been systematically reported in the literature.
However, expert opinion indicates that patients attending CFM
clinics report positive improvements in interactions with family,
peers, and the wider community following speech and language
intervention. Increased communication confidence is reported,
demonstrating the key strands of the ICF (International Classifica-
tion of Functioning) of participation, functioning, impairment and
wellbeing (17).
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
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providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core
values. However, in some countries the national organisation of
healthcare might impede centralisation. National implementation
of the ERNs that fits the situation of each country is necessary. For
the member states with the lowest number of inhabitants, the
establishment of a craniofacial centre might not be feasible, and
collaboration with a craniofacial centre in the surrounding coun-
tries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Individuals with CFM are at risk of communication difficulties
due to oral-facial anomalies, cleft palate and velopharyngeal dys-
function, and/or hearing impairment. Other features that can
adversely impact communication skills in CFM are: facial nerve
palsy which can affect facial expression (18), velopharyngeal
function (7); airway difficulties requiring tracheostomy interven-
tion and its impact on speech articulation, language development
and voice; cognitive impairment ranging from neurotypical to
severely impaired with associated specific language difficulties
(12, 14) some of the time; and visual impairment as it may affect
play, motor, cognitive, social and communication skills in children
(12, 19).
Individuals with CFM are at risk of communication difficulties
due to the following inter-related predisposing factors which are






















At the age of two years, the child’s phonetic repertoire should be
initially assessed to examine his/her velopharyngeal function for
speech due to the potential risk of VPD related to a unilateral
hypodynamic palate and/or cleft palate. If there are concerns about
velopharyngeal dysfunction (VPD), a referral to the specialist
Velopharyngeal Investigations clinic attached to a cleft centre is
recommended from age three onwards. If there are concerns
regarding cleft speech characteristics, therapy is recommended.
The specialist Cleft-Craniofacial SLT may deliver this or support
the community SLT in providing this intervention. After five years,
bi-annual screening of velopharyngeal function for speech is
recommended until age 20. Speech screening should follow the
guidelines set out in the Universal Parameters for Reporting Speech
Outcomes in Individuals with Cleft Palate (20). This consists of
obtaining a spontaneous speech sample, rote speech elicitation (e.g.
counting, nursery rhyme), single words for younger children and
sentence repetition for all speech sounds to examine the phonetic
repertoire and the features of resonance and nasal airflow (Table 1
in Appendix 5, http://links.lww.com/SCS/B697). The parameters of
resonance and nasal airflow can be rated according to severity
(Table 1 in Appendix 5, http://links.lww.com/SCS/B697).
In the case of non-cleft CFM, speech requires ongoing moni-
toring throughout childhood as the child’s speech and language
skills mature, to ensure that any emerging velopharyngeal dysfunc-
tion is detected. In later childhood, as the nasopharyngeal tract alters
with maturity and with adenoidal involution, previously absent
features of VPD, including hypernasality and nasal airflow errors,
may emerge. It is thus important that the Speech and Language
Therapist acknowledges the changing profile of resonance and
speech over time and does not discharge the patient in early
childhood. Examination of oral-facial structure and function is
strongly recommended when evaluating speech. Features of
CFM such as tongue anomalies, orofacial hypotonia, macrostomia,
dental malocclusion, mandibular hypoplasia contribute to articula-
tion difficulties. Individuals with tracheostomy should be screened
for speaking valve suitability or an augmentative and alternative
communication system (communication methods used to supple-
ment or replace speech or writing). Given the reported social
communication difficulties that may present in this population,
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either occurring in isolation or related to visual impairment, early
screening and monitoring of social interaction skills are recom-
mended from the age of 9 months onwards. It is important to
acknowledge that social communication difficulties may become
more apparent in later childhood as abstract language features more
in social interactions and the educational curriculum.
Recommendations
 Screen preverbal communication and babbling skills at
the age of nine months to decide if intervention
is warranted.
 Evaluate receptive and expressive language skills at the
age of two years and biannually until the age of eight
years in all patients with craniofacial microsomia.
Those identified with difficulties should be referred to
their community speech and language therapist service
for ongoing intervention.
 Oral-facial evaluation of structure and function is
recommended at each screening consultation to exam-
ine any impact of asymmetry on speech production.
This should include examination of facial symmetry,
lips, dental occlusion and intra-oral examination of
tongue movement, dentition, hard palate and soft palate
movement on sustained ‘ah’ vowel.
 Screen patients with tracheostomy for speaking valve
suitability or an augmentative and alternative commu-
nication system.
 Social communication skills should be monitored in
tangent with all of the afore-mentioned communication
skills.
 Children with craniofacial microsomia and associated
cleft palate should be screened annually from 2–5 years
by the Cleft-Craniofacial speech and language therapist
and should follow the local Cleft Palate Protocol.
Velopharyngeal dysfunction should be assessed from
the age of two years or when verbal output has emerged.
 Children with craniofacial microsomia without a cleft
palate should also be screened at the age of two years to
examine for potential risk of velopharyngeal dysfunc-
tion related to their asymmetrical structure. If velo-
pharyngeal dysfunction is identified, these children
should follow the same pathway as children with a
cleft palate.
Research gap
No literature is available regarding the policy of screening and
monitoring of speech difficulties in patients with craniofacial
microsomia. Availability of studies could help to develop a better
screening and monitoring.
4.3.3 What are the indications and policy for treatment of
speech difficulties in patients with craniofacial microsomia?
The literature was specifically examined for evidence on treat-
ment options, symptoms, requirements, complications, and advan-
tages and disadvantages of treatment of speech problems (appendix 1,
http://links.lww.com/SCS/B697). Unfortunately, no literature is
available on the indications and policy for treatment of speech
and language difficulties in patients with CFM. However, there is
evidence for the management of VPD in the cleft palate only
population which can be applied to CFM. In addition, the local
policies and guidelines that have been developed in different coun-
tries (21) for the management of receptive and expressive language
difficulties can also be used with individuals CFM. Considerations for
these questions were based on expert opinion and on the wider
literature on management of speech and language difficulties.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
Early treatment of speech and language difficulties is crucial to
minimise lower school achievement and psychosocial sequelae
(22). Early intervention can facilitate improved parent awareness
of their child’s communication difficulty, enabling them to support
their child appropriately in their everyday interactions.
 Outcome importance
Early intervention and ongoing therapy for language, articula-
tion and social communication difficulties contributes to enhanced
patient QoL. Likewise, improving the child’s VP function for
speech, can contribute to this. The community SLT working with
a child with CFM may not be aware of the management of VP
function; therefore, regular review by a specialist craniofacial/cleft
SLT will ensure good clinical practice.
 Costs and resources
The impact on costs and resources of the given recommendations
will vary per member state, depending on the available care providers
and facilities. The recommendations concern the essential require-
ments for adequate treatment of patients with CFM and should thus be
implemented. Costs are lowest and resources are most efficiently
used when care for craniofacial disorders is centralised in a limited
number of expert centres per member state. A general rule that can be
applied is one expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
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 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Individuals with CFM can present with a range of communica-
tion difficulties, not least, early language delay, articulation dis-
orders and velopharyngeal dysfunction. These may be related to one
or a combination of the following: cleft palate, asymmetrical oral-
facial structures, hearing difficulties and visual impairment. In
addition, this population can also present with difficulties in
receptive and expressive language skills, requiring alternative
communication modes such as signing in early childhood. Where
the screening/evaluation has highlighted difficulties, any of the
following recommendations may apply and should be considered on
an individual basis. The duration and intensity of treatment is not
stipulated, as this will depend on the needs of the child, engagement
of the child and family in the intervention process, available
resources and local policies for speech and language therapy
services. These recommendations have been made to facilitate
the best long-term outcome for the individual and to decrease
the burden of care for all agencies involved, as the literature shows
that poor outcomes for literacy, employability and mental health in
adults (23).
Recommendations
 Recommend early language stimulation for delayed
babble onset from nine months.
 Facilitate receptive and expressive language develop-
ment using a range of behavioural techniques such as
modelling, imitation, repetition and extension.
 Patients with cleft speech characteristics should have
articulation therapy when identified. Direct therapy
using an articulation approach is recommended from
age three onwards
 Monitor patients with tracheostomy and speaking valve
use on a regular base.
 Introduce low or high tech augmentative and alternative
communication systems to children who are non-verbal
or whose speech is unintelligible. These include
gestures, signing, symbols, word boards, communica-
tion boards and books, as well as Voice Output
Communication Aids (VOCAs). A low-tech system
such as signing can be introduced from one.
 Intervention for social communication difficulties is
recommended; e.g. development of non-verbal com-
munication skills (e.g. eye contact, turn-taking);
conversational skills, recognitions of emotions and
emotional regulation.
Research gap
No literature is available regarding indications and policy for
treatment of speech difficulties in patients with craniofacial micro-
somia. Availability of studies could help determine an optimal
treatment strategy.
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.4 Hearing difficulties in craniofacial
microsomia
Introduction
Hearing is a sensory experience that facilitates communication
and social interaction. Hearing impairment may lead to difficulties
in learning, language and cognitive development, academic
achievements, and can have a negative social impact on children
(1). Hearing loss may be either conductive and/or sensorineural.
Conductive hearing loss is based on any obstruction in the passage
of sound through the outer ear, ear canal and/or middle ear. The
inner ear, with the cochlea and vestibulocochlear nerve, processes
the sound wave. Pathology in this system leads to sensorineural
hearing loss. Mixed hearing loss is a combination of sensorineural
and conductive hearing loss.
The degree of hearing loss is divided into mild, moderate, severe
and profound hearing loss. Mild hearing loss is defined as a hearing
loss of 26-40 decibels, moderate hearing loss as 41–60 decibels,
severe hearing loss as 61–80 decibels, and profound hearing loss as
over 81 decibels (2).
In the general population, the prevalence of hearing difficulties
in childhood is approximately 0.08% (3). The incidence of sensori-
neural hearing loss is found to be 0.001% to 0.004%, but in patients
with craniofacial syndromes this increases to 3% to 4% (4).
Patients with craniofacial microsomia (CFM) may be at
increased risk for reduced hearing due to various congenital anom-
alies, such as microtia, and outer and middle ear hypoplasia/
dysplasia. Also, patients with CFM are prone to have Eustachian
tube dysfunction and recurrent ear infections, which increases the
risk for hearing loss too (5). Besides conductive hearing loss,
patients with CFM may be at increased risk for sensorineural
hearing loss due to inner ear malformations.
Early detection and intervention of hearing loss is associated
with improved outcomes in all children, hence the implementation
of neonatal hearing screening programmes worldwide. To obtain
more knowledge on hearing loss and impairment in CFM and to
offer potential recommendations on (additional) screening and
treatment, the following questions were posed:
4.4.1 What is the type, prevalence and severity of hearing
difficulties in craniofacial microsomia?
4.4.2 What is the policy for screening and monitoring of
hearing difficulties in patients with craniofacial microso-
mia?
4.4.3 What are the indications and policy for treatment of
hearing difficulties in patients with craniofacial microso-
mia?
Literature search
A systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic
review matches the question of the
guideline.
- The search of the systematic review
was conducted in at least two relevant
databases, such as the Cochrane
Library, Medline/Pubmed.
- The full search strategy was
reported.
- No relevant items were missing in
the search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Hearing, ear anomalies
Exclusion criteria - Original studies with <10 included
patients






Literature was screened on title and abstract. A total of eighteen
articles were included. Most were retrospective cohort studies:
Bassila et al. (6), Carvalho et al. (4), Cousley et al. (7), Heike
et al. (8), Hennersdorf et al. (9), Jacobsson et al. (10), Llano-Rivas
et al. (11), Mitchell et al. (5), Rahbar et al. (12), Strömland et al.
(13), and Wan et al. (14). Three studies were case series: Bisdas
et al. (15), Engiz et al. (16), and Rosa et al. (17). Four cross-
sectional studies were included, by Cohen et al. (18), Davide and
Renzo et al. (19), Goetze et al. (20), and Sleifer et al. (21). No
articles on the indication or outcomes of treatment of hearing
difficulties in patients with CFM were available.
4.4.1 What is the type, prevalence and severity of hearing
difficulties in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type of hearing loss (conductive,
sensorineural) and type of congenital malformations (outer, middle,
or inner ear anomalies), prevalence and severity (mild, moderate,
severe or profound hearing loss) of hearing difficulties in CFM
(Appendix 1, http://links.lww.com/SCS/B697). Since this question
does not relate to interventions or diagnostics, no considerations,
rationale or recommendations are provided.
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Review of literature
The prevalence of unspecified, conductive, sensorineural and
mixed hearing loss reported in literature is shown in Figure 1. The































Unspecified Conducve Sensorineural Mixed
Figure 2. Prevalence of hearing loss in patients with
craniofacial microsomia.
Mitchell et al. evaluated facial malformations and hearing loss in
patients with CFM (5). A total of 79 patients with CFM were
included: 39 patients had bilateral CFM and 40 patients had
unilateral CFM. Microtia was present in 94% of the patients and
hearing loss in 82% (n¼ 65) of the patients. Of the patients with
hearing loss, twelve patients had bilateral hearing loss and 53
patients had unilateral hearing loss. Interestingly, two patients with
bilateral hearing loss had a normal ear phenotype and two patients
had unilateral microtia. The severity of hearing loss was mild in 7%,
moderate in 3%, moderately severe in 30%, severe in 10%, and
profound in 2% of the ears. A positive correlation was present
between the severity of hearing loss and the severity of ear
hypoplasia (Spearman rank correlation coefficient 0.755,
p¼<0.001). Conductive hearing loss was found in 73% of the
ears, mixed hearing loss in 10% and sensorineural hearing loss in
1%. In 16% of the ears the type of hearing loss could not be
identified. In 78% of the ears, conductive or mixed hearing loss was
based on stenosis or atresia of the external auditory canal. Other
causes for conductive or mixed hearing loss were middle ear
effusion (n¼ 4), negative pressure (n¼ 2), or tympanic membrane
perforations (n¼ 1). Hearing loss was frequently associated with
ipsilateral hypoplasia of the ear or mandible, although 8% of the
patients had contralateral hearing loss. Of the patients with man-
dibular hypoplasia and microtia, 90% had hearing loss, whereas in
patients with mandibular hypoplasia and normal ears, only 33.5%
had hearing loss. The authors emphasise the importance of early
diagnostic hearing assessment and close audiologic follow-up in
patients with CFM.
Rahbar et al. retrospectively evaluated 40 patients with CFM to
evaluate the clinical, audiologic and temporal bone CT findings
(12). Seven patients had bilateral CFM and 33 patients had unilat-
eral CFM. Auricular anomalies were found in 95% of the patients,
conductive hearing loss in 86% of the patients (n¼ 35) and senso-
rineural hearing loss in 10% of the patients (n¼ 4). Ten patients
were successfully using hearing aids: five patients with unilateral
CFM and five patients with bilateral CFM. The severity of conduc-
tive hearing loss in unilateral CFM was mild in 6%, moderate in 3%,
moderately severe in 15%, severe in 42%, and profound in 9% of the
patients. Profound sensorineural hearing loss was found in 6% of
the patients with unilateral CFM. Two patients with unilateral CFM
(6%) had bilateral moderately severe conductive hearing loss. In
patients with bilateral CFM, bilateral conductive hearing loss was
moderately severe in 43% (n¼ 3) and severe in 29% (n¼ 2)
patients. Chronic otitis media was reported frequently: 20 patients
with unilateral CFM (60%) and three patients with bilateral CFM
(43%) had a history of chronic otitis media. Fifteen patients with
unilateral CFM (45%) and one patient with bilateral CFM (14%)
required tympanostomy tube placement. Unilateral atresia or ste-
nosis of the external auditory canal were found in respectively 61%
and 12% of the patients with unilateral CFM and in respectively
57% and 28% of the patients with bilateral CFM. Hypoplasia or
atresia of the middle ear was present in respectively 70% and 18%
of the patients with unilateral CFM. All patients with bilateral CFM
had hypoplastic middle ears. The ossicles were dysplastic in 73% of
the patients with unilateral CFM and in 86% of the patients with
bilateral CFM. The most common inner ear abnormality was a
hypoplastic oval window and was found in 36% of the patients with
unilateral CFM and in 29% of the patients with bilateral CFM. One
unilateral and one bilateral patient had an abnormal cochlea. Other
reported anomalies were: hypoplastic vestibule (n¼ 2), hypoplastic
semicircular canals (n¼ 1), atretic facial nerve recess (n¼ 1), and
an atretic round window (n¼ 2). Patients with unilateral CFM and
severe ear malformations (i.e. a high E of the O.M.E.N.S. score) had
a significantly higher risk for inner ear anomalies (Spearman rank
correlation coefficient 0.57, p¼<0.001). Both unilateral and bilat-
eral patients with a higher total O.M.E.N.S. score have a higher risk
for inner ear malformations (Spearman rank correlation coefficient
0.47 and 0.83, p¼ 0.006 and p¼<0.001). No correlation was
present between the O.M.E.N.S. score and the degree or type of
hearing loss. The authors strongly recommend complete audiologic
evaluation of every child with CFM, regardless of the type or
severity of the facial malformations. If a CT scan for mandibular
surgery is performed this should include a scan of the temporal bone
to examine inner ear anomalies.
Systemic and functional difficulties in a group of eighteen
patients were retrospectively studied by Strömland et al (13).
Fifteen patients had hearing loss: four patients unilateral conductive
hearing loss, five patients bilateral conductive hearing loss, three
patients bilateral mixed hearing loss, and three patients bilateral
sensorineural hearing loss. Seventeen patients had external ear
malformations. Twelve patients had middle ear malformations,
which were bilateral in five patients. A fusion of the malleus
and incus or a hypoplastic middle ear cavity occurred most fre-
quently, although no numbers were given. Inner ear malformations
were found in three patients, which was bilateral in a single patient.
All patients with inner ear malformations had a defect vestibular
organ. The authors stress the importance of hearing tests in patients
with CFM early in childhood that should be repeated if not
conclusive. In addition, a CT-scan to evaluate the middle and inner
ear and thorough otolaryngological investigation should be per-
formed in patients with CFM.
To investigate intracranial anomalies in CFM a cross-sectional
study was set up by Davide and Renzo et al (19). Thirty-five patients
with CFM underwent CT imaging of the head; additional MRI of
the head was performed in 32 patients. Nineteen patients fulfilled
the criteria for Goldenhar syndrome which was defined by having
ocular or cervical vertebral abnormalities additional to CFM and
microtia. Inner ear malformations, such as atretic oval windows,
abnormal facial nerve bony canal, or dysplasia of the semicircular
canals, were found in 31% of the patients (n¼ 11). Inner ear
abnormalities were correlated with ipsilateral seventh and eighth
cranial nerve abnormalities.
In 1989, Bassila et al. retrospectively studied 50 patients with
CFM to gain more knowledge of the clinical features of CFM, with
special interest in facial nerve palsy and hearing loss (6). Thirty-
eight unilateral and twelve bilateral patients were included. Auric-
ular anomalies such as microtia or preauricular skin tags or pits were
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present in 92% of the patients. Facial nerve paralysis or paresis was
reported in eleven patients. A total of eight patients had sensori-
neural hearing loss (prevalence of 16%). In six patients the senso-
rineural hearing loss was accompanied by facial nerve palsy and in
two patients it was not. All eight patients with sensorineural hearing
loss had unilateral CFM. Interestingly, four of the eight patients
with hearing loss had bilateral sensorineural hearing loss. In two
patients with sensorineural hearing loss a CT scan was obtained
which showed an absent cochlea and abnormal vestibulum in one
patient, and a normal cochlea and vestibulum in the other patient.
The relationship between auditory and facial nerve dysfunction
was assessed by Carvalho et al. too, in a retrospective cohort study
of 99 patients with CFM (4). Thirty patients had bilateral CFM and
69 unilateral CFM. Auricular anomalies, including microtia and
ear tags/pits, were present in 91 patients. A total of 75% of the
patients (n¼ 74) had hearing loss. Fourteen of the 74 patients with
hearing loss (19%) required rehabilitation with auditory amplifi-
cation. Conductive hearing loss was found in 74% (n¼ 73)
patients. Patients with auricular anomalies had conductive hearing
loss twice as often (p¼ 0.03). Sensorineural hearing loss was
present in eleven patients, ten of these patients had conductive
hearing loss too. In eight of the eleven patients, the sensorineural
hearing loss was unilateral and in three patients it was bilateral.
Patients with auricular anomalies had a higher incidence of sen-
sorineural hearing loss compared to patients without auricular
anomalies (p¼ 0.04). Twenty-two patients had facial nerve dys-
function (all unilateral CFM). No correlation was found between
facial nerve dysfunction and sensorineural hearing loss or auricular
anomalies. Patients with a more severe form of CFM or bilateral
CFM were not found to have a higher risk for sensorineural hearing
loss or facial nerve dysfunction. The authors strongly recommend a
complete audiologic evaluation of every child in which the diag-
nosis of CFM is considered.
Wan et al. retrospectively studied the clinical, temporal bone and
audiological findings in 70 patients with CFM (14). Seventeen
patients (24%) had bilateral CFM and 53 patients (76%) unilateral
CFM. Almost all patients (99%) had auricular deformities. Hearing
aids were used by 19 patients (27%). A total of 87 ears were
evaluated: conductive hearing loss in 82%, mixed hearing loss in
15%, sensorineural hearing loss in 3% of the ears. The external
auditory canal was normal in 8%, stenotic in 10% and atretic in 81%
of the 87 ears. The middle ear was hypoplastic in 67% and atretic in
7% of the 87 ears. The ossicles were fused in 59% and absent in 23%
of the 87 ears. The inner ear was abnormal in 8% of the 87 ears. The
facial nerve was displaced in 40% and not identified in 15% of
the 87 ears. The severity of the facial malformations, displayed by
the total O.M.E.N.S. score, was correlated with the malformation on
radiography of the temporal bone (p¼<0.001). The severity and
type of hearing loss was not related to the total O.M.E.N.S. score or
the malformations on temporal bone radiography. This emphasises
the importance of audiological testing in all patients with CFM.
A cross-sectional study of 89 patients with CFM was undertaken
by Cohen et al. to study the type and frequency of maxillofacial and
systemic malformations in CFM (18). All patients were evaluated
for hearing impairment. External ear anomalies (microtia or anotia)
were present in 83% of the patients of which 15% had bilateral ear
malformations. Atresia of the auditory canal was found in 58% of
the patients, and 21% of the patients had stenosis of the auditory
canal. Hearing impairment, which is associated with auditory canal
malformations, was present in 79% (n¼ 69) of the patients. Bilat-
eral deafness due to cochlea or acoustic nerve damage was found in
five patients (6%).
Cousley et al. included 50 CFM patients in a retrospective cohort
study to compare two classification systems (SAT and O.M.E.N.S.)
(7). Data on hearing difficulties was included in this study: 66% of
the patients had hearing difficulties. Three patients had unilateral
conductive hearing loss combined with bilateral sensorineural
hearing loss. No further data on hearing loss or auricular anomalies
was provided.
A large retrospective cohort study was set up by Heike et al. to
develop a standardised approach to assess and describe facial
characteristics in patients with CFM and controls (8). A total of
142 patients with CFM and 290 controls without a craniofacial
syndrome were included. Sixty-seven percent (n¼ 91) of the
patients with CFM and four percent (n¼ 9) were reported to have
hearing difficulties. Hearing devices were used by 21% of the
patients with CFM and 0.3% of the controls. No further information
on hearing difficulties was available in this study.
Engiz et al. studied 31 patients with CFM to describe the
phenotypic features (16). In 21 patients the hearing status was
known. Eighteen of these patients had hearing loss: conductive in
twelve patients, mixed- in two patients, and sensorineural hearing
loss in a single patient. Three patients with an atretic ear had normal
hearing in the other ear.
A cross-sectional study on hearing difficulties in a group of ten
patients with CFM was performed by Goetze et al (20). All included
patients had microtia. Two patients had unilateral conductive
hearing loss, respectively mild and moderate. One patient had
moderate bilateral conductive hearing loss. Sensorineural hearing
loss was present in two patients, both bilateral. One patient had
profound sensorineural hearing loss in both ears and the other
patient had moderate and mild sensorineural hearing loss.
Sleifer et al. studied audiological findings in CFM in a cross-
sectional study (21). All ten included patients with CFM underwent
tonal and vocal hearing evaluations. Conductive hearing loss was
present in 40% of the left ears and 60% of the right ears. Sensori-
neural hearing loss was found in five ears, mild (n¼ 2), moderate
(n¼ 1), and profound (n¼ 2). It is unclear if any patient had isolated
sensorineural hearing loss. External ear malformations were found
in 70% of the left ears (n¼ 7) and in 80% of the right ears (n¼ 8).
No correlation was found between the severity of ear malformation
and hearing loss.
To assess inner ear anomalies in Goldenhar syndrome, a retro-
spective review of temporal bone changes in 21 patients with
Goldenhar syndrome was undertaken by Hennersdorf et al (9).
Ninety percent (n¼ 19) of the patients had atresia or stenosis of the
external auditory canal. Dysplasia of the ossicles was present in
90% of the patients; absence of ossicles was found in one patient
(5%). A narrowed or opacified tympanic cavity was found in 67%
(n¼ 14) of the patients. The antrum mastoidium was opacified in
57% (n¼ 12) of the cases. Thirty-three percent of the patients had
inner ear anomalies of the cochlea, semicircular canals or vestibule.
Cochlear hypoplasia and a common cavity deformity were both
found in a single patient. Anomalies of the semicircular canals were
found in five patients (24%) and were associated with dysplasia of
the vestibule, which was seen in four patients (19%). Information on
hearing difficulties was available for seven patients: four patients
had isolated severe conductive hearing loss and three patients had
combined hearing loss, which was correlated to severe inner ear
malformations in a single patient. Interestingly, the other two
patients with mixed hearing loss had no apparent inner ear mal-
formations on imaging. The authors state that inner ear deformities
are not always correlated to external and middle ear malformations,
which stresses the importance of a high-resolution CT or MRI of the
temporal bone in all CFM patients.
Jacobsson et al. studied the clinical appearance of syndromes
that affect the structures originated from the first and second
pharyngeal arches (10). This retrospective cohort study included
26 patients with unilateral CFM. Twenty-five patients had atretic
external ear canals. One patient with unilateral CFM had bilateral
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middle ear deformities. Dysplasia of the ossicles was common in the
studied population: malleus malformation in 25 ears, malleus fusion
in three ear, incus malformation in 24 ears, incus fusion in three
ears, stapes malformation in 21 ears, and a missing stapes in five
ears. Two patients had a cochlear malformation, one of these
patients had sensorineural hearing loss. No information on hearing
in the other patients was available.
A case series of twelve patients with CFM to describe ear
anomalies was initiated by Rosa et al (17). All twelve patients had
external ear anomalies, eight patients had middle ear anomalies and
three patients inner ear anomalies. Type of middle ear anomalies:
displacement (n¼ 2), opacification (n¼ 2), and malformation (n¼ 2)
of the ossicles. Agenesis of the inner ear canal was found in two
patients. No information about hearing difficulties was reported.
A case series of fourteen patients with Goldenhar syndrome was
presented by Bisdas et al. to study inner ear malformations in
patients with Goldenhar syndrome (15). No clear criteria were used
to include patients; no information on laterality of Goldenhar
syndrome was available. Atresia of the external auditory canal
was present unilaterally in ten patients and bilaterally in two
patients. Inner ear malformations were seen in five (36%) patients:
dysplastic or absent ossicles in 13 patients, absence or dysplasia of
the semicircular canals in four patients, enlarged vestibule in four
patients, enlarged internal auditory canal in two patients, and a
common cavity deformity in one patient. No information about
hearing difficulties in these patients was provided.
Llano-Rivas et al. included 87 patients with isolated microtia
and 58 patients with CFM, to study the clinical and genetic
behaviour of microtia (11). A normal external auditory canal
was present in 48% of the patients with CFM (n¼ 28); 47%
(n¼ 27) of the patients had a unilateral atretic external auditory
canal and 5% (n¼ 3) of the patients had a bilateral atretic external
auditory canal. The prevalence of a normal or unilateral atretic
external auditory canal was equal in patients with CFM and isolated
microtia. However, patients with isolated microtia were found to
have a higher prevalence of bilateral atretic external auditory canal
(16% versus 5%, p¼ 0.05). Data on hearing loss was only available
for all 145 patients and not specified for patients with CFM. Eighty-
five percent of the patients had conductive hearing loss (n¼ 123).
Five patients (3%) had sensorineural hearing loss and six patients
(4%) had mixed hearing loss.
The types of ear anomalies and its prevalence found in patients
with CFM are displayed in Table 1.
Table 3. Types of ear anomalies.
Type of malformation Prevalence Reference
Outer ear Atresia or stenosis external
auditory canal
90% (9)
Atresia external auditory canal 52% - 96% (10–12, 14, 15, 18)
Stenosis external auditory canal 10% - 35% (12, 14, 18)
Middle ear Dysplastic or absent ossicles 93% (15)
Dysplastic ossicles 17% - 90% (9, 12, 17)
Agenesis ossicles 5% - 23% (9, 14)
Opacification of ossicles 17% (17)
Displacement of ossicles 17% (17)
Fusion of ossicles 59% (14)
Malleus malformation 96% (10)
Malleus fusion 12% (10)
Incus malformation 92% (10)
Incus fusion 12% (10)
Stapes malformation 81% (10)
Stapes aplasia 19% (10)
Hypoplastic oval window 35% (12)
. (continued )
Type of malformation Prevalence Reference
Agenesis round window 5% (12)
Agenesis facial nerve recess 3% (12)






Hypoplastic middle ear 67% (14)
Agenesis middle ear 7% (14)
Inner ear Inner ear malformations not
specified
8% - 31% (14, 19)
Cochlear anomaly 5% - 10% (9, 12)
Dysplastic or absent semicircular
canals
3% - 29% (9, 12, 15)
Vestibule deformity 5% - 29% (9, 12, 15)
Enlarged internal auditory canal 14% (15)
Common cavity deformity 7% (15)
Agenesis inner ear canal 17% (17)
Conclusions
- Prevalence
The prevalence of hearing difficulties in patients with craniofacial
microsomia is:
- Unspecified hearing loss: 50% - 82%
- Conductive hearing loss: 30% - 86%
- Sensorineural hearing loss: 1% - 20%
- Mixed hearing loss: 6% - 17%
Ref (4–8, 12–14, 16, 18, 20, 21)
Level 3 Prevalence
In 6% - 10% of the patients with unilateral craniofacial
microsomia, hearing difficulties can be present bilaterally or
solely on the contralateral side.
Ref (5, 6, 12)
Level 3 Type
The most common anomalies of the ear in patients with
craniofacial microsomia are:
- Outer ear: Atresia or stenosis of the external auditory canal
- Middle ear: Dysplastic or absent ossicles
- Inner ear: vestibule deformity or semicircular canal anomalies
Ref (9–12, 14, 15, 17, 18)
Level 3 Risk factors
Severe microtia or anotia is positively correlated with hearing
loss.
Although a higher total O.M.E.N.S. score was found to be
correlated with inner ear malformation, no correlation was
present between the total O.M.E.N.S. score and the degree or
type of hearing loss.
No correlation was present between facial nerve dysfunction and
sensorineural hearing loss or auricular anomalies. However,
facial and vestibulocochlear nerve dysfunction were
correlated with ipsilateral inner ear anomalies.
Patients with bilateral craniofacial microsomia were not found to
have a higher risk for hearing difficulties compared to patients
with unilateral craniofacial microsomia.
Ref (4, 5, 12, 14, 19)
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4.4.2 What is the policy for screening and monitoring of
hearing difficulties in patients with craniofacial microso-
mia?
The literature search for this question was directed towards more
specific questions related to the consequences and impact of
screening and monitoring, the available screening tests and proce-
dures for monitoring, and responsibilities for screening and moni-
toring (Appendix 1, http://links.lww.com/SCS/B697).
Review of literature
Various manuscripts included in Chapter 4.4.1. conclude that
every child diagnosed with CFM should have complete audiologic
evaluation (4, 5, 9, 11–14, 20). Imaging of the temporal bone by
using high-resolution CT or MRI to assess middle and inner ear
anomalies is recommended by various authors as well (9, 12, 13,
17). Although screening is recommended, timing and frequency
were not further specified.
Conclusion
No conclusions based on CFM-specific literature could be made.
Considerations
 Overall quality of evidence
Because there is no applicable literature available the recom-
mendations are based on expert opinion with a low quality
of evidence.
 Balance of benefits and harms
The steering group reasons that most parents of patients want
their children to be screened for hearing difficulties, to ensure
optimal speech and language development.
 Outcome importance
A delay in detecting or failure to detect hearing loss could have
considerable consequences for speech, and language development
(bilateral hearing loss) and/or social interaction (unilateral or
bilateral hearing loss), while a hearing test is a low burden for
the patient or parents. The Joint Committee on Infant Hearing
emphasise the importance of early detection of hearing difficulties.
A guideline for early hearing detection and intervention was
published in 2007 (22).
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
All new-born infants that do not pass the neonatal hearing test
should have an auditory brainstem response (ABR) test included as
part of their screening. Referral to an otolaryngologist experienced
in paediatric hearing loss should be made to have complete screen-
ing of both ears. Complete audiological evaluation should be done
within three months of age in patients who do not pass the initial
hearing test. Audiologic intervention should be initiated before the
age of six months in these patients. Children who pass the neonatal
hearing test but have a higher risk for hearing difficulties should be
re-evaluated in 24 to 30 months. Since patients with hearing loss are
at risk for a delay in speech and language development, regular
monitoring for speech and language development at six months
intervals should be initiated.
Screening for hearing loss will incur costs but outweighs the risk
of not screening for hearing difficulties. The main aspects in
determining these risks are the age of the patients and severity
of CFM. Overall, all young patients in whom speech and language
skills are developing should be examined by a hearing test yearly.
Recommendations
 Perform neonatal hearing test in all new-borns with
craniofacial microsomia. If indicated, complete audio-
logical evaluation in an experienced audiology centre
should be performed before the age of three months to
ensure timely treatment.
 Re-evaluate hearing tests in patients with craniofacial
microsomia by the age of 24–30 months.
 Regularly perform otoscopy and audiometry in patients
with craniofacial microsomia including microtia and/or
cleft palate by the ENT doctor/otolaryngologist.
 Audiologic intervention should be initiated before the
age of six months in patients with congenital
hearing loss.
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Research gap
The available literature mainly focuses on the prevalence of
hearing loss but provides little information on the severity of
hearing loss, types of treatment, and results of treatment.
4.4.3 What are the indications and policy for treatment of
hearing difficulties in patients with craniofacial microso-
mia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of hearing difficulties (Appendix 1, http://links.lww.com/
SCS/B697). Unfortunately, no literature is available on the indica-
tions and policy for treatment of hearing difficulties in patients with
CFM. Therefore no conclusions were written. Considerations for
this question were only based on expert opinion.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
The steering group reasons that most parents of patients want
their children to be screened for hearing difficulties, to ensure
optimal speech and language development.
 Outcome importance
Untreated hearing loss could have significant consequences for
the well-being of the patient, his or her speech and language
development, and his or her social participation.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The Joint Committee on Infant Hearing states that the initiation
of early intervention for hearing loss should begin as soon as
possible after the diagnosis of hearing loss but no later than the
age of six months (22). Intervention before the age of six months
gives significantly better outcomes on language, speech and social-
emotional development compared to later-identified children. Per-
sonal amplification devices should be provided by an experienced
audiologist soon after the diagnosis of hearing loss. Surgical
treatment may be indicated in some patients to reconstruct mal-
formed outer and/or middle ears and includes bone-anchored
hearing aids. Cochlear implantation should be considered in
patients who have limited benefits from (bone-anchored)
hearing aids.
The International Microtia and Atresia Workgroup advises that
all patients with microtia and external auditory atresia should be
seen in a multidisciplinary team (23). It is important for patients
with bilateral aural atresia to be treated with bone conduction
devices or cochlear implants to support language and speech
development (23). Timing of placement should be discussed with
a microtia surgeon to ensure the possibility of microtia reconstruc-
tion in the future (23).
Recommendations
 Treat moderate to severe hearing loss, either with non-
surgical or surgical options.
 Coordinate surgical approach and timing in a multidis-
ciplinary team regarding hearing augmentation and
other surgical procedures including ear reconstruction
and mandibular surgeries.
Research gap
No literature is available regarding indications and policy for
treatment of hearing difficulties in patients with craniofacial micro-
somia. Availability of studies could help determine an optimal
treatment strategy.
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.5 Eye anomalies in craniofacial microsomia
Introduction
Originally, the triad of Goldenhar syndrome, now believed to be
part of the craniofacial microsomia (CFM) ‘spectrum’, consisted of
mandibular dysostosis, ear malformations and epibulbar dermoids
(1). This illustrates the prominent role eye anomalies have in CFM.
Patients with CFM regularly present with epibulbar dermoids or
other eye anomalies, such as colobomata. This chapter focusses on
eye anomalies in CFM. Orbital malformations will not be taken
into account.
Colobomata are caused by incomplete closure of embryonic
fissures and can clinically present as gaps or notches of the eyelids,
lens, and/or choroid and retina. Epibulbar dermoids are benign,
ectopic, congenital neoplasms that vary in composition (dermoid or
lipodermoid) or location (corneal or limbal) (2). It is the most
common congenital benign tumour of the eye, occurring in 1–3 per
10,000 births in the general population (3). The aetiology of
epibulbar dermoids remains unclear.
Epibulbar dermoids have been classified in three grades (4, 5):
Grade I: Superficial dermoids measuring less than 5 mm,
located on the limbus
Grade II: Limbal dermoid covering most of the cornea,
down into the stroma up to Descemet’s
membrane, without involving the membrane.
Grade III: Large dermoids covering the whole cornea
extending up to the pigmented epithelium of the
iris.
To develop recommendations on screening, monitoring and
treatment of eye anomalies in CFM the following questions were
posed:
4.5.1 What is the type, prevalence and severity of eye anomalies
in craniofacial microsomia?
4.5.2 What is the policy for screening and monitoring of eye
anomalies in patients with craniofacial microsomia?
4.5.3 What are the indications and policy for treatment of eye
anomalies in patients with craniofacial microsomia?
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An overview of the type, prevalence and severity of eye
anomalies seen in patients with CFM makes it possible to develop
recommendations on screening and treatment of these anomalies.
Commonly seen eye anomalies in patients with CFM, such as
epibulbar dermoids and colobomata, can lead to various patient
relevant consequences. Limbal dermoids, including grade I der-
moids, can cause amblyopia, difficulties with eyelid closure, irrita-
tion, corneal erosion, and/or aesthetic difficulties. This may be an
indication for surgical resection. Other eye anomalies, as colobo-
mata, can lead to exposure keratopathy, corneal ulceration, retinal
detachment and/or cataract (6). Since timely treatment is important
to maintain optimal vision, recommendations on screening and
monitoring should be made.
Literature search
A systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material. The
inclusion and exclusion criteria are as follows:
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic
review matches the question of the
guideline.
- The search of the systematic review
was conducted in at least two relevant
databases, such as the Cochrane
Library, Medline/Pubmed.
- The full search strategy was
reported.
- No relevant items were missing in
the search strategy.
Type of patients - Patients with craniofacial
microsomia
- Patients with epibulbar dermoids
Subject - Eye anomalies, epibulbar dermoids,
coloboma
Exclusion criteria - Original studies with <10 included
patients





Literature was screened on title and abstract. All literature on
eye anomalies in CFM that was available was included in this
chapter. A total of five manuscripts were included: a large retro-
spective cohort study by Caron et al. (7), a cross-sectional study by
Cohen et al. (8), and four retrospective cohort studies by Hertle et al.
(9), Ewart-Toland et al. (10), Strömland et al. (11), and Mansour
et al (3).
Since no literature on the indication for treatment was available,
an additional search was done. This search contained epibulbar
dermoids and variants and was performed in Medline/Pubmed.
Literature on indications for treatment for epibulbar dermoids in
general was included in this chapter. The full search strategy is
included in the supplementary material. A total of 254 articles were
identified; exclusion based on title and abstract led to the inclusion
of two articles. Although narrative reviews were excluded in
previous chapters, a review by Pirouzian et al. (5) was included
in this chapter due to the extensive nature of the review and the good
link with the research question. A case series by Matsuo was
included too (12).
4.5.1 What is the type, prevalence and severity of eye
anomalies in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type (epibulbar dermoids and
colobomata), prevalence and severity (mild, moderate or severe)
of eye anomalies in CFM (Appendix 1, http://links.lww.com/SCS/
B697). Since this question does not relate to interventions or
diagnostics, no considerations, rationale or recommendations
are provided.
Review of literature
In 1985, Mansour et al. aimed to report ocular findings in a large
cohort of patients with CFM (3). A total of 57 patients were
included in this retrospective cohort study. Half of the patients
(51%) had ocular anomalies: 32% (n¼ 18) epibulbar (lipo)der-
moids, 19% (n¼ 11) ocular motility disorders, 12% (n¼ 7) ble-
pharoptosis, 11% (n¼ 6) eyelid coloboma, and 11% (n¼ 6)
lacrimal duct or gland anomalies. Two-thirds of the epibulbar
(lipo)dermoids were unilateral, the others were bilateral. All
patients with an eyelid coloboma had epibulbar (lipo)dermoids
too, although in one case the coloboma was located in the other
eye than the (lipo)dermoid. Ocular motility disorders included
esotropia in six patients, exotropia in three patients, a single patient
with Duane’s syndrome, a patient with abduction deficiency, and a
patient with unspecified strabismus. It is unclear whether the ocular
motility disorders were caused by epibulbar (lipo)dermoids. Inter-
estingly, data on anomalies of the posterior pole of the eye was
present in nineteen patients and three patients were found to have
anomalies: a patient with a choroidal coloboma, one patient with a
large peripapillary hypopigmentation, and a patient with a retinal
vascular tortuosity.
Hertle et al. reported the ocular and adnexal findings of 49
patients with CFM (44 unilateral and 5 bilateral CFM) who all had
ophthalmologic evaluation (9). Two-thirds (67%) of the patients
had some ocular or adnexal anomaly. Frequently seen ocular
anomalies included: astigmatism (18%), amblyopia (16%) and
anisometropia (8%). Amblyopia was caused by multiple factors
including strabismus, refractive errors, and ptosis. Another fre-
quently seen ocular anomaly was strabismus (22%, n¼ 11). Six of
these patients had noncomitant strabismus (Duane syndrome
(n¼ 2), sixth nerve palsies (n¼ 2) and bilateral superior oblique
palsies (n¼ 2)). Comitant exotropia was reported in three patients
and esotropia in two patients. No globe or optic nerve anomalies
were seen, although a single patient had tortuous retinal vasculature
with normal vision in both eyes. Lid or adnexal anomalies were seen
in 41% of the patients and included: dacryostenosis (15% of all
patients), blepharoptosis (12% of all patients), canthal dystopia (8%
of all patients), lagophthalmos (8% of all patients), entropion (4% of
all patients), lipodermoids (4% of all patients), lid retraction (2% of
all patients), and telecanthus (2% of all patients). This study shows a
high frequency of ocular and adnexal anomalies in patients with
CFM, which according to the authors necessitates ophthalmologic
examination for all patients (9). It is important to diagnose and treat
strabismus, amblyopia, and adnexal anomalies early to prevent
visual loss (9).
Caron et al. reviewed 755 patients with CFM retrospectively to
analyse typical phenotypes within CFM (7). Most patients had
unilateral CFM (88.6%) and 11.4% had bilateral CFM. A total of
13.4% of patients had ophthalmic anomalies such as epibulbar
dermoids and/or colobomata. The location of the colobomata were
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not further specified. Patients with bilateral CFM had a significantly
higher risk for ocular anomalies (Pearson X2¼ 27.191,
p¼<0.001). Epibulbar dermoids were present in 81 patients
(10.7%): 74% of these patients had unilateral CFM and 26%
patients had bilateral CFM. Colobomata were less frequently seen:
in eleven patients (1.5%) colobomata were present together with
epibulbar dermoids and nine patients (1.2%) solely had colobomata.
No further information on ocular anomalies was reported.
Other studies reported briefly on ocular anomalies. Cohen et al.
reported in a cross-sectional study of 89 patients with CFM that 41
patients (46%) had ocular anomalies: 23 dermoid cysts (56%), 15
blepharoptosis (37%), 13 ocular and/or eyelid coloboma (32%), 6
dermolipoma (15%), and 12 other eye defects (29%) (8). A micro-
phtalmic eye was present in 29 patients (71%) and two patients had
anophtalmia (5%). Ewart-Toland et al. studied 21 patients with
CFM (10). Two patients had epibulbar dermoids; other anomalies
reported in single patients: bilateral conjunctival dermoids, corneal
opacity, eye lipoma, microphthalmus, and hypoplastic tear duct.
Strömland et al. retrospectively studied 18 patients with CFM (11).
Eleven patients (61%) had lipodermal dermoids of the eye and eight
patients (44%) had epibulbar dermoids. All patients with epibulbar
dermoids had lipodermal dermoids too. Three patients had unilat-
eral microphthalmus and one patient bilateral microphthalmus.
Other eye anomalies that were reported: upper eyelid coloboma




Reported eye anomalies in craniofacial
microsomia and its prevalence:
- Lipodermal dermoids - prevalence: 4% - 61%
- Epibulbar dermoids - prevalence: 10% - 56%
- Colobomata (eyelid) - prevalence: 3% - 32%
- Blepharoptosis - prevalence: 9% - 37%
- Microphthalmus - prevalence: 5% - 71%
- Lacrimal duct or gland anomalies - prevalence: 5% - 11%
- Strabismus - prevalence: 12% - 22%
- Reported eye anomalies in CFM
in a single study
- Astigmatism - prevalence: 18%
- Amblyopia - prevalence: 16%
- Anisometropia - prevalence: 8%
- Anomalies of the posterior pole
of the eye
prevalence: 5%
- Anophtalmia - prevalence: 5%
Colobomata are often accompanied




Patients with bilateral craniofacial microsomia
have a significant higher risk for eye




Visual loss could be seen in 8% of the patients
with craniofacial microsomia, although this
was reported in a single study with small
sample size (n¼ 49).
Ref (9)
4.5.2 What is the policy for screening and monitoring of eye
anomalies in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the consequences and impact of screen-
ing and monitoring, the available screening tests and procedures for
monitoring, and responsibilities for screening and monitoring
(Appendix 1, http://links.lww.com/SCS/B697). Unfortunately, no
literature on screening and/or monitoring of eye anomalies in patients
with CFM is available.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
CFM is found to be associated with a high percentage of ocular
anomalies (67%). The main concern is the risk of permanent visual
impairment caused by a treatable obstacle/anomaly. Therefore, all
children with CFM should be screened regarding visual develop-
ment at an early stage. Persistent amblyopia causes a reduced
quality of life especially, if the better eye is lost later in life and
a significant (financial) burden on society. Therefore, the benefits of
screening outweigh the harms.
 Outcome importance
The reduced quality of life in patients with poor visual acuity
requires adequate screening, monitoring and treatment, especially if
the visual acuity in the better eye is lost later in life.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
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 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The main purpose of screening children with CFM is to diagnose
risk factors that negatively influence visual development and provide
optimal treatment. Therefore, screening of all children with CFM by
an orthoptist and ophthalmologist in a specialised centre at an early
stage in the visual development, i.e. age three or four, is necessary; or,
in case there is an obvious anomaly obstructing the visual pathway,
patients should be referred at an earlier age. Depending on the results,
follow-up visits need to be scheduled on a regular basis.
Recommendations
 All patients with craniofacial microsomia should be
screened at least once during the visual development
(before the age of five) by an orthoptist and
ophthalmologist. Depending on the results, follow-up
visits need to be scheduled on a regular basis.
Research gap
No literature is available regarding the policy of screening and
monitoring of eye anomalies in patients with craniofacial micro-
somia. Availability of studies could help to develop better screening
and monitoring.
4.5.3 What are the indications and policy for treatment of eye
anomalies in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of eye anomalies (Appendix 1, http://links.lww.com/SCS/
B697). Unfortunately, no literature on the indications and policy for
treatment of eye anomalies in patients with CFM is available.
However, since epibulbar dermoids/lipodermoids is the most com-
monly seen eye anomaly in patients with CFM, literature on treatment
of these anomalies in non-CFM patients was included in this chapter.
Review of literature
Matsuo (12) described the process of clinical decision making in
ocular dermoids or dermolipomas by retrospectively studying
thirteen patients with epibulbar dermoids. Eight of the thirteen
patients underwent surgical resection of the dermoids and the other
five patients were observed. None of the patients had complaints of
irritation or redness of the eye. The indication for surgery was not
reported. Of the eight patients that had surgical resection, six
patients had elevated, dome-shaped limbal dermoids and two
patients had conjunctival fornix dermolipomas. No complications
were seen after surgery, although all six patients that had the limbal
dermoid removed showed superficial flat corneal opacification and
minimal neovascularization at the place of removal. The patients
and families were satisfied with the surgical outcome. The degree of
postoperative astigmatism was 0–7 diopters (median 2.9) in
patients with limbal dermoids and 0–1 diopters in the two patients
with conjunctival fornix dermolipomas. Surgical resection of the
limbal dermoids did not significantly influence the degree of
astigmatism (p¼>0.05). Of the five patients that did not undergo
surgery, three had flat limbal dermoids, one a dome-shaped limbal
dermoid, and one patient a conjunctival fornix dermolipoma. In the
observation group, the patient with the dome-shaped limbal der-
moids showed astigmatism. No changes in size of the dermoids was
found during observation. The authors conclude that dome-shaped
limbal dermoids were associated with a large degree of astigmatism
and were more frequently resected, and that flat-shaped limbal
dermoids and conjunctival fornix dermolipomas were not associ-
ated with astigmatism and were more frequently observed. All
patients with ocular surface dermoids or dermolipomas should have
a visual acuity check-up yearly. Dermoids and dermolipomas not
affecting the visual axis and not impairing visual acuity can be
observed at first. Surgical resection may also be indicated because
of cosmetic appearance. Timing of surgery could be based on
patients’ preferences, although combination with other surgical
procedures such as skin tag removal if indicated, should be consid-
ered in mind to reduce the risk of general anaesthesia. Ultrasound
imaging could help in decision making and conducting surgery in
patients with ocular dermoids that do not affect the visual axis.
A review of literature on medical and surgical management of
paediatric limbal dermoids was published by Pirouzian in 2013 (5).
Removal of dermoids may lead to scarring and development of
pseudopterygium. Therefore, it is discouraged to remove small,
asymptomatic grade I limbal dermoids. These patients should be
monitored on a regular basis, once every two-three months, when
the visual acuity and absence or presence of amblyopia should be
examined. If the patient develops amblyopia or anisometropia,
dermoid growth resulting in harm or defects of the cornea, and/
or aesthetic difficulties, surgical removal of the dermoid may be
indicated. In Table 1 the indications for surgical removal of grade I
limbal dermoids in children proposed by the authors are shown. For
grade II or grade III limbal dermoids surgical removal is commonly
indicated since these dermoids often cause amblyopia. In some
dermoids a tail extending into the orbit may be present, in which
case simple excision can result in perforation of the globe or
incomplete resection (13). Careful evaluation by using imaging
is indicated in dermoids suspected of posterior tail extension.
Table 1. Indications for surgical removal of grade I limbal
dermoids, from Pirouzian (5).
Chronic eye rubbing due to irritation and recurrent conjunctivitis
Amblyopia unresponsive to medical management
Progressive dellen, with corneal surface decompensation
Growth and encroaching into pupillary area or optical zone
Aesthetic considerations
Induction of irregular astigmatism
Inadequate lid closure
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Simple excision of corneal dermoids can lead to scar formation,
persistent epithelial defects, or corneal vascularisation at the der-
moid excision site, presumably due to focal limbal stem cell
deficiency at the resection site. To prevent complications of simple
excision, various additional techniques have been proposed. Use of
autologous limbal stem cell appear to prevent complications (14). In
patients with proven limbal stem cell deficiency with a partial
limbal deficiency, amniotic membrane transplantation was found to
be superior to allograft limbal transplantation (15). Except for two
of the 31 studied eyes, all amniotic membrane-covered defects
showed rapid epithelialisation and reduced inflammation, scarring
and vascularisation (15). A pericardial patch graft after grade II
limbal dermoid excision can be used too and is found to give good
cosmetic results (16). The use of fibrin glue-assisted multi-layered
amniotic membranes for reconstruction of the defect after lamellar
dissection in grade I perilimbal dermoids, has been shown to be
clinically successful (17). The membrane leads to volumetric filling
of the defective area and should be in height with the surrounding
corneal tissue. In patients with a grade III dermoid, in which the
cornea and anterior chamber are involved, reconstruction of the
anterior segment of the eye should be anticipated. Enucleation or
evisceration with orbital reconstruction has been proposed for
microphtalmic patients. A summary of the proposed treatment
options is presented in Table 2.
Table 2. Recommendations for surgical removal of ocular
dermoids. From Pirouzian (5).
Grade of paediatric limbal/
corneal dermoid Recommended techniques
Grade I: <50 mm thickness
and <1 mm diameter
Simple excision
Grade I: <100 mm thickness
and <1 mm diameter
Keratectomy þ AMT þ ALSCA
Grade II and deeper Grade I Keratectomy þ AMT þ LSCA þ
PPG
versus anterior or deep anterior
lamellar keratoplasty  AMT
Grade III Total anterior segment
reconstruction
Abbreviations: AMT, amniotic membrane transplantation (multilayered); ALSCA,
autologous limbal stem cell allograft; PPG, pericardial patch graft.
Conclusions
Level 3 Indications and Policy
Surgical resection of grade I limbal dermoids may be
indicated if complaints of eye irritation,
conjunctivitis, growth, inadequate eyelid closure,
corneal erosion, astigmatism, or aesthetic
difficulties start to occur.
Simple excision of corneal dermoids may lead to scar
formation, epithelial defects, or corneal
vascularization. Surgical resection of small,
asymptomatic grade I limbal dermoids with no
aesthetic complaints is discouraged.
Ref (5, 12)
Level 3 Policy
Grade II or grade III limbal dermoids and/or dome-
shaped limbal dermoids lead to astigmatism more
frequently. Therefore, surgical resection of these
dermoids is commonly indicated.
Ref (5, 12)
Level 3 Policy
Dermoids suspected of for having a tail extending into
the orbit should be carefully evaluated by using
imaging before surgical resection to avoid
incomplete resection or globe perforation.
Ref (5, 12)
Policy
Surgical removal of ocular dermoids:
Grade of paediatric limbal/
corneal dermoid
Recommended techniques
Grade I: <50 mm thickness
and <1 mm diameter
Simple excision
Level 4 Grade I: <100 mm thickness
and <1 mm diameter
Keratectomy þ AMT þ
ALSCA
Grade II and deeper Grade I Keratectomy þ AMT þ
LSCA þ PPG
versus anterior or deep anterior
lamellar keratoplasty 
AMT
Grade III Total anterior segment
reconstruction
Abbreviations: AMT, amniotic membrane transplantation
(multilayered); ALSCA, autologous limbal stem cell
allograft; PPG, pericardial patch graft.
Ref (5)
Considerations
 Overall quality of evidence
The quality of evidence is graded on level 3 or 4 as it is based on
non-comparative studies: a case series by Matsuo et al. (12) and a
narrative review by Pirouzian et al. (5). In addition, the literature is
regarded as indirect as no patients with CFM were included.
 Balance of benefits and harms
The risks of removing of the dermoid should be carefully
evaluated before surgical removal as even ‘simple excision’ can
cause severe complications. Ultrasound imaging needs to be con-
ducted in case extension posteriorly and into the orbit is suspected.
When refractive errors, astigmatism and/or anisometropia, are
present this should be corrected at all times with optimal spectacle
correction and occlusion of the better eye in case of amblyopia.
Persistent amblyopia causes a significant burden on society, finan-
cially as well as in terms of a reduced quality of life especially if the
better eye is lost later in life.
 Outcome importance
The primary purpose of treatment is to achieve optimal visual
outcome and cosmetic appearance. If left untreated, patients with
poor visual acuity are a significant concern for society, financially
as well as in terms of a reduced quality of life; especially if the
visual acuity in the better eye is lost later in life.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
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requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The main purpose of treating children with CFM is to optimise
visual acuity outcome and cosmetic appearance. Therefore, chil-
dren with ocular disturbances need to be evaluated by a specialised
orthoptist and ophthalmologist during the visual development
(before the age of five). In addition, amblyopia should be treated
before the age of six. Surgery has to be discussed in a multidisci-
plinary team, especially in the case of young children in whom
vision is still developing.
Recommendations
 Children with ocular disturbances need to be evaluated
by a specialised orthoptist and ophthalmologist during
the visual development (before the age of five).
 Optimal spectacle correction should be provided in case
of a refractive error.
 Amblyopia should be treated before the age of six.
 When surgery is considered this has to be discussed in a
multidisciplinary team, carefully evaluating the harms
and the benefits, especially in the case of young children
in whom vision is still developing.
 Ultrasound imaging of the ocular dermoid needs to be
conducted if extension posteriorly and into the orbit
is suspected.
Research gap
As only indirect literature was available, future studies on eye
anomalies in CFM studying treatment outcomes with long-term
follow-up and patient specific outcomes, are needed. The ICHOM
Craniofacial Microsomia standard set will help to create a good
prospective dataset from a large number of patients with CFM (18).
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.6 Dental deformities in craniofacial
microsomia
Introduction
The prevalence of teeth agenesis in the general population is
around 6.9% (range 1.4% – 11.3%), excluding third molar agenesis
(1). Patients with craniofacial microsomia (CFM) are presumably at
increased risk for teeth agenesis or other dental deformities. A
relation with mandibular hypoplasia or other characteristics of CFM
may be present.
To obtain more knowledge on dental deformities in CFM and
offer potential recommendations on screening, monitoring, and
treatment the following questions were posed:
4.6.1 What is the type, prevalence and severity of dental
deformities in craniofacial microsomia?
4.6.2 What is the policy for screening and monitoring of
dental deformities in patients with craniofacial microsomia?
4.6.3 What are the indications and policy for treatment of
dental deformities in patients with craniofacial microsomia?
Awareness of dental deformities in patients with CFM is essen-
tial to identify problems in an early phase and start treatment if
needed. Occlusal problems may occur due to dental anomalies,
which could lead to oral health damage and/or feeding difficulties.
Orthodontic treatment may be indicated to treat these deformities.
Literature search
A systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material. The
inclusion and exclusion criteria are as follows:
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the
question of the guideline.
- The search of the systematic review was conducted in at
least two relevant databases, such as the Cochrane
Library, Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Dental anomalies
Exclusion criteria - Original studies with <10 included patients






Literature was screened on title and abstract. All available
literature on dental anomalies in CFM was included in this chapter.
A total of eight manuscripts were included: retrospective cohort
studies by Ahiko et al. (2), by Farias et al. (3), by Jacobsson et al.
(4), by Maruko et al. (5), and by Silvestri et al. (6), two retrospective
cohort studies with a healthy control group by Seow et al. (7) and by
Ongkosuwito et al. (8), and lastly a case series by Silvestri et al. (9).
4.6.1 What is the type, prevalence and severity of dental
deformities in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type, prevalence and severity of dental
deformities in CFM (Appendix 1, http://links.lww.com/SCS/B697).
Since this question does not relate to interventions or diagnostics, no
considerations, rationale or recommendations are provided.
Review of literature
The dental development in patients with CFM was studied by Ahiko
et al. by comparing the affected side with the unaffected side (2). A total
of 24 patients with unilateral CFM were included. Third molars were
excluded from the analysis. Frontal and lateral cephalogram analysis
showed that the included patients had a short mandibular ramus and –
body, a steep mandibular plane angle, large gonial angle, and a slightly
convex facial structure. Orthopantomograms showed an upward cant-
ing of the occlusal plane toward the affected side in 87.5% of the
patients. Eight patients (33.3%) had a total of fourteen missing teeth.
The lateral incisor of the mandible, on both the affected and unaffected
side, was missing most frequently. No significant difference in tooth
agenesis on the affected- versus unaffected side was present. However,
a delay in tooth calcification of the first and second mandibular molars
on the affected side compared to the unaffected side was found. This
may be related to the mandibular hypoplasia.
Seow et al. studied dental casts of fifty patients with unilateral
CFM to analyse dentitions and compared this with control subject
that were matched for dental age (7). Twenty patients had casts of
primary dentition (40%), 15 patients of mixed dentition (30%) and
15 patients of permanent dentition (30%). The mesiodistal diameter
of the primary second molar and permanent first molar was found to
be significantly smaller on the affected side compared to the
unaffected side in patients with CFM (p<0.05). There were no
differences in faciolingual dimensions. Patients with CFM had
significantly smaller first and second molars in both maxilla and
mandible compared to controls, on both the affected and unaffected
side (p<0.05). Although teeth on the unaffected side were smaller
compared to controls, this was to a lesser extent compared to teeth
on the affected side. No changes in teeth size of the anterior region
of the dental arches were present.
Tooth size and morphology in patients with CFM was also studied
by Farias et al (3). Plaster casts of 40 patients with CFM, age 8-21,
were studied. Patients with severe CFM had significantly smaller
mandibular first molars and canines on the affected side compared to
patients with less severe CFM. All other teeth were not significantly
different in size. The authors suspect that tooth size is closely related
to the degree of mandibular hypoplasia. Also, morphological abnor-
malities of the mandibular first molar, such as cusp asymmetry, was
seen more frequently on the affected side compared to the unaffected
side (p<0.001), and mostly in patients with severe CFM.
Silvestri et al. retrospectively studied the incidence of teeth
agenesis and failure of teeth eruption in 63 patients with CFM (6).
The presence of third molars was included in the analysis for
patients age > eight. Almost all included patients had unilateral
CFM (n¼ 61); two patients had bilateral CFM. A total of 17.4%
(n¼ 11) had teeth agenesis of in total 29 teeth. All eleven patients
had a tooth missing on the affected side and eight patients had a
missing tooth on the contralateral side. If third molars were
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excluded from the analysis, the prevalence of teeth agenesis was
7.9%, missing 13 teeth. The teeth missing most frequently was the
third molar (16 of the 29), followed by the first and second premolar
(7/29), and inferior lateral incisor (3/29). Agenesis of premolars
appeared more frequently in patients with severe CFM. Six patients
(7.9%) had a failure of eruption of teeth, which was associated with
dental agenesis in two patients.
Jacobsson et al. studied the clinical appearances of 26 patients
with CFM (4). Eight patients (30.8%) had teeth agenesis. Teeth
missing most frequently were the first premolar (n¼ 5), second
premolar (n¼ 4), and the third molar (n¼ 2).
Maruko et al. retrospectively studied 125 patients with CFM to
describe the patterns of teeth agenesis in CFM and to compare its
prevalence with healthy persons (5). Panoramic radiographs were
reviewed, and teeth were reported as present if any part of the tooth
bud, follicle, or tooth was visible. Third molars were excluded from
the analysis. To study missing teeth in CFM, only patients age >4
years with presurgical panoramic radiographs were included. A total
of 76 patients met these criteria. A third (32.9%) of the 76 patients had
at least one missing tooth, 17.1% had bilateral absence of teeth, 13.2%
had missing teeth on the ipsilateral side of the mandibular deformity,
and 2.6% of the patients had contralateral absence of teeth. Patients
with severe mandibular hypoplasia had a significantly higher preva-
lence of teeth agenesis (p¼<0.024). A small difference was present
between the prevalence of mandibular teeth agenesis (26%) and
maxillary teeth agenesis (24.6%). The number of missing teeth varied
from one to ten; most patients (24%) had one missing tooth. The most
common missing tooth was the second premolar (11 mandibular, 5
maxillary), followed by the second molar (7 mandibular, 7 maxillary)
and lateral incisor (6 mandibular, 4 maxillary). To determine the
prevalence of teeth agenesis in CFM, only patients age >8 were
included since by this age the enamel has formed in the permanent
second molars. A total of 52 patients with CFM and 45 healthy
controls were included for this analysis. The prevalence of teeth
agenesis in patients with CFM was 26.9%, whereas none of the
controls had teeth agenesis (p¼<0.001).
To compare the dental development of the affected and unaffected
mandibular sides in patients with CFM, a retrospective cohort study
with a healthy control group was initiated by Ongkosuwito et al (8). A
total of 84 patients with unilateral CFM and 451 healthy controls were
included. Patients with two or more missing mandibular teeth were
excluded because no dental maturity score could be determined in
those patients. Patients with severe mandibular hypoplasia, Pru-
zansky-Kaban III, showed a significant delay in dental development
on the affected side (p<0.05). However, no significant difference in
dental development between the affected and unaffected side was
present in the other patients with CFM. The mean dental age was
significantly younger in patients with Pruzansky-Kaban I and sig-
nificantly older in patients with Pruzansky-Kaban IIb and III, com-
pared to the healthy controls (p<0.05). Initially, patients with
Pruzanksy-Kaban IIb/IIII do have a delay in dental development,
which is followed by a catch-up in growth.
Conclusions
Level 3 Prevalence and type
Tooth agenesis
The prevalence of tooth agenesis in craniofacial microsomia
varies from 8% to 33%, excluding third molar agenesis,
and is thus more frequent than in the general population
(range 1% - 11%).
Most frequently missing teeth in patients with craniofacial
microsomia are the first and second premolars, followed
by the second molar and lateral incisor.
Ref (2, 4–6)
Level 3 Prevalence and severity
Affected versus unaffected side in patients with unilateral
craniofacial microsomia
No significant difference in the prevalence of tooth agenesis
was found between the affected and unaffected side in
patients with unilateral craniofacial microsomia.
Patients with a Pruzansky-Kaban type III mandible deformity
showed a significant delay in dental development on the
affected side compared to the unaffected side. This
difference in dental development between sides was not
present in all other patients with craniofacial microsomia
(p<0.05).
Patients with severe craniofacial microsomia (Pruzansky-
Kaban type IIb/III) showed a delay in dental development
compared to milder patients (Pruzansky-Kaban type I/IIa)
and to healthy children (p<0.05).
Ref (2, 5, 8)
Level 3 Severity and prevalence
Tooth size
Mandibular first molars and canines were significantly
smaller in patients with severe craniofacial microsomia
compared to mild craniofacial microsomia, and smaller on
the affected side compared to the unaffected side
(p<0.05). All other teeth were not significantly different
in size in patients with craniofacial microsomia.
The first and second mandibular and maxillary molars on
both the affected and unaffected side were found to be
significantly smaller in patients with craniofacial
microsomia compared to healthy controls (p< 0.05).
Morphological abnormalities of the mandibular first molar,
such as cusp asymmetry, were significantly more
frequently seen on the affected side compared to the
unaffected side, and mostly in patients with severe
craniofacial microsomia (p< 0.001).
Ref (3, 7)
4.6.2 What is the policy for screening and monitoring of
dental deformities in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the consequences and impact of screen-
ing and monitoring, the available screening tests and procedures for
monitoring, and responsibilities for screening and monitoring
(Appendix 1, http://links.lww.com/SCS/B697). Unfortunately, no
literature is available on the policy for screening and/or monitoring
of dental deformities in patients with CFM. Therefore no conclusions
were written. Considerations for this questions were only based on
expert opinion.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
Screening and monitoring for dental deformities in patients with
CFM is needed as the prevalence of these deformities in these
patients is high. Diagnosing dental deformities early helps make a
timely treatment plan to optimise future treatment. The harms are
limited as the assessment consists of intra-oral inspection and
an orthopantomogram.
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 Outcome importance
Screening of outcomes through standard dental records and oral
health-related quality of life questionnaires should be performed to
monitor growth and treatment. Therefore a follow-up and taking
orthodontic records (5/6, 9, 12, 15 and 18 years) to evaluate growth,
timing of treatment and dental deformities are needed.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. Intra-oral inspection and orthopantomo-
gram will provide a great deal of insight while the cost is relatively
low. The recommendations concern the essential requirements for
adequate treatment of patients with CFM and should thus be
implemented. Early diagnosis by means of an orthopantomogram
to diagnose dental malformations should be done; this diagnostic
tool is widely available and at relatively low cost. In the case that a
CBCT is taken for other diagnostic reasons, the CBCT should be
sufficient and no additional OPT should be taken. However, the use
of 3D stereophotogrammetry brings additional costs. Costs are
lowered and resources are most efficiently used when care for
craniofacial disorders is centralised in a limited number of expert
centres per member state. A general rule that can be applied is one
expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an expert
centre for CFM, or the level of provided care does not (yet) meet all the
requirements that are outlined in this guideline. By defining the
baseline of required care for CFM, this guideline will help these
member states to reach the appropriate level. The ERN on craniofacial
anomalies and ENT disorders (ERN-CRANIO) can guide a patient in
Europe to the available centres of expertise (www.ern-cranio.eu) and
can support care providers with diagnosis and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
In order to diagnose dental deformities, an intra oral inspection
should be combined with the assessment of an orthopantomogram
preferably by an orthodontist and/or a special care dentist who has
affinity with craniofacial malformations. Since these dental defor-
mities including growth may alter over time, the craniofacial
orthodontist needs to do a follow-up over time. Both the first
screening and follow-up should be done in a multidisciplinary team
setting. Standard dental records should be obtained for orthodontic
management. Screening of outcomes through standard dental
records and oral health-related quality of life questionnaires should
be performed to monitor growth and treatment. Therefore a follow-
up and taking orthodontic records (5–6, 9–10, 12, 15 and 17–18
years) to evaluate growth, timing of treatment and dental deformi-
ties are needed. Screening should start by the age of six as at this age
eruption of the first molars occur.
Patients with craniofacial deformities, including CFM, should
have routine dental care, as these patients are at increased risk for
dental decay.
Recommendations
 Patients with craniofacial microsomia should have
routine dental care.
 Patients with craniofacial microsomia should be seen
from age five by an orthodontist within a multidisci-
plinary team to diagnose dental deformities.
 Perform screening for dental deformities by intra-oral
inspection and standard dental records.
 Take orthodontic records in a structured schedule, at 5–
6, 9–10, 12, 15 and 17–18 years of age.
Research gap
Research should focus on following CFM patients with 3D
examinations to determine whether progressiveness is a problem
for growth over time. To understand growth and other dental
deformities in CFM patients better, research should at least use a
design that involves a control group. CFM does not involve the
mandible only, therefore research should also look into the com-
plete craniofacial complex. The exact impact on having additional
dental malformations in CFM patients is unclear compared to CFM
patients that don’t have these additional dental malformations.
Therefore, a component should be included in any oral health-
related quality of life research in CFM patients related to the dental
malformations described above.
The ICHOM initiative has produced a manual for specific data
collection for CFM patients. In these patients they also recommend
gathering quality of life data. However, much work is still to be
done and it would be worthwhile to investigate which parts of the
overall treatment have the most impact on the OHrQol of CFM
patients. This can be combined with taking the orthodontic records.
4.6.3 What are the indications and policy for treatment of
dental deformities in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of dental deformities (Appendix 1, http://links.lww.com/
SCS/B697). Only one study that reported on treatment options for
dental deformities in CFM and met the inclusion criteria was found
in the literature. No literature based conclusions on the policy for
treatment of dental deformities could be drawn.
Review of literature
Silvestri et al. presented a case series of sixteen children with
unilateral CFM who were treated with an asymmetrical functional
activator (AFA) (9). Before and after therapy, electromyography
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was performed to evaluate neuromuscular deficits of the mastica-
tory muscles on the affected and unaffected sides. Treatment out-
comes were evaluated based on panoramic radiographs. Functional
therapy, by using an AFA, gave additional mandibular and maxil-
lary growth on the affected side and increased neuromuscular
function in seven patients with mild CFM. No additional surgery
was needed in these patients. Another five patients with moderate
CFM underwent functional therapy followed by conventional
orthodontics which induced a growth response. Four of these
patients required surgical mandibular repositioning around the
age of ten. In another four patients with severe CFM, functional
therapy and orthodontic treatment with fixed appliances was initi-
ated to prepare for surgical intervention around the age of ten. The
authors conclude that it is possible to induce balanced maxilla-
mandibular growth by using an AFA in children with unilateral
CFM. In mild cases, the use of an AFA can induce mandibular
growth. Additional orthodontic treatment with fixed appliances can
be used to perfect the occlusion. In patients with severe CFM, the
use of an AFA is limited. Nevertheless, the authors advocate the use
of an AFA in these patients too, to correct dento-alveolar disorders
and prepare the neuromuscular system for the new spatial position
after surgery. The aim of functional therapy in patients with severe
CFM is to lay the basis for surgery and not to stimulate growth.
Conclusions
Level 3 Indications
Dentofacial orthopaedic treatment has been proposed but due
to study limitations no conclusions on mandibular growth
effect can be drawn.
Ref (9)
Considerations
 Overall quality of evidence
The conclusion on treatment with an asymmetrical functional
activator was based on a single case series, which studied a very
small patient sample (n¼ 16) (9). The reported outcome of treat-
ment, mandibular growth, can be questioned since it was based on
comparison of panoramic radiographs. The duration of treatment is
thus unknown. The quality of evidence is graded on level 3 because
the conclusion was based on a non-comparative study, but is
considered to be very weak. No conclusions on the indications
and policy for treatment of dental deformities in CFM can be drawn.
 Balance of benefits and harms
Treatment of dental deformities leads to a better occlusal
relationship and is therefore beneficial for the patient. Some
patients might require treatment with an activator, which may have
a negative influence on the quality of life of the patient, although
this hasn’t been studied in patients with CFM.
 Outcome importance
Treatment of dental deformities may be needed to achieve good
oral health in the patient and should always be discussed in a
multidisciplinary team. It is important to distinguish between a
functional and a non-functional condyle or mild versus severe CFM.
In mild cases an activator treatment can be started in dialogue with
patient and parents. In more severe cases treatment planning should
aim to get congruent arches by orthodontic treatment trying to avoid
later surgical expansion or implant placement when orthodontic
closure would have been an option in collaboration with
the surgeon.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Since the CFM phenotype is so highly variable, it is very
difficult to generalise a study over the whole CFM patient group.
Therefore it is advised to use a classification system like the
Pruzansky/Kaban or the O.M.E.N.S. Clinicians can then distinguish
between cases that have a functional condyle at the affected side
versus a non-functional or absent condyle. In very mild cases in
which no surgical correction is expected to be necessary at a later
age, mild corrections may be gained by an activator. However, the
activator should then be activated in a sagittal direction but also in a
cranial-caudal direction. The last direction is best addressed during
the largest development of the jaws. This is the period in which
permanent teeth erupt and can gain height. This also means a long
treatment duration with the activator and may be less (cost) efficient
in more severe cases. Therefore this should only be done in mild
cases, while more severe cases profit more from not providing
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activator treatment, when surgical correction may be necessary in
the future. Whether long-duration activator treatment or a policy of
‘wait and see’ may have a different outcome in terms of OHrQol
remains to be answered. Another reason not to use a prolonged
activator treatment is that the development of soft tissue is ques-
tionable in CFM cases and may affect speech. Additionally, it is
important not to lose cooperation of the patient due to prolonged
treatment before the moment you really need cooperation. In both
mild and severe cases, the solution and planning to solve the
problem of dental malformations should be determined early and
a clear treatment goal should be described.
The most important aspect is avoiding use of orthodontic
resources and the risk of overtreatment and thereby loss of cooper-
ation in the process. Interaction with all members of the multidis-
ciplinary team is needed to provide the best overall treatment.
Recommendations
 Dentofacial orthopaedic treatment can be considered
appropriate in very mild craniofacial microsomia cases.
In severe craniofacial microsomia patients, current
evidence does not promote activator treatment.
 Orthodontic treatment should be discussed and coordi-
nated in a multidisciplinary team depending on the
decision to conduct orthognathic surgery or not.
Research gap
The ICHOM initiative has produced a manual for specific data
collection for CFM patients. In these patients they also recom-
mend gathering quality of life data. However, much work is still
to be done and it would be worthwhile to investigate which parts
of the overall treatment have the most impact on the OHrQol of
CFM patients. This can be combined with taking the orthodontic
records.
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.7 Vertebral anomalies in craniofacial
microsomia
Introduction
The prevalence of vertebral anomalies in the general population
is considered to be 0.1% to 2% (1, 2). In patients with craniofacial
microsomia (CFM) these anomalies are more frequently observed.
Originally, patients with the facial characteristics of CFM and
vertebral anomalies were considered to have Goldenhar syndrome
or oculo-auriculo-vertebral spectrum/disorder. These syndromes
are now considered to be a variant of CFM. Various types of
vertebral anomalies have been reported in patients with CFM, such
as hemivertebrae, blockvertebrae, or scoliosis (3–5).
To obtain more knowledge on vertebral anomalies in CFM and
offer potential recommendations on screening, monitoring and
treatment the following questions were posed:
4.7.1 What is the type, prevalence and severity of vertebral
anomalies in craniofacial microsomia?
4.7.2 What is the policy for screening and monitoring of
vertebral anomalies in patients with craniofacial micro-
somia?
4.7.3 What are the indications and policy for treatment of
vertebral anomalies in patients with craniofacial micro-
somia?
Vertebral anomalies may have several negative consequences
and be present without symptoms (6, 7). Dysplastic cervical verte-
brae can lead to cervical spine instability (6). Manipulation of the
cervical spine in patients with cervical spine instability can cause
compression of the spinal cord or vertebral artery, which can have
various neurological consequences (7–9). Another risk of vertebral
anomalies is the development of progressive scoliosis or fractures
of ankylosed vertebrae. This may be caused by incorrect formation
or fusion of vertebrae (6). Progressive scoliosis should be prevented
in patients with early-onset scoliosis. This type of scoliosis occurs
before the age of ten (10, 11). It is relevant to optimise the
development of the spine, chest wall and lungs, which could
potentially be achieved by surgical treatment. Early identification
and treatment of vertebral anomalies is relevant to prevent these
potential harms.
Literature search
A systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material. The
inclusion and exclusion criteria are as follows:
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the
question of the guideline.
- The search of the systematic review was
conducted in at least two relevant databases, such
as the Cochrane Library, Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search
strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Vertebral anomalies
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Exclusion criteria - Original studies with <10 included patients






Literature was screened on title and abstract. All literature
available on vertebral anomalies in CFM was included in this
chapter. A retrospective cohort study on craniofacial and extra-
craniofacial anomalies in CFM by Caron et al. (12) was excluded
because the same cohort was studied by Renkema et al. (13), with
more detail on vertebral anomalies. A total of six manuscripts were
included, five on the prevalence and types of vertebral anomalies
and one article on treatment: a cross-sectional study by Cohen et al.
(14), a systematic review by Renkema et al. (15), and four retro-
spective cohort studies by Pegler et al. (16), Davide et al. (17),
Renkema et al. (13), and Connell et al. (18).
4.7.1 What is the type, prevalence and severity of vertebral
anomalies in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type (block vertebrae, hemiverteb-
rae, scoliosis, and rib anomalies), prevalence and severity of
vertebral anomalies in CFM (Appendix 1, http://links.lww.com/
SCS/B697). Since this question does not relate to interventions or
diagnostics, no considerations, rationale or recommendations
are provided.
Review of literature
The prevalence and type of vertebral anomalies in CFM reported
in literature was examined in a systematic review by Renkema et al.
(15). A systematic search of literature was performed and studies on
patients with isolated microtia or case-reports were excluded. A
total of 31 articles were included in this review: 26 articles
described the prevalence of vertebral anomalies in CFM and 22
articles the type of vertebral anomalies in CFM. In two of the 31
included studies fewer than ten patients were analysed; both studies
only assessed the type of vertebral anomalies in CFM. The preva-
lence of vertebral anomalies in CFM varied from 8% to 79%. This
large variability was due to differences in sample size, study
characteristics, patient selection and the level of spine investigation.
Studies with larger sample size tended to show prevalences around
25%. Vertebral anomalies were most frequently reported in the
cervical and thoracic spine and were less often seen in the lumbar
spine. Hemivertebrae, block vertebrae and scoliosis were most often
described. Rib anomalies, such as fusion, aplasia, hypoplasia, or
extra ribs were commonly seen and reported in ten studies. Some
studies found a higher prevalence of additional extracraniofacial
anomalies in other tracts in patients with CFM and vertebral
anomalies (19, 20). Patients with CFM and cervical spine anomalies
also had lower cognitive, fine motor, and expressive language
scores (21). A more severe facial deformity, by using the sum of
the O.M.E.N.S. score, increased the risk for the presence of extra-
craniofacial, and thus vertebral, anomalies (22). The authors con-
clude that vertebral anomalies are present in a substantial proportion
of patients with CFM. To prevent harmful consequences, careful
and extensive physical and neurological examination of each
patient with CFM is indicated to diagnose these anomalies at an
early stage.
Four studies on vertebral anomalies in CFM were published after
publication of the systematic review. Davide et al. found a preva-
lence of 40% of vertebral anomalies in 35 studied patients (17). No
further information on these anomalies was provided. Cohen et al.
reported a prevalence of 47% (n¼ 40) of vertebral anomalies in their
studied cohort of 89 patients (14). The type of vertebral anomalies
was hemivertebrae (n¼ 20), scoliosis (n¼ 18), rib anomalies
(n¼ 10), vertebral fusion/block vertebrae (n¼ 9), butterfly vertebrae
(n¼ 8), vertebral schisis (n¼ 8), and spina bifida (n¼ 3). No corre-
lation between the severity of extracraniofacial anomalies and facial
deformities by using the O.M.E.N.S. score was present. Pegler et al.
studied 41 patients with CFM and 65.9% (n¼ 27) had vertebral
anomalies (16). Similar vertebral anomalies were reported: scoliosis
(n¼ 13), hemivertebrae (n¼ 10), block vertebrae (n¼ 9), incomplete
fusion of vertebral arches (n¼ 4), sacral dimple (n¼ 5), spina bifida
(n¼ 4), and transitional vertebrae (n¼ 4).
A large, multicentre, retrospective cohort study aiming to study
the prevalence, types and symptoms of vertebral anomalies in CFM
was performed by Renkema et al. (13). Patients with isolated
microtia were excluded in this study. A total of 991 patients were
included. Vertebral anomalies were present in 28% (n¼ 275) of the
patients. Patients with bilateral CFM had a higher prevalence of
vertebral anomalies compared to unilateral patients (Pearson x2
(df1)¼15.93, odds ratio¼2.21, p¼<0.001). Furthermore, patients
with a more severe facial deformity had a higher risk for vertebral
anomalies. A correlation between the Orbit, Mandible, Nerve, and
Soft tissue scores on the O.M.E.N.S. scale and the presence of
vertebral anomalies was found. The Mandible score on the
O.M.E.N.S. scale was based on the Pruzansky-Kaban score in this
study. Vertebral anomalies were present in all sections of the spine:
cervical spine (n¼ 158), thoracic spine (n¼ 187), lumbar spine
(77), and/or in multiple segments of the spine (n¼ 131). The
anomalies reported most frequently were block vertebrae, hemi-
vertebrae, rib anomalies, and scoliosis. The curvature of the scoli-
osis extended to multiple segments in 83 patients. Specific
anomalies of the cervical spine such as cervical ribs (n¼ 12),
cervical spine instability (n¼ 7), occipitalisation of the atlas
(n¼ 6), rotated subluxation of C1-C2 (n¼ 4), or os odontoideum
(n¼ 2) were seen in multiple patients. Clinical symptoms of
vertebral anomalies were present in 44% (n¼ 122) of the 275
patients with vertebral anomalies. The symptoms most frequently
reported were torticollis (n¼ 40), back or neck pain (n¼ 28), and
limited neck movement (n¼ 22). These symptoms were most
frequently reported by patients with vertebral anomalies, but also
by some patients without vertebral anomalies. Besides vertebral
anomalies, other extracraniofacial anomalies were often reported in
the studied cohort. A total of 462 (47%) patients had extracranio-
facial anomalies. Of the patients with vertebral anomalies, 61% had
additional extracraniofacial anomalies in other tracts. A signifi-
cantly higher risk for extracraniofacial anomalies in patients with
vertebral anomalies was found for almost all tracts: central nervous
system (odds ratio¼ 4.46), spinal cord anomalies (odds
ratio¼ 77.84), cardiac anomalies (odds ratio¼ 3.01), gastrointesti-
nal anomalies (odds ratio¼ 3.67), and urogenital anomalies (odds
ratio¼ 3.41). Although the prevalence of pulmonary anomalies was
higher in patients with vertebral anomalies and a trend towards
significance could be observed, no statistically significant differ-
ence was found (odds ratio¼ 2.17, p¼ 0.055). The authors advised
to screen all patients with CFM for vertebral anomalies by perform-
ing physical and neurological examination. Patients suspected of
having vertebral anomalies or patients with a higher risk for
vertebral anomalies should be assessed by using standard upright
posterior-anterior and lateral radiographs. Flexion-extension radio-
graphs of the cervical spine should be made in patients with cervical
spine anomalies to rule out cervical spine instability. Since patients
with vertebral anomalies are at increased risk for having additional
extracraniofacial anomalies, cardiac, renal, and neurological eva-
luations are indicated in patients with vertebral anomalies, accord-
ing to the authors.
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Conclusions
- Prevalence
The prevalence of vertebral anomalies in




Vertebral anomalies in craniofacial
microsomia are seen in all segments of the
spine, but more frequently in the cervical
and thoracic spine than in the lumbar spine.
The types of vertebral anomalies that are most
frequently seen in patients with
craniofacial microsomia: block vertebrae,




Almost half of the patients (44% of 991
patients studied) with craniofacial
microsomia show symptoms of vertebral
anomalies: torticollis, back or neck pain,
and/or limited neck movement.
Ref (13)
Level 3 Risk factors
Patients with bilateral craniofacial
microsomia have a higher risk for having
vertebral anomalies compared to patients
with unilateral craniofacial microsomia.
Patients with a high Pruzansky–Kaban score,
or a high orbit, nerve, and/ or soft tissue
score on the O.M.E.N.S. scale have a
higher risk for having vertebral anomalies.
Patients with craniofacial microsomia and
vertebral anomalies have a higher risk for
additional extracraniofacial anomalies in
other tracts.
Ref (13, 15)
4.7.2 What is the policy for screening and monitoring of
vertebral anomalies in patients with craniofacial micro-
somia?
The literature search for this question was directed towards
more specific questions related to the consequences and impact of
screening and monitoring, the available screening tests and pro-
cedures for monitoring, and responsibilities for screening and
monitoring (Appendix 1, http://links.lww.com/SCS/B697). Unfor-
tunately, no literature on screening and/or monitoring of vertebral
anomalies in patients with CFM is available. Therefore no con-
clusions were written. Considerations for this question were only
based on expert opinion.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
To the best of our knowledge evidence on the harms and benefits
of screening for vertebral anomalies do not exist. Some evidence on
the harms of screening for adolescent idiopathic scoliosis is avail-
able. It has been reported that false-positive screening may cause
important potential harms, including unnecessary surgery or brac-
ing. Rates of potential harms are reported from 0.8% to 21.5% (23).
The direct harms of screening are subject to debate. Potential direct
harms of false-positive results include multiple unnecessary follow-
up visits, unnecessary radiation exposure with an increased cancer
risk, overtreatment and exposure treatment-related (iatrogenic)
risks, or psychosocial effects including hospitalisation and the
diagnosis of clinically non-significant scoliosis (23). Children,
especially those younger than five years, are not only more prone
to radiation-induced malignancies due to increased radio-sensitivity
of certain organs but also due to the fact that they have a longer
latency period to develop a cancer (24). The use of CT for paediatric
spine should be limited because of the 50% increase in mean
radiation dose to the spine in paediatric patients relative to conven-
tional radiography (25). It has been reported that lifetime cancer
mortality risks attributable to the radiation exposure from a CT of
the cervical spine for a one year old is approximately 0.07 to 0.18%
which is much higher than that for adults who are exposed to a CT of
the cervical spine (26).
 Outcome importance
The main reason to perform screening of the spine in patients
with CFM is the early detection of spine anomalies and to
prevent scoliosis and/or neurological deficits including spinal
cord injury. In patients who are asymptomatic, neurological and
radiological imaging should be performed. Patients who develop
symptoms should be referred to a neurologist or orthopaedic
surgeon.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
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 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
In CFM a variety of structural developmental anomalies of the
vertebral column may occur (block vertebrae, hemivertebrae, sco-
liosis including rib anomalies). Often, these anomalies are simple
with minimal clinical consequence, but sometimes they are or may
become complex with structural and neurologic implications.
For screening and monitoring of vertebral anomalies we have to
consider some general aspects of the normal spine. It is known that
children under the age of eight are more susceptible to injury to the
craniocervical junction (C0-C2) due to specific features of their
anatomic development (27). First of all the paediatric body is
relatively smaller than the head which may increase the force
moment on the CVJ in trauma. Secondly, the cervical musculature
is not strong enough to stabilise the head appropriately. Thirdly, due
to the increased laxity of the ligaments there is a greater mobility of
the upper cervical spine as compared to the spinal cord. Hence
spinal cord injury can occur without radiographic abnormalities
(SCIWORA). For screening of vertebral abnormalities in CFM
patients knowledge about the normal age-specific anatomy is
important to distinguish these anomalies from trauma (bipartite
atlas versus Jefferson fracture, butterfly vertebra versus burst
fracture) especially in acute situations.
Almost half of the patients with CFM show symptoms of
vertebral anomalies (13). Trenga et al. have shown a high preva-
lence of cord abnormalities associated with congenital spinal
anomalies (28). Approximately 55% of children with congenital
bony spinal deformities are associated with intraspinal neural axis
defects. From these two point estimates we may conclude that one
out of four CFM patients will have spinal cord anomalies. Trenga
et al recommend to order MRIs of the brainstem and spinal cord for
all patients with congenital vertebral malformation. The timing of
the MRI remains controversial. Due to the high incidence of
underlying neural defects, all patients with congenital spinal defor-
mities should have regular examinations including a neurological
survey. For screening of vertebral anomalies in CFM no consensus
exists on when, how and why screening should be performed. For
adolescent idiopathic scoliosis existing screening guidelines are
available (29). To summarise, these guidelines recommend visual
inspection of the spine to look for asymmetry of the shoulders,
shoulder blades, and hips. In the United States, the forward bend test
is commonly used to screen for idiopathic scoliosis. The clinician
visually inspects the spine of a patient while the patient is standing
upright. Next, the patient stands with feet together and bends
forward at the waist with arms hanging and palms touching while
visual inspection is repeated. A scoliometer, which measures the
angle of trunk rotation, may be used during the forward bend test.
An angle of trunk rotation of 58 to 78 is often the threshold for
referral for radiography to confirm the diagnosis and to quantify the
Cobb’s angle.
Screening questions and clinical examinations related to neck/
back symptoms should be undertaken at initial consultation and as
part of pre-operative workup. Patients should be referred appropri-
ately and attention should be payed when patients are undergoing
general anaesthesia.
Recommendations
 Screening questions and clinical examinations related
to neck/back symptoms should be undertaken at initial
consultation and as part of pre-operative workup.
 All patients with craniofacial microsomia who have
neurologic symptoms (e.g., paraesthesia, numbness, or
weakness) or neck pain suggestive of neuronal injury
should be evaluated as soon as possible by a (paediatric)
neurologist.
 Patients should be referred appropriately and attention
to the cervical spine should be payed when patients are
undergoing general anaesthesia.
Research gap
No literature on screening anomalies in patients with CFM is
available. Since the incidence of CFM is rare with the knowledge
that not every CFM patient has vertebral anomalies, prospective
randomised controlled screening studies are difficult but also
maybe unethical to perform. Controlled trials that allow for com-
parison of screened and non-screened patients will provide insight
on the effect of screening but are likely to be unethical. Studies on
the potential harms of screening and treatment are also needed and
more feasible to perform. Registries with information on long-term
outcomes would be helpful. For idiopathic scoliosis, a study
regarding benefits and harms has been published. The study by
the US Preventive Services Task Force concludes that the current
evidence is insufficient to assess the balance of benefits and harms
of screening for adolescent idiopathic scoliosis in children and
adolescents aged 10 to 18 (29). Since RCTs are not very feasible and
unethical a multi-centre prospective study with centre-based allo-
cation with and without screening will provide some more insights
on screening for vertebral anomalies in patients with CFM. The
clinical relevance of vertebral anomalies in CFM remains unclear
and should be studied.
4.7.3 What are the indications and policy for treatment of
vertebral anomalies in patients with craniofacial micro-
somia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of vertebral anomalies (Appendix 1, http://links.lww.-
com/SCS/B697).
Review of literature
Connell et al. studied the effect of growth-friendly surgery for
early-onset scoliosis associated with CFM (18). The radiographic
results and complications of this surgery were evaluated. A total of
17 patients with CFM and scoliosis were included. Ten patients
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were treated with growth-friendly surgery, three patients with
fusion of vertebrae, one patient was treated with a brace, and three
patients were observed. The preoperative scoliosis of the three
patients who had fusion was 698, which improved to 608 two years
postoperatively. The single patient who had a brace had a scoliosis
of 118 at start of the treatment. And the three patients who were
observed had a scoliosis of 388 (range 308-448) at start, which was
unchanged at two-year follow-up with a mean of 418 (range 368-
518). The ten patients who received growth-friendly surgery were
assessed in more detail. Nine patients had rib-based distraction
(including vertical expandable prosthetic titanium rib) and one
patient was treated with traditional growth-friendly rods. The mean
age of the first surgery was 4.6 years (range 10 months - 8 years).
The mean scoliosis improved from 648 (318-988) to 528 (p¼ 0.15)
and remained constant over two-year follow-up (508, p¼ 0.09). The
mean maximum kyphosis increased a bit after treatment from 368
(138-508) pre-surgery, to 388 (p¼ 0.40) post-surgery and 42.48
(p¼ 0.08) at two-year follow-up, although the results were not
significant. At two-year follow-up post-surgery a slight, non-sig-
nificant increase in high of the spine (T1-S1) was seen (23.6 cm to
27.3 cm, p¼ 0.06); an increase of convex hemithoracic height
(7.9 cm to 12.8 cm, p¼ 0.05); a non-significant increase in concave
hemithoracic height (8.8 cm to 9.9 cm, p¼ 0.30); a non-significant
increase in right hemithoracic width (7.2 cm to 7.9 cm, p¼ 0.07);
and a non-significant increase of left hemithoracic width (7.2 cm to
7.9 cm, p¼ 0.43). The average number of lengthening surgeries per
patient was 3.0 (range 2-4). Eight of the ten patients had complica-
tion of surgery, such as infection (n¼ 4), migration (n¼ 3), pneu-
monia (n¼ 2), and instrumentation failure (n¼ 2). No severe
complications were noted. The authors conclude that these results
show that growth-friendly surgical intervention for early-onset
scoliosis in CFM tends to improve scoliosis and spine height,
but significantly improves convex hemithoracic height.
Conclusions
Level 3 Policy
Growth-friendly surgical intervention for
early-onset scoliosis in craniofacial
microsomia may improve the scoliosis,
spine height, and hemithoracic width and
height (studied in 17 patients).
Ref (18)
Considerations
 Overall quality of evidence
Data on treatment modalities was based on a single retrospective
study, with a small patient sample, and without comparison between
treatment modalities (18). No strong conclusions on the indications
and policy for treatment of vertebral anomalies in CFM can be
made. The quality of evidence was graded on level 3.
 Balance of benefits and harms
An important benefit of surgery is to keep patients mobile and to
prevent neurological injury. Later surgery may reduce rib promi-
nence and diminish spinal deformity. It could lead to a cosmetic
improvement for some patients. Whenever surgery is indicated the
benefit should clearly outweigh the risks of being conservative.
Patients undergoing spinal surgery are at significant risk for the
development of complications including unplanned readmission
and reoperations. These outcomes are unwanted for patients and
doctors and will increase costs for the healthcare system in general.
Results of surgery may vary. Mortality and complications like
infection, blood loss, nerve damage, wrong screw placement,
CSF leakage, and bowel and bladder problems are some of the
potential risks of any type of spinal surgery, including spinal fusion
for the treatment of scoliosis. Additional complications that may be
associated with surgery include loss of proper spinal balance,
pseudoarthrosis (no fusion), instrumentation failure and vertebral
degeneration in the levels adjacent to the fused section.
Data on risks and benefits are scarce. Recently the database of
the American College of Surgeons National Surgical Quality
Improvement Program (ACS NSQIP), a multicentre paediatric
database that aims to collect short-term data on paediatric patients,
was used to determine clinical outcomes in paediatric patients
undergoing spinal arthrodesis (30). The objectives were to analyse
the short-term mortality rate, complications, reoperation rates and
readmission rates and to identify significant patient risk factors
associated with these risks. A total of 4420 paediatric patients who
underwent spinal fusion were identified. Common indications for
surgical intervention included acquired/idiopathic scoliosis or
kyphoscoliosis (71.2%) and genetic/syndromic scoliosis (10.7%).
They found that for paediatric patients undergoing spinal arthrode-
sis for all causes, there was a 3.6% unplanned reoperation rate, a
3.96% unplanned readmission rate, and a 9.0% complication rate.
Furthermore, the presence of pulmonary comorbidities and female
sex represent significant risk factors for reoperation. By using risk
stratification these data will allow the surgeons to identify high-risk
groups to optimise shared decision making and improve outcomes.
The benefit of bracing is that it is easily applied, non-invasive
and will prevent surgery in some cases. The potential harms of
bracing include pressure ulcers, chest pain, physical and social
limitations, anxiety, and depression. Since bracing improves out-
comes in patients with idiopathic scoliosis it is likely to have the
same effect in patients with CFM.
 Outcome importance
To achieve optimal outcome in care and treatment of vertebral
anomalies in CFM, risk-balanced proper surgical indication and the
avoidance of complications are the main goals for physicians and
their patients. Not only from a surgical point of view but also from a
screening and conservative point of few the goals are comparable.
Surgical and non-surgical treatment, even in the best hands, has
complications. Benefit to the patient should be the primary concern
in the attempt to avoid negative outcomes and legal issues. Com-
plications will have detrimental effects and will always increase the
costs of treatment. Hence, a multidisciplinary approach is warranted
to optimise outcomes for these patients.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. Treatment of spine anomalies may reduce
costs by preventing neurological deterioration. The recommenda-
tions concern the essential requirements for adequate treatment of
patients with CFM and should thus be implemented. The costs of
bracing are low and will prevent expensive surgery in some cases.
Since the costs of spinal cord injury are high, prevention of neuronal
damage is essential and will be cost effective in the long term.
Surgical prevention of (neurological) deterioration including spinal
cord injury will prevent additional care being necessary, especially
when tertraparesis occurs (31). Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
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 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core
values. However, in some countries the national organisation of
healthcare might impede centralisation. National implementation
of the ERNs that fits the situation of each country is necessary. For
the member states with the lowest number of inhabitants, the
establishment of a craniofacial centre might not be feasible, and
collaboration with a craniofacial centre in the surrounding coun-
tries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
In the most recent recommendation Statement of the USPSTF
(29) there is evidence from five studies that treatment with bracing
may decrease curvature progression in adolescents with mild or
moderate curvature severity (an intermediate outcome). However,
no adequate evidence on the association between reduction in spinal
curvature in adolescence and long-term health outcomes in adult-
hood was found. We may extrapolate these findings to scoliosis in
patients with CFM.
If the spine is unstable, surgical fusion and/or bracing may be
necessary to obtain spinal stability and to prevent secondary injury
of the spinal structures, including spinal cord. When conservative
treatment fails, surgical intervention is usually necessary. When
surgery is considered, adequate radiological imaging including
MRI, CT and CT-Angiography is warranted. Surgery is less feasible
in children especially at a younger age and smaller size. Awareness
of age-related anatomy is indispensable in the surgical treatment of
these patients. A multidisciplinary approach and shared decision-
making should be part of treatment strategies. The choice for a
specific surgical technique should be based on its benefits and
harms and the surgeon’s experience. Every surgical treatment
technique has its own harms and benefits which are specific to
the individual patient and the level of instability. For example, when
cervical stabilisation is considered, detailed information about the
vertebral arteries is warranted whereas for scoliosis information
about tethering of the spinal cord is more important. The important
objective of surgery for vertebral anomalies including scoliosis in
patients with CFM is to prevent neurological damage and progres-
sion of spinal deformity and to maintain spine, chest wall, and lung
development. Intraoperative neuromonitoring is considered indis-
pensable for these types of surgery. Evidence on when, what and
how surgery should be performed is often lacking. One of the
evidence-based techniques available is the growth-friendly surgical
intervention for early-onset scoliosis in patients with CFM. This
technique improves convex hemithoracic height significantly and
has a tendency to improve scoliosis (18).
Recommendations
 Surgical fusion and/or bracing in patients with vertebral
anomalies may be necessary to obtain spinal stability
and to prevent secondary injury of the spinal structures.
 A multidisciplinary approach in treatment and timing is
warranted to optimise outcomes for these patients.
Research gap
Low-quality data make the use of evidence-based medicine in
decisions on surgery for vertebral anomalies in CFM difficult. Data
on the natural history, imaging, treatment, and outcomes of CFM
patients with vertebral paediatric spondylolysis are scarce and
treatment is mostly based on expert opinions. In most surgical
cases the technique used is mainly dependent on the surgeon’s
preference rather than based on evidence. Large registries will
provide more insight into the best treatment strategies and could
be of help with making evidence-based medical decisions.
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CHAPTER 4. SCREENING, MONITORING AND
INDICATION FOR TREATMENT
4.8 Psychosocial difficulties in craniofacial
microsomia
Introduction
Atypical facial appearance can lead to poor social acceptance by
others and cause psychosocial difficulties (1, 2). Social comparison
begins in primary school and increases at least into adolescence,
with comparisons to peers and those portrayed in the media, as well
as the influence of comments from peers and parents, transforming
beliefs and stereotypes about attractiveness into self-evaluation
concerning appearance (1). Patients with an unusual facial appear-
ance or craniofacial syndromes can have difficulties with psycho-
logical adjustment and experience teasing. Various forms of teasing
or bullying have been described, such as staring, whispering,
making inappropriate comments, aggression, emotional distress,
and/or social withdrawal (3–5). Teasing was found to be associated
with a higher risk for depression, social difficulties, and aggression
in patients with microtia (6, 7). Teasing is common in these patients:
30% to 100% of patients with microtia reported being teased,
starting in early childhood (8, 9).
Although patients with craniofacial syndromes are at increased
risk for psychosocial problems, parents/caregivers of these patients
also experience difficulties. Raising a child with a craniofacial
anomaly is demanding and leads to stress in parents due to various
reasons, such as multiple medical appointments, functional pro-
blems, teasing, psychosocial problems, or learning difficulties
(10–14).
Intellectual abilities, language or speech development, or other
neurodevelopmental processes are important for adequate psycho-
social functioning. Although some craniofacial syndromes are
associated with neurodevelopmental delay, this is less clear for
patients with craniofacial microsomia (15).
To obtain more knowledge regarding psychosocial difficulties in
craniofacial microsomia (CFM) and offer potential recommenda-
tions on screening, monitoring, and treatment, the following ques-
tions were posed:
4.8.1 What is the type, prevalence and severity of
psychosocial difficulties in craniofacial microsomia?
4.8.2 What is the policy for screening and monitoring of
psychosocial difficulties in patients with craniofacial micro-
somia?
4.8.3 What are the indications and policy for treatment of
psychosocial difficulties in patients with craniofacial micro-
somia?
Some characteristics of patients with CFM may increase the risk
for psychosocial difficulties. Difficulties in facial expressiveness or
eye contact may be caused by facial nerve deficits in some patients
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with CFM (16). Difficulties with hearing, speech or vision have
been associated with psychiatric disorders, behavioural problems,
and/or social difficulties (17–20). Additionally, the increased risk
for teasing or potential neurodevelopmental delays may also cause a
higher risk for psychosocial difficulties in patients with CFM.
Literature search
A systematic search of literature was performed to identify all
available literature on craniofacial microsomia and synonyms. The
search was conducted in Embase, Pubmed/Medline Ovid. The full
search strategy is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the
question of the guideline.
- The search of the systematic review was conducted in
at least two relevant databases, such as the Cochrane
Library, Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Psychosocial functioning/difficulties,
neurodevelopment
Exclusion criteria - Original studies with <10 included patients






The inclusion and exclusion criteria are reported in Chapter 2 –
Methodology. Literature was screened on title and abstract. A total
of fifteen articles were included in this chapter: eight articles on
psychosocial functioning in CFM and seven articles on neurode-
velopment of patients with CFM. Of the eight articles on psycho-
social difficulties, three were case-control studies: Dufton et al.
(21), Khetani et al. (22), and Wallace et al. (23). The other five
studies were cross-sectional studies: Johns et al. (24), Luquetti et al.
(25), Ongkosuwito et al. (26), Padwa et al. (27), and Volpicelli et al.
(28). Seven studies on neurodevelopment of patients with CFM
were included. Three case-control studies: Collett et al. (29), Speltz
et al. 2017 (30), and Speltz et al. 2018 (31). Of the other four studies,
three were cross-sectional studies by Cohen et al. 1995 (32), Cohen
et al. 2017 (33), and Johansson et al. (34), and one study was a
retrospective cohort study by Strömland et al. (35).
4.8.1 What are the type, prevalence and severity of
psychosocial difficulties in craniofacial microsomia?
The literature search for this question was directed towards more
specific questions related to the type, prevalence and severity of
psychosocial difficulties in CFM (jAppendix 1, http://links.lww.-
com/SCS/B697). No literature was available on the severity of
psychosocial difficulties, therefore no conclusions were written.
Since this question does not relate to interventions or diagnostics, no
considerations, rationale or recommendations are provided.
Review of literature
Psychosocial
Dufton et al. (21) aimed to determine the risk for psychosocial
difficulties in children with CFM compared to controls. A total of
136 children with CFM and 568 healthy controls, age five to ten,
were assessed for social competence, and behavioural and emo-
tional difficulties using questionnaires that were completed by the
parents and teachers of the children. Parents scored patients with
CFM higher on the social difficulties scale compared to controls,
but the effect size was small (ES¼ 0.30, p¼ 0.002). Teachers rated
patients with CFM to have slightly more behavioural problems,
such as feeling depressed/withdrawn (ES¼ 0.27), social difficulties
(ES¼ 0.55), cognitive difficulties (ES¼ 0.29), attention problems
(ES¼ 0.24), and aggressive behaviour (ES¼ 0.21). Teachers rated
patients with CFM as having poorer academic skills (ES¼ 0.21),
poorer communication skills (ES¼ 0.19), and as having lower
overall social competence (ES¼ 0.24), compared to controls. These
differences on social competence were largest for female patients
(ES¼ 0.35) and for cases of young mothers (ES¼ 0.70). Teachers
ranked patients with CFM as having slightly lower peer acceptance
in the classroom (difference of 10%), compared to controls. Espe-
cially patients with oral clefts and eye anomalies in combination
with jaw and/or ear anomalies were scored as having lower peer
acceptance compared to controls. Although teachers rated children
with CFM to have more behavioural and social problems than
controls, parents of patients and controls did not report a difference
regarding these topics. This variance may be caused by a difference
in the social context in which the children are observed. However,
reporting bias may also have led to this difference, where parents
might minimise problems of their own child or teachers might
overestimate problems due to the different facial appearance of
patients with CFM.
In 2018, Johns et al. (24) asked patients with CFM and parents of
patients to describe experiences in their daily life and give sugges-
tions for improving healthcare. A total of 42 caregivers and 9 adult
patients with CFM were included. Caregivers (62%) and patients
(57%) noted social stigma as a primary concern. In the community
setting, 29% of the patients sometimes hid their diagnosis and 17%
of the caregivers experienced explaining the diagnosis of CFM to
others as difficult. Caregivers found support through support web-
sites (71%), their partner/spouse (62%), family (57%), medical
professionals (48%), friends (41%), and communicating with fel-
low patients (41%). Around half of the adult patients (56%) and
27% of the caregivers reported active teasing. Passive social
exclusion was also frequently reported (33% of the patients and
12% of the caregivers). A fifth (22%) of the patients tried to hide
their diagnosis, and 11% experienced issues with social comparison
and difficulties in having a romantic relationship.
Khetani et al. (22) aimed to study the health-related quality of
life in children with CFM by assessing parents of patients and
patients during the elementary school years. More controls
(n¼ 568) than patients with CFM (n¼ 136) were included. Both
patients and controls had a mean age close to seven years ( one
year). Parents scored children with CFM lower on measures of
physical, social, and school functioning, compared to controls.
Although this was a significant difference, the effect sizes were
small (ES: 0.26–0.34). On the child-reported assessment, no dif-
ferences in in physical, social, or emotional functioning between
children with CFM and controls were found.
Luquetti et al. (25) studied the diagnostic, treatment-related, and
early psychosocial experiences of 9 adult patients with CFM and 42
caregivers of children with CFM. Caregivers experienced feelings
of concern/anxiety (79%), surprise/shock (64%), sadness (64%),
guilt (55%), and confusion (31%) in response to hearing the
diagnosis of CFM. Teasing was common for patients with CFM:
all adults but one were teased during childhood and caregivers
reported that 43% of the children aged four and older were teased.
Most teasing occurred in childhood (age five to ten) with a peak of
teasing at a mean age of nine years (SD 2.5). Name calling was the
most frequent form of teasing (caregivers 56%, patients 83%),
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although questions about their appearance or nonverbal negative
reactions of mimicking or running away occurred too (caregivers
22%, patients 17%). In response to teasing most caregivers (45%)
and patients (67%) said to ignore the teasing. Being stared at was
also frequently noted by patients. Although some patients did not
care (13%), others described feeling shy or having negative emo-
tional responses (caregivers 13%, patients 38%). Most patients had
adaptive coping responses to staring (caregivers 26%, patients
38%), others ignored staring (caregivers 6%, patients 13%), or felt
reminded about their diagnosis of CFM (caregivers 3%, patients
25%).
Stress in parents of children with CFM and their coping styles
were studied by Ongkosuwito et al. (26). Questionnaires on parental
stress and on cognitive emotion-regulation were completed by 31
parents of patients with CFM. Learning difficulties and psychoso-
cial difficulties were associated with an increase in parental stress
(r¼ 0.71, r¼ 0.63, both p¼<.001). No relation between hearing
difficulties (r¼ 0.32, p¼ 0.08), articulation difficulties (r¼ 0.34,
p¼ 0.06), or the facial appearance of the child (r¼ 0.07, p¼ 0.72)
and parental stress was found. The coping strategies that had a
positive correlation with parental stress were acceptance and posi-
tive reappraisal (r¼ 0.50, p¼ 0.01 and r¼ 0.54, p¼ 0.002). Multi-
variate regression analysis showed that learning difficulties and the
use of acceptance as a coping strategy explained a large proportion
of parental stress. Interventions for parents of children that address
learning difficulties and coping strategies could potentially be
beneficial to lower parental stress.
Padwa et al. (27) studied psychosocial adjustment in children
with craniofacial anomalies to examine the relationships between
symmetry, functional impairments, and social adaptation. Of the 30
patients included, 11 had CFM. Most patients (80%) with CFM
were able to socialise in a positive way by joining the group, which
was higher when compared to other craniofacial anomalies (52%-
57%). Low self-esteem and negative self-concept were reported by
35–40% of all children; no subgroup data of patients with CFM was
reported. Patients with symmetrical craniofacial anomalies had a
significantly higher prevalence of low mood. Patients with sym-
metrical and non-CFM craniofacial anomalies had lower social
competences scores. This suggests a higher prevalence of low
mood, behavioural problems, and socialising problems were present
in this group when compared to patients with asymmetrical cranio-
facial disorders, and to patients with CFM. The authors debate
whether children with facial asymmetry may be viewed as having a
normal face with imperfections, while patients with a symmetrical
craniofacial anomaly could be seen as having a severe medical
condition or syndrome. Patients with an asymmetric deformity may
be more acceptable to themselves and experience fewer psychoso-
cial difficulties. The study concludes that early surgery in patients
with symmetrical craniofacial deformities may help to prevent
psychosocial difficulties. However, no evidence supporting this
theory is provided. Additionally, it is important to note the small
sample size of patients with CFM in this study.
The timing of paediatric craniofacial surgery and its effect on
psychosocial development was further examined by Volpicelli et al.
(28). They aimed to study differences in psychosocial outlook in
children with craniofacial anomalies under active treatment. A total
of 99 patients with a craniofacial disorder such as cleft lip/palate or
craniofacial syndrome, age 8–17 years, were included. Of these 99
patients, 22 patients had CFM (21.6%). Younger patients (age 8–
10) were found to have significantly higher anxiety, depression, and
anger scores, and lower peer relationship scores, compared to older
patients (age 11–13 and/or age 14–17) and to the U.S. average
scores. The authors argue that more prevention and intervention
methods may be needed for families and schools to help younger
patients (age 8–10).
Wallace et al. (23) studied psychosocial adjustment in adoles-
cents with CFM and compared this with controls. A total of 142
patients with CFM and 316 healthy controls were included, with a
mean age of 13.4 years (SD 1.4 years, range 10–17 years). Both
patients with CFM and controls reported similar levels of beha-
vioural problems. However, lower social and school functioning
scores were reported by patients with CFM and parents of patients
due to various reasons such as teasing, not being able to participate
with other teens, or missing school due to hospital visits. Although
patients with CFM had slightly more difficulties in social function-
ing compared to controls, fewer problems with externalising behav-
iour were reported compared to controls. The authors discuss that
the higher frequency of social difficulties in patients with CFM may
be the result of teasing, rejection, or stigmatisation, instead of a
personal trait. No strong evidence for differences in behavioural
adaptation or socialisation based on the severity of the facial
malformations was found.
Neurodevelopment
Speltz et al. (2017) (30) studied the intelligence and academic
achievements of adolescents with CFM. A total of 142 patients with
CFM and 316 controls were included (mean age 13 years, range 11–
17 years). Patients with CFM scored significantly lower on IQ and
academic achievements (ES¼0.01 to 0.3, p-values range 0.01
to 0.92). It is important to note that this effect size is relatively
small. Learning difficulties occurred in 25% of the controls and in
38% of the patients with CFM (adjusted OR¼ 1.5, 95% CI 0.9–
2.4). Patients with mandibular hypoplasia and microtia had signifi-
cantly lower IQ and achievement scores as did patients with isolated
microtia, when compared to controls. Although 70% of the patients
with CFM had hearing difficulties compared to 1% of the controls,
an effect of hearing difficulties on IQ and achievements scores was
not found. The authors conclude that these findings should be
viewed ‘primarily as hypothesis-generating, rather than as firm
conclusions’. According to the authors, developmental surveillance
of children and adolescents with CFM should be undertaken.
In another study by Speltz et al. (2018) (31) the neurodevelop-
mental profile of infants with CFM was assessed and compared with
controls. A total of 108 patients with CFM and 84 controls, all age
12–24 months, were included. Developmental delay was found in
21% of the patients with CFM and in 16% of the controls. However,
no differences in terms of developmental delay were present after
adjustment for demographic factors (OR¼ 0.68, 95% CI 0.29–
1.61). No differences in development were found based on the CFM
phenotype. The authors conclude that no evidence for neurodeve-
lopmental differences between infants with CFM (age one to two)
and controls could be found.
Collett et al. (29) aimed to determine the risk for neurodevelop-
mental delay in 136 children with CFM compared to 568 healthy
controls. Lower verbal, nonverbal, and academic skills were seen in
patients with CFM compared to controls. Patients with CFM had a
significantly higher risk for receptive language delays and visuo-
motor skills delay compared to controls. Worse outcomes on the
neurodevelopmental profile were seen in patients born to mothers
who were 25 or younger at time of birth. The authors emphasise the
need to carry out routine neurodevelopmental screening for patients
with CFM.
A smaller, cross-sectional study by Cohen et al. (1995) (32)
included 24 patients with CFM to examine their neurodevelop-
mental profile. No significant difference in mean IQ compared to
the general population was found. A delay was found in gross (38%)
and fine (20%) motor development and in receptive (32%) and
expressive (37%) language development compared to the general
population. Receptive and expressive language development were
significantly lower in patients with bilateral CFM compared to
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unilateral CFM. In a larger cross-sectional study by Cohen et al.
(2017) (33) on facial and systemic malformations in a cohort of 89
patients with CFM, 5% (n¼ 4) were found to have an intellectual
disability. No further information on developmental delay was
provided in this study.
Johansson et al. (34) aimed to study autism spectrum disorder in
20 patients with CFM (mean age 8 years, range 8 months – 17
years). Eleven patients (55%) were found to have normal intelli-
gence and nine patients (45%) had learning disabilities, which were
mild in four patients (20%), severe in three patients (15%), and
profound in two patients (10%). Autism spectrum disorder was
diagnosed in two patients (10%), autism-like condition in one
patient (5%), and autistic traits in five patients (25%). Behavioural
disturbances, such as aggressive behaviour or hyperactivity, were
solely seen in patients with autism spectrum disorders.
Strömland et al. (35) also studied autism spectrum disorder in
CFM. One of their eighteen included patients with CFM had autism
and two met the criteria for childhood autism/autistic-like disorder.
Six other patients had learning disabilities (30%): three had severe
(17%) and three had mild (17%) learning disabilities.
Conclusions
Level 3 Type
Patients and/or parents of patients with craniofacial
microsomia have a higher risk of experiencing social
stigma, low self-esteem and active or passive bullying,
especially in childhood.
Parental stress in parents of patients with craniofacial
microsomia is linked to their child’s learning difficulties,
and parental acceptance. The facial appearance of the
child does not appear to be an important influential factor
in parental stress.
Ref (24–27)
Level 3 Risk factors
Patients with symmetrical craniofacial anomalies may
experience more behavioural problems, depressed
feelings, and socializing problems compared to patients
with an asymmetrical craniofacial anomaly.
Younger children (age 8–10) with a craniofacial anomaly
may experience more problems with anxiety, low mood,
anger, and peer relationships compared to older children
(age 11–17).
Ref (27, 28)
Level 3 Type - Neurodevelopmental
Patients with craniofacial microsomia may have a slightly
lower IQ score and more learning difficulties compared to
healthy controls.
The neurodevelopmental profile of infants with craniofacial
microsomia (age 1–2 years) is not different from healthy
controls.
Patients with craniofacial microsomia might have a higher
risk for language- and motor skills delays compared to
healthy controls.
Ref (29–35)
4.8.2 What is the policy for the screening and monitoring of
psychosocial difficulties in patients with craniofacial micro-
somia?
The literature search for this question was directed towards more
specific questions related to the consequences and impact of
screening and monitoring, the available screening tests and
procedures for monitoring, and responsibilities for screening and
monitoring (Appendix 1, http://links.lww.com/SCS/B697). Unfor-
tunately, no literature is available on the policy for screening and/or
monitoring of psychosocial difficulties in patients with CFM.
Therefore no conclusions were written. Considerations for this
question were only based on expert opinion.
Considerations
 Overall quality of evidence
Because of the lack of evidence, the recommendations on
screening and monitoring of psychosocial difficulties in CFM
are based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
Having access to a psychologist and a team specialising in CFM
will have obvious biopsychosocial benefits for patients and their
families including providing a high standard of care, improving
patient quality of life and potentially reducing hospital stays
and communications.
 Outcome importance
The main reason to perform screening is to help to reduce
emotional distress experienced by patients and their families,
promote information sharing and a holistic approach, and pre-empt
psychological difficulties developing as a result of the patient’s
physical health condition.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
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 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The rationale for having psychological input in a specialist
team for CFM is to pre-empt any psychological issues experi-
enced by the child and family that could have an impact on the
patient journey, and to ensure that the team approach is holistic
(36). It may involve mediating on behalf of the family with
medical teams or schools, or between child and parent if there
is a difference in opinion regarding intervention. The overall aim
is to reduce distress and to enhance and promote psychological
wellbeing. The amount of distress does not always seem to be
proportionate to objective appearance, as it is a psychological
process that determines response to differences in appearance.
Regular review by the specialist team offers the patient and family
holistic and up-to-date help. Regular contact fosters good rela-
tionships between professionals and the family and allows the
team to discuss intervention in an age-appropriate manner. It also
allows the family to ask about new developments in the field and
if necessary, to discuss psychosocial, educational and hearing
issues which may arise. Being provided with this information and
support promotes parental adjustment and acceptance and enables
them to communicate positive themes of normalisation and
reassurance, which children mirror in their own responses and
adjustment (37). The ICHOM Standard Set for Craniofacial
Microsomia advises to see patients and their family at age 2,
5, 8, and 22 to measure psychosocial wellbeing and quality of life
using the ClefQ, YP-CORE, HADS, and CFEQ. It is advised to
use the Distress Thermometer for Parents to measure
family stress.
It is good practise to advise families of active voluntary sector
support groups and relevant charities. Support groups and charities
can help children and their families deal with difference, and
promote confidence, resilience and positive self-image. Healthcare
providers play a key role in family adjustment by clarifying
misinformation, providing education regarding treatment options,
modelling acceptance, screening for psychosocial concerns, pro-
viding resources and connecting families to support networks. With
regards to visible differences, patient coping and level of concern is
related to personality, family responses, school support and devel-
opmental stage. Predictors of good psychosocial outcomes are
social and family support, perceptions of severity and social
interaction skills, and clinicians (with regular contact and working
with the system) can to have a positive influence on these factors.
Recommendations
 All craniofacial microsomia patients should have access
to a clinical psychology service with appropriate
professional expertise and knowledge of craniofacial
microsomia.
 Time points for reviews and screening should observe
key life transitions such as birth, starting school,
transition to secondary school, etc.
 To measure psychosocial wellbeing and family stress,
validated self-reported psychological outcome mea-
sures should be obtained from to all craniofacial
microsomia patients as a matter of routine to screen for
the presence of behavioural, emotional, social and/or
learning difficulties. This includes the CleftQ, CFEQ,
YP-CORE, HADS and Distress Thermometer for
Parents and should be performed at age 2, 5, 8 and
22. Elevated scores should alert clinicians to the
potential need for further assessment or support.
Standardised measures should assess levels of emo-
tional distress as well as evaluate difficulties related to
visible differences.
Research gap
It is recognised that there is a lack of quantitative and qualitative
research looking at the psychological impact of CFM, and a need for
longitudinal studies to further inform psychological assessments and
interventions. Use of measures pre- and post-operatively provides
valuable data for audit and research as well as quickly identifying any
psychological difficulties that can potentially be addressed, and
themes and issues identified in clinics directly from patients and
their families could be assessed using qualitative methods.
4.8.3 What are the indications and policies for the treatment
of psychosocial difficulties in patients with craniofacial
microsomia?
The literature search for this question was directed towards more
specific research questions related to treatment options, symptoms,
requirements, complications, and advantages and disadvantages of
treatment of psychosocial difficulties (Appendix 1, http://
links.lww.com/SCS/B697). Unfortunately, no literature is available
on the policy for treatment of psychosocial difficulties in patients
with CFM. Therefore no conclusions were written. Considerations
for this question were only based on expert opinion.
Considerations
 Overall quality of evidence
Because of the lack of evidence, the recommendations on
treatment of psychosocial difficulties in CFM are based on expert
opinion with a low quality of evidence.
 Balance of benefits and harms
Psychological therapy can be time consuming, but interventions
are individualised and planned collaboratively with the patient and
their family, which increases acceptability and adherence. Manag-
ing the patient ‘system’ can be heavy work for clinicians, requiring
communications and meetings with family members, school, other
medical teams etc.
 Outcome importance
Psychosocial support and psychological intervention are
designed to promote quality of life, which is important to patients,
family, and clinicians. Early psychological intervention would
reduce the risk of patients developing long-term mental health
difficulties and their associated sequela, thus reducing the strain
on healthcare resources in future years.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
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providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and should
thus be implemented. Costs are lowest and resources are most
efficiently used when care for craniofacial disorders is centralised
in a limited number of expert centres per member state. A general rule
that can be applied is one expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an expert
centre for CFM, or the level of provided care does not (yet) meet all the
requirements that are outlined in this guideline. By defining the
baseline of required care for CFM, this guideline will help these
member states to reach the appropriate level. The ERN on craniofacial
anomalies and ENT disorders (ERN-CRANIO) can guide a patient in
Europe to the available centres of expertise (www.ern-cranio.eu) and
can support care providers with diagnosis and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
We suggest that including a psychologist in the specialist team
or having access to paediatric or adult health psychologists
improves overall psychosocial outcomes for people with CFM.
Interventions can be targeted to the patient, family or the wider
system, to enhance psychological wellbeing, acceptance and adjust-
ment. Having a psychologist present enables psychosocial difficul-
ties to be identified, with the aim being early intervention. Support
groups and charities play a key role in psychosocial wellbeing,
helping children and their families to deal with difference and
promote confidence, resilience and positive self-image.
Healthcare providers play a key role in individual coping and
adjustment, for example, by promoting positive and assertive
strategies when dealing with the reactions of others, focusing on
personal achievements, and encouraging participation in social and
physical activities, which in turn can lead to greater self-acceptance.
They also play a key role in supporting parents/carers of children
with CFM in terms of making decisions regarding whether or not to
proceed with surgical reconstruction, which can feel like a huge
responsibility for a parent/carer to have (38).
In terms of involving the child in decision making surrounding
surgery, we suggest that (where possible) there is a strong argument
for waiting until the child is old enough, with the necessary level of
abstract conceptual thinking and emotional maturity, to enable
informed decision making. A study that interviewed adolescents
with CFM found that the children were glad that their parents had
allowed them to be involved in the decision-making process sur-
rounding surgery (39). They also did not feel that concern regarding
current or potential bullying was a good reason to have surgery at a
young age, and that promoting self-acceptance and resilience were far
more important. They were asked to list positive aspects of growing
up with a craniofacial condition (39). Positive changes in personality
included being more open-minded, less judgemental, kinder, and
more independent. Participants also expressed the belief that they are
strong individuals who are able to overcome challenges. When asked
what advice they would give younger children growing up with
similar conditions, participants said they would advise them to be
open and honest and not be ashamed of their visible differences.
If indicated, a psychologist should be involved when proceeding
with surgery at preadmission stage to assess psychological readiness for
surgery, including identifying any procedural anxiety that will impact
on the surgery itself, and psychosocial issues that may affect treatment
adherence post-operatively. Assessment of readiness for surgery
should occur before or at the preadmission clinic. A semi-structured
interview format should be used to establish current emotional state,
family functioning, mental and physical health history, significant life
events, risk factors for poor psychological adjustment post-surgery –
including unrealistic expectations, concerns regarding the process of
hospital admission, surgery, post-operative pain etc. As well as collat-
ing feedback for the medical team, the aim should be to attempt to
ascertain if surgical reconstruction will contribute to long-term psy-
chological wellbeing. Post-operative follow-up should occur following
completion of surgical reconstruction to assess emotional state, satis-
faction with surgical process, and body image issues. It is important that
the patient understands the nature of the healing process and its
potential impact on their body image. With patients often waiting a
long time before the surgery can be performed and with the cosmetic
result not fully visible for a number of weeks due to bruising and
swelling, expectations must be carefully managed. Whilst it can be
several weeks before patients feel fully physically recovered from
reconstructive surgery, it could be argued that the bigger challenge at
this time will be the need to adapt to the look and feel of their new
appearance. Revealing the newly reconstructed area for the first time
must be done with sensitivity and in a way that allows them some
control over how and when it is seen, as well as who will see it.
Recommendations
Parental adjustment and support
 Parents of newly diagnosed children with craniofacial
microsomia should have access to a specialist clinical
psychology service with expertise and knowledge of
the condition.
 Information on support groups and organisations should
be provided, both at initial contact and at regular review.
Behavioural and/or learning difficulties
 When appropriate, clinicians should liaise with local
services and schools to discuss the child’s support needs.
 Cognitive assessment may be offered if warranted
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Coping with visible difference
 Patients with craniofacial microsomia should have access
to specialist psychological support, particularly those
who are presenting with low self-esteem, depression/low
mood, anxiety, appearance- or treatment-related con-
cerns, including adjustment difficulties or trauma as a
result of surgical/medical interventions.
 Clinicians with appropriate professional expertise in
craniofacial microsomia should consider liaising with
local schools to offer advice on how to support children
who have visible differences.
 Information about support groups and organisations
should be provided.
 Psychological input is required pre- and post- facial
surgery to monitor expectation and acceptance.
 The psychologist is part of the coordinated care in the
multidisciplinary team. See recommendations in
Chapter 6.
Research gap
As described in Chapter 4.8.2.
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CHAPTER 5. SURGICAL TREATMENT
5.1 Mandible & Maxilla
Introduction
Mandibular hypoplasia is seen in 73% to 91% of patients with
CFM with varying severity (1, 2). The Pruzansky classification,
later modified by Kaban, has been developed to characterise the
mandibular deformity in patients with CFM based on radiographic
assessment (3–5). A small but normal shaped mandibular ramus
and temporomandibular joint (TMJ) is classified as type I. In type
IIa, the mandibular ramus is malformed in size and shape but the
TMJ is adequately positioned. Type IIb is characterised by an
abnormal shape, size, and location of the mandibular ramus and
TMJ. In type III, the ramus, condyle and TMJ are absent. Most
patients with CFM have a type I or IIa deformity (respectively 41%
and 26%), although severe mandibular hypoplasia, i.e. type IIb or
III, is also seen in a considerable number of patients (respectively
14% and 10% of all patients with CFM) (2).
Maxillary hypoplasia in patients with CFM could be secondary
to the mandibular deformity. A deviation of the mandible to the
affected side is seen in patients with CFM, causing facial asymme-
try and canting of the occlusal plane (6). Treatment of the maxillo-
mandibular complex to achieve facial symmetry and restore occlu-
sion may be needed.
Besides occlusal problems, other functional problems may occur
due to the mandibular/maxillary deformity in CFM. The risk for
obstructive sleep apnoea (OSA) increases in patients with mandib-
ular hypoplasia due to obstruction of the upper airway at tongue
base level (7). Although OSA may be treated non-surgically, as is
described in Chapter 4.1 – Breathing problems, surgical correction
of the mandibular deformity may be needed. Besides functional
problems, psychosocial problems may occur due to aesthetic con-
cerns related to the facial asymmetry, which may require
surgical correction.
To study indications for surgical treatment of the mandibular/
maxillary deformity in patients with CFM and offer recommenda-
tions for treatment, the following questions were posed:
5.1.1 What is the indication for surgical treatment of
mandibular and maxillary deformity in patients with
craniofacial microsomia?
5.1.2 What is the most optimal treatment modality and its
timing for mandibular/maxillary deformity in craniofacial
microsomia regarding severity, breathing problems, occlu-
sal problems and aesthetics?
The variety of indications for treatment, differences in severity,
and diversity in types of treatment make it difficult to standardise
care. Nevertheless, recommendations for the indications and types
of treatment would help to achieve standardisation in the care
process and enable surgeons and patients to make better, well-
informed decisions.
Literature search
A systematic search of literature was performed to identify all
available literature on CFM and synonyms. The search was con-
ducted in Embase, Pubmed/Medline Ovid. The full search strategy
is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review matches the
question of the guideline.
- The search of the systematic review was conducted in
at least two relevant databases, such as the Cochrane
Library, Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Treatment for mandible/maxilla deformity
Exclusion criteria - Original studies with <10 included patients






Literature was screened on title and abstract. A total of 31
studies were included that addressed (surgical) treatment of man-
dible or maxilla deformity in patients with CFM. Three systematic
reviews were included: Nagy et al. (8), Pluijmers et al. (9), and Van
de Lande et al. (10). Two case-control studies by Meazzini et al.
were included (11, 12). Nineteen retrospective cohort studies were
included: Ascenco et al. (13), Gui et al. (14), Kearns et al. (15), Ko
et al. (16), Caron et al. (17), Lam et al. (18), Pluijmers et al. (2019)
(19), Suh et al. (20), Wang et al. (21), Weichman et al. (22), Zhang
et al. (23), Bertin et al. (24), Padwa et al. (25), Tahiri et al. (26),
Fattah et al. (27), Yamaguchi et al. (28), and Pluijmers et al. (2018)
(29). And seven case series were included: Kaban et al. (1986) (4),
Kaban et al. (1988) (30), Rachmiel et al. (2000) (31), Rachmiel et al.
2014 (32), Santamarı́a et al. (33), Liu et al. (34), and Polley et al.
(35).
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An additional search on the treatment for mandibular of maxil-
lary hypoplasia in all types of patients was performed to include any
additional literature that might be relevant for patients with CFM.
All articles that described outcomes or complications of treatment
of mandibular/maxillary hypoplasia were included. Only system-
atic reviews or meta-analysis were included. The full search
strategy is shown in the addendum. A total of 53 articles were
identified and seven articles met the inclusion criteria. An addi-
tional two articles were found trough a reference check, leading to
the inclusion of a total of nine systematic reviews: Breik et al.
(2016) (36), Breik et al. (2016) (37), Breik et al. (2016) (38), Ow
and Cheung (39), Paes et al. (40), Tsui et al. (41), Verlinden et al.
(42), Master et al. (43), and Tahiri et al. (44).
5.1.1 What is the indication for surgical treatment of
mandibular and maxillary deformity in patients with
craniofacial microsomia?
The literature search for this question was directed towards more
specific research questions related to clinical problems, symptoms,
treatment options, consequences of not treating, and requirements
for surgical treatment of mandibular and maxillary deformity
(Appendix 1, http://links.lww.com/SCS/B697). This chapter was
divided into psychosocial/aesthetic problems, breathing problems,
and occlusal/feeding problems.
Review of literature
The indication for surgical treatment of mandibular/maxillary
deformity in patients with CFM is patient specific and is based on
the clinical consequences caused by the deformity, which includes
psychosocial/aesthetic problems, breathing problems, or occlusal/
feeding problems.
Psychosocial / aesthetic problems
No comparative studies assessing the outcomes of surgical treat-
ment of mandibular/maxillary deformity in patients with CFM
regarding psychosocial problems have been performed. It is debated
in literature whether treatment of the mandibular deformity should be
performed in children with CFM without functional complaints,
solely to prevent potential negative psychosocial effects. Patients
with CFM may experience psychosocial problems, as is discussed in
‘Chapter 4.8 – Psychosocial problems’. It is unclear whether treat-
ment of the mandibular/maxillary deformity improves or prevents the
psychosocial problems related to CFM. Some authors advocate early
correction of the mandibular deformity to prevent potential psycho-
social problems (13, 23–25). The potential beneficial psychosocial
effects of treatment should outweigh the risk of complications and re-
interventions, which may be the case in patients with severe man-
dibular hypoplasia (9, 13). If the aim of surgery is to restore symmetry
throughout growth, it is important to clearly explain the risks of
surgery and the need for subsequent procedures (12). The potential
beneficial psychosocial effects of surgical treatment should be ‘eval-
uated and justified’ by psychologists and not by surgeons or ortho-
dontists, according to Meazzini et al. (12).
Breathing problems
Bilateral mandibular distraction osteogenesis (MDO) is a pre-
ferred method for treatment of respiratory distress / obstructive sleep
apnoea in patients (<18 years) with mandibular hypoplasia who are
unresponsive to non-surgical treatment. Rachmiel et al. (2014)
included 37 patients who underwent MDO for the treatment of
OSA over a period of nine year. Fourteen of these patients had
CFM, fifteen patients had Pierre Robin sequence and eight patients
Treacher Collins. Of the 37 patients included, 21 patients had
respiratory distress and 16 patients were tracheostomy dependent
(32). No information on other additional therapy, such as CPAP, was
provided. The authors found that mandibular distraction led to
improved airway patency in all 21 patients with respiratory distress.
All 16 patients who were tracheotomy dependent could be decan-
nulated after MDO (32). No specific outcomes of the included
patients with CFM could be extracted. Lam et al. performed a
retrospective cohort study to assess the success of MDO on airway
problems and included 123 patients who underwent MDO (including
11 patients with CFM) (18). The authors studied all patients who
underwent initial MDO between 1995 to 2009. The indication for
treatment was to improve upper airway obstruction. Surgical success
was defined as the avoidance of tracheostomy due to MDO being
performed first or as successful decannulation in patients with a
tracheostomy after MDO. The median age at time of MDO was
21 months (IQR 2.2-48.2 months). Patients treated with MDO first
had a significant lower mean age compared to tracheostomy first (5.1
versus 30 months, p<0.001). No specific results of the included
patients with CFM could be extracted. Two thirds (n¼ 42, 67.7%) of
the patients with a tracheostomy could be decannulated after MDO
and 83.6% of the patients (n¼51) did not need a tracheostomy after
MDO. The surgical success of MDO in patients who had a tracheos-
tomy first was found to be the lowest in patients with CFM compared
to other syndromic conditions including Pierre Robin sequence or
Treacher Collins syndrome (OR: 0.05 (CI 0.005–0.43), p¼0.007;
adjusted for sex and age). Due to these lower odds of success, the
authors recommend that patients with CFM and respiratory distress
who are unresponsive to non-surgical treatment should have a
tracheostomy as an initial procedure and MDO secondarily to achieve
decannulation (no specific age for treatment was proposed) (18).
MDO as treatment for OSA in patients with CFM and unilateral
mandibular hypoplasia was found to have a much lower success rate
of 36.4% as only four of the eleven treated patients had normal PSG
after MDO. The reason for this low success rate was not reported (e.g.
bad timing or quality of the MDO). It is relevant to be aware that
decannulation may not be achieved (17).
The additional search on MDO in non-CFM patients led to the
inclusion of five systematic reviews on the treatment of MDO to
improve respiratory distress. Breik et al. included 51 articles on
MDO outcomes in their meta-analysis and studied 490 patients with
micrognathia who underwent bilateral MDO (mean age: 10.4
months, range 5 days to 8 years) (37). All patients were treated
for upper airway obstruction and had unsuccessfully undergone
non-surgical therapy. A successful outcome of MDO was defined as
the relief of upper airway obstruction or prevention of tracheos-
tomy. They found that MDO was successful in 95.5% of the patients
and that 4.5% (22 patients) required a tracheostomy. Most patients
with a failed outcome had undiagnosed lower airway anomalies
including laryngomalacia and tracheal or subglottic stenosis, or
central apnoeas (19/22). This suggests an incomplete pre-operative
work-up as these factors should have been noted before starting
MDO. Of the patients with a tracheostomy (n¼ 152), 80.3%
(n¼ 122) could be decannulated after MDO. The follow-up varied
between the studies included, although all studies had a minimum
follow-up of one year. The authors state that, due to the variation in
follow-up, the outcomes could only be interpreted as short-term (up
to one year). All patients considered for MDO should have poly-
somnography and nasoendoscopy to confirm the upper airway
obstruction and rule out lower airway anomalies, according to
Breik et al. (37). The success rate of MDO to achieve decannulation
is higher in patients age<24 months compared to older patients. No
differences in age on the success rate of primary MDO were found
(37). The rate of successful MDO in patients with micrognathia as
prevention of tracheostomy was 89% - 91.3%; and the rate of
decannulation after MDO was 78.4% - 94% in the other systematic
reviews included (39, 40, 44). The follow-up after treatment varied
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in the studies included: Tahiri et al. reported a mean follow-up time
of 2.4 years, Paes et al. reported a follow-up time >12 months in
nine of their twelve included articles, and Ow and Cheung did not
report the time of follow-up (39, 40, 44). Tsui et al. found a
significant improvement in apnoea-hypoapnoea index scores
(AHI) after MDO, which successfully corrected the OSA in 90–
100% of the patients (41).
Occlusal / feeding problems
The prevalence of feeding problems in CFM is 26% to 63% and is
further analysed in ‘Chapter 4.2 – Feeding problems’ (45, 46). Many
factors may lead to feeding problems, including chewing problems
which may be caused by mandibular hypoplasia. However, the precise
role of mandibular hypoplasia in feeding problems in CFM is not
described in literature. Liu et al. and Fattah et al. emphasise the
importance of orthognathic surgery to restore facial symmetry and
improve the occlusal cant in patients with CFM (27, 34). Tahiri et al.
advises to restore significant occlusal abnormalities in patients with
CFM and severe mandibular hypoplasia (Pruzansky IIB, III) with a
costochondral graft (26). Nevertheless, no literature is available on
the exact indication for surgical treatment of occlusal problems
in CFM.
Breik et al. studied 21 articles, including 300 non-CFM patients
with micrognathia and feeding problems (mean age seven months,
range five days – six years) (38). After treatment with bilateral MDO,
82% of the children (n¼ 246) were able to feed completely orally
within twelve months of treatment (mean follow-up three years, range
one to seven years). These patients did no longer need feeding adjunct
and could be fed exclusively orally. The authors hypothesise that this
is due to an increase in upper airway continuity and possibly due to
improved lip closure creating a better-quality suckling reflex. Addi-
tionally, four articles on gastro-intestinal reflux disease (GERD) were
studied and the authors found that 66 of the 70 patients (94%) with
GERD (based on pH monitoring) had no reflux after treatment with
bilateral MDO. The authors conclude that early MDO is successful in
treating feeding problems in patients with micrognathia. However,
they note that upper airway obstruction should first be treated with
non-surgical management, which could be followed by surgical
treatment if non-invasive techniques fail (38).
Conclusions
Level 3 Indications for surgical treatment of the mandibular and/or maxillary
deformity in patients with craniofacial microsomia include:
 Breathing problems
 Feeding / occlusal problems.
 Psychosocial / aesthetic considerations
Ref (9, 12, 13, 17, 18, 23–27, 34)
Level 3 Bilateral mandibular distraction osteogenesis (MDO) appears to be an
effective treatment in patients with micrognathia, respiratory distress
and a tracheostomy (mean age range two months to five years).
 Most patients with a tracheostomy can be decannulated after
bilateral MDO: 78% - 94% (‘tracheostomy first’ group).
 Some patients still require a tracheostomy after initial treatment
with bilateral MDO: 5% - 11% (‘MDO first’ group).
Large differences in outcomes of MDO in patients with craniofacial
microsomia for treatment of breathing problems are observed:
 The success rate of mandibular distraction osteogenesis for
obstructive sleep apnoea in patients with unilateral craniofacial
microsomia appears to be low (36.4%).
 The success rate of decannulation after mandibular distraction
osteogenesis may be lower in patients with craniofacial microsomia
compared to other craniofacial syndromes including Pierre Robin
sequence or Treacher Collins syndrome (reported in a single study
including 62 patients (7 with CFM) in the tracheostomy first group; OR
0.05, CI 0.005–0.43).
Ref (17, 18, 37, 39–41, 44)
Level 3 Bilateral mandibular distraction osteogenesis (MDO)
appears to be an effective treatment in patients with
micrognathia and feeding problems:
 82% of the patients (n¼ 246/300) in need of
feeding adjuncts were able to feed exclusively orally
within twelve months after bilateral MDO.
Ref (38)
Considerations
 Overall quality of evidence
The conclusions on patients with CFM were based on studies
on retrospective cohort studies, case series or a systematic review
of these types of studies. Since all studies were non-comparative
studies, the quality of evidence was graded on level 3. The
conclusions which were based on the systematic reviews
(included after an additional search) were graded on level 3,
since almost all studies included in the systematic reviews were
retrospective cohort studies and other non-comparative studies. In
addition, it should be kept in mind that this evidence is based on
patients with micrognathia and not specifically on patients with
CFM. This indirectness of evidence also leads to a lower quality
of evidence.
 Balance of benefits and harms
No literature on the psychosocial consequence of the mandibular
deformity specifically is available. However, some patients experi-
ence difficulties due to their different facial appearance compared
to other children/persons (47). Treatment of the mandibular/maxil-
lary deformity may help to improve self-esteem or prevent psycho-
social problems. Additionally, mandibular hypoplasia can cause
breathing and feeding/occlusal problems. The potential harms of
these problems and need for therapy are further explained in
‘Chapter 4.1 – Breathing problems’ and ‘Chapter 4.2 – Feeding
problems’. The burden of surgical treatment of the mandibular/
maxillary deformity and its potential risks are important to
acknowledge. The benefits of (early) treatment should outweigh
the risks. The risk for re-surgery, nerve or dental damage, scar
formation, insufficient bone quality, infection, etc. should be taken
into account. Therefore, conservative treatment for breathing/feed-
ing problems in CFM is considered the first choice of treatment,
which can be followed by surgical treatment if conservative
therapy fails.
 Outcome importance
No literature is available on the psychosocial consequences of
mandibular and maxillary deformity in patients with CFM. Never-
theless, aesthetic difficulties could cause psychosocial problems
which may be prevented or treated by surgical correction of the
mandibular/maxillary deformity. Besides aesthetic concerns,
breathing or feeding problems could make surgical intervention
necessary. Mandibular hypoplasia could lead to obstructive sleep
apnoea, which may have severe consequences for growth, daily
functioning and (cognitive) development. Feeding problems can
lead to impaired growth and development. Presence of these
functional problems calls for surgical treatment of the mandibu-
lar/maxillary deformity in patients with CFM, especially if conser-
vative treatment fails.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
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providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core
values. However, in some countries the national organisation of
healthcare might impede centralisation. National implementation
of the ERNs that fits the situation of each country is necessary. For
the member states with the lowest number of inhabitants, the
establishment of a craniofacial centre might not be feasible, and
collaboration with a craniofacial centre in the surrounding coun-
tries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
A patient-specific approach is needed for surgical treatment of
mandibular/maxillary deformity in patients with CFM due to the
various indications for treatment, including psychosocial/aes-
thetic, breathing problems and feeding/occlusal problems. Provid-
ing information about the treatment options and their benefits and
harms is important for patients to make a well-informed decision
and have a realistic view of what can be expected, especially in
patients with aesthetic concerns. For all patients with aesthetic
difficulties, as mentioned in other chapters of this guideline,
psychosocial help is important before starting with (surgical)
treatment. In patients with functional problems (i.e. breathing,
feeding/occlusal), there might be a strong indication for surgical
correction of the mandibular/maxillary deformity to prevent worse
outcomes, especially if conservative treatment fails. The choice for
treatment is based on clinical assessment and should be discussed
in a multidisciplinary team, taking all other (future planned)
procedures into account.
Recommendations
 Consider surgical management (tracheostomy, adeno-
tonsillectomy, mandibular and/or maxillary surgery) in
patients with craniofacial microsomia for the treatment
of breathing problems if non-surgical therapy fails or to
end non-surgical therapy.
 Inform patients and parents about of the uncertainty of
respiratory outcomes following mandibular and/or
maxillary surgery for OSA in patients with CFM.
 If surgical treatment of the mandibular/maxillary
deformity in patients with craniofacial microsomia is
indicated to prevent or treat psychosocial problems, it is
important to inform the patient about the potential
benefits and harms and to ensure that the patients/
parents have a realistic view of what can be expected.
 It is advised to integrate the (surgical) treatment of the
mandibular/maxillary deformity in patients with cra-
niofacial microsomia in the planning of other surgeries,
especially for those that affect facial symmetry, palsy,
soft tissue augmentation and treatment of atresia
or microtia.
Research gap
Future studies on the indication for mandibular distraction in
patients with CFM could help determine an optimal treatment
strategy. Literature on the impact of mandibular/maxillary surgery
on psychosocial problems due to aesthetic concerns is missing.
Multicentre prospective cohort studies with long-term outcome
measures and an assessment of the impact of surgery on psychoso-
cial health could offer insight into the indication for MDO.
5.1.2 What is the most optimal treatment modality and its
timing for mandibular/maxillary deformity in patients with
craniofacial microsomia regarding severity, breathing
problems, occlusal problems and aesthetics?
The literature search for this question was directed towards more
specific research questions related to treatment options, complica-
tions, advantages and disadvantages, short and long term results and
treatment burden for treating mandibular/maxillary deformity in
patients with CFM (Appendix 1, http://links.lww.com/SCS/B697).
This review of literature addresses the most optimal treatment
modalities related to the severity of mandibular/maxillary defor-
mity, breathing problems, occlusal problems and aesthetics.
Included patient outcomes were related to breathing problems,
occlusal problems and aesthetics. This chapter was subdivided into
the type of mandibular/maxillary surgery in patients with CFM,
bilateral mandibular distraction osteogenesis (MDO), unilateral
MDO, internal or external distractor for MDO, complications of
MDO, mandibular reconstruction with bone graft, free bone flap,
orthognathic surgery, and temporomandibular joints (TMJ)
implants. Additional literature on complications of MDO and




In a systematic review, Pluijmers et al. studied the outcomes of
surgical correction of the mandible in patients with unilateral CFM
(9). A total of 19 articles were included with a mean follow-up of
4.3 years after treatment. Mandibular reconstruction (43.9%) and
distraction (13.7%) with a costochondral bone graft, or less fre-
quently used iliac crest or rib grafts, were the most common types of
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surgery used in patients with severe mandibular hypoplasia (Pru-
zansky type IIB and III). These patients often needed reconstruction
of the mandibular ramus and/or temporomandibular joint. Patients
with mild mandibular hypoplasia (Pruzansky I and IIA) were
generally treated with distraction osteogenesis (30.4%) or osteo-
tomies (2.1%). The indications for surgery were not reported. Most
of the studies on mandibular distraction and bone grafts that were
included in the systematic review by Pluijmers et al. showed a
recurrence in facial asymmetry after treatment in patients with
severe mandibular hypoplasia (Pruzansky II-III), which may be due
to resorption, relapse, or asymmetric growth (9). More stable results
were seen in patients with mild mandibular hypoplasia (Pruzansky
I, IIA), receiving distraction osteogenesis or osteotomies. Distrac-
tion osteotomies with bone grafts led to the most stable long-term
results for both mild and severe mandibular hypoplasia. The authors
conclude that the outcomes of mandibular correction in patients
with unilateral CFM are ‘not so much treatment-dependent, but
more patient-dependent’. In patients with mild mandibular hypo-
plasia, a single-stage surgical correct might be sufficient to correct
the facial asymmetry, compared to patients with severe mandibular
hypoplasia who benefit from a multi-stage treatment protocol. The
psychosocial benefits of treatment must outweigh the risks of
treatment. Therefore, Pluijmers et al. advise to perform single-stage
correction after the permanent dentition phase or in skeletal mature
patients (9).
A large retrospective cohort study of 565 patients with CFM
showed that 33.5% of all patients with CFM had mandibular surgery
(19). The percentage of patients that needed mandibular surgery
increased with the severity of mandibular hypoplasia: 5% of the
patients with Pruzansky I, 22% of the patients with Pruzansky IIA,
51% of the patients with Pruzansky IIB, and 68% of the patients
with Pruzansky III had mandibular surgery. The types of surgery
also varied with the severity: osteotomies, genioplasties and MDO
were most frequently performed in patients with mild mandibular
hypoplasia (Pruzansky I and IIA), whereas MDO followed by
mandibular reconstruction with a bone graft or initial reconstruction
of the condyle with a bone graft were most often performed in
patients with severe mandibular hypoplasia (Pruzansky IIB and III).
Complications occurred in 33% of the patients who had mandibular
reconstructions and included graft infections, postoperative
hypoesthesia, (graft) ankylosis, infection, or malposition. Addi-
tional surgeries were most frequently needed in patients with severe
mandibular hypoplasia and often included bimaxillary or sagittal
split osteotomies and genioplasties. Correction of the maxilla was
needed in 13% of all patients with CFM and was always performed
at the end of puberty. Treatment included bimaxillary osteotomies
and Le Fort 1 procedures. Patients with bilateral CFM had a higher
number of surgical interventions compared to patients with unilat-
eral CFM (average 2.44 versus 1.85, p¼ 0.007). The total number
of surgeries is influenced by the age at which the first surgical
intervention was performed. Linear regression analysis showed a
higher number of operations for every year decrease in age,
independent of the severity of mandibular hypoplasia. According
to the authors this suggests it is beneficial to perform mandibular
corrections at an older age, unless functional problems warrant
earlier treatment (19).
Bilateral mandibular distraction osteogenesis
Bilateral MDO is considered to be an effective treatment
modality for breathing problems in patients with micrognathia,
as is further described in the previous Chapter 5.1.1. – Indications
for mandibular surgery. In the literature on MDO, the highest
quality of evidence is based on large systematic reviews on patients
with retrognathia/micrognathia. Although this evidence is indirect
as it is based on patients with micrognathia and not CFM, studies
that included patients with CFM showed similar results (17, 18, 32).
As described in the previous chapter, results of MDO for the
treatment of OSA in patients with unilateral CFM may be associated
with lower success rates (17).
Unilateral mandibular distraction osteogenesis
The long-term stability of MDO after early osteodistraction in
patients with unilateral CFM was studied in a systematic review by
Nagy et al. (8). A total of 13 studies (155 patients) on unilateral
MDO aimed to correct asymmetry in patients with CFM that was
performed before the age of 16 were included. The mean age at the
time of MDO was 7.8 2.6 years, with a mean follow-up of 4 3.5
years. The effectiveness of MDO was based on the long-term
stability of mandibular dimensions. Although seven studies showed
stable results after MDO and six studies did not, most studies could
not prove long-term stability or were based on non-objective
evaluation methods. Especially in patients with a Pruzansky IIB
or III deformity, the facial asymmetry and affected ramus height are
unpredictable after unilateral MDO.
Nagy et al. found no evidence for long-term stability of unilat-
eral MDO in patients with CFM (8). Revisional surgery is often
indicated after early MDO to maintain facial symmetry during
growth, indicating unstable long-term results (8, 19). This was also
found in the systematic review by Pluijmers et al., which showed an
increase in facial asymmetry after MDO and placement of bone
grafts in Pruzansky II-III patients. However, patients with mild
mandibular hypoplasia (Pruzansky I-IIA) showed more stable
results (9). Ascenco et al. found that 90% (n¼ 30) of their studied
patients had recurrence of their facial asymmetry after unilateral
MDO (13).
Nagy et al. concluded that literature shows that CFM is a non-
progressive disease (8). The facial and mandibular asymmetry in
patients with CFM does not increase over time. However, some
authors advocate early unilateral MDO to stimulate midfacial
growth of the affected side, which would lead to better facial
symmetry and fewer surgical interventions during development
(4, 15, 30). Kaban et al. showed that creating an open bite on
the affected side during childhood could lead to vertical growth of
the maxilla and alveolar bone (4, 30). Additional surgery was not
needed in some patients with mild mandibular hypoplasia (4 of the
17 patients). Early unilateral MDO was also advocated by Weich-
man et al. (22). They studied the long-term outcomes of unilateral
MDO (16.5 4.2 years) in patients with mild to moderate unilateral
CFM (Pruzansky I and IIA). Their retrospective analysis of 19
patients showed satisfactory results (based on randomised photo-
graphic judgement by a panel) in 12 patients and unsatisfactory
results in 7 patients. Patients with satisfactory results appeared to be
treated at a younger age compared to the unsatisfactory group (4.7
years versus 7.5 years, p¼ 0.07). Additionally, the average per-
centage of overcorrection was greater in the satisfactory cohort
compared to the unsatisfactory cohort (41.3% compared to 1.8%)
(22). However, based on these data it cannot be concluded that
overcorrection leads to better outcomes. Overcorrecting has been
proposed to compensate for any relapse or lack of growth on the
affected side. However, this has its limits since it creates a contra-
lateral crossbite leading to occlusal problems, it may increase facial
asymmetry by overcorrecting the position of the chin, and it does
not prevent the need for additional surgery (8).
Ko et al. compared the long-term facial growth of 20 patients
with unilateral CFM: 9 patients had early MDO (age 5–9 years) and
11 patients without early MDO or other reported treatment (mean
follow-up 13.08 years) (16). All patients had a Pruzansky grade II
mandible deformity. The indication for MDO was to correct facial
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asymmetry, to treat occlusal problems, or to treat psychological/
aesthetic difficulties. The growth of the mandible was lower on the
affected side compared to the unaffected side and showed a similar
growth pattern to that of untreated patients. The mandibular ramus
length reduced from 90% direct after MDO to 69% after follow-up.
Nevertheless, early MDO may lead to a smaller chin deviation in the
long term (8.42 mm versus 12.7 mm) (16). A retrospective study by
Suh et al. with 10-year follow-up showed no differences in man-
dibular, maxillary, and occlusal tilting after early unilateral MDO
(n¼ 26 patients) (20). The changes of mandibular dimensions after
treatment gradually returned asymmetrical with growth in all
treated patients (20). Meazzini et al. showed in a comparative
study of 24 patients with unilateral CFM (all Pruzansky I and II)
that the results of early MDO were temporary and the ramus length
returned to values almost identical as prior to treatment (12).
However, adding functional orthodontic stimulation after unilateral
MDO may lead to less canting of the occlusal plane although no
differences in ramus length were seen (11). This conclusion is based
on the results of a study by Meazinni et al. with a very small sample
size (ten patients treated with functional orthodontic stimulation
and seven without) (11).
Most patients with CFM need orthognathic surgery after early
MDO to treat the recurrent facial asymmetry and/or occlusal
problems (13). The benefits of early MDO, which may yield
positive psychosocial effects, should be balanced with the need
for later surgery (13). Zhang et al. compared the need for orthog-
nathic surgery in 17 patients who had early MDO and in 21 patients
without MDO (23). The severity of the mandibular deformity in
both groups was similar. No differences between the MDO and non-
MDO group were seen with regard to the need for orthognathic
surgery: 59% of the MDO group and 38% of the non-MDO group
needed orthognathic surgery (p¼ 0.203). Patients who needed
repeated MDO (six patients, 35%) appeared to have a higher rate
of additional orthognathic surgery 83.3%) compared to patients
who had single MDO (45.5%) or no MDO (38.8%) (p¼ 0.162) (23).
Internal or external distractor
The outcomes of the use of an external and internal distractor for
bilateral MDO in patients with CFM were studied by Rachmiel et al.
in two different case series, including 37 patients in total and 14
patients with CFM (31, 32). The age at time of treatment varied
from 6 months to 14 years. Outcomes of treatment, defined by
mandibular advancement and improved airway, were successful in
all patients treated with both external and internal distractors.
Placement of external distractors was considered simpler and
permitted longer distraction compared to internal distractors (31,
32). However, loosening of the pins (22.5% of the patients), pin
tract infections (16.7% - 27.5% of the patients), and earlier removal
of the pins (15% of the patients) was reported in some patients.
Relapse after distraction was higher after external versus internal
distraction (23.5% versus 13.3%), which may be due to bending of
the pins. Additionally, scars on the buccal skin were notable after
external distraction. Internal distractors led to stable distraction with
precise and predictable vector of lengthening in most patients,
although one patient (5.8%) had a device failure which led to an
additional operation to remove the device. No facial nerve damage
was seen after external distraction, although internal distraction led
to transient damage to the mandibular branch of the facial nerve in
14.7% of the patients. Local infection of internal distractors was
seen in two patients (5.8%). In addition, two patients had a
contralateral open bite after internal distraction due to reduced
vector control, which had to be corrected with orthodontic treat-
ment. Another important aspect of internal distraction is the need
for a second operation under general anaesthesia to remove the
distractor. The authors advocate the use of internal distractors
whenever possible due to less discomfort and less visible scars,
and a lower risk of pin loosening and relapse. Nevertheless, external
distraction could be used in patients with severely hypoplastic
mandibles or when optimal vector control is necessary (31, 32).
Potential differences in outcomes of MDO with internal or
external distractors were studied in a systematic review by Breik
et al., which was included after our additional search (36). A total of
43 articles on surgical outcomes of bilateral MDO in patients with
micrognathia were included. A similar number of patients was
treated with internal (n¼ 207) and external (n¼ 206) distractors.
The age of treatment and potential differences in timing of treat-
ment with either internal or external distractors was not reported.
The number of device-related failures was significantly lower in
patients treated with internal distractors (two failures) compared to
external distractors (thirteen failures) (p¼ 0.012). Failure of the
device was often caused by loosening of the pins during distraction.
A higher number of complications occurred in patients treated with
external distractors (33%) compared to internal distractors (23%),
which was also observed in a systematic review by Tahiri et al.
(22.1% external distractor versus 8.3% internal distractors) (44).
Significant scarring (9.4% versus 0.61%, p¼ 0.006) and technical
failures (8.72% versus 3.05%), p¼ 0.39) were more frequently seen
in patients treated with external distractors compared to internal
distractors (36). However, all cases with infections that needed
surgical drainage (n¼ 3) were seen in the internal distractor group.
Complications of mandibular distraction
osteogenesis
Wang et al. studied complications of MDO in 71 patients with
unilateral CFM (21). All distractors were internal and placed in
patients aged 5 to 14 years (mean follow up: 2.75 years). The overall
complication rate was 36.6%. Minor complications, which could be
resolved without invasive treatment, were seen in 18.3% of the
patients and included local soft tissue infections (n¼ 11) and
neurapraxia (n¼ 2). Moderate complications were reported in
12.7% of all patients and required invasive treatment. This included
temporary resorption of the temporal bone (n¼ 5), loosening of the
device (n¼ 3), and hypertrophic scars (n¼ 1). Temporary resorp-
tion of the bone was considered a remarkable complication and may
have been caused by an elongated distractor, which led to the
formation of a hole in the temporal bone. Major complications,
which not could be resolved with invasive therapy, were seen in 4
patients (5.6%). This included tooth or tooth germ damage (n¼ 2)
and long-term limitations of mouth opening due to ankylosis (n¼ 1)
and coronoid process hyperplasia (n¼ 1). Tooth germ damage was
expected to occur and was considered inevitable due to an extreme
short mandibular ramus. Complications of MDO were seen in 4
(23.5%) of the 17 patients with CFM studied by Zhang et al. and
included ankylosis, distractor replacement due to malfunction, and
re-surgery due to premature fusion of the mandible (23).
The additional search to identify literature on distraction osteo-
genesis in non-CFM patients led to the inclusion of four systematic
reviews that described the risk of complications after bilateral MDO.
Verlinden et al. found an overall complication rate of 34.4% in 1,258
treated patients (42). Again, the age at which treatment was initiated
was not reported. Most complications resolved spontaneously or
could be treated (15% of all patients). This included temporary
hypoesthesia, local infection, dehiscence, pin loosening, or incorrect
vector. Technical complications, such as device failure, pin loosening
or incomplete osteotomy were seen in in 4% of the patients. Perma-
nent disabling complications or unsatisfactory results were reported
in 7.9% of all patients and included permanent teeth damage or facial
nerve palsy, TMJ ankylosis, non-union, hypertrophic scars, and a
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skeletal open bite. In another systemic review on complications of
MDO, Master et al. reported a complication rate of 20.5% to 25.6%
(43). Most seen complications were: relapse (64.8%), tooth injury
(22.5%), hypertrophic scars (15.6%), nerve injury (11.4%), infection
(9.5%), incorrect vector (8.8%), device failure (7.9%), non/malunion
(2.4%), and TMJ injury (0.7%) (43).
Tahiri reported a slightly lower complication rate of 23.8% in a
total of 711 patients, which mainly included abscess formation,
nerve injury, hypertrophic scar formation, and a skeletal open bite
(44). Interestingly, the authors found that complications mainly
occurred in patients who were treated at an older age. The mean age
of patients who experienced complications was 1.5 years older than
the mean age of all patients (36.9 months versus 18.1 months).
Breik et al. found in their systematic review that patients treated
with a higher distraction rate of 2 mm/day or 1.1- to 1.9 mm/day,
had a lower incidence of complications compared to 1 mm/day
distraction (respectively 28.6% and 26.5% versus 36.7% complica-
tions, number of patients per distraction rate respectively 199, 113,
and 143) (36). The mean age of patients treated with a distraction
rate of 2 mm/day was significantly younger (9.9 months) compared
to patients with a 1 mm/day distraction rate (38.6 months). The
types of complications, which included infection, ankylosis, scar-
ring, dental injury, and premature ossification were similar between
the three distraction rates groups. However, facial nerve injuries
were less frequently observed in patients with a distraction rate of
>2 mm/day compared to 1 mm/day (p<0.018) (36). The risk for
transient hypoesthesia of the inferior alveolar nerve was found be
greater in patients with a distraction rate of >1 mm/day (19.5%
versus 2.4% in patients with 1 mm/day distraction) (43, 48). The
authors concluded that rapid distraction with 2 mm/day is favour-
able and safe in children younger than 12 months of age, due to the
shorter period of treatment (36).
Mandibular reconstruction with bone graft
The systematic review of Pluijmers et al. on mandibular recon-
struction in CFM showed that patients with severe mandibular
hypoplasia often need reconstruction of the ramus and TMJ (9).
The most popular graft was the costochondral graft, follow by iliac
crest, rib graft, and fibular free flap. In patients with mild mandibu-
lar hypoplasia (Pruzansky I and IIA), bone grafts were sometimes
used in combination with MDO or as interposed bone grafts for
mandibular lengthening (9). More than 50% of the patients treated
with bone grafts showed a recurrence of facial asymmetry, which
often led to additional surgery. In a retrospective cohort study of 33
patients with CFM treated with costochondral grafts, Padwa et al.
showed that patients with a lower O.M.E.N.S. score had better
outcomes of treatment (25). These patients had symmetrical and
equivalent growth of the reconstructed ramus compared to the
healthy side, in contrast to more severely affected patients who
did not (25).
Tahiri et al. studied 22 patients with CFM who had mandibular
reconstruction with a costochondral graft (26). The mean age at
treatment was 7 years (range 2 - 15 years) and follow-up was 6.75
years (range 7 months - 15 years). No failures of the bone grafts, no
malunion or non-union, and no donor-site complications were
reported. Adequate, symmetrical growth was seen in 81.8% of
the hemimandibles, whereas 18.2% (n¼ 6) of the costochondral
grafts grew insufficiently. These patients required additional dis-
traction osteogenesis to correct mandibular asymmetry. Ankylosis
of a rib graft was seen in one patient, which was in retrospect the
only patient who was treated with an osseous rib graft without
cartilage. This led to a modification of the technique by always
using a costochondral graft with a cartilage cap. The authors
advised to perform mandibular reconstruction with rib grafts from
the age of five, since the quality of the rib is sufficient at this time
(26), or during mid-mixed dentition phase (8 to 10 years) according
to Nagy et al. and Padwa et al. (8, 25).
Mandibular occlusal canting was improved in all patients after
treatment with a costochondral graft in a retrospective cohort study
of 39 patients with CFM (treated at a mean age of 13 years) (24).
However, a slight recurrence of mandibular asymmetry was seen at
follow-up. Aesthetic outcomes were reported to be good. Compli-
cations of costochondral grafting included post-surgical infections
(n¼ 2), lower labial facial nerve paresis (n¼2), hypertrophic scar-
ring (n¼ 1), and costochondral graft overgrowth (n¼ 2). Secondary
surgery due to occlusal canting relapse or chin deviation was needed
in 23% of the patients (24).
Complications after mandibular reconstruction occurred in
33.3% (n¼ 21) of the 63 patients retrospectively studied by Pluij-
mers et al. (19). This included autologous graft infections (n¼ 12),
postoperative hypoesthesia (n¼ 9), graft ankylosis (n¼ 8), ankylo-
sis (n¼ 8), wound infection (n¼ 6), malunion/non-union (n¼ 5),
rib overgrowth (n¼ 3), and graft dehiscence and hypertrophic scars
(n¼ 1).
Free bone flap
Mandibular reconstruction with a free flap may be an option for
patients with severe mandibular hypoplasia (Pruzansky IIB and III)
in which MDO is not feasible. Santamarı́a et al. reported successful
mandibular reconstruction with a vascularised fibula flap in 9 of the
10 included patients (mean age 7.2 years, range 3–10) (33). Facial
symmetry, mastication and patient satisfaction improved after
treatment (mean follow-up 3.75 years, range 1–8 years). Two
patients had minor donor site complications including dehiscence
and partial skin paddle necrosis. No extremity weakness, ankle
stiffness or gait disturbances were observed. Half of the patients had
prior reconstruction with bone grafts that failed. The ideal age of
reconstruction was considered to be between 5 and 7 years, since
harvesting of the fibula and the microsurgical procedure is more
challenging in younger patients.
Orthognathic surgery
Orthognathic surgery, including bimaxillary osteotomies, Le
Fort I osteotomies, sagittal split osteotomies, and genioplasties,
is often indicated in patients with CFM. This may be as additional
treatment in patients with severe mandibular hypoplasia or bilateral
CFM, or as initial treatment in patients with mild mandibular
hypoplasia (19). The aim of treatment is to level the occlusal cant,
achieve a good occlusal relationship, and align the dental midline to
the facial midline (19, 27). Since CFM is considered to be a non-
progressive disorder, treatment may be delayed until skeletal
maturity to achieve stable results (27). Facial symmetry and occlu-
sal outcomes improved after orthognathic surgery in 10 patients
with CFM studied by Fattah et al. and remained stable at long-term
follow-up (3 years, range 1.1 - 7.75 years). Bertin et al. reported that
all their 39 included patients who had mandibular reconstruction
needed restoration of the occlusal canting at skeletal maturity (24).
Orthognathic surgery may be combined with fat grafting when
performed in adulthood, to improve the facial deformity in patients
with CFM (28). Especially in patients with a notable soft tissue
deficiency, orthognathic surgery alone may not be sufficient to
achieve facial symmetry (28).
Surgical correction of the maxillary deformity in patients with
unilateral CFM was studied in a systematic review by Van de Lande
et al. (10). Seven articles including a total of 57 patients, with at
least 6 months follow-up after treatment were included. Patients had
either a bimaxillary osteotomy (20 patients, mean age of treatment
19.7 years) or a Le Fort I osteotomy with MDO (37 patients, mean
The Journal of Craniofacial Surgery  Volume 31, Number 8S, November/December 2020 European Guideline Craniofacial Microsomia
# 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of Mutaz B. Habal, MD 2455
age of treatment 19.9 years). No surgical correction of exclusively
the maxilla was reported. Bimaxillary osteotomies were more
frequently performed in patients with severe mandibular hypopla-
sia, whereas a Le Fort I osteotomy with MDO was more often
reported in patients with mild mandibular hypoplasia. Similar
results were seen in a retrospective cohort study by Pluijmers
et al., who showed that nearly half of the patients who had a
bimaxillary osteotomy had prior mandibular surgery, especially
patients with severe mandibular hypoplasia (Pruzansky III) (29).
All of the included studies in the systematic review by Van de
Lande et al. showed improvement of the occlusal cant after maxil-
lary surgery, although four articles reported a slight residual cant of
a maximum of 2.3 degrees (10). Improvement of facial symmetry
and aesthetic outcomes, based on patients’ or surgeon’s opinion,
was reported in four studies. Most studies advised to surgically
correct the maxillo-mandibular asymmetry combined with ortho-
dontic pre-treatment at skeletal maturity or permanent dentition, on
the condition that no functional or psychological problems are
present (10, 24, 27, 29).
Temporomandibular joint (TMJ) implants
Polley et al. presented a case series of ten patients with CFM and
a Pruzansky III mandibular deformity who had custom-made
titanium TMJ implants placed at skeletal maturity (35). The fol-
low-up was six months to four years. Treatment led to stabilisation
of the occlusal relationship, maintained or improved mouth open-
ing, and improved facial aesthetics. No permanent facial nerve
paresis, no infection, and no implant incidents or dislocation was
recorded. Placement of TMJ implants at skeletal maturity appears to
be a solution for patients with failed autogenous mandibular
reconstructions (35).
Conclusions
Level 3 Mandibular surgery
A third of all patients with craniofacial microsomia require
mandibular surgery.
Mandibular and facial asymmetry in patients with craniofacial
microsomia is non-progressive.
Most stable long-term results of mandibular surgery in patients
with craniofacial microsomia are seen in patients with mild-
moderate mandibular hypoplasia (Pruzansky I-IIA) compared
to severe mandibular hypoplasia (Pruzansky IIB-III).
The total number of mandibular/maxillary surgeries increases if
patients are treated at a younger age, independent of the
severity of the mandibular hypoplasia.
Ref (4, 8, 9, 19, 30)
Level 3 Mandibular distraction osteogenesis (MDO)
MDO is often (approximately 30%) performed in
craniofacial microsomia patients with mild-moderate
mandibular hypoplasia (Pruzansky I - IIA).
Bilateral MDO in patients with micrognathia and
respiratory distress has a high success rate and may
prevent tracheostomy or lead to decannulation.
Success rates may be lower in patients with unilateral
CFM. (See Chapter 5.1.1)
The outcomes of early unilateral MDO in patients with
craniofacial microsomia and severe mandibular
hypoplasia (Pruzansky IIB-III) regarding facial
asymmetry and affected ramus height are
unpredictable.
The long-term stability of early unilateral MDO
(performed<16 years) in patients with CFM appears to
be poor. Facial asymmetry often reoccurs, necessitating
secondary (orthognathic) surgery.
Ref (8, 9, 12, 13, 16, 19, 20, 22, 23)
Level 2 Internal or external distractor for bilateral MDO (based
on studies on patients with micrognathia)
Internal distractors are, compared to external distractors,
associated with a significantly lower number of
complications (22% to 33% versus 8% to 23%;
p¼ 0.006–0.012).
External distractors may, compared to internal
distractors, be associated with more relapse, a higher
number of technical failures, and scarring of the
skin.
More optimal vector control is seen when using external
distractors, which may especially be needed in
patients with severe mandibular hypoplasia.
Ref (31, 32, 36, 44)
Level 3 Complications of mandibular distraction osteogenesis
(based on studies on patients with micrognatia)
The overall complication rate of mandibular distraction
osteogenesis is 20% to 34%, which is similar for
patients with craniofacial microsomia (24% - 37%).
Minor, temporary complications occurred in 15% - 18%
of the patients and included hypoesthesia, local
infections, pin loosening, dehiscence, or incorrect
vector.
Moderate complications which required invasive
treatment occurred in 4% - 12% of the patients and
included technical complications such as loosening of
the device or pins.
Major, permanent complications occurred in 5% - 8% of
the patients and included teeth damage, facial nerve
palsy, TMJ ankylosis, non/malunion, hypertrophic
scars, or a skeletal open bite.
Treatment with MDO at a younger age (<2 years) may be
associated with a lower risk of complications (mean
follow up 2 years).
A higher distraction rate (>1 mm/day) is associated with
a lower risk of complications compared to a
conventional distraction rate of 1 mm/day, and is
applied in significantly younger patients (10 months
compared to 39 months).
Ref (21, 23, 36, 42–44)
Level 3 Mandibular reconstruction with bone grafts
Mandibular reconstruction with non-vascularised bone
grafts is most commonly performed in craniofacial
microsomia patients with severe mandibular
hypoplasia (Pruzansky IIB - III).
Secondary surgery to restore the remaining or recurrence
of mandibular asymmetry after mandibular
reconstruction with costochondral grafts is needed in
18% - 23% of the patients.
Complications occur in 0–33% of the patients with
craniofacial microsomia who had mandibular
reconstructions with bone grafts.
Complications of mandibular reconstruction in
craniofacial microsomia include graft infections,
postoperative hypoesthesia, (graft) ankylosis,
infection, malposition, or graft overgrowth.
Mandibular reconstruction with a free vascularised fibula
flap may be an option for patients with craniofacial
microsomia and severe mandibular hypoplasia who
have no other therapeutic options.
Ref (9, 19, 24–26, 33)
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Level 3 Orthognathic surgery
Orthognatic surgery is often performed as primairy
treatment in patients with mild mandibular hypoplasia
or as secondary treatment in patients with severe
mandibular hypoplasia or bilateral craniofacial
microsomia.
Orthognathic surgery is performed to improve occlusal
canting and facial symmetry at skeletal maturity.
Ref (9, 10, 19, 24, 27–29)
Level 3 Temporomandibular joint implants
Placement of custom-made TMJ implants at skeletal
maturity may be a good solution for patients with
failed autogenous mandibular reconstructions.
Improvement in occlusal relationship, mouth opening
and aesthetics without complications were seen in ten
studied patients with craniofacial microsomia (follow
up six months to four years).
Ref (35)
Considerations
 Overall quality of evidence
All conclusions that are based on literature that included patients
with CFM are graded as level 3 evidence as all papers, besides two
articles by Meazzini et al. (11, 12), are non-comparative studies.
Conclusions on the type of distractors are based on large meta-
analysis that showed consistent results and are based on compara-
tive studies. This leads to a level 2 quality of evidence. Complica-
tions of mandibular distraction osteogenesis were also based on
large meta-analysis, showing consistent results. Results are based
on descriptive data and no comparison can be made. Therefore, this
conclusion was graded as level 3 evidence.
 Balance of benefits and harms
The balance of benefits and harms is hard to assess due to the
variance in indications for surgical treatment of mandibular/maxil-
lary deformity in patients with CFM. In addition, the indication for
surgical treatment may be strong in some cases, such as in patients
with severe OSA, but less strong in other patients, such as patients
with aesthetic concerns. Patients and their parents should be able to
make a well-informed decision for surgical treatment. Therefore, it
is important to inform the patients on the potential benefits and
harms of treatment. This may include treatment of OSA, better
occlusion or mouth opening leading to fewer or no feeding pro-
blems, better aesthetics, or fewer psychosocial problems. Using an
internal distractor necessitates secondary surgery under general
anaesthesia to remove the device, whereas the extraoral pins of
an external distractor can be removed under local anaesthesia.
Equally important is the need to inform patients on the risks of
treatment, the burden of treatment, the risks of complications, and
the need for potential additional surgeries in the future. In some
cases, the benefits easily outbalance the potential harm. However,
in other cases, such as in patients with aesthetic problems, the
potential benefits and harms may be more difficult to assess.
Patients and their parents should be well informed to optimise
the process of shared decision making.
 Outcome importance
The importance of treatment for OSA is further delineated in
Chapter 4.1 – Breathing problems. Occlusal problems or a limited
mouth opening may lead to feeding problems. Besides, occlusal
problems should be treated to minimise oral health damage. The
severity of occlusal problems determines the need for and timing of
treatment. Treatment of the mandibular/maxillary deformity to
reduce psychosocial problems that are related to aesthetic concerns
is based on the balance of benefits and harms. Treatment should
only be considered after psychosocial support by a psychologist.
 Costs and resources
The impact on costs and resources of the given recommendations
will vary per member state, depending on the available care providers
and facilities. The recommendations concern the essential require-
ments for adequate treatment of patients with CFM and should thus be
implemented. The use of custom-made TMJ implants is expensive.
Additionally, developments in 3D planning could lead to an increase
in costs. Costs are lowest and resources are most efficiently used
when care for craniofacial disorders is centralised in a limited number
of expert centres per member state. A general rule that can be applied
is one expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Treatment of mandibular/maxillary deformity may be indi-
cated for various reasons, including obstructive sleep apnoea,
occlusal problems, and aesthetics. The preferred treatment option
is based on several factors, including the severity of mandibular
hypoplasia, age of the patient, risk of complications, other
optional treatment modalities, and so forth. There are various
treatment options for correction of mandibular/maxillary defor-
mity in patients with CFM.
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Nevertheless, based on the available literature, conclusions and
recommendations can be made to improve care for patients with
CFM. Recommendations on the optimal types of treatment for the
previously reported indications for treatment (in Chapter 5.1.1.)
were provided.
Obstructive sleep apnoea should be treated with non-surgical
therapy if possible, to prevent the risks that are associated with
surgery, which includes complications and a high burden for the
patient. In patients with severe OSA, tracheostomy or mandibular
distraction osteogenesis may be indicated. Primary mandibular
distraction could prevent placement of a tracheostomy, but may
not be suitable for all patients. Mandibular distraction could also be
performed after placement of a tracheostomy for decannulation.
The selection of a type of treatment is patient specific and should be
based on multidisciplinary assessment. MDO may be indicated to
end non-surgical treatment for sleep apnoea (e.g. CPAP), to allow
decannulation, or to prevent tracheostomy. There is a difference in
preference of timing of MDO. If possible, it is advised to perform
mandibular distraction after the age of six because at this age, the
first permanent teeth start to erupt and occlusal problems could be
treated with a combined surgical and orthodontic approach. The
benefits of early mandibular distraction should outweigh the need
for additional surgery later in life, since Pluijmers et al. found that
the total number of surgeries in patients with CFM is influenced by
the age at which the first surgical intervention was performed (19).
Mandibular distraction osteogenesis could be performed in
young, infant patients, which is associated with a lower risk of
complications (44), but a bigger likelihood of repeat surgery (19).
Additionally, a rapid distraction rate could be used in young patients
under the age of twelve months, which is also associated with a
lower risk of complications (36). Literature shows that the use of an
internal distractor is preferable in most patients due to fewer
relapses, lower complications rates, fewer technical failures and
less scarring compared to an external distractor. However, second-
ary surgery under general anaesthesia is needed in patients with an
internal distractor to remove the device. The use of an external
distractor is preferred in patients with severe mandibular hypopla-
sia, when a high level of vector control is needed. Besides these
aspects, the surgeon should be experienced with both
treatment modalities.
Severe occlusal problems in patients with CFM could be treated
with mandibular surgery/distraction during childhood. The ortho-
dontist should be included in the team to optimise the treatment
plan. If surgery can be postponed, it is advised to perform orthog-
nathic surgery with or without mandibular distraction in patients
who are skeletally mature to ensure stable results and to limit the
number of procedures with the associated complication risks (27).
Early surgery in patients with CFM to achieve facial symmetry is
frequently debated in literature. Today, literature shows that CFM is
a non-progressive disorder, meaning the facial and mandibular
asymmetry in CFM does not increase over time (8). Psychosocial
problems may be present due to aesthetic issues. Therefore, it is
essential to start with psychosocial support during childhood.
Surgical correction of the facial asymmetry with unilateral man-
dibular distraction or other treatment options could be helpful to
prevent or treat psychosocial problems. However, the positive
psychosocial effects of treatment should outweigh the risks of
surgery and the risks of the need for additional surgeries (13). If
surgical treatment is considered, the patients should be seen by a
psychologist pre- and post-operatively to monitor expectation and
acceptance. The risk for additional surgeries is important, since
literature shows that most patients with CFM need additional
surgery if they are treated at a young age (19). Therefore, it is
advised to postpone mandibular/maxillary surgery for correction of
facial asymmetry until skeletal maturity.
Mandibular reconstruction with a bone graft may be indicated in
patients with severe mandibular hypoplasia and absence of the
temporal mandibular joint. Various types of bone grafts have been
reported in literature, but the costochondral graft is the most
frequently used graft (19). It is advised to perform mandibular
reconstruction with a costochondral graft during mid-dentition
phase (after the age of six) to ensure good quality of the rib. In
selected cases there might be an indication for free vascularised
bone grafts. Reconstruction with a temporomandibular joint pros-
thesis shows promising results in a small group in a single centre
and could be implanted in patients before or after skeletal maturity.
This may be indicated in patients with failed previous mandibular
reconstruction or (graft) ankylosis.
3D planning is gaining in popularity and results in improved
outcomes in orthognatic surgery (49). Therefore, it might help to
improve planning and outcomes of mandibular/maxillary surgeries
in patients with CFM. However, it requires facilities and imposes
additional costs and might therefore not be applicable in all
countries. The steering group considers access to 3D planning
for treatment of the mandibular/maxillary deformity in patients
with CFM as obligatory to ensure good quality of care.
Recommendations
Obstructive sleep apnoea
 Start with non-surgical treatment for the management
(e.g. oxygen, CPAP) of mild-moderate OSA in infants
with craniofacial microsomia. See Chapter 4.1 –
Breathing difficulties for recommendations.
 Perform a tracheostomy or mandibular distraction
osteogenesis in infants with mandibular hypoplasia and
severe OSAwho do not respond to non-surgical treatment.
 If the aim of surgical treatment is to end non-surgical
treatment (e.g. CPAP), perform elective mandibular
distraction osteogenesis.
 Mandibular reconstruction with costochondral bone
grafts should be performed after the age of six.
Occlusal problems
 For patients with craniofacial microsomia and severe
occlusal problems, perform mandibular distraction
osteogenesis in mixed dentition phase.
 A combined orthodontic and orthognathic surgery plan
is mandatory to achieve and optimise stable long-
term outcomes.
 Perform secondary orthognathic surgery to correct
occlusion at skeletal maturity.
Aesthetic problems
 Postpone surgical correction of the mandibular/maxil-
lary deformity for aesthetic reasons in patients with
craniofacial microsomia until skeletal maturity.
 The implications of early surgery (i.e. repeat surgery)
for psychosocial reasons should be discussed within the
multidisciplinary team and with patient and caregivers.
 Psychological input is required pre- and post-opera-
tively to monitor expectation and acceptance.
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3D planning
 Use 3D planning to optimise surgical outcome of
mandibular and maxillary surgery in patients with
CFM.
Research gap
Future studies on the ideal timing and long-term effects of
mandibular distraction in patients with CFM could help determine
an optimal treatment strategy. Breathing and feeding problems
resulting from mandibular hypoplasia are probably more strongly
related clinical issues in CFM than in other diagnoses. Studies on
the optimal timing of MDO, choice for type of distractor, TMJ
prosthesis, and safety of early MDO are needed. Multicentre
prospective cohort studies with long-term outcome measures could
offer insights into ideal timing and choice of treatment.
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CHAPTER 5. SURGICAL TREATMENT
5.2 Facial nerve
Introduction
Palsy of the facial nerve can be seen in patients with cranio-
facial microsomia (CFM). The prevalence of facial palsy in
patients with CFM is 22% - 53% and may be unilateral or
bilateral (1–4). In the O.M.E.N.S. classification, which is com-
monly used to grade the severity of patients with CFM, the Nerve
score categorises the loss of function of the upper (N1), lower
(N2), or total facial nerve (N3) (5).
After exiting the brain stem, the facial nerve progresses through
the skull and branches to the chorda tympani, posterior auricular
nerve and to the digastric and stylohyoid muscles. The main
branches of the facial nerve originate in the parotid and include
the frontal, zygomatic, buccal, marginal mandibular, and cervical
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branch. Palsy of the facial nerve, which is due to congenital
underdevelopment in patients with CFM, may cause problems with
eye closure, articulation of speech, oral continence, or asymmetric
facial mimics and smile (6).
Since a considerable number of patients with CFM experience
facial palsy, recommendations on the indications for treatment and
the most optimal treatment modalities are needed. Therefore, the
following questions were posed:
5.2.1 What is the indication for surgical treatment of facial
nerve anomaly in patients with craniofacial microsomia?
5.2.2 What is the most optimal treatment modality for facial
nerve anomaly in patients with craniofacial microsomia
related to functional deficits and aesthetics?
The answers to these questions are important to patients since
various functional and aesthetic problems may occur due to facial
palsy. For example, palsy of the upper branches of the facial nerve
can lead to an inability to close the eye (lagophthalmos). Awareness
of the consequences of lagophthalmos is important, since corneal
exposure can lead to keratitis, ulceration, and eventually
endophthalmitis which can cause blindness. Palsy of the lower
eyelid may also lead to ptosis and lagophthalmos.
Besides insufficient eye closure, ptosis of the eyebrow due to
paralysis of the frontalis muscle may also be seen in patients with
facial palsy. Since ptosis may lead to vision loss, surgical treatment
may be indicated. In addition, facial palsy may also cause oral
related problems, such as drooling, dysphagia, or speech- or feeding
problems, due to lack of lower lip support and oral sphincteric
incompetence (7).
Inadequate functioning of facial mimics can lead to social
problems and psychological stress (8). Although patients with
CFM commonly experience more facial differences besides facial
palsy, the impact on psychosocial functioning may be significant.
Literature search
A systematic search of literature was performed to identify all
available literature on CFM and synonyms. The search was con-
ducted in Embase, Pubmed/Medline Ovid. The full search strategy
is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review
matches the question of the guideline.
- The search of the systematic review was
conducted in at least two relevant
databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the
search strategy.
Type of patients - Patients with craniofacial microsomia
- Patients with facial palsy
Subject - Facial palsy
Exclusion criteria - Original studies with <10 included patients





Literature was screened on title and abstract. No articles on the
indication or outcomes of treatment of facial nerve deformity in
patients with CFM were available. Therefore, the Dutch Guideline
on peripheral facial palsy was included in this chapter (9). Since
this guideline was published in 2009 and included literature until
2007, an additional search, based on the search strategy used in the
Dutch Guideline, was performed. The full search strategy is shown
in the appendix. All literature on indication and/or treatment
outcomes of facial palsy from 2007 to the present was included.
A total of 888 articles was screened on title and abstract. Since the
quality of evidence of the identified literature was considered to be
low, narrative reviews were also included. Besides the Dutch
Guideline on peripheral facial palsy, 27 other articles were
included: two systematic reviews/meta-analyses by Luijmes
et al. (10) and Bos et al. (11); eleven retrospective-cohort studies
by Hontanilla et al. (12), Loyo et al. (13), Terzis et al. (2010) (14),
Chen et al. (15), Lindsay et al. (16), Roy et al. (7), Chuang et al.
(17), Gousheh et al. (18), Harrison et al. (19), Hontanilla et al. (20),
and MacQuillan et al. (21); seven case series by Baheerathan et al.
(22), Banks et al. (23), Bianchi et al. (24), Panossian et al. (25),
Terzis et al.(2009) (26), and Terzis et al. (2009) (27); and seven
narrative reviews by Heike et al. (5), Reddy et al. (6), Volk et al.
(28), Rahman et al. (29), Majid et al. (30), Barr et al. (31), and
Terzis et al. (2008) (32).
5.2.1 What is the indication for surgical treatment of
facial nerve anomaly in patients with craniofacial
microsomia?
The literature search for this question was directed towards more
specific research questions related to clinical problems, symptoms,
treatment options, consequences of not treating, and requirements
for treating facial nerve anomalies (Appendix 1, http://links.lww.-
com/SCS/B697). Unfortunately, no literature on the indication for
treatment of lagophthalmos in patients with CFM was found.
Therefore, the Dutch Guideline on peripheral facial palsy was
included in this question.
Review of literature
The Dutch guideline on peripheral facial palsy advises to start
lubrication of the eye if the patient has complaints of the eye
(dryness, irritation, tears, photophobia), difficulties with full closure
of the eyelid, a positive Bell’s phenomenon, or irritation of the
conjunctiva. Surgical treatment of the eyelid is, according to the
Dutch guideline, indicated if conservative treatment (lubrication) is
no longer sufficient. To prevent blindness, eyelid surgery is indi-
cated in patients with a corneal ulcer (9). Surgical treatment of
facial palsy in patients with CFM may also be indicated to restore
facial animations and improve aesthetics. Various techniques have
been described in literature, static or dynamic, to restore the smile in
patients with facial palsy. However, no literature on the indication
for surgical treatment to restore facial function, eyebrow ptosis or
oral incompetence was found.
Birgfeld and Heike state that the timing of facial reanima-
tion surgery in patients with CFM should be based on
patient’s preferences and other surgical interventions. Microtia
reconstruction and major craniofacial or orthognathic surgery
should ideally be performed prior to facial reanimation
surgery (5).
In their systematic review on the quality of life in patients with
peripheral facial palsy, Luijmes et al. found that patients had a
significant increase of the quality of life after (surgical) treatment
of their facial palsy (mean FaCE score 43.38; 95% CI: 40.48–
46.27; p<0.001) (10). Quality of life was measured using various
questionnaires and various treatment modalities, such as botu-
linum toxin injections, free flaps, or static procedures, were
included. It should be noted that patients with CFM have multiple,
often complex, facial deformities, making comparison of the out-
comes of treatment on the quality of life of other patient
groups difficult.
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Conclusions
Level 4 Indication
Surgical treatment of the upper or lower eyelid in patients
with facial palsy to protect against prolonged corneal
exposure is indicated if conservative treatment is no
longer sufficient.
Surgical treatment of the upper or lower eyelid in patients




The timing of facial reanimation surgery should be based
on patients’ preferences and other surgical
interventions. Microtia reconstruction and major
craniofacial or orthognathic surgery should ideally be
performed prior to facial reanimation surgery.
Ref (5)
Level 1 In patients with peripheral facial palsy, quality of life
significantly increases after treatment (p<0.001).
Ref (10)
Considerations
 Overall quality of evidence
Literature on the indications for treatment of facial nerve
problems in patients with CFM is very limited. Therefore, indirect
literature on facial palsy in general was also included. The Dutch
guideline on peripheral facial palsy advised treatment in case of
corneal exposure. Since this was based on agreement among the
guideline committee, the level of evidence was graded on level 4.
The advice of Birgfeld and Heike to wait to perform facial
reanimation surgery after other major surgery was also based on
expert opinion and therefore graded on level 4 (5). The conclusion
on quality of life was based on a meta-analysis of prospective and
retrospective cohort studies and case series. The quality of evidence
is graded on level 1, since it was a well-designed meta-analysis of
fourteen articles that used different predetermined questionnaires
and the results were all positive for quality of live.
 Balance of benefits and harms
Since the prevalence of facial palsy in patients with CFM is high
(22%-53%) and can have functional consequences, treatment may
be indicated. Especially for problems with eye closure, which may
result in a corneal ulcer, endophthalmitis, and eventually blindness,
it is essential to treat timely. In case of aesthetic problems, the
indication for treatment may be less strong, but nevertheless some
patients may experience negative psychosocial consequences that
may make treatment necessary. Since patients with CFM do often
have additional facial deformities besides the facial nerve deficits,
psychosocial support and treatment by a psychologist is of major
importance. If the indication for treatment of the facial nerve
deformity is purely aesthetic, the potential complications of surgery
(such as hematomas, abscesses, flap failure) are important to keep in
mind. The patients should be well informed about the risks of
treatment to make a well-considered decision.
 Outcome importance
A considerable number of patients with CFM experience facial
palsy. If functional problems occur, treatment is essential to prevent
further harm such as blindness. In case of aesthetic problems,
treatment may still be of great importance to patients. Treatment
should be considered after psychosocial support by a psychologist.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The indications for treatment of facial nerve palsy vary from
functional to aesthetic. In patients unable to achieve full closure of
the eye treatment with lubricants is indicated, although the cause of
problems is not treated. Surgical interventions should be considered
in these patients. Other functional problems, such as eyebrow ptosis
or oral incompetence may also occur in patients with facial palsy
and should be treated to improve the quality of life. Referral to an
ophthalmologist is needed in all patients with lagophthalmos.
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Aesthetic problems are considered to be another reason to treat
facial nerve palsy in patients with CFM, although no literature on
this topic is available. The involvement of a psychologist is essen-
tial during childhood for patients with CFM to learn to cope with
their facial differences. The ICHOM Standard Set for Craniofacial
Microsomia advises to assess smile and facial movement by using
the CleftQ appearance questionnaire at age 8, 12, and 22. Treatment
of facial nerve palsy for aesthetic reasons should be based on well-




 Provide all patients with craniofacial microsomia with
psychosocial support.
 Refer all craniofacial microsomia patients with
lagophthalmos to an ophthalmologist.
 Surgical treatment of the upper or lower eyelids should
be considered in patients with craniofacial microsomia
and loss of function of the upper facial nerve branches.
 Coordinate the timing of facial reanimation surgery in
patients with craniofacial microsomia in the planning of
other major surgeries.
 Facial movement should by assessed with the CleftQ
Appearance at age 8, 12, and 22.
Research gap
No literature on the indication for treatment of facial palsy in
CFM was available. Literature on the (psychological) consequences
of facial palsy in CFM could help determine the indication for
treatment.
5.2.2 What is the most optimal treatment modality for facial
nerve anomaly in patients with craniofacial microsomia
related to functional deficits and aesthetics?
The literature search for this question was directed towards more
specific research questions related to treatment options, complica-
tions, advantages and disadvantages, short and long term results and
treatment burden for treating facial nerve anomalies (Appendix 1,
http://links.lww.com/SCS/B697). Patient outcomes that are rele-
vant for this chapter are functional deficits and aesthetics. This
review of literature addresses the most optimal treatment modalities
related to the functional and aesthetic consequences of facial palsy.
The functional problems and their treatment modalities in this
chapter are subdivided into problems with eye closure, oral pro-
blems, and dynamic facial reanimation.
Review of literature
Eye
Various treatment modalities are available to treat the inability
to close the eye in patients with facial palsy. The guideline on
peripheral facial palsy advises to start conservative treatment using
lubrication in all patients with facial palsy and complaints of the
eye. In patients with CFM, the facial palsy is congenital and more
permanent solutions should be striven for. The goal of surgery of the
upper eyelid is to improve vision, prevent corneal erosion and
maintain or improve aesthetics (20).
The upper eyelid can be lowered using botulinum toxin, muscle
transfers, or placing a gold weight. Injection of botulin toxin has
been found to be effective by establishing a ptosis by temporarily
paralysing the levator palpebrae superioris muscle (28). The dura-
tion of the effect is approximately three months and there is a
chance that therapy is unsuccessful due to injecting too little or too
much botulinum toxin (9).
Lengthening of the levator palpebrae superioris muscle by
aponeurosis interposition could be performed to achieve full eye
closure, although this technique is less frequently described in
literature. The technique is complex compared to botulinum toxin
or placement of a gold weight, but may be have a better cosmetic
outcome compared to gold weights (9).
Placement of a gold weight in the upper eyelid is a popular
technique to correct lagophthalmos. A predetermined gold weight
is implanted in the eyelid that supports closure of the eye. Other
materials such as a platinum chain are currently used too (13).
Although placement of gold weights is reported to be the preferred
method for several surgeons due to the predictable results, good
aesthetic outcome, reversibility, relatively easy technique the fact
that and it can be placed under local anaesthesia in adults, various
complications may occur (20). This includes migration or extru-
sion of the gold weight, soreness, or persistent lagophthalmos (22).
The incidence of extrusion of the gold weight was 2.6% in 2,000
studied patients, which may be prevented by attaching the gold
weight on the tarsal plate using sutures (22, 29). In a case series by
Baheerathan that described the experience with gold weights in 16
patients, one patient reported extrusion of the gold weight after five
months and one patient needed a heavier gold weight due to
residual lagophthalmos (22). No infections, implant migration,
visual problems or keratopathy occurred. All patients had adequate
eyelid closure at the last follow-up and fifteen of the sixteen
patients were satisfied with the outcome (22). Surgical revision
after placement of a upper eyelid weight was needed in 18 of the 95
patients (19%) studied by Loyo et al. (13). One patient had implant
extrusion, two patients bulging/superficial implants, two patients
implant migration, five patients had persistent lagophthalmos, and
nine patients eyelid ptosis. In a retrospective cohort study by
Hontanilla et al. 58 patients had gold weights implanted (20).
All patients had complaints of dry eyes. Five patients (8.6%) had
extrusion of the gold weight, which was due to material intolerance
in two patients and exchanged for a different weight in the other
three patients without complications. The complaints of eye dry-
ness improved in 90.7% of the patients (n¼ 49). Corneal ulcers,
which were present in 14 patients, resolved without further treat-
ment in 85.7% of the patients (n¼ 12) (20). It is important to note
that all these studies included adult patients only and no literature
on children is available.
Facial palsy may also lead to laxity or ectropion of the lower
eyelid which disrupts physiological tear drainage (20, 28). This
inability to achieve full closure of the eye may again lead to keratitis
or corneal erosion. The aim of surgery of the lower eyelid is to
improve tear drainage and correct the ectropion or ptosis (20).
Tarsorrhaphy has been the golden standard to achieve this, but other
techniques such as lateral tarsal suspension or the use of a fascia lata
strip, which also provide corneal coverage but produce better
aesthetic appearance, have replaced this (20). In addition, tarsor-
rhaphy may cause loss of peripheral vision and its use is therefore
discouraged (29). In the retrospective study by Loyo et al. lower
eyelid surgery was performed in 47% of the patients with paralytic
lagophthalmos (47/101 patients) (13). All patients had procedures
that addressed the lateral canthal tendon and 10 of the 47 patients
underwent medial canthopexy. Of these patients, 29% (14/47
patients) required additional lower eyelid procedures. Hontanilla
et al. retrospectively studied 43 patients with lower eyelid suspen-
sion with a tendon sling (20). Successful correction of the ectropion/
ptosis and epiphora was achieved in respectively 93.9% and 91.9%.
Eight patients (18.6%) needed additional surgery to increase tendon
tension. No complications that required surgical intervention
occurred. The authors discourage the use of a dynamic technique
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to reanimate the lower eyelid since there is little movement of the
lower eyelid during physiological closure of the eye.
Terzis et al. studied paediatric patients who underwent
dynamic reanimation procedures to restore the blink reflex
(14). A total of 42 patients underwent nerve transfers such as
cross-facial nerve grafting or minihypoglossal nerve transfers,
and 14 patients underwent eye sphincter substitution techniques,
using the temporalis, platysma, frontalis, or pectoralis minor
muscle. A statistically significant improvement in blink scores,
calculated as the reduction of the palpebral fissure during
blinking, was seen in all patients who underwent dynamic
procedures (p¼<0.05). Improvement in blinking was especially
seen in patients who underwent direct orbicularis oculi muscle
neurotisation. Regarding the various types of muscle transfers,
the frontalis transfer was found to achieve the highest level of
improvement in blinking. Complications occurred in a single
patient, who had a severe postoperative infection in a pedicled
frontalis, which was successfully treated.
Besides difficulties in eye closure, brow ptosis may also lead to
visual problems or cosmetic concerns. A brow lift was performed in
47 of the 101 patients studied by Loyo et al.(13). Revision of
surgery was needed in 17% of the patients (8/47), which included a
direct brow lift (5/8 patients), temporal brow lift (2/8 patients), and
pretrichial approach (1/8 patients).
Oral problems
Facial palsy may also cause problems in oral competence,
speech, or feeding due to weakened lower lip support. Asymmetry
caused by the labial depressors of the face can be restored by
injecting botulinum toxin or by myomectomy of the contralateral
depressor labii inferioris. Injection of botulinum toxin in the
contralateral depressor labii inferioris can be used as a temporary
approach to evaluate the effect which can be followed by myomec-
tomy of the muscle. Chen et al. found good to fair results of dynamic
balance after myomectomy and injections with botulinum toxin in
their studied cohort of 76 patients (15). No significant differences in
posttreatment results between the two groups were seen. Although
no complications occurred, a recurrence rate of 24% was seen in the
patients who had surgical myomectomy. This was further treated
with botulinum toxin injections.
A different, potentially superior approach is to restore lip
depression with dynamic techniques. This includes transposition
of the ipsilateral anterior belly of the digastric muscle or the use of a
fascia lata sling to the ipsilateral platysma muscle (6, 28, 31).
Interestingly, the anterior belly of the digastric muscle may be
underdeveloped in 40% of the patients with CFM, and in 55% of the
patients with CFM and marginal mandibular nerve palsy (21).
Therefore, imaging to check the presence of the digastric muscle
should be performed before lower lip reanimation surgery starts
(21). Lindsay et al. retrospectively studied the outcomes of treat-
ment of an asymmetric lower lip and proposed a treatment algo-
rithm (16). A total of 58 patients were included. Of the 57 patients
treated with botulinum toxin injections in the contralateral depres-
sor labii inferioris, 48 were satisfied with the result. No poor
aesthetic outcome, oral incompetence, or speech problems were
seen after injection with botulinum toxin. Four patients were treated
with a digastric muscle transfer; three were satisfied with the result
and one patient needed additional debulking. The authors’ proposed
treatment algorithm starts with injecting lidocaine into the contra-
lateral depressor labii inferioris. If this results in improvement,
injection of botulinum toxin could be offered. This can be repeated
every four to six months and after two to three treatments a more
definitive treatment by performing myomectomy of the depressor
labii inferioris can be considered. If the botulinum toxin injections
do not lead to satisfactory results, alternative treatments such as
digastric muscle transfer should be considered (16).
Dynamic facial reanimation
Dynamic surgical techniques can be used in children with
congenital facial palsy for facial reanimation. The aim of surgery
is to achieve a symmetric face at rest and reanimate a spontaneous,
symmetric smile (18). Cross-facial nerve grafting with a gracilis
transfer is considered to be the most favourable option in literature,
although the use of other nerves or of local regional flaps can also be
considered (6, 31). The sural nerve is often used as a graft and
attached to a cranial nerve for the procedure of cross-facial nerve
grafting. The selection of the nerve transfer is based on patient-
specific characteristics, such as the type of palsy (uni- or bilateral,
complete or incomplete), the availability of the preferred or neigh-
bouring nerve(s), or the rehabilitation needs (23, 32). The contra-
lateral facial nerve is considered to be the most favourable nerve,
due to its ability to induce spontaneous contraction of the innervated
muscle and thereby create a natural smile (9, 11, 32). If the
contralateral facial nerve can’t be used to innervate the free muscle
on the paralytic side, alternative motor nerves such as the masseter,
hypoglossal and accessory nerves can be used (32). For rare cases,
other motor nerves such as the ipsilateral C7 root or the cervical
plexus can be used for facial reanimation (32).
Although the contralateral facial nerve is considered to be the
most favourable nerve transfer, the masseter nerve is also frequently
used, especially in patients with bilateral facial palsy due to its
direct connection and relatively good outcomes (7, 12, 32). In a case
series by Bianchi et al. the aesthetic results of masseter nerve
transfer were considered to be moderate in 17%, good in 51%, and
excellent in 32% of the patients (24). Major complications not seen
and minor complications included hematomas, abscesses, or post-
operative thrombosis (7, 18, 23, 24). In patients with a masseter
nerve transposition compared to cross-facial nerve graft, movement
was found to be more symmetrical, and displacement and contrac-
tion velocity of the commissure were significantly greater (11, 12).
However, spontaneous movement of the innervated free flap after
masseter nerve transfer is hard to achieve and the rates of a
spontaneous smile are 0% in some studies, although other studies
report higher rates of 55–100% (11, 12, 17, 18). In addition,
outcomes of masseter nerve transfer were found to be more
successful (> 2 mm change in smile excursion) in patients with
flaccid facial paralysis (88% success) compared to patients with
postparalysis facial palsy (20% success) (23). The masseter nerve
transfer is considered to be useful in patients with bilateral facial
palsy, patients with limited facial movement on the healthy side,
patients with major asymmetry at rest, or patients who want to avoid
a two-stage procedure (11, 23, 24, 32).
Six to twelve months after this first nerve grafting procedure, the
free muscle is harvested and transferred to the donor site (6, 31).
The gracilis muscle is frequently preferred because of the low
donor-site morbidity, re-innervation potential, reliability of the flap,
and ease of dissection (6, 31). Other donor flaps such as the
latissimus dorsi or pectoralis minor have also been described in
literature (18). Harrison et al. described outcomes of 528 patients
who were treated with a pectoralis minor muscle transfer and 28
patients with a latissimus dorsi transfer (19). Results were excellent
in 63%, good in 28%, poor in 5%, and no improvement was seen in
3% of the patients (19). The authors prefer the use of the pectoralis
minor because of its size and shape (19).
Complications after dynamic facial reanimation are not very
common. Gousheh et al. reported complications in twelve of the 655
patients (2%). All complications were minor and all grafts survived
(18). Chuang et al. reported failure of four gracilis muscles in 362
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patients (1%), which were successfully replaced in all cases (17).
The long-term outcomes of free-muscle transfer were studied by
Terzis et al. (26, 27). A total of 32 children with a follow-up of at
least five years were included (26). Almost all patients (91%)
needed additional surgical revisions, which included debulking,
defatting, reanchoring the muscle graft, or a mini-temporalis trans-
fer to the oral commissure. All flaps survived and all patients
showed improved function and symmetry at two-year follow-up
(p¼<0.001). This improvement remained over time. Muscle func-
tion and aesthetic outcomes showed further improvement over time
(p¼<0.001). These results were also seen in a different study by
the same authors that addressed the long-term outcomes of free-
muscle transfers in adults (27). The authors conclude that these data
support the use of free-muscle transfer in children and the technique
is effective to restore a coordinated functional and symmetric smile
(26, 27).
The use of regional flaps can be considered in patients in
whom a cross-facial nerve graft or free-muscle transfers is not an
option (18). Regional flaps cause shorter hospital stay and
operative times, and limited donor-side morbidity compared to
cross-facial nerve grafting (25). Regional temporalis or masseter
flaps are less commonly used in children due to the bulky aspect
of the masseter, temporal hollowing, and the inability to
respond to emotions and form a natural smile (28, 31). Although
no spontaneous smile can be achieved, commissure
displacement after lengthening temporalis myoplasty was found
to be 8.2 mm (range 5–13 mm) in the 14 patients studied by
Panossian et al. (25).
Conclusions
Level 3 Eye
Lowering of the upper eyelid to prevent keratitis or
corneal erosion can be achieved by injection of
botulinum toxin, lengthening of the levator palpebrae
superioris muscle or placement of a gold weight in the
upper eyelid.
Placement of a gold or platinum weight to correct
lagophthalmos is a preferred method due to good
aesthetic outcome, predictable results, reversibility,
easy technique, and the fact that it can be placed under
local anaesthesia in adults.
Surgical revision after placement of a gold weight is
needed in up to 19% of patients, due to extrusion or
migration of the implant, persistent lagophthalmos, or
ptosis.
Ref (9, 13, 20, 22, 29)
Level 3 Eye
Eye sphincter substitution techniques by using muscle
transfers or cross-facial nerve grafting can lead to a
significant improvement in blinking (p¼<0.05).
The highest level of improvement in blinking is seen after
transfer of the frontalis muscle compared to the use of
the platysma, frontalis, or pectoralis minor muscle.
Surgical correction of ptosis of the eyebrow in patients




Symmetric lip depression may be restored by repeated
injections of botulinum toxin or myomectomy of the
non-affected depressor labii inferioris, or by dynamic
reconstruction.
Results after botulinum toxin injections or myomectomy
of the non-affected depressor labii inferioris are
considered to be fair to good and no significant
difference in post treatment results of the two
treatment options are seen.
Dynamic reconstruction of lower lip depression includes
transposition of the ipsilateral anterior belly of the
digastric muscle or the use of a fascia lata sling to the
ipsilateral platysma muscle.
Due to the high prevalence of agenesis of the anterior
belly of the digastric muscle in patients with
craniofacial microsomia (55%), imaging of the muscle
should be performed before reanimation surgery of the
lower lip is undertaken.
Ref (6, 9, 15, 16, 21, 28, 31)
Level 4 Oral
Proposed treatment algorithm for the asymmetric lower
lip:
- Start with injection of botulinum toxin in
contralateral depressor
- Repeat treatment if results are satisfactory
- After 2–3 treatments and good results, myomectomy
can be considered




Correction of the lower eyelid can be achieved by tendon
sling, lateral tarsal suspension, or by a fascia lata strip.
Successful correction can be achieved in >90% of
patients.
The use of tarsorrhaphy is discouraged due to poor
cosmetic outcome and risk of peripheral vision loss.
The rate of surgical revisions after a tendon sling or
medial canthopexy to correct paralytic lagophthalmos
varies from 18 to 29%.
Ref (9, 13, 20, 29)
Level 4 Dynamic facial reconstruction / aesthetics
To restore facial animation and a spontaneous smile,
cross-facial nerve grafting is considered to be the
preferred treatment for unilateral craniofacial
microsomia.
Other motor nerves, such as the masseter, hypoglossal,
accessory or cervical nerves can be used if cross-facial
nerve grafting is not possible.
The gracilis muscle is often preferred due to the low
donor-site morbidity, re-innervation potential,
reliability of the flap, and ease of dissection. Other free
flaps, such as the latissimus dorsi or pectoralis minor
could also be used.
Ref (6, 9, 11, 18, 19, 23, 31, 32)
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Level 3 Dynamic facial reconstruction / aesthetics
Regional flaps, such as temporalis muscle transfers, can
be considered for dynamic facial reanimation if cross-
facial nerve grafting or free-muscle transfers are not
possible.
The use of regional flaps leads to shorter hospital stay and
operative times and limited donor-side morbidity
compared to free flaps. But no spontaneous smile can
be achieved and temporal hollowing may occur.
Ref (18, 25, 28, 31)
Level 3 Dynamic facial reconstruction / aesthetics
The masseteric nerve transfer is considered to be useful in
patients with bilateral facial palsy, patients with
limited facial movement on the healthy side, patients
with major asymmetry at rest, or patients who want to
avoid a two-stage procedure.
Displacement, velocity, and symmetrical movement of
the commissure is greater in patients with a masseteric
nerve transposition compared to a cross-facial nerve
graft.
Spontaneous movement of free flap reconstruction using
masseteric nerve reanimation is not observed in most
patients, although some studies report a high rate of
spontaneous movement.
Ref (7, 11, 12, 17, 18, 23, 24, 32)
Level 3 Dynamic facial reconstruction / aesthetics
Complications of nerve grafting with flap transfers
include hematomas, abscesses and free flap failure
(1–2%).
Most patients (91%) needed additional surgical revisions
after free flap transfers, such as debulking or
reanchoring of the muscle graft.
Long-term results of free-muscle transfer for smile
restoration in children and adults show good muscle
function and aesthetic outcomes that improve over
time.
Ref (7, 17, 18, 23, 24, 26, 27)
Considerations
 Overall quality of evidence
Most conclusions were based on case series or retrospective
cohort studies without controls. This type of non-comparative
research is graded as level 3. The proposed treatment algorithm
by Lindsay et al. (16) and the advice to achieve facial animation
with cross-facial nerve grafting were based on expert opinion and
are therefore graded on level 4.
 Balance of benefits and harms
The preferred method of treatment for the various functional
and aesthetic problems related to facial nerve palsy in patients
with CFM is based on the balance of the potential benefits and
harms and the selection of a certain type of treatment should
therefore be made together with the patient. Some procedures,
such as free muscle transfer, involve a high burden for the
patient, long surgery, donor-side morbidity, and risk of compli-
cations. Nevertheless, the final results may be better compared to
less burdensome treatment. It is essential to inform patients about
the risk and potential benefits for optimal shared decision
making.
 Outcome importance
A considerable number of patients with CFM experience facial
palsy. If functional problems occur, treatment is essential to prevent
further harm such as blindness. In case of aesthetic problems,
treatment may still be of great importance to patients. Treatment
should be considered after psychosocial support by a psychologist.
 Costs and resources
The impact on costs and resources of the given recommendations
will vary per member state, depending on the available care providers
and facilities. The recommendations concern the essential require-
ments for adequate treatment of patients with CFM and should thus be
implemented. Costs are lowest and resources are most efficiently
used when care for craniofacial disorders is centralised in a limited
number of expert centres per member state. A general rule that can be
applied is one expert centre per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an expert
centre for CFM, or the level of provided care does not (yet) meet all the
requirements that are outlined in this guideline. By defining the
baseline of required care for CFM, this guideline will help these
member states to reach the appropriate level. The ERN on craniofacial
anomalies and ENT disorders (ERN-CRANIO) can guide a patient in
Europe to the available centres of expertise (www.ern-cranio.eu) and
can support care providers with diagnosis and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
Treatment of lagophthalmos is important in patients with facial
palsy to prevent severe corneal pathology, endophthalmitis or even
blindness. For all different indications, various techniques have
been described, all with their own benefits and harms. Figure 1
shows a flowchart of the recommendations on the various treatment
modalities that can be performed to treat the facial nerve deformity
based on the multiple indications. This makes the choice for a
certain type of treatment very patient specific and the choice for
treatment should be made together with the patient. In patients with
bilateral CFM, the masseter nerve could be used for dynamic
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reanimation. Although good displacement, velocity, and symmet-
rical movement of the commissure can be achieved, most patients
won’t be able to smile naturally. Therefore, cross-facial nerve
grafting is regarded as the most optimal treatment. Cross-facial
nerve grafting with functional muscle transfer can be offered from
the age of four to five onwards (33, 34). To achieve optimal results a
facial physical therapist is considered an integral part of the
management of facial palsy. It is important to provide information
on the various treatment modalities help patients to make a well-
considered choice. Another important aspect is the involvement of
psychosocial support by a psychologist prior to and after treatment,
especially in patients with aesthetic concerns.
Recommendations
Eye
 Correct lagophthalmos due to facial palsy in patients
with craniofacial microsomia with placement of a gold
weight or platinum chain, muscle transfers and/or
tendon slings, or cross-facial nerve grafting.
 Tarsorrhaphy as a treatment for lagophthalmos in
patient with craniofacial microsomia is discouraged.
Oral
 Start with the injection of botulinum toxin in the non-
affected depressor labii inferioris muscle if therapy is
indicated in patients with craniofacial microsomia and
asymmetrical lip depression due to facial palsy.
 Consider myomectomy of the non-affected depressor
labii inferioris muscle if the outcome of treatment with
botulinum toxin injections are satisfactory.
 Consider the use of dynamic techniques such as
digastric muscle transfers if the outcome of treatment
with botulinum toxin injections are not satisfactory.
 Perform imaging of the digastric muscle prior to
surgical muscle transfer due to the high prevalence of
agenesis of the anterior belly of the digastric muscle.
Aesthetics
 Psychological input is required pre- and post-opera-
tively to monitor expectation and acceptance.
 Strive for spontaneous facial animations by using a
cross-facial nerve graft with a free flap.
 Consider functional muscle transfer from the age of
four onwards.
 Reserve the use of the masseteric nerve to innervate the
free muscle transfer for patients in whom cross-facial
nerve grafting is not favourable, in bilateral cases, or as
a babysit procedure.
 Consider the use of regional muscle transfers to achieve
facial animation in patients with craniofacial micro-
somia and facial palsy if cross-facial nerve grafting with
free muscle transfers is not preferred.
 A facial physical therapist is part of the multidisciplin-
ary team.
 Collect clinician- and patient-reported outcome mea-
sures pre- and posttreatment.
Figure 1. Flowchart recommendations treatment facial palsy in
craniofacial microsomia
Research gap
Future studies on the timing of treatment of facial nerve
deformity in patients with CFM that addresses psychosocial, aes-
thetic and functional concerns, and other facial surgeries in these
patients, could help establish a protocol on optimal timing
of treatment.
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CHAPTER 5. SURGICAL TREATMENT
5.3 Soft tissues
Introduction
One of the relevant factors leading to asymmetry in patients with
craniofacial microsomia (CFM) is soft tissue deficiency. This is
mainly characterised by a lack of subcutaneous fat or a deficiency of
the musculature. A large retrospective study of 755 patients with
CFM reported a soft tissue deficiency in 82% of all patients: mild
(S1) in 43%, moderate (S2) in 30%, and severe (S3) in 9% of
patients (1). In the O.M.E.N.S. classification, which is often used to
categorise patients with CFM, the soft tissue score (S) is originally
graded from S0 – no obvious deficiency, to S1 – minimal subcu-
taneous/muscle deficiency, S2 – moderate, between S1 and S3, and
S3 – severe soft tissue deficiency due to subcutaneous and muscular
hypoplasia (2). The phenotypic assessment tool by Birgfeld et al.
translated this to S0 – normal, S1 – minimal soft tissue deficiency,
S2 – moderate soft tissue deficiency, and S3 – severe soft tissue
deficiency (3).
The aim of treatment is to restore a normal shape of the face and
strive for symmetry (4). Various types of treatment are currently
used to treat soft tissue deficiency, including fat grafting, pedicles
flaps, free tissue transfers, or alloplastic implants. The main factors
in the selection of a type of treatment are the severity of the soft
tissue deficiency, the presence of other (bony) facial deformities,
and the patient’s age.
To make recommendations on the indications for treatment and
the optimal treatment strategy to address soft tissue deficiency in
patients with CFM, the following questions were posed:
5.3.1 What is the indication for surgical treatment of soft
tissue deficiency in patients with craniofacial microsomia?
5.3.2 What is the most optimal treatment modality for soft
tissue deficiency in patients with craniofacial microsomia
related to severity and its timing?
Recommendations on the indications and optimal treatment
strategy for soft tissue deficiency in patients with CFM are impor-
tant to optimise outcomes. It is essential to inform the patient on the
potential harms and benefits of treatment and to ensure that the
patient has a realistic view on what can be expected, especially if the
indication for treatment is patient specific and based on aesthetic
concerns. Shared decision making is only possible if the patient is
well informed. The aim of these questions is to guide surgeons and
to help patients in the choice for treatment.
Literature search
A systematic search of literature was performed to identify all
available literature on CFM and synonyms. The search was con-
ducted in Embase, Pubmed/Medline Ovid. The full search strategy
is reported in the supplementary material.
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Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review
matches the question of the guideline.
- The search of the systematic review was
conducted in at least two relevant
databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the
search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Treatment of soft tissue deficiency
Exclusion criteria - Original studies with <10 included patients





Literature was screened on title and abstract. Ten studies that
addressed (surgical) treatment of soft tissue deficiency in patients
with CFM were included. Seven of these articles were included in a
systematic review by Sinclair et al. (4). The other two studies
included were a narrative review by Birgfeld and Heike (5) and a
prospective cohort study on autologous free fat grafting by Denadai
et al. (6). The systematic review of Sinclair et al. studied the surgical
techniques used to treat soft tissue deficiency in patients with CFM
(4). Case reports, case control studies, retrospective cohort studies,
and non-randomised prospective studies that addressed treatment of
soft tissue deficiency in patients with CFM were included. A total of
38 articles were included. Although 27 of the 38 original articles in
this systematic review included fewer than 10 patients, each
treatment modality described in the review included >10 patients
due to combining of data. Therefore, the full systematic review was
included in this chapter.
5.3.1 What is the indication for surgical treatment of soft
tissue deficiency in patients with craniofacial microsomia?
The literature search for this question was directed towards more
specific research questions related to clinical problems, symptoms,
treatment options, consequences of not treating, and requirements
for treating soft tissue deficiency (Appendix 1, http://links.lww.
com/SCS/B697). Unfortunately, no literature on the indication for
surgical treatment of soft tissue deficiency in patients with CFM is
available. Therefore no conclusions were written. Considerations
were only based on expert opinion.
Considerations
 Overall quality of evidence
Because there is no literature available the recommendations are
based on expert opinion with a low quality of evidence.
 Balance of benefits and harms
A considerable number of patients with CFM have a deficiency
of the soft tissue. This deficiency, in combinations with other
(aesthetic) concerns that may be present in patients with CFM,
may lead to psychosocial problems. The aesthetic differences with
other, ‘healthy’ persons can lead to low self-esteem, bullying, or
negative feelings. This underlines the importance of psychosocial
support for all patients with CFM, which should start during
childhood.
 Outcome importance
No literature is available on the importance of correcting soft
tissue deficiency in patients with CFM. Patients with CFM often
experience multiple difficulties and the facial deficiency/asymme-
try is usually not solely due to soft tissue deficiency. Nevertheless, a
deficiency of the facial soft tissue, mild or severe, can have a big
impact on the patient. Aesthetic concerns could lead to psychosocial
problems in some patients. Treatment of soft tissue deficiency may
help patients to feel less ‘atypical’.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The indication for treatment of soft tissue deficiency in patients
with CFM is based on aesthetic problems. The aim of treatment is to
strive for facial symmetry. Since the indication for treatment is
largely aesthetic and psychosocial with few functional problems, it
is essential that the patient is well-informed about the potential risks
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of therapy. Psychosocial help or therapy may help patients to learn
to cope with their aesthetic differences. Additionally, psychosocial
help enhances the ability to make a well-considered decision to
choose whether or not to have treatment. All patients with CFM
should be provided with psychosocial support, as is recommended
in Chapter 5.3.2. The ICHOM Standard Set for Craniofacial Micro-
somia advises to assess any difficulties with facial form/asymmetry
by using the CleftQ appearance questionnaire at age 8, 12, and 22.
Recommendations
 The indication for surgical treatment of soft tissue
deficiency in patients with craniofacial microsomia is
mainly aesthetic. Inform the patient about the potential
benefits and harms to ensure that the patient has a
realistic view of what can be expected.
 Patients’ difficulties with facial form/asymmetry should
be assessed with the CleftQ Appearance at age 8, 12,
and 22.
Research gap
There is a lack of knowledge on the effectiveness of and
patients’ reported satisfaction with soft tissue augmentation in
patients with CFM. Future research on this topic could help doctors
to support patients in the decision-making process for potential soft
tissue augmentation. Patient outcome measures, such as FaceQ
kids, could be used to evaluate patients perspective on their soft
tissue deficiency.
5.3.2 What is the most optimal treatment modality for soft
tissue deficiency in patients with craniofacial microsomia
related to severity and its timing?
The literature search for this question was directed towards more
specific research questions related to treatment options, complica-
tions, advantages and disadvantages, short and long term results and
treatment burden for treating soft tissue (Appendix 1, http://
links.lww.com/SCS/B697). The surgical treatment modalities were
divided into five groups: pedicled flaps, functional reconstruction,
alloplastic reconstruction, free flaps, and structural fat grafting.
Timing refers to the age of the patient. Included patient outcomes
were (psychological) impact of the treatment, complications and
satisfaction with the result. Literature on alloplastic reconstructions
was scarce and no conclusions on this treatment modality could
be drawn.
Review of literature
In 2019, a systematic review by Sinclair et al. was published that
studied the surgical techniques used to treat soft tissue deficiency in
patients with CFM (4).
Pedicled flap
Five articles described a total of thirteen patients with CFM who
were treated with a pedicled flap to correct the facial soft tissue
deficiency. The mean age of treatment with a pedicled flap was 12.3
years (range 3-27 years). Various pedicled flaps were used: sub-
mental flap (n¼ 3), a composite osteomyocutaneous flap based off
of the thoracodorsal artery (n¼ 4), a pedicled parietal osteofascial
flap (n¼ 2), and a pedicled temporoparietal fascial flap (n¼ 4). The
outcomes of treatment were specified in three articles that were
included in the review, and were reported to be ‘acceptable’,
‘satisfactory’ or a ‘good result’. No quantitative outcomes or
complication rates were specified and no information about the
need for revisional surgery to improve final aesthetics
was available.
Alloplastic reconstruction
The systematic review by Sinclair et al. included one article by
Liu et al. that assessed the use of alloplastic materials for soft tissue
augmentation, which included thirteen patients with CFM (7).
However, no outcomes, complications, severity of the soft tissue
deficiency, or location of the implant were reported.
Free flaps
The use of free flaps was studied in 24 articles including 129
patients with CFM. The severity of the soft tissue deficiency was
specified in only one of the 24 studies, which reported a ‘severe soft
tissue deficiency’ in the treated patients. Therefore, the indication
for treatment was unknown. The mean age of treatment was 19.0
years (range 2.5–29 years). Most frequently used flaps were the
parascapular fasciocutaneous flap (n¼ 67) and the inframammary
extended circumflex scapular flap (n¼ 18), although in more recent
literature perforator flaps were often preferred. The parascapular
fasciocutaneous flap is often used due to its larger size, reliable
harvest, and long pedicle (4). Follow-up varied from seven months
to seven years and most studies did not report the length of follow-
up. Outcomes were satisfactory or positive in most studies. Most
frequently reported complications included hematoma (n¼ 7),
partial flap loss (n¼ 2) or donor site infection (n¼ 1). One patient
had a total flap loss. Debulking procedures were needed in 28 flaps
(20%). Two studies mentioned that fat grafting was indicated after
free flap reconstruction. The indication for fat grafting in these
patients, which may be to correct a low volume of the free flap or
sagging of the flap, was not provided in the manuscript.
According to Birgfeld and Heike (5), patients with severe soft
tissue deficiencies can best be treated with an adipofascial free flap,
such as the scapula, parascapular, groin, omentum, anterolateral
thigh, and deep inferior epigastric perforator flap. Drawbacks of the
use of free flaps are the need for microsurgical skills, length of the
procedure, possible need for debulking, and the donor-site morbid-
ity and scarring (5). Free tissue flaps may sag over time or disrupt
normal facial movement.
Fat grafting
Structural fat grafting to correct the soft tissue deficiency in
patients with CFM was addressed in eight articles included in the
systematic review. The mean age of treatment was 16.3 years
(range 3 - 25 years) and patients needed a mean of 2.7 fat
grafting sessions (range 1-6 sessions). Three studies used quan-
titative analysis to study the outcomes of fat grafting and all three
studies reported a (statistically significant) increase in facial
symmetry (facial symmetry from 75–86% to 95–99%,
p<0.003). Complications of treatment were specified in one
study, which reported a 5% complication rate which included
infections and contour irregularities.
Birgfeld and Heike (5) argued that the advantages of fat
grafting include minimal scarring and donor-site morbidity, pre-
cision of the treated location, and it is less likely to droop or
disrupt normal facial movement compared to free tissue grafts.
However, multiple sessions may be needed to achieve optimal
results. Birgfeld and Heike prefer to use fat grafting to improve
facial symmetry during childhood and adolescence and combine
fat grafting with other procedures.
To assess fat graft retention in patients with craniofacial contour
deformities, a prospective cohort study was undertaken by Denadai
et al. (6). Pre- and postoperative soft tissue thickness was measured
using ultrasound linear measurements. A total of 142 patients were
included; 46 of these patients had CFM. No complications were
reported. After the first three months of treatment, a significant
and progressive reduction of soft tissue thickness was found
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(p¼>0.05). However, these rates stabilised from three to twelve
months postoperatively (p¼>0.05). Confounding factors such as
postoperative swelling and persistent inflammation may have con-
tributed to the reduction of soft tissue thickness in the first three
months. The retention rate of the fat graft was 67.7%. Multivariate
analysis showed that patients’ age, previous craniofacial bone
surgery at the site of fat grafting, and the grafted volume are all
independent negative predictors of fat graft retention (p¼<0.05).
The higher retention rates in paediatric patients compared to adults
advocate fat grafting in young patients to achieve facial symmetry,
according to the authors (6).
In the systematic review by Sinclair et al., the complication rate of
free tissue transfers was compared to fat grafting (4). Patients who had
a free tissue transfer had significantly more complications compared
to patients who underwent fat grafting (27.1% vs 4.2%, p¼<0.001,
odds ratio 6.7). However, the authors state that it is difficult to
compare the effectiveness of different reconstructive modalities
due to differences in reported data, soft tissue deficiency, volume
of the flap reconstruction, or quantity of fat grafted. One of the
included studies, by Tanna et al. (8), compared free tissue transfer to
serial fat grafting and included 31 patients with CFM. Patients with
CFM who had fat grafting reported fewer complications (5% vs 12%)
and had a posttreatment symmetry score of 99% (5.4%) compared
to 121% (7.9%) in patients with a free tissue transfer. The post-
reconstruction symmetry score was significantly closer to 100% in
patients with CFM who had fat grafting compared to a free tissue
transfer (p¼ 0.05%). However, no statistically significant difference
was found in patient and physician satisfaction between the two
groups. The symmetry analysis and patient and physician satisfaction
were measured in the follow-up period, the length of which was not
specified. Free tissue transfers achieved a higher (in fact too high)
amount of volume augmentations compared to fat grafting (p¼ 0.05).
Tanna et al. concluded that free tissue transfers are considered to be
the appropriate management in adolescent patients with significant
soft tissue hypoplasia and that fat grafting can be used in growing
patients combined with other surgical interventions to improve the
craniofacial contour (8). This conclusion was underlined by the
authors of the systematic review. Sinclair et al. (4) stated that a
minor to moderate soft tissue deficiency can be treated by serial fat
grafting, but major soft tissue deficiencies should be treated with a
fasciocutaneous free tissue transfer. This may be followed with
subsequent fat grafting if indicated. Additionally, surgeons should
be aware of the possibility of alterations in vessel anatomy in case of
free tissue transfers in patients with CFM.
Conclusions
Level 3 Pedicled flaps
Pedicled flaps have been used to treat soft tissue
deficiency in patients with craniofacial microsomia in
a very small number of patients (n¼ 13) and therefore
it is difficult to comment on results.
Ref (4)
Level 3 Free flaps
The results of free tissue transfers to treat soft tissue
deficiency in patients with craniofacial microsomia
are considered to be satisfactory or positive in most
studies.
Complications after free tissue transfer occur in 27% of
patients and include hematoma, partial or total flap
loss, infections, or sagging.
Debulking procedures of the free tissue graft are needed
in 20% of the patients with craniofacial microsomia.
Ref (4, 5)
Level 3 Free tissue transfer versus fat grafting
The severity and rate of complications of free tissue
transfers is significantly higher compared to fat
grafting in patients with craniofacial microsomia
(27% vs 4%, p¼<0.001).
Fat grafting leads to a higher level of post-treatment
symmetry in patients with craniofacial microsomia
compared to free tissue transfers.
Ref (4, 8)
Level 3 Fat grafting
Serial fat grafting to correct soft tissue deficiency in
patients with craniofacial microsomia causes a
statistically significant increase in facial symmetry
(facial symmetry from 75–86% to 95–99%,
p<0.003).
The complication rate of fat grafting in patients with
craniofacial microsomia is 4–5% and includes
infections and contour irregularities.
The retention rate of the fat graft is 68–82%, which
stabilises three months after treatment.




 Overall quality of evidence
The conclusions from the literature are mainly based on the
systematic review by Sinclair et al. (4), which included 38 articles.
The studies included were case reports, case series, or retrospective
reviews, all with a level of evidence of 3 to 4 (according to the
PRISMA statement (9)). The quality of evidence of conclusions
based on this systematic review were therefore graded as level 3.
Denadai et al. (6) performed a prospective cohort study without
controls which was graded as level 3. The study by Tanna et al. (8)
was a retrospective cohort study that compared the outcomes of two
different groups. The indication for a type of treatment and the
length of follow-up were unclear in this study. The quality of
evidence was graded as level 3.
 Balance of benefits and harms
The preferred method of treatment for the aesthetic problems
related to soft tissue deficiency in patients with CFM is based on
the balance of the potential benefits and harms, and the selection
of a certain type of treatment should therefore be made together
with the patient. Some procedures, such as free tissue transfers,
involve a high burden for the patient, long surgery, donor-side
morbidity, and a higher of complications compared to fat grafting.
Other drawbacks of this surgery that remain underreported in
literature are sagging of the flap in the long run and loss of facial
expression. In addition, if complications occur after free tissue
transfer these are often severe and involve a high burden for the
patient. Free tissue transfers are a suitable solution for patients
with a severe soft tissue deficiency, but a substantial volume
augmentation can also be achieved with multiple sessions of fat
grafting. Limited literature is available on the use of alloplastic
materials for soft tissue augmentation in patients with CFM.
Complication rates of alloplastic implants such as silicone or
polyethylene are similar (4.7% and 4.8%) and include infection,
hematoma, displacement or prominence (10, 11). It is essential to
inform patients about the risk and potential benefits for optimal
shared decision making.
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 Outcome importance
It is important to consider timing of treatment and optimal
treatment strategy to correct soft tissue deficiency in patients with
CFM, because the indication for treatment may vary depending on
the patient’s age. It is important that patients who prefer treatment to
correct the soft tissue deficiency during childhood, adolescence, or
adulthood know what types or treatments are available, how these
methods might interfere with each other, and what the benefits and
harms of these various treatment modalities are. True shared
decision making between doctor and patients is only possible if
the patient is well informed.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core
values. However, in some countries the national organisation of
healthcare might impede centralisation. National implementation
of the ERNs that fits the situation of each country is necessary. For
the member states with the lowest number of inhabitants, the
establishment of a craniofacial centre might not be feasible, and
collaboration with a craniofacial centre in the surrounding coun-
tries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The outcomes of fat grafting in literature are considered to be
good with relatively low complication rates and a low burden for
the patient. This makes fat grafting the first choice of treatment
for most patients in which treatment of soft tissue deficiency is
indicated. Especially patients with a mild soft tissue deficiency
and all children or adolescents are preferred to be treated with fat
grafting. Free tissue transfers are considered to be a good
treatment modality for patients with severe soft tissue deformities
due to the high volume of soft tissue augmentation. Nevertheless,
this type of treatment has more impact on the patient: higher
complication rates compared to fat grafting (27%), a longer
procedure, and donor-site morbidity and scarring. Patients often
need additional debulking procedures due to overcorrection or fat
grafting to optimise the results. The risk for drooping or other
long-term effects of free tissue grafts is not reported in literature.
This suggests the use of free tissue grafts should be limited; they
should solely be used in the treatment of patients with CFM and a
severe soft tissue deficiency, particularly if the patients have
insufficient fat at the donor sites. Although literature on allo-
plastic implants for soft tissue augmentation in patients with
CFM is very limited, alloplastic implants such as silicone or
polyethylene, could be a preferred method to treat soft tissue
deficiency in patients with CFM, especially for the mandibular
angle. The long-term effects of alloplastic implants for soft tissue
augmentation are unknown due to the limited follow-up in most
studies. Therefore, alloplastic implants for soft tissue augmenta-
tion should not be used in growing patients and placement should
be postponed until the patient is eighteen years or older. If
placement of alloplastic implants is considered, it is advised
to postpone fat grafting procedures after placement of alloplastic
implants since it changes facial symmetry. The flowchart of the
recommendations for treatment of soft tissue deformity in
patients with CFM is shown in Figure 1.
Recommendations
 Psychological input is required pre- and post-opera-
tively to monitor expectations and acceptance.
 Reconstruct soft tissue deficiencies in patients with
craniofacial microsomia with fat grafting from child-
hood.
 Free tissue transfer is only considered in patients with a
very severe soft tissue deficiency.
 Alloplastic implants to correct soft tissue deficiency in
patients with craniofacial microsomia are ideally
performed at skeletal maturity.
 The use of pedicled flaps for correction of soft tissue
deficiency in patients with craniofacial microsomia is
strongly discouraged.
 Coordinate the timing of surgical treatment of soft
tissue deficiency in patients with craniofacial micro-
somia with the planning of other surgeries, especially
for surgeries that affect facial symmetry such as
mandibular surgeries or placement of facial implants.
Research gap
Future studies on the long-term effects of soft tissue augmenta-
tion in patients with CFM could help determine an optimal treat-
ment strategy. Especially treatment with alloplastic implants and
free tissue transfers should be studied with special attention to the
long-term outcomes. Patient outcome measures, such as FaceQ
kids, could be used to evaluate of the patients’ perspective on their
soft tissue deficiency. 3D stereometry is a good tool to study
outcomes of treatment.
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Figure 2. Flowchart recommendations of treatment for the soft
tissue deformity in patients with craniofacial microsomia
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CHAPTER 5. SURGICAL TREATMENT
5.4 Microtia
Introduction
Microtia is one of the most common characteristics of patients
with CFM as it is seen in 83% to 88% of the patients (1, 2). Besides
external ear malformations, patients may have other malformations
such as middle ear malformations or atresia, or the presence of
branchial remnants (3). These malformations may lead to hearing
problems which are further described in Chapter 4.4 – Hearing
difficulties.
In the management of microtia and atresia improving hear-
ing is the most important functional goal, followed by external
ear reconstruction if the patient and family feel that is required.
The first option for microtia is ‘no reconstruction’; however, if
the patient and family are keen to proceed, then there are a
number of options for treatment, including an external silicone
prosthesis attached with either adhesives or an osseointegrated
implant, a porous polyethylene buried prosthesis, and ear
reconstruction with autologous rib graft. The porous polyeth-
ylene prosthesis is implanted by the surgeon and covered by a
flap and skin graft (4). Ear reconstruction with rib can be
performed using different techniques established by Brent,
Firmin and Nagata (4). The Nagata and Firmin technique is
often used and involves a two-stage approach. Rib cartilage is
harvested and constructed into a detailed ear framework, which
is placed in a pocket at the site of the ear. After six months, a
second operation is performed to elevate the ear from the head
and to create a sulcus.
To offer recommendations on the indications for treatment and
the optimal treatment strategy to restore ear deformity in patients
with CFM, the following questions were posed:
5.4.1 What is the indication for surgical treatment of ear
deformity in patients with craniofacial microsomia?
5.4.2 What is the most optimal treatment modality for ear
deformity in patients with craniofacial microsomia related
to its timing?
It is essential to inform the patient on the potential harms and
benefits of treatment and to ensure that the patient has a realistic
view on what can be expected, especially if the indication for
treatment is patient specific and based on aesthetic concerns. Shared
decision making is only possible if the patient and family are well
informed. The aim of these questions is to guide surgeons and to
help patients in the choice for treatment.
Literature search
A systematic search of literature was performed to identify all
available literature on CFM and synonyms. The search was con-
ducted in Embase, Pubmed/Medline Ovid. The full search strategy
is reported in the supplementary material.
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Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review
matches the question of the guideline.
- The search of the systematic review was
conducted in at least two relevant
databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the
search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Indication and/or treatment for ear
reconstruction
Exclusion criteria - Original studies with <10 included patients






Only literature that described indications, outcomes or compli-
cations of ear reconstruction was included. The aim of this chapter
is to provide patients and clinicians with guidance on the available
treatment options for ear reconstruction in patients with CFM.
Therefore, articles that studied surgical techniques in detail were
excluded, as this is beyond the scope of this chapter.
Literature was screened on title and abstract. A total of three
retrospective cohort studies were included that addressed outcomes
on ear reconstruction in patients with CFM: by Mandelbaum et al.
(5), Park et al. (6), and Qian et al. (7)
The ‘UK Care Standards for the Management of Patients with
Microtia and Atresia’ (2018) was also included in this chapter (4).
This UK guideline on microtia/atresia makes clinically relevant
recommendations to improve care, but is not been based on the
same methodological criteria as this guideline on CFM. Hence the
UK guideline on microtia/atresia did not provide information on
the literature search, the inclusion/exclusion criteria, and quality of
evidence of the individual studies and conclusions. Nevertheless,
the guideline is considered to be clinically relevant, especially since
the general quality of evidence of literature on auricular reconstruc-
tion is low (8).
An additional literature search was performed to include liter-
ature on auricular reconstruction in patients with microtia or atresia.
All articles that described indications, outcomes or complications
on treatment modalities for auricular reconstruction were included.
The full search strategy is shown in the addendum. A total of 369
articles were identified and ten articles met the inclusion criteria and
were included in this chapter. One systematic review by Long et al.
was included (9), and two cross-sectional studies by Younis et al.
(10) and Braun et al. (11), five retrospective cohort studies by
Constantine et al. (12), Fu et al. (13), Roos et al. (14), Al Kadah et al.
(15), and Si et al. (16), and two case series by Vijverberg et al. (17)
and Wright et al. (18)
5.4.1 What is the indication for surgical treatment of ear
deformity in patients with craniofacial microsomia?
Auricular deformities in patients with CFM are often accompa-
nied by other congenital facial malformations. These deformities
can cause aesthetic or psychosocial concerns and may be an
indication for surgical reconstruction. As patients with CFM often
have multiple facial malformations, the indication for treatment
may be more complex compared to patients with isolated microtia/
anotia. Therefore, only literature on patients with CFM was
included in this chapter.
Review of literature
The characteristics of patients with CFM and external ear and
hearing problems were studied by Mandelbaum et al. (5) Their
retrospective analysis included 68 patients with CFM. Most of these
patients had auricular abnormalities (91%), which were most
frequently characterised as grade III microtia (in 75% of the
patients). Data on complications, surgical revisions, aesthetics,
and psychosocial function were collected. Psychosocial problems
or deficits in school functioning were seen in 30.7% of the patients.
However, no control group was included, which makes this per-
centage hard to interpret. Data on psychosocial problems were
based on retrospective review of medical records and were graded
as ‘good’ or ‘poor’. Regression analysis showed that any treatment
of hearing loss (which led to significantly better hearing results after
treatment) was a significant predictor of good psychosocial out-
come (OR, 4.889; 95% CI, 1.459–16.381; p¼ 0.010). No statisti-
cally significant influences of auricular reconstruction on
psychosocial functioning were found.
Conclusion
Level 3 One study did not find a difference in psychosocial
functioning after ear reconstruction in patients with
craniofacial microsomia (n¼ 68).
Ref (5)
Considerations
 Overall quality of evidence
The quality of evidence on the indication for treatment of
auricular deformity in patients with CFM was graded on level 3,
since the study of Mandelbaum et al. was a retrospective cohort
study (5). It is important to keep in mind the retrospective nature of
the study and the imperfect method of determining psychosocial
problems (by chart review) in assessing the quality of the conclu-
sion. Due to this methodological weakness, the conclusion is
considered less strong.
 Balance of benefits and harms
Microtia can have negative psychosocial consequences due to
aesthetic difficulties and the visibility of the disorder. Patients often
cover their disfigurement by wearing their hair down, avoiding wet
hair or windy weather, avoiding physical activities, social situa-
tions, mirrors, photographs and so on (4). A higher prevalence of
social problems, aggressive behaviour, and mood disorders are seen
in patients with microtia compared to healthy controls (19). The
aesthetic differences with other, ‘healthy’ persons could lead to low
self-esteem, bullying, or negative feelings. This underlines the
importance of psychosocial support for all patients with CFM,
which should start during childhood. Ear reconstruction may be
beneficial for patients to feel less ‘atypical’ and prevent the
previously mentioned potential harms.
 Outcome importance
No literature is available on the importance of correction of the
auricular deformity in patients with CFM. Patients with CFM often
experience multiple facial differences compared to healthy controls.
Nevertheless, it has been shown that the management of microtia or
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anotia has significant positive impact for the patient (20). Aesthetic
concerns could lead to psychosocial problems in some patients.
Auricular reconstruction may help patients feel less ‘atypical’. To
assess the benefits of ear reconstruction, the use of a new PROM
Ear-Q was agreed at the International Society for Auricular Recon-
struction ISAR congress in Beijing in 2017. All surgeons should use
the Ear-Q pre- and post operatively.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. Treatment with porous polyethylene pros-
thesis (Medpore) especially could contribute to an increase in costs.
Health insurance reimbursement and the willingness to cover these
costs may differ between countries. The recommendations concern
the essential requirements for adequate treatment of patients with
CFM and should thus be implemented. Costs are lowest and
resources are most efficiently used when care for craniofacial
disorders is centralised in a limited number of expert centres per
member state. A general rule that can be applied is one expert centre
per 10 million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core values.
However, in some countries the national organisation of healthcare
might impede centralisation. National implementation of the ERNs
that fits the situation of each country is necessary. For the member
states with the lowest number of inhabitants, the establishment of a
craniofacial centre might not be feasible, and collaboration with a
craniofacial centre in the surrounding countries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
The indication for treatment of microtia is primarily aesthetic
but has been shown to have large psychosocial benefits in patients
with isolated microtia (21). The aim of treatment is to improve the
patient’s quality of life. Since the indication for treatment is
aesthetic, it is essential that the patient is well-informed about
the potential risks of therapy. Hearing problems should be assessed
and treated, as is explained in Chapter 4.4 – Hearing difficulties.
Psychosocial help or therapy may help patients learn to cope with
their different appearance. In an even earlier phase, parents of
patients should receive information on the possible treatment
options for the ear deformity. The multidisciplinary craniofacial
team should assess the psychosocial problems and reconstructive
options in an individualised manner (4). If treatment is considered,
it is essential to inform patients and parents on the expected
outcomes and the burden of treatment such as the frequency and
length of hospital stays, and risk of complications.
Recommendations
 The indication for auricular reconstruction in patients
with craniofacial microsomia is aesthetic and psycho-
social. Inform the patient about the potential benefits
and harms to ensure that the patient has a realistic view
of what can be expected.
 Provide all patients with craniofacial microsomia with
psychosocial support.
 Use the PROM Ear-Q pre- and postoperatively to assess
benefit of treatment.
Research gap
There is a lack of knowledge on the effectiveness of and patients
reported satisfaction with auricular reconstruction in patients with
CFM. Future research on this topic could help doctors support
patients in the decision-making process. It is hoped that the use of
the new PROM Ear-Q will reduce this gap.
5.4.2 What is the most optimal treatment modality for ear
deformity in patients with craniofacial microsomia related
to its timing?
The literature search for this question was directed towards more
specific research questions related to treatment options, complica-
tions, advantages and disadvantages, short and long term results and
treatment burden for treatment of microtia/anotia in patients with
CFM (Appendix 1, http://links.lww.com/SCS/B697). Besides lit-
erature on CFM, the ‘UK Care Standards for the Management of
Patients with Microtia and Atresia’ (2018) and literature identified
from the additional search on auricular reconstruction was included
(4). Treatment modalities were divided into four groups: external
silicone prosthesis attached with adhesives, external silicone pros-
thesis attached on implants, porous polyethylene implants (Med-
pore), and auricular reconstruction with autologous rib grafts.
Included patient outcomes were (psychological) impact of the
treatment, complications and satisfaction with the result.
Review of literature
Craniofacial microsomia
Mendelbaum et al. retrospectively studied 68 patients with
CFM, all age >13 (5). Microtia was present in 91% of the patients,
and was characterised as type III microtia in 75% of the patients
(n¼ 58). Total auricular reconstruction with rib grafts was per-
formed in 56 ears, starting at a mean age of 8.5 years (range 5.5-18.7
years). Aesthetic outcomes were assessed by three independent
observers on a scale of 1 to 3. The mean aesthetic outcome score
was 5.56 (range 3-9). Patients with severe microtia required more
surgeries to achieve optimal results and had lower aesthetic out-
come ratings after reconstruction compared to less severe cases
(respectively IRR, 4.350; 95% CI, 2.140–8.843; p < 0.001, and
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IRR, 0.763; 95% CI, 0.658–0.886; p < 0.001). Complications
occurred in 18% of the patients and were all secondary to wound
complications. Most patients (n¼ 46) needed revisions after com-
pletion of ear reconstruction such as deepening of the helical root,
tragus, or concha, revision of the lobule, or projection of the new
ear. No correlation between the complication rate and the severity
of microtia was observed (p¼ 0.193).
Microtia in patients with CFM is difficult to treat due to
additional abnormalities such as facial asymmetry, a low hairline,
depression of the temporomandibular joint or temporal bone, and
low ear vestige. These characteristics can lead to a deficiency in the
skin volume, making covering of the auricular reconstruct difficult
(6). Three types of coverage techniques in microtia reconstruction
in patients with CFM were studied by Park et al., who included 52
patients with CFM with a mean follow-up of 40 months (range
6 months to 10 years) (6). All patients had auricular reconstruction
with rib and were treated with three types of coverage techniques.
Results on the comparison of these coverage techniques were
considered to be too surgically detailed for this chapter and were
not included. However, results on aesthetic outcomes and compli-
cations were considered relevant and extracted from the article. The
aesthetic outcome of treatment was rated on a 1–10 scale, based on
senior author assessment. The mean aesthetic score varied from
6.30 to 8.26. Poor postoperative outcomes were due to large size of
the reconstructed ears (n¼ 11), partial resorption of the cartilage
framework (n¼ 11), mismatched skin colour (n¼ 8), different ear
axis (n¼ 7) or shape (n¼ 5), ear convolution (n¼ 2), or bad-looking
scars (n¼ 2). The severity of microtia had no effect on the aesthetic
outcome (6).
Qian et al. studied 111 patients with CFM to study the effect of
the expanded two-flap method (7). Results on this specific surgical
technique were considered to be too detailed for this chapter and
were not included. General outcomes of ear reconstruction with rib
graft were included. The mean age of the patients was 9 years (range
5 to 27 years) and mean follow-up was 8.3 months (range 5 to 20
months). Aesthetic outcomes of treatment were rated on a 0–15
scale, and were satisfactory in 92.8% of the patients, partially
satisfactory in 6.3% of the patients, and unsatisfactory in one
patient (0.9%). Nine patients (8.1%) had surgical complications:
tissue expander-related complications and hematoma (1.8%). Three
patients had complications in the second treatment stage: cartilage
framework exposure in two patients (1.8%) and poor skin graft
survival in one patient (0.9%).
External silicone prosthesis attached with adhesives
The UK Guideline Microtia and Anotia considers external
silicone ear prosthesis as a good treatment modality for microtia,
which can achieve an excellent shape and colour (4). The prosthesis
may be attached with adhesives or with implants. No literature on
the outcomes or complications of treatment with external silicone
prosthesis with adhesives was identified. The benefits and disad-
vantages of the use of this type of external prosthesis are discussed
in the considerations.
External silicone prosthesis attached on
osseointegrated implants
The additional search on non-CFM patients with microtia led to
the inclusion of five articles on external prosthesis. Vijverberg et al.
studied the outcomes and patient satisfaction of osseointegrated
auricular (VXI) implants (17). A total of 31 implants were placed in
11 patients, with a mean age of 44 years (range 13–85 years) and a
minimal follow-up of 7 months (mean follow-up 2.6 years). Soft
tissue reaction was observed in 32.2% of the implants, which all
resolved after topical treatment with antibiotic/corticosteroid
ointment. All patients reported an improvement in quality of life
after receiving the implants with prosthesis, although two patients
(18%) reported a slight physical disadvantage using the prosthesis
(17). Si et al. also reported the troublesome complication of skin
reaction (16). All their studied patients (n¼ 24, 25 ears) who
received osseointegrated auricular implants for an external pros-
thesis had skin reaction. The degree of skin redness, moist, or
granulation tissue gradually decreased over time. Almost all
patients (95.8%) wore the prosthesis for more than eight hours
per day (16).
Wright et al. studied the survival rate of auricular implants in 16
patients and 39 implants. The average age at placement was 40 years
(range 6 to 76 years) and the mean follow-up was 45 months (range
6 months to 17 years). The survival rate was 100% as no implant
failures occurred. Most patients (n¼ 13) had soft tissue inflamma-
tion, which resolved in 54% of the patients with hygiene support or
soft tissue reduction (18).
Younis et al. examined the patient satisfaction in a cross-
sectional study of 20 patients who completed prosthetic ear recon-
struction (average age 37 years, range 17–56 years) (10). The
indication for ear prosthesis was due to a congenital deformity
(n¼ 10), trauma (n¼ 9) or malignancy (n¼ 1). Most patients
(n¼ 14) had previous failed autologous reconstruction. Skin pro-
blems, such as granulation tissue (n¼ 14) or skin infection (n¼ 10),
were often reported. Nevertheless, 14 patients wore the prosthesis
daily. The aesthetic appearance of the prosthesis was considered
excellent or very good by 17 of the 20 patients. Only 12 of the 20
patients were satisfied with their prosthesis. The authors consider
the high rate of skin complications to be the reason for the low
overall satisfaction rate (10).
Osseointegrated implant-supported external
silicone prosthesis versus porous polyethylene
implants (Medpore)
Al Kadah et al. reported their experience with silicone or porous
polyethylene ear prosthesis in 39 patients (43 implants) with a
minimal follow-up of two years (15). Eighteen patients had porous
polyethylene implants placed (mean age 19 years, range 8–56
years) and 21 patients had silicone ear protheses fixed on implants
(mean age 41 years, range 6–84 years). None of the 18 patients with
a porous polyethylene implant saw the implant rejected, although
four patients needed revisions due to keloid (n¼ 1), retroauricular
adhesion (n¼ 2), and local infection leading to partial resection of
the implant (n¼ 1). In the silicone prosthesis group, 18 patients
(85%) wore the prosthesis for at least 10 hours a day. No extrusion
of the implants for the external prosthesis was observed. Revision
surgeries were needed in five patients due to: exposure of the
implants (n¼ 2), infection (n¼ 1), loose screw (n¼ 1), tumour
recurrence (n¼ 1). Local skin reaction at the abutment was seen
in 71.4% of the patients (n¼ 15) during follow-up. No skin reac-
tions in the porous polyethylene implant group were reported.
Porous polyethylene implants (Medpore)
Porous polyethylene implants could yield good aesthetic results
with lower burden for the patient compared with autologous
reconstruction, although complications such as extrusion or fracture
of the implant could be seen in up to 13–15% of the patients
according to the UK microtia/anotia guideline (4). Unfortunately,
no literature was provided to validate these numbers and the
methodological quality of the articles.
In the study by Al Kadah et al. (described above), no extrusion
of the alloplastic implants was observed, although one of the
eighteen patients needed partial resection of the implant after local
infection (15).
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Braun et al. studied the patient-reported outcome after ear recon-
struction with porous polyethylene implants (Medpore) in a cross-
sectional study (11). A total of 65 patients were included, who all
received a questionnaire. Most patients (84.6%) were treated due to
congenital microtia and 15 patients were found to have CFM. The
median age at time of treatment was 18 years (range 4-68 years), and
the mean follow-up was 2.9 years (range 0.5–6.0 years). Adult
patients (n¼ 45) reported an overall increase in quality of life after
auricular reconstruction (p<0.0001). Most of these patients (72.7%)
were satisfied with the aesthetic outcome. Of the 27.3% (n¼ 12) of
the patients who were not satisfied, eight would again decide to have
the operation. A negative score, indicating an adverse effect, was
reported by 17.8% of the adults. Most frequently reported complaints
by patients include difficulties with scars (n¼ 18, 40%), feeling
(n¼ 17, 37%), shape of the ear (n¼ 16, 36%), numbness (n¼ 11,
24%), skin colour (n¼ 8, 18%) or position of the ear (n¼ 4, 9%). No
failures leading to removal of the prosthesis were reported. Two thirds
of the patients were not limited in their physical activities due to the
reconstructed ear and 62.8% of the patients could sleep on the
reconstructed ear (11). Similar results were seen in the paediatric
cohort (n¼ 20). An increase in the health-related quality of life was
observed (p¼ 0.01). Most patients (85%) and parents of patients
(73.7%) were satisfied with the aesthetic results, and all patients and
parents who were not satisfied would again decide to have the
operation. The main complaints were similar to the adults, including
scars and feeling. Complaints regarding the position, shape and
colour were less frequently reported compared to the adult population
(no numbers were reported). One patient psychologically rejected the
new ear. Most children had no physical limitations (75%) and could
sleep on the reconstructed ear (85%) (11).
Porous polyethylene implants (Medpore) versus ear
reconstruction with autologous rib graft
The outcomes of porous polyethylene implants and autologous ear
reconstruction with rib were compared by Constantine et al (12).
Their retrospective analysis included 35 patients (36 ears) who had
complete microtia repair: 17 polyethylene implants (mean age 6.9
years, SD 3.0), 17 reconstructions with rib (mean age 8.0 years, SD
3.8), and 2 with both. The follow-up ranged from 2 to 11 years. Two
blinded observers rated the aesthetic outcomes of treatment. The
mean number of operations was higher in the rib reconstruction group
(4.88, SD 1.54) compared to the polyethylene implant group (3.35,
SD 1.27, p¼ 0.004). One complication occurred in the rib recon-
struction group: cartilage exposure. Two complications occurred in
the implant group: one infection and one extrusion of the implant.
And in the two patients who had both types of reconstruction, two
infections and two extrusions of the polyethylene implants occurred.
A trend toward more infections and extrusions in the polyethylene
group compared to the rib reconstruction group may be present.
Concerning the aesthetic outcomes, the rib reconstruction group had
significantly better outcomes regarding the definition, shape, and
colour match compared to polyethylene implants (p¼ 0.05, p¼ 0.08,
p¼ 0.05 respectively). The size of the ear was better in the implant
group (p¼ 0.05). No statistically significant differences in ear pro-
trusion and location were observed.
Ear reconstruction with autologous rib graft
Ear reconstruction with autologous rib cartilage has been con-
sidered the golden standard in microtia reconstruction for years (4).
In the first operation, performed at age nine to ten, the rib cartilage is
harvested and constructed into a framework, which is then placed in
a pocket at the site of the ear. Six months later, the second procedure
is performed in which the ear is elevated from the head. This
reconstruction is considered to be durable, showing no softening or
shrinkage of the cartilage and having minimal long-term complica-
tions (4). The newly reconstructed ears with rib cartilage were found
to grow as much as normal ears after reconstruction (after a median
follow-up of 5.6 years, range 2.1–10.6 years) (14).
A systematic review on the complications of autologous ear recon-
struction with rib was conducted by Long et al. in 2013 (9). A total of 60
articles, including 9,415 patients, were included in the analysis. The
overall complication incidence was 16.2% (range 0–72.9%). Compli-
cations included: dissatisfying final results (8.5%), hypertrophic scar
(6.3%), asymmetry (2.1%), wire or suture extrusion (1.6%), flap venous
congestion (1.6%), cartilage absorption (1.3%), facial nerve injury
(1.1%), frame exposure (1.0%), infection (0.9%), hematoma (0.3%),
and grafted skin necrosis (0.4%). Leakage or exposure of the tissue
expander has an incidence of respectively 1.4% and 3.5%. Complica-
tions at the donor site included atelectasis, pleural tear, chest wall
deformity, thoracic scoliosis, and hypertrophic scar. The overall inci-
dence of these complications varied from 5.6% to 36.1%.
A recent retrospective cohort study of 470 ear reconstructions with
rib grafts by Fu et al. (13) reported a complication rate of 9.43%. All
patients included (n¼ 429) were treated in the same centre, by the
same surgeon. The mean follow-up was 3.7 years (2.5 years). Age,
sex, and laterality were not associated with the complications
(p>0.05). The risk of complications was significantly higher in
patients treated with the Nagata technique (12.2%, 38/311) compared
with the Brent technique (2.98%, 4/134) (OR 6.14, 95% CI 1.63–
23.19; p< 0.01). The authors suggest that this is presumably the result
of a more complicated and stereoscopic technique in the Nagata
technique, with a higher risk for vascular compromise of the skin flap
compared to the Brent technique (13). Despite the higher risk of
complications when using the Nagata technique, the authors advise
the use of this technique since it requires fewer surgical stages (two
stages) compared to the Brent technique (three to four stages).
Conclusions
Level 3 External silicone prosthesis
Non-craniofacial microsomia patients who wear an
osseointegrated implant- supported external silicone
prosthesis are often satisfied with the result (placed at a
mean age of 37–44 years).
Implants for an external prosthesis often lead to local skin
reactions (in 32–100% of patients), which may decrease
the satisfaction with the prosthesis. Treatment with
antibiotic/corticosteroid ointment or increased hygiene is
often successful.
No conclusion on revision- or failure rates of implants can be
drawn, as studies were based on small patient samples
with limited follow-up.
Implants for external silicone prosthesis were placed at a
mean age of 19–44 years (range 8–85 years) in non-
craniofacial microsomia patients.
Ref (4, 10, 15–18)
Level 3 Porous polyethylene implants (Medpore) (inserted at mean
age of 6–18)
Most patients (73%) report an increase in quality of life and
are satisfied with the aesthetic result (73–75%) after ear
reconstruction with porous polyethylene implants.
Dissatisfying results were mainly due to complaints
regarding scars, hair loss, and numbness.
Extrusion or fracture of the implant was seen in up to 13 -
15% of patients.
Polyethylene implants have better aesthetic outcomes
regarding the size of the ear compared to reconstruction
with rib, whereas rib-reconstructed ears show better
outcomes regarding definition, shape, and colour match.
Ref (4, 11, 12, 15)
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Level 3 Ear reconstruction with rib in patients with craniofacial
microsomia
Patients with craniofacial microsomia and severe
microtia required more operations to achieve optimal
results compared to patients with less severe microtia.
Evidence on the effect of the severity of microtia on the
aesthetic outcome of ear reconstruction in patients
with craniofacial microsomia is contradictory and no
conclusions can be drawn.
Reasons for poor postoperative outcomes after ear
reconstruction in patients with craniofacial
microsomia include: mismatch in size, skin colour, ear
axis, shape, or partial resorption of the cartilage
framework.
Ref (5, 6)
Level 3 Covering techniques for ear reconstruction with rib in
patients with craniofacial microsomia
Various covering techniques can be used for ear
reconstruction in patients with craniofacial
microsomia:
- The embedded technique is associated with good
aesthetic outcomes.
- The fascia flap technique is associated with good
aesthetic outcomes and is often used in patients with
severe craniofacial microsomia. A mismatch in skin
colour is more frequently observed in patients treated
with this technique compared to others.
- The expansion technique is associated with good
aesthetic outcomes, but has worse outcomes compared
to the other techniques.
Ref (6, 7)
Level 3 Ear reconstruction with rib
Ear reconstruction with rib is considered a durable
treatment option with minimal long-term
complications. The reconstructed ears show a similar
growth pattern to the normal ear.
Ear reconstruction with rib is usually performed at age
eight to ten.
The overall complications incidence of ear reconstruction
with rib is 16%.
Reported complications include dissatisfying final results
(9%), hypertrophic scar (6%), asymmetry (2%), wire
or suture extrusion (2%), flap venous congestion (2%),
cartilage absorption (1%), facial nerve injury (1%).
Donor site complications include pain, atelectasis, pleural
tear, chest wall deformity, thoracic scoliosis, and
hypertrophic scar.
Ref (4, 9, 13, 14)
Considerations
 Overall quality of evidence
The levels of evidence were considered to be level 3 due to the
non-comparative nature of most studies. The systematic review by
Long et al. on complications of ear reconstruction with rib
excluded case reports and case series with fewer than 15 patients.
This study is descriptive and non-comparative, leading to a level 3
quality of evidence. Al Kadah et al. and Constantine et al. made a
retrospective comparison between two groups: polyethylene
implants versus reconstruction with rib (12) and polyethylene
implants versus silicone prosthesis (15). Park et al. retrospectively
compared three different covering methods for the reconstructed
ear (6). Although these studies are comparative, the level of
evidence is graded as level 3 since the studies were not randomised
and no other comparative studies could be included that supported
the conclusions.
 Balance of benefits and harms
External silicone prosthesis on adhesives
The prosthesis can be attached with adhesives at a young age,
although this is controversial. Early use of the prosthesis to let
the child get used to it, could make the child feel less-conscious
of the prosthesis when school starts. However, no evidence is
available that supports this theory. Additionally it may prevent
teasing, although no literature is available to support this theory
either. Early treatment is likely to be a reaction to parental
anxiety rather than clinical need. The use of an external pros-
thesis in young children could also imply that the deformed ear
needs to be camouflaged and could lead to the association of
negative feelings (4).
External silicone prosthesis on implants
Advantages of an external silicone prosthesis are the realistic
looks and its relatively simple use/placement. Disadvantages
include the need for replacement of the implants, cleaning of the
pin sites, risk of losing the prosthesis during physical activities, skin
colour changes, or problems with the implants (e.g. infection or
over-granulation) (4).
If implants are placed for prosthesis attachment, the microtic
remnant often needs to be removed. It is important that the patient
and family are aware that other forms of ear reconstruction are
impaired after this treatment (4).
Alloplastic implants
Reconstruction with Medpore implants is quicker and has a
lower burden for the patient compared to autologous ear recon-
struction, as no rib cartilage has to be harvested using this technique.
In addition, reconstruction with Medpore is less technically chal-
lenging compared to autologous reconstruction, although technical
expertise is still required to achieve good results (4).
Medpore implants can be placed at a young age (three to five
years), although the size of the implants has to be bigger to
account for future growth of the contralateral ear (4). At this age,
the child is not aware of its facial differences, which makes the
indication for this invasive treatment debatable. Also, if an
implant is placed, future autologous reconstruction with rib is
impaired given the scarring of the local soft tissues. Another
important aspect is the risk of complications, especially if the
implant is placed in children and if the child engages in contact
sports. The complications, such as extrusions or fractures of the
implants, are serious and make future reconstruction with other
methods challenging. Therefore, it is advised to be cautious in
treating children with Medpore implants. If reconstruction with
Medpore is indicated, it is advised to postpone treatment until
after the age of six since at this age the width of the normal ear is
approaching its mature size (22).
Ear reconstruction with rib
The aesthetic results of ear reconstruction with autologous rib
grafts are considered to be good in the hands of experienced
surgeons (4, 12). The main benefit of this treatment is the long-
term outcome. The cartilage responds naturally to trauma and no
changes in the cartilage over time are observed. Long-term com-
plications are minimal, leading to lower costs and burden for the
patient compared to other techniques.
The surgical technique of ear reconstruction with rib grafts is
technically challenging with a steep learning curve. Treatment by
specialised surgeons who perform this type of surgery on a regular
basis is preferred to achieve the best results. Other drawbacks of this
surgery include the burden for the patient, which is higher compared
to other treatments due to harvesting the rib graft (4, 5).
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 Outcome importance
The choice for one of the treatment options for ear recon-
struction is based on the potential outcomes, benefits and harms
of treatment. Patients and parents should be able to make their
choice based on the available information and weigh the advan-
tages and disadvantages of treatment options and should be
supported if they decide that no reconstruction is the correct
option for them. The conclusions and recommendations in this
chapter aim to help for patients and doctors in the process of
choosing a type of treatment.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. Treatment with porous polyethylene pros-
thesis (Medpore) could contribute to an increase in costs. Health
insurance reimbursement and the willingness to cover these costs
may differ between countries. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core
values. However, in some countries the national organisation of
healthcare might impede centralisation. National implementation
of the ERNs that fits the situation of each country is necessary. For
the member states with the lowest number of inhabitants, the
establishment of a craniofacial centre might not be feasible, and
collaboration with a craniofacial centre in the surrounding coun-
tries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will be
applying the recommendations, because they are employed in ERN-
acknowledged institutions. National implementation plans are nec-
essary to ensure that recommendations fit the situation in each
country. In addition, not all countries participating in the ERN-
CRANIO are represented in the guideline development group, and
new members will join within the coming years. For these countries,
acceptance and implementation of ERN guidelines such as this
guideline on CFM is obligatory.
Rationale of the recommendations
There is no strongly preferred treatment option to treat
microtia in patients with CFM. The selected treatment should
be based on patients’ preferences, which is only possible if the
surgeon informs the patient (and parents) on all the advantages
and disadvantages of the various options. Autologous reconstruc-
tion with rib grafts is considered the most durable treatment
options with good long-term outcomes. This is especially rele-
vant in patients with congenital microtia, since these patients
need a life-long treatment solution. The timing of treatment
depends on the psychosocial development of the child, the
availability of cartilage for reconstruction with rib, the size of
the natural ear, and the ability of the child to be part of the
decision-making process and to cooperate with the surgical
management. Ear reconstruction with an autologous rib graft
can be performed from the age of eight since by then enough
cartilage can be harvested to reconstruct the ear. It is advised to
place Medpore implants after the age of six, because by then, the
width of the ear approaches its mature size (22). Treatment with
external silicone prosthesis attached with adhesives may be
initiated in children. However, treatment at a young age is
discouraged since this emphasises that the child is ‘different
from normal’. Treatment of the ear deformity at a young age is
therefore often done to comfort the parents, which makes the
indication for treatment debatable. Their worries about their
child being bullied should be taken seriously and support should
be provided, but surgery will not be the solution. Psychosocial
support by a psychologist prior to and after treatment is impor-
tant, especially in patients with aesthetic concerns. Given all the
advantages and disadvantages of all options, ear reconstruction
with rib grafts is considered to be the gold standard. An external
prosthesis on osseointegrated implants is ideally used as a
secondary option for salvage cases. Treatment should be dis-
cussed within the multidisciplinary team to ensure optimal
timing in the planning of other surgeries. Figure 1 shows a
flowchart of the recommendations on the various treatment
modalities that can be performed to treat microtia in patients
with CFM.
Recommendations
 Patients should be treated within a multidisciplinary
team setting.
 Discuss the advantages and disadvantages of the various
treatment modalities with the patient and base the
choice for treatment on patients’ preferences.
 Psychological input is required pre- and postoperatively
to monitor expectation and acceptance.
 Ear reconstruction with rib grafts is the first choice
of treatment.
 Perform ear reconstruction with rib from the age of
eight onwards.
 Treatment before the age of eight is not recommended,
but if chosen, use external silicone prosthesis attached
with adhesives.
 If chosen, place polyethylene implants (Medpore) from
the age of six onwards.
 Osseointegrated implants are an option for salvage
procedures.
 Outcome measures should be obtained pre- and
postoperatively with all techniques and interventions.
Research gap
Measurement of an agreed set of outcomes should be done
before and after surgery in order to assess and compare the benefit
of the procedure to allow benchmarking.
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Figure 3. Flowchart of recommendations for treatment of micro-
tia in craniofacial microsomia
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14. Roos EW, S.O. Öberg, M. Growth of ears reconstructed from
autologous rib cartilage. Eur J Plast Surg. 2015(38):443–8.
15. Al Kadah B, Naumann A, Schneider M, Schick B,
Linxweiler M, Papaspyrou G. Auricular reconstruction
with polyethylene implants or silicone prosthesis: A single
institution experience. J Craniomaxillofac Surg. 2018;46
(12):2150-6.
16. Si Y, Fan SC, Sun W, Chen YB, Zhang ZG. Osseointegration
technique in patients with acquired auricular deformities and
failed previous reconstruction: a retrospective study of long-
term follow-up and Chinese experience. ORL J Otorhinolar-
yngol Relat Spec. 2012;74(3):129-35.
17. Vijverberg MA, Verhamme L, van de Pol P, Kunst HPM,
Mylanus EAM, Hol MKS. Auricular prostheses attached to
osseointegrated implants: multidisciplinary work-up and
clinical evaluation. Eur Arch Otorhinolaryngol. 2019;276
(4):1017-27.
18. Wright RF, Zemnick C, Wazen JJ, Asher E. Osseointegrated
implants and auricular defects: a case series study. J
Prosthodont. 2008;17(6):468-75.
19. Li D, Chin W, Wu J, Zhang Q, Xu F, Xu Z, et al. Psychosocial
outcomes among microtia patients of different ages and
genders before ear reconstruction. Aesthetic Plast Surg.
2010;34(5):570-6.
20. Akter F, Mennie JC, Stewart K, Bulstrode N. Patient reported
outcome measures in microtia surgery. J Plast Reconstr
Aesthet Surg. 2017;70(3):416-24.
21. Soukup B, Mashhadi SA, Bulstrode NW. Health-related
quality-of-life assessment and surgical outcomes for auricular
reconstruction using autologous costal cartilage. Plast
Reconstr Surg. 2012;129(3):632-40.
22. Farkas LG, Posnick JC, Hreczko TM. Anthropometric growth
study of the ear. Cleft Palate Craniofac J. 1992;29(4):324-9.
CHAPTER 6. ORGANISATION OF CARE
Minimal care standards and monitoring
outcomes
Introduction
Craniofacial microsomia (CFM) is a condition involving various
congenital disorders which requires the involvement of multiple
healthcare professionals. A multidisciplinary team is needed to
provide and align the complex, long-lasting care for patients
with CFM.
Since CFM is a relatively rare congenital disorder, with an
incidence of 1:3,000 to 1:5,000 live births, centralisation of care in
specialised craniofacial centres is preferred since this makes it
possible to build experience in treating these patients, improve
the quality of care, and to perform clinically relevant scientific
research.
Multidisciplinary care requires good coordination and commu-
nication among healthcare professionals, but also with patients and
parents of patients. The responsibility and division of tasks of all
professionals should be clear for all team members. Centralisation
of care and formation of multidisciplinary craniofacial teams makes
it possible to perform comparative studies between centres. Com-
paring outcomes of the various craniofacial centres would have a
positive effect on the quality of care.
To make recommendations on the minimal care standards for the
treatment of patients with CFM, the following question was posed:
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3.1 What are the minimal care standards to treat patients
with craniofacial microsomia and how should outcomes of
care be monitored?
Defining the minimal care standards to treat patients with CFM
is important to guarantee good quality of treatment for all patients
with CFM. Patients of the hospitals participating in the ERN-
CRANIO were asked to identify current problems in the care
process (patient bottlenecks). Patients reported problems in getting
referred to a specialised centre, the lack of a multidisciplinary
approach and long travel distance. Additionally, patients advised
appointing a care provider as point of contact within the craniofacial
team, who can be contacted by patients, parents of patients and
healthcare professionals.
Literature search
A systematic search of literature was performed to identify all
available literature on CFM and synonyms. The search was con-
ducted in Embase, Pubmed/Medline Ovid. The full search strategy
is reported in the supplementary material.
Inclusion and exclusion criteria:
Type of studies - Original articles
- Systematic review of sufficient quality:
- The question in the systematic review
matches the question of the guideline.
- The search of the systematic review was
conducted in at least two relevant
databases, such as the Cochrane Library,
Medline/Pubmed.
- The full search strategy was reported.
- No relevant items were missing in the
search strategy.
Type of patients - Patients with craniofacial microsomia
Subject - Organisation of care
- Patient reported bottleneck in care process
- Outcome measures
Exclusion criteria - Original studies with <10 included patients






Literature was screened on title and abstract. One article, by
Johns et al., was included which discussed the experiences of
patients with CFM during medical care (1).
6.1 What are the minimal care standards to treat patients
with craniofacial microsomia and how should outcomes of
care be monitored?
The literature search for this chapter was directed towards
bottlenecks mentioned by patients regarding communication, infor-
mation, referral, and collaboration. Results of the bottleneck anal-
ysis that was performed by the authors of this guideline are
displayed in the appendix. The review of literature and conclusions
will be based on the article of Johns et al (1). The considerations and
recommendations in this chapter will be based on both expert
opinion, patient preferences and literature.
Review of literature
Johns et al. approached patients with CFM and caregivers of
patients with CFM from the USA to share their views and experi-
ences regarding their situation at home, school, community and
medical care. A total of 42 caregivers and 9 adult patients were
included. When asked about the difficulties in medical care, 25%
of the caregivers reported a lack of knowledge about CFM among
healthcare professionals along the whole healthcare pathway.
Additionally, 16% of the caregivers and 20% of the patients
reported that there was little guidance during treatment. The
coordination of care was troublesome for some patients: 13% of
the caregivers reported difficulties accessing treatment; unfortu-
nately it was not clarified what the reasons for these difficulties
were (e.g. organisational or insurance problems). Another 13% of
the patients received conflicting medical recommendations, and
9% found it difficult to coordinate care with the multiple
healthcare providers.
A third of the caregivers and half of the adult patients suggested
improving treatment communication and coordination during the
care process. Caregivers recommended providing clear information
about the diagnosis CFM (16%) and stated they would like to be
more informed about CFM (13%). Appropriate referral to specialist
care (13%), parent support (10%), help with insurance coverage
(6%) and support of patient organisations (17%) were other issues
that caregivers and patients mentioned. A patient-centred approach
and involving the family in decision making regarding treatment
was recommended by the patients.
Conclusions
Level 3 The most frequently reported difficulties in care for
patients and parents of patients with craniofacial
microsomia include healthcare professionals’ lack of
knowledge regarding the diagnosis craniofacial
microsomia, lack of guidance during treatment and
unclear coordination of care.
Ref (1)
Level 3 Communication about and coordination of the treatment
during the care process should be improved to
optimise treatment for patients with craniofacial
microsomia. A patient-centred approach and




 Overall quality of evidence
The quality of evidence of the conclusions was graded as level 3
since the study by Johns et al. is a cross-sectional, non-
comparable study.
 Balance of benefits and harms
Information
Patients mentioned that they would prefer to have more knowl-
edge about the condition, about possible treatments, and about
specialised professionals and institutions in their own or neighbour-
ing country. Information about CFM is scarce in most countries. In
addition, patients mentioned that they were forced to find their own
information on the internet and in books. CFM might result in
lifelong medical treatment or disability of the patient. Information is
rarely available throughout the healthcare process. Similarly, doc-
tors in urban hospitals are not always aware where CFM is best
treated in their country. Clear protocols and patient information
are necessary.
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Developing information for patients, parents and professionals
takes effort, but it will eventually help both patients, parents and
professionals. This guideline will point out gaps in knowledge on
which further research can focus.
Communication
Patients mentioned that different teams in various hospitals
might come up with different treatment options. This is quite
difficult for patients and parents to understand. Patients prefer to
have a contact person each centre; a care coordinator who will
function as a point of reference for the patient, parents and profes-
sionals and will clarify and facilitate communication between
different institutions and within her/his own institution. This role
could be played, for example, by a (specialist) nurse.
Communication between and within teams is necessary to
facilitate the best possible treatment and help patients and parents
in the best way possible. This might require an extra effort from the
team but it will make communication for parents, patients and
professionals much better.
Referral
Patients mentioned that they were often referred after many
months. In addition, there was unclearness about the city or country
of specialists. Timely referral to the correct centre of expertise
facilitates the whole healthcare process for patients and parents.
Optimal referral will result in less overtreatment, receiving the
wrong treatment, and less waiting time for the patient and the
professional. It will make the healthcare path smoother and will
result in less unnecessary healthcare.
Collaboration and conditions
Patients mentioned that it sometimes felt as if people from
different disciplines worked individually instead of functioning
as a multidisciplinary team. Specialists often worked in different
hospitals, which would not be an issue if optimal communication
could be arranged. Multidisciplinary care requires good coordi-
nation and communication within the team itself, towards practi-
tioners involved outside the center and with the patient and
parents. This can be difficult. The responsibility and division
of tasks for the various care providers within the team should
therefore be clearly described. This is a responsibility of the
centre of expertise.
Treating patients with CFM requires input from several experts;
therefore, coordination of healthcare is important. A multidisciplin-
ary team should meet the following requirements:
1. Composition of and collaboration within a multidisciplinary
team
2. Experience with treatment of CFM
3. Access to the necessary facilities:
a. (3D)photography, roentgen, CT, MRI, 3D-planning facility
b. Paediatric ICU




Good accessibility of care
























Continuity of care for patients who reach adulthood
(transitional care)
8. Systematic evaluation of outcomes and implementing changes
that are the result of these evaluations
9. Innovation and scientific research (congresses and publica-
tions)
10. Additional and continuing training of all team members
11. Updated information for patients and caregivers
Centralisation
Healthcare for patients with CFM requires a multidisciplinary
approach, given the complex care these patients need. Centralisa-
tion results in more expertise, higher quality of care and more
possibilities for scientific research to improve care.
Healthcare for patients with CFM is centralised in expertise
centres in different countries in Europe. However, patients are
not always aware of this. In addition, not every European country
will have an specialist centre for CFM. Centralisation might
result in less expertise being present in other institutions and a
longer travel distance for patients. Because a large part of the
healthcare for CFM concerns elective care this rarely leads to
medically undesirable situations. Centralisation is the only way
to achieve good evaluation of new treatment methods and
comparative studies.
Professionals treating CFM are already connected in European
Reference Networks (ERNs) with a focus on complex craniofacial
anomalies and ear, nose and throat (ENT) disorders (ERN-CRA-
NIO).
European Reference Networks (ERNs) are virtual networks of
healthcare providers from across Europe. The networks aim to pool
together expertise on complex and rare diseases and concentrate
knowledge and resources. There are 24 ERNs, each focusing on a
particular disease area. A general rule of thumb is that one expertise
centre is required for a specific group of diagnoses for every 10
million inhabitants.
ERN-CRANIO seeks to facilitate cooperation between mul-
tidisciplinary experts across Europe to support the provision of
high-quality care. Initially there are 29 European hospitals
involved in ERN-CRANIO, from 11 member states. It is a
multidisciplinary network of highly specialised healthcare pro-
fessionals. Further information can be found on the website
https://ern-cranio.eu.
By encouraging cooperation between countries, patients in need
of specialised treatment or patients with rare diseases are offered the
possibility to choose from a wider range of healthcare providers and
to access alternative or specialised treatment abroad more easily.
Monitoring
Current practice varies in different European countries. In
addition to developing a guideline with standards of care, it is
relevant to monitor the outcome of these standards of care in the
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future with the participating institutions. Monitoring standards of
care should encourage institutions to change their current prac-
tice if results of treatment are falling short. In addition, institu-
tions can learn from each other and can help each other by
implementing optimal organisation of care. It is important to
mention that monitoring standards of care will not be set up to
criticise each other but to improve the quality of healthcare
together.
Monitoring standards of care might require some effort from the
team but can result in many valuable (international) results that will
improve quality of care.
 Outcome importance
Patients mentioned in the bottleneck analysis that they prefer
a care coordinator, clear referral, a multidisciplinary approach,
more cooperation between several specialists, and more knowl-
edge about the disease, about possible treatments, and about
specialised professionals and institutions in their own neighbour-
ing country.
 Costs and resources
The impact on costs and resources of the given recommenda-
tions will vary per member state, depending on the available care
providers and facilities. The recommendations concern the essential
requirements for adequate treatment of patients with CFM and
should thus be implemented. Costs are lowest and resources are
most efficiently used when care for craniofacial disorders is cen-
tralised in a limited number of expert centres per member state. A
general rule that can be applied is one expert centre per 10
million inhabitants.
 Inequity of the recommendation
The goal of the European Reference Networks (ERNs) is to
eliminate inequality within Europe with regard to care for patients
with rare diseases. At present, not every member state offers an
expert centre for CFM, or the level of provided care does not (yet)
meet all the requirements that are outlined in this guideline. By
defining the baseline of required care for CFM, this guideline will
help these member states to reach the appropriate level. The ERN on
craniofacial anomalies and ENT disorders (ERN-CRANIO) can
guide a patient in Europe to the available centres of expertise
(www.ern-cranio.eu) and can support care providers with diagnosis
and treatment advice.
 Feasibility of the recommendation
Recommendations refer to the general requirements for deliv-
ering optimal healthcare and are discussed with members from
participating European countries. Quality of care was paramount in
the discussions. Centralisation is proposed as one of the core
values. However, in some countries the national organisation of
healthcare might impede centralisation. National implementation
of the ERNs that fits the situation of each country is necessary. For
the member states with the lowest number of inhabitants, the
establishment of a craniofacial centre might not be feasible, and
collaboration with a craniofacial centre in the surrounding coun-
tries can be an option.
 Acceptability of the recommendation
It is expected that all stakeholders want to apply and will
be applying the recommendations, because they are employed in
ERN-acknowledged institutions. National implementation plans are
necessary to ensure that recommendations fit the situation in
each country. In addition, not all countries participating in the
ERN-CRANIO are represented in the guideline development group,
and new members will join within the coming years. For these
countries, acceptance and implementation of ERN guidelines such
as this guideline on CFM is obligatory.
Rationale of the recommendations
The guiding principle of the recommendations is to offer the
most optimal care to children with CFM and their parents. The
assessment and treatment of this condition is complex and has a
lifelong impact on the patients. This necessitates a dedication
from healthcare providers to continue training in all aspects of
this care.
Information
 The multidisciplinary team should provide information
regarding the condition and treatment options based on




 Patients should be referred to the multidisciplinary
craniofacial microsomia team in a timely manner.
Collaboration
 Care for patients with craniofacial microsomia should
be delivered by the multidisciplinary team.
 The clinical pathway based on this guideline should
be followed.
Communication
 Communication between and within teams (also in
different hospitals) should be initiated to facilitate the
best possible treatment. A contact person in each centre
- a care coordinator - clarify and facilitate communica-
tion between different institutions and within her/his
own institution.
Conditions
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A craniofacial centre has access to the following care
facilities:
 (3D)photography, roentgen, CT, MRI, 3D-planning
facility
 Paediatric ICU




 Continuity of care should be ensured for patients with
craniofacial microsomia who reach adulthood.
Centralisation
 Patients with craniofacial microsomia are only treated
for craniofacial microsomia-related difficulties in a
centres that meets the criteria (including volume of
care) defined by the ERN-CRANIO.
Monitoring
 Patient measure should be performed as stated in
each chapter.
 Adhere to the ERN-CRANIO registry.
Research gap
Research can be directed towards the following gaps: distribu-
tion of information on CFM for patients, parents and professionals;
optimising referral to specialised care centres; optimising coordi-
nation and communication between specialist within and between
different hospitals; and optimising the role of psychosocial care for
patients with CFM. All patient reported outcome measures should
be studied for patients with CFM and be translated and validated in
all ERN-CRANIO languages.
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